
<html lang="en"     class="pb-page"  data-request-id="c892528e-7f8e-48ce-9ae3-dd6d30143dff"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2017.60.issue-23;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.7b00736;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Pyrrolobenzodiazepine Dimer Antibody–Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-Linkers" /></meta><meta name="dc.Creator" content="Stephen J.  Gregson" /></meta><meta name="dc.Creator" content="Luke A.  Masterson" /></meta><meta name="dc.Creator" content="Binqing  Wei" /></meta><meta name="dc.Creator" content="Thomas H.  Pillow" /></meta><meta name="dc.Creator" content="Susan D.  Spencer" /></meta><meta name="dc.Creator" content="Gyoung-Dong  Kang" /></meta><meta name="dc.Creator" content="Shang-Fan  Yu" /></meta><meta name="dc.Creator" content="Helga  Raab" /></meta><meta name="dc.Creator" content="Jeffrey  Lau" /></meta><meta name="dc.Creator" content="Guangmin  Li" /></meta><meta name="dc.Creator" content="Gail D.  Lewis Phillips" /></meta><meta name="dc.Creator" content="Janet  Gunzner-Toste" /></meta><meta name="dc.Creator" content="Brian S.  Safina" /></meta><meta name="dc.Creator" content="Rachana  Ohri" /></meta><meta name="dc.Creator" content="Martine  Darwish" /></meta><meta name="dc.Creator" content="Katherine R.  Kozak" /></meta><meta name="dc.Creator" content="Josefa  dela Cruz-Chuh" /></meta><meta name="dc.Creator" content="Andrew  Polson" /></meta><meta name="dc.Creator" content="John A.  Flygare" /></meta><meta name="dc.Creator" content="Philip W.  Howard" /></meta><meta name="dc.Description" content="Three rationally designed pyrrolobenzodiazepine (PBD) drug-linkers have been synthesized via intermediate 19 for use in antibody–drug conjugates (ADCs). They lack a cleavable trigger in the linker ..." /></meta><meta name="Description" content="Three rationally designed pyrrolobenzodiazepine (PBD) drug-linkers have been synthesized via intermediate 19 for use in antibody–drug conjugates (ADCs). They lack a cleavable trigger in the linker ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 16, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b00736" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00736" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b00736" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00736" /></link>
        
    
    

<title>Pyrrolobenzodiazepine Dimer Antibody–Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-Linkers | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b00736" /></meta><meta property="og:title" content="Pyrrolobenzodiazepine Dimer Antibody–Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-Linkers" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0012.jpeg" /></meta><meta property="og:description" content="Three rationally designed pyrrolobenzodiazepine (PBD) drug-linkers have been synthesized via intermediate 19 for use in antibody–drug conjugates (ADCs). They lack a cleavable trigger in the linker and consist of a maleimide for cysteine antibody conjugation, a hydrophilic spacer, and either an alkyne (6), triazole (7), or piperazine (8) link to the PBD. In vitro IC50 values were 11–48 ng/mL in HER2 3+ SK-BR-3 and KPL-4 (7 inactive) for the anti-HER2 ADCs (HER2 0 MCF7, all inactive) and 0.10–1.73 μg/mL (7 inactive) in CD22 3+ BJAB and WSU-DLCL2 for anti-CD22 ADCs (CD22 0 Jurkat, all inactive at low doses). In vivo antitumor efficacy for the anti-HER2 ADCs in Founder 5 was observed with tumor stasis at 0.5–1 mg/kg, 1 mg/kg, and 3–6 mg/kg for 6, 8, and 7, respectively. Tumor stasis at 2 mg/kg was observed for anti-CD22 6 in WSU-DLCL2. In summary, noncleavable PBD-ADCs exhibit potent activity, particularly in HER2 models." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b00736"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00736">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b00736&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b00736&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b00736&amp;href=/doi/10.1021/acs.jmedchem.7b00736" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 23</span><span class="cit-fg-pageRange">, 9490-9507</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/23" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b00663" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b00785" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Pyrrolobenzodiazepine Dimer Antibody–Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-Linkers</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stephen+J.++Gregson">Stephen J. Gregson</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-6859-9772" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Luke+A.++Masterson">Luke A. Masterson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Binqing++Wei">Binqing Wei</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Thomas+H.++Pillow">Thomas H. Pillow</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Susan+D.++Spencer">Susan D. Spencer</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gyoung-Dong++Kang">Gyoung-Dong Kang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shang-Fan++Yu">Shang-Fan Yu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Helga++Raab">Helga Raab</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jeffrey++Lau">Jeffrey Lau</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Guangmin++Li">Guangmin Li</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gail+D.++Lewis+Phillips">Gail D. Lewis Phillips</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Janet++Gunzner-Toste">Janet Gunzner-Toste</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Brian+S.++Safina">Brian S. Safina</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rachana++Ohri">Rachana Ohri</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Martine++Darwish">Martine Darwish</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Katherine+R.++Kozak">Katherine R. Kozak</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Josefa++dela+Cruz-Chuh">Josefa dela Cruz-Chuh</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andrew++Polson">Andrew Polson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John+A.++Flygare">John A. Flygare</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol "><sup>§</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Philip+W.++Howard">Philip W. Howard</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Spirogen, QMB Innovation Centre, 42 New Road, London E1 2AX, United Kingdom</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div><div class="corresp-info"><strong>*</strong>S.J.G.: e-mail, <a href="/cdn-cgi/l/email-protection#2f485d4a485c40415c6f424a4b4642425a414a014c4042"><span class="__cf_email__" data-cfemail="d5b2a7b0b2a6babba695b8b0b1bcb8b8a0bbb0fbb6bab8">[email protected]</span></a>; phone, (+44)2037496251.</div><div class="corresp-info"><strong>*</strong>T.H.P.: e-mail, <a href="/cdn-cgi/l/email-protection#ef9f8683838098c19b8780828e9caf888a818ac18c8082"><span class="__cf_email__" data-cfemail="23534a4f4f4c540d574b4c4e42506344464d460d404c4e">[email protected]</span></a>; phone, (+01)6502251652.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00736&amp;href=/doi/10.1021%2Facs.jmedchem.7b00736" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 23</span><span class="cit-pageRange">, 9490–9507</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 7, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>18 May 2017</li><li><span class="item_label"><b>Published</b> online</span>16 November 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 December 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b00736" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00736</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9490%26pageCount%3D18%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DStephen%2BJ.%2BGregson%252C%2BLuke%2BA.%2BMasterson%252C%2BBinqing%2BWei%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D23%26contentID%3Dacs.jmedchem.7b00736%26title%3DPyrrolobenzodiazepine%2BDimer%2BAntibody%25E2%2580%2593Drug%2BConjugates%253A%2BSynthesis%2Band%2BEvaluation%2Bof%2BNoncleavable%2BDrug-Linkers%26numPages%3D18%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9507%26publicationDate%3DDecember%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b00736"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3092</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">19</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b00736" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Pyrrolobenzodiazepine Dimer Antibody–Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-Linkers&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Stephen&quot;,&quot;last_name&quot;:&quot;J. Gregson&quot;},{&quot;first_name&quot;:&quot;Luke&quot;,&quot;last_name&quot;:&quot;A. Masterson&quot;},{&quot;first_name&quot;:&quot;Binqing&quot;,&quot;last_name&quot;:&quot;Wei&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;H. Pillow&quot;},{&quot;first_name&quot;:&quot;Susan&quot;,&quot;last_name&quot;:&quot;D. Spencer&quot;},{&quot;first_name&quot;:&quot;Gyoung-Dong&quot;,&quot;last_name&quot;:&quot;Kang&quot;},{&quot;first_name&quot;:&quot;Shang-Fan&quot;,&quot;last_name&quot;:&quot;Yu&quot;},{&quot;first_name&quot;:&quot;Helga&quot;,&quot;last_name&quot;:&quot;Raab&quot;},{&quot;first_name&quot;:&quot;Jeffrey&quot;,&quot;last_name&quot;:&quot;Lau&quot;},{&quot;first_name&quot;:&quot;Guangmin&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Gail&quot;,&quot;last_name&quot;:&quot;D. Lewis Phillips&quot;},{&quot;first_name&quot;:&quot;Janet&quot;,&quot;last_name&quot;:&quot;Gunzner-Toste&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;S. Safina&quot;},{&quot;first_name&quot;:&quot;Rachana&quot;,&quot;last_name&quot;:&quot;Ohri&quot;},{&quot;first_name&quot;:&quot;Martine&quot;,&quot;last_name&quot;:&quot;Darwish&quot;},{&quot;first_name&quot;:&quot;Katherine&quot;,&quot;last_name&quot;:&quot;R. Kozak&quot;},{&quot;first_name&quot;:&quot;Josefa&quot;,&quot;last_name&quot;:&quot;dela Cruz-Chuh&quot;},{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;Polson&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;A. Flygare&quot;},{&quot;first_name&quot;:&quot;Philip&quot;,&quot;last_name&quot;:&quot;W. Howard&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;16&quot;,&quot;issue&quot;:&quot;23&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;9490-9507&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b00736&quot;},&quot;abstract&quot;:&quot;Three rationally designed pyrrolobenzodiazepine (PBD) drug-linkers have been synthesized via intermediate 19 for use in antibody–drug conjugates (ADCs). They lack a cleavable trigger in the linker and consist of a maleimide for cysteine antibody conjugation, a hydrophilic spacer, and either an alkyne (6), triazole (7), or piperazine (8) link to the PBD. In vitro IC50 values were 11–48 ng/mL in HER2 3+ SK-BR-3 and KPL-4 (7 inactive) for the anti-HER2 ADCs (HER2 0 MCF7, all inactive) and 0.10–1.73 μg/mL (7 inactive) in CD22 3+ BJAB and WSU-DLCL2 for anti-CD22 ADCs (CD22 0 Jurkat, all inactive at low doses). In vivo antitumor efficacy for the anti-HER2 ADCs in Founder 5 was observed with tumor stasis at 0.5–1 mg/kg, 1 mg/kg, and 3–6 mg/kg for 6, 8, and 7, respectively. Tumor stasis at 2 mg/kg was observed for anti-CD22 6 in WSU-DLCL2. In summary, noncleavable PBD-ADCs exhibit potent activity, particularly in HER2 models.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00736&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00736" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00736&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00736" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00736&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00736" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00736&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00736&amp;href=/doi/10.1021/acs.jmedchem.7b00736" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b00736" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b00736" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b00736%26sid%3Dliteratum%253Aachs%26pmid%3D29112410%26genre%3Darticle%26aulast%3DGregson%26date%3D2017%26atitle%3DPyrrolobenzodiazepine%2BDimer%2BAntibody%25E2%2580%2593Drug%2BConjugates%253A%2BSynthesis%2Band%2BEvaluation%2Bof%2BNoncleavable%2BDrug-Linkers%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D23%26spage%3D9490%26epage%3D9507%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291909" title="Immunology">Immunology</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=290975" title="Biopolymers">Biopolymers</a>,</li><li><a href="/action/doSearch?ConceptID=292425" title="Oligomers">Oligomers</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/23" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/jmcmar.2017.60.issue-23/20171214/jmcmar.2017.60.issue-23.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/medium/jm-2017-00736q_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00736&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Three rationally designed pyrrolobenzodiazepine (PBD) drug-linkers have been synthesized via intermediate <b>19</b> for use in antibody–drug conjugates (ADCs). They lack a cleavable trigger in the linker and consist of a maleimide for cysteine antibody conjugation, a hydrophilic spacer, and either an alkyne (<b>6</b>), triazole (<b>7</b>), or piperazine (<b>8</b>) link to the PBD. In vitro IC<sub>50</sub> values were 11–48 ng/mL in HER2 3+ SK-BR-3 and KPL-4 (<b>7</b> inactive) for the anti-HER2 ADCs (HER2 0 MCF7, all inactive) and 0.10–1.73 μg/mL (<b>7</b> inactive) in CD22 3+ BJAB and WSU-DLCL2 for anti-CD22 ADCs (CD22 0 Jurkat, all inactive at low doses). In vivo antitumor efficacy for the anti-HER2 ADCs in Founder 5 was observed with tumor stasis at 0.5–1 mg/kg, 1 mg/kg, and 3–6 mg/kg for <b>6</b>, <b>8</b>, and <b>7</b>, respectively. Tumor stasis at 2 mg/kg was observed for anti-CD22 <b>6</b> in WSU-DLCL2. In summary, noncleavable PBD-ADCs exhibit potent activity, particularly in HER2 models.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02847" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02847" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">There is a great deal of pharmaceutical industry interest in the development of antibody–drug conjugates (ADCs) for the treatment of cancer.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The majority of ADCs have a common design concept that generally consists of three variable parts: a tumor antigen targeting monoclonal antibody, a covalent linking group, and a cytotoxic warhead.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Two ADCs have been on the market for several years (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>): trastuzumab emtansine (<b>1</b>, HER2 [human epidermal growth factor receptor 2] targeting, noncleavable linker, emtansine warhead) and brentuximab vedotin (<b>2</b>, CD30 targeting, cleavable dipeptide linker, self-immolative <i>p</i>-aminobenzyl [PAB] spacer, monomethyl auristatin E warhead).<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/medium/jm-2017-00736q_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0001.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of marketed ADC drug-linkers trastuzumab emtansine (<b>1</b>) and brentuximab vedotin (<b>2</b>) and a standalone PBD dimer and PBD (<b>3</b> and <b>4</b>)/IBD (<b>5</b>) ADC drug-linkers in clinical trials and development. Notable PBD atom numbers are shown in <b>3</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00736&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">At present there are >60 ADCs<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a> in clinical trials and several of these contain the pyrrolo[2,1-<i>c</i>][1,4]benzodiazepine (PBD) ring system as the cytotoxic component of the ADC (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> PBDs were originally discovered in the 1960s and a number of natural products containing the ring system were isolated from various <i>Streptomyces</i> species.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> The mode of antitumor action was later established and shown to involve sequence-selective alkylation in the minor groove of DNA, where an N2 of guanine forms a covalent bond with the electrophilic N10/C11 imine on the PBD.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Advances in PBD synthesis enabled the preparation of many synthetic derivatives including dimeric DNA cross-linking PBDs with extended base sequence recognition capability and increased cytotoxic potency.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> One such PBD dimer, SJG-136, was evaluated as a standalone agent in phase I/II clinical trials for cancer.<a onclick="showRef(event, 'ref5 ref8'); return false;" href="javascript:void(0);" class="ref ref5 ref8">(5, 8)</a></div><div class="NLM_p">With the resurgence of interest in ADC technology, it became apparent that potent PBD dimers were ideal candidates for the cytotoxic component. The number of potential chemical linking positions in PBDs offers great flexibility for antibody connection, and this is apparent in the two PBD drug-linker molecules [<b>3</b> (SGD1910)<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9, 10)</a> and <b>4</b> (SG3249),<a onclick="showRef(event, 'ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13">(11-13)</a><a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>] which feature in numerous ADCs being evaluated in clinical trials.<a onclick="showRef(event, 'ref14 ref15 ref16 ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16 ref17 ref18 ref19">(14-19)</a><b>3</b> is linked via the C2 position of the PBD and <b>4</b> via the N10 position and to the antibody through a maleimide–cysteine connection. Both molecules contain a dipeptide (valine–alanine) trigger that is cleaved by cathepsin in the lysosome. A self-immolative PAB spacer is necessary in <b>4</b> to liberate the bis-imine DNA cross-linking PBD dimer upon catabolism of the ADC, while the PEG group aids water solubility. An indolobenzodiazepine (IBD) <b>5</b> (IMGN779) is also in clinical development as an ADC drug-linker and is linked to the antibody through an aryl tether in the IBD.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Again, the linkage in <b>5</b> is cleavable (disulfide trigger) but it is linked to the antibody through a lysine connection.</div><div class="NLM_p">Given that a noncleavable linker is employed in the approved drug <b>1</b>, we wanted to apply this notion to the PBD dimer platform and envisaged that linking through an aryl tether would provide a symmetrical molecule and facilitate the possibility of a noncleavable linkage to an antibody. A noncleavable linker similar to that of <b>1</b> could give active metabolites from lysosomal antibody degradation that may be less membrane permeable and decrease potential toxicities in neighboring healthy tissue through lack of bystander effect.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Another motive for investigating noncleavable PBD-ADCs was that although dipeptide cleavable linkers are stable in human and primate plasma models, some are unstable in rodent plasma.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Therefore, premature drug release prior to internalization may affect efficacy and tolerability data when assessing cleavable ADCs in rodents at the preclinical stage.</div><div class="NLM_p">As proof of principle for the novel noncleavable ADCs, HER2 (found in many solid tumors) and CD22 (found in many hematological cancers) were attractive antigen targets to investigate. There are several next generation anti-HER2 ADCs in development including topoisomerase 1 inhibitor-based<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> and duocarmycin-based payloads<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> and a biparatopic ADC containing a tubulysin warhead.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> For CD22, inotuzumab ozogamicin has demonstrated promising clinical activity and has recently received FDA approval for patients with relapsed or refractory acute lymphoblastic leukemia.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> We report molecular modeling, synthesis, and efficacy evaluation of the first examples of noncleavable anti-HER2 (trastuzumab, 4D5) and anti-CD22 PBD ADCs based on three drug-linker molecules <b>6</b>, <b>7</b>, and <b>8</b> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). The compounds described here consisted of an alkyne (<b>6</b>), triazole (<b>7</b>), or piperazine (<b>8</b>) incorporated in the PBD aryl tether and a maleimide connecting group for site-specific antibody cysteine conjugation. A PEG spacer was included in the linkers to enhance conjugation solubility in aqueous media. These molecules were accessible from the key iodoaryl intermediate <b>19</b> using Sonogashira, click, or Buchwald chemistry.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/medium/jm-2017-00736q_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0002.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. PBD dimer ADCs evaluated in this study. The drugs were conjugated to either anti-HER2 (thio Hu anti-HER2 4D5 HC-A118C) or anti-CD22 (thio Hu anti-CD22 10F4v3 HC-A118C) cysteine engineered antibodies.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00736&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The belief was the active drugs released from ADCs of <b>6</b>, <b>7</b>, and <b>8</b> would be cysteine adducts, and this hypothesis was based on published evidence for other noncleavable ADCs: In the case of marketed noncleavable ADC <b>1</b>, catabolism in the lysosome yields the released drug as a lysine adduct of the cytotoxin emtansine;<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27, 28)</a> similarly the noncleavable ADC cAC10-maleimidocaproyl-monomethylauristatin F releases a cysteine adduct of monomethylauristatin F.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27571" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27571" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Molecular Modeling</h3><div class="NLM_p">Previous studies have shown that PBD dimer <b>4a</b>, containing a pentyldioxy tether, efficiently forms DNA interstrand cross-links in a sequence-dependent fashion and exhibited subnanomolar antiproliferative activities against a panel of cancer cell lines (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>a).<a onclick="showRef(event, 'ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32">(30-32)</a> On the basis of the solution structure of a PBD monomer covalently bound in a standard B-DNA helix (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2KTT">2KTT</a><a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a>), we modeled how PBD dimers, including <b>4a</b>, would bind in a 10-nucleotide long DNA duplex (5′-AACCATCGTT-3′). In a similar fashion to the pentyl tether in <b>4a</b>, modeling predicted that released linker-cysteine adducts containing a 1,3-bismethylbenzene tether would fit equally as well into the DNA minor groove (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>b). Furthermore, modeling suggested that substitution at the 5-position of the benzene tether could directly protrude out of the minor groove without interfering with the DNA backbone and provide a novel way of linking a symmetrical PBD dimer to the antibody. Candidate noncleavable drug-linkers were evaluated in terms of their steric and electrostatic interactions complementary to the minor groove of DNA (particularly the phosphate backbone), and their conformational preferences. The search identified three diverse scaffolds that contain an alkyne, a triazole, or a piperazine moiety, respectively (<b>6</b>, <b>7</b>, and <b>8</b> in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). For example, in the model of compound <b>6</b> bound to DNA (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>c and <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>d), two covalent bonds (bond length 1.47–1.49 Å) between the C11/C11′ of the PBD and the exocyclic N2 atoms of two deoxyguanines, separated by four base pairs on opposing DNA strands, serve to anchor the PBD dimer snugly inside the minor groove. Potential hydrogen bonds between the N10 of the PBD and an adjacent DNA base may also contribute to binding. Alkyne substitution on the central benzene allows a tether linker to reach above the phosphate rim of the DNA minor groove. The rest of the linker provides ample separation between the antibody attachment point (maleimide–cysteine, <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>) and the DNA minor groove. Assuming the ethylene glycol moieties adopt an energetically favored gauche conformation,<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> the separation was estimated to be >10 Å. For drug-linker compounds <b>7</b> and <b>8</b>, the triazole and piperazine moieties were predicted to be largely coplanar with the benzene tether due to conjugation and were well accommodated in the DNA minor groove (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>e and <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>f). A similar separation of the DNA and the antibody point for that observed with <b>6</b> was also realized for <b>7</b> and <b>8</b>.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/medium/jm-2017-00736q_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0003.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (a) Structure of pentyldioxy tethered PBD dimer <b>4a</b>. (b) Schematic representation of an aryl tether PBD dimer bound to 10-nucleotide long DNA duplex (5′-AACCATCGTT-3′). (c) Model of <b>6</b> (carbon atoms in cyan) bound in the DNA minor groove, where the molecular surface of the drug-linker cysteine adduct is shown in yellow. (d) Alternative view of the same complex with <b>6</b> looking down the minor groove. The covalent bonds between C11/C11′ of the PBD and the exocyclic N2 atom of two deoxyguanines are marked by solid lines and labeled with the bond length values (in Å), and potential hydrogen bonds between N10/N10′ of the PBD and an adjacent DNA base are marked by dashed lines. (e) Model of <b>7</b> (carbon atoms in brown) bound in the DNA minor groove. (f) Model of <b>8</b> (carbon atoms in green) bound in the DNA minor groove.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00736&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">The known nitrobenzoic acid <b>9</b><a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> was converted to its corresponding acid chloride and coupled to methyl (2<i>S</i>,4<i>R</i>)-4-hydroxypyrrolidine-2-carboxylate·HCl to give amide <b>10</b> in 68% yield (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). The methyl ester was reduced to the diol <b>11</b> in 90% yield, followed by SnCl<sub>2</sub> mediated reduction of the nitro group. The crude aniline <b>12</b> was Boc protected to give <b>13</b> in 60% yield, which was followed by simultaneous ring closure and secondary alcohol oxidation to provide ketone <b>14</b>. Debenzylation by hydrogenolysis, followed by protection of the free phenol and C11-OH with THP, gave <b>16</b> which was isolated as a mixture of diastereoisomers arising from the THP group. Wittig olefination followed by selective cleavage of THP from the phenol furnished <b>18</b>, in which the C11 THP group was still required to prevent racemization at C11a<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36, 37)</a> during the subsequent dimerization step. A DMF solution of known 1,3-bis(bromomethyl)-5-iodobenzene<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> (obtained in two steps<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> by LiBH<sub>4</sub> reduction and then Appel halogenation from commercially available dimethyl 5-iodoisophthalate) was reacted at 60 °C with 2 equiv of phenol <b>18</b> in the presence of K<sub>2</sub>CO<sub>3</sub> and TBAI to provide the key iodoaryl intermediate <b>19</b> in 91% yield.</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/medium/jm-2017-00736q_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0008.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <b>19</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00736&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (1) (COCl)<sub>2</sub>, DCM, DMF, rt, 16 h; (2) methyl (2<i>S</i>,4<i>R</i>)-4-hydroxypyrrolidine-2-carboxylate·HCl, DCM, TEA, −20 °C, 16 h, 68% yield; (b) LiBH<sub>4</sub>, THF, 0 °C, 4 h, 90% yield; (c) SnCl<sub>2</sub>, MeOH, reflux, 3 h, <b>12</b> carried through crude; (d) (Boc)<sub>2</sub>O, THF, reflux, 16 h, 60% yield; (e) TEMPO, DAIB, DCM, rt, 16 h, 46% yield; (f) 10% w/<i>w</i> Pd–C, EtOH, rt, 4 h, 53% yield; (g) DHP, PTSA, EtOAc, rt, 1 h, 65% yield; (h) PPh<sub>3</sub>CH<sub>3</sub>Br, KO<sup><i>t</i></sup>Bu, THF, 0 °C to rt, 18 h, 72% yield; (i) THF, AcOH, H<sub>2</sub>O, rt, 3 h, 87% yield; (j) 1,3-bis(bromomethyl)-5-iodobenzene, K<sub>2</sub>CO<sub>3</sub>, TBAI, DMF, 60 °C, 3 h, 91% yield.</p></p></figure><div class="NLM_p">The synthesis of alkyne drug-linker <b>6</b> from intermediate <b>19</b> is shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Initially, a linear approach was explored starting with a Sonogashira reaction on <b>19</b> with propargylamine, followed by amide coupling with 1-maleimido-3-oxo-7,10,13,16-tetraoxa-4-azanonadecan-19-oic acid. This was unsatisfactory due to the instability of the resulting arylpropargylamine <b>22a</b> affording small quantities of <b>24</b> in low overall yield (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a> and <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). Instead, a more convergent approach was adopted, which involved reacting propargylamine with 2,2-dimethyl-4-oxo-3,8,11,14,17-pentaoxa-5-azaicosan-20-oic acid (<b>20</b>) to give the Sonogashira coupling partner <b>21</b> in 71% yield. The subsequent Sonogashira reaction on <b>19</b> was performed under microwave conditions and gave <b>22</b> in 70% yield. Attempted triple Boc deprotection of <b>22</b> to give <b>23b</b> with 95% TFA/H<sub>2</sub>O was unsuccessful and instead resulted in polymerization using these conditions. Therefore, selective primary <i>N</i>-Boc deprotection was investigated as an alternative approach.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> This involved a two-stage process where the Boc carbamate was converted to a TBS carbamate followed by TBAF cleavage to reveal the desired amine. Although the Boc removal was not as selective as anticipated (side products <b>23a</b> and <b>23b</b> resulting from secondary <i>N</i>-Boc cleavage were observed by LC–MS), recovery was respectable and crude material was carried through to the next step. Amine <b>23</b> (and side products <b>23a</b> and <b>23b</b>) was coupled to <i>N</i>-maleoyl-β-alanine to provide a mixture of predominantly <b>24</b>, plus <b>24a</b> and <b>6</b>. Treatment with 95% TFA afforded drug-linker <b>6</b> in 60% yield over the four steps.</div><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/medium/jm-2017-00736q_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0009.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <b>6</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00736&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) propargylamine, EDCI, DCM, rt, 16 h, 71% yield; (b) <b>19</b>, Pd(PPh<sub>3</sub>)<sub>4</sub>, CuI, diethylamine, DMF, 4 Å molecular sieves, microwave at 100 °C, 26 min, 70% yield; (c) (1) TBSOTf, 2,6-lutidine, DCM, rt, 16 h; (2) TBAF, THF, rt, 1 h, <b>23</b> carried through crude; (d) EDCI, <i>N</i>-maleoyl-β-alanine, DCM, rt, 3 h, <b>24</b> carried through crude; (e) 95% TFA/H<sub>2</sub>O, 0 °C, 1 h, 60% yield from <b>22</b> (in 4 steps).</p></p></figure><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/medium/jm-2017-00736q_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0004.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Structures of compounds to assist discussion of <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00736&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The synthesis of triazole-linked drug-linker <b>7</b> is shown in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. Alkyne <b>25</b> was obtained in 95% yield using Sonogashira on <b>19</b> under microwave conditions at 100 °C, and subsequent TMS cleavage with K<sub>2</sub>CO<sub>3</sub> gave click substrate <b>26</b> in 78% yield. Copper-catalyzed click reaction of <b>26</b> with 11-azido-3,6,9-trioxaundecan-1-amine provided triazole <b>27</b>. Amide coupling of <b>27</b> with 6-maleimidohexanoic acid <i>N</i>-hydroxysuccinimide ester was slow and gave precursor <b>28</b> in 45% yield. Cleavage of Boc and THP protecting groups with 95% TFA furnished <b>7</b> in 53% yield.</div><figure id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/medium/jm-2017-00736q_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0010.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of <b>7</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00736&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) TMS-acetylene, Pd(PPh<sub>3</sub>)<sub>4</sub>, CuI, diethylamine, DMF, microwave at 100 °C, 30 min, 95% yield; (b) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt, 3 h, 78% yield; (c) 11-azido-3,6,9-trioxaundecan-1-amine, CuSO<sub>4</sub>·5H<sub>2</sub>O, sodium ascorbate, <i><sup>t</sup></i>BuOH, H<sub>2</sub>O, rt, 16 h, <b>27</b> carried through crude; (d) 6-maleimidohexanoic acid <i>N</i>-hydroxysuccinimide ester, DCM, rt, 3 d, 45% yield; (e) 95% TFA/H<sub>2</sub>O, 0 °C, 1 h, 53% yield.</p></p></figure><div class="NLM_p">Buchwald chemistry<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> was chosen for installation of the piperazine in drug-linker <b>8</b>; a solution of <b>19</b> in the presence of base, Boc-protected piperazine, and RuPhos/RuPhos Pd G1 methyl <i>tert</i>-butyl ether adduct was heated at 85 °C in a sealed tube to give <b>29</b> in 34% yield (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). The formation of unwanted dehalogenated <b>19</b> was minimized by using cesium carbonate as base rather than sodium <i>tert</i>-butoxide. Simultaneous THP cleavage and triple Boc deprotection with 95% TFA gave <b>30</b>, which was carried through without purification. Finally, EDCI coupling of 1-maleimido-3-oxo-7,10,13,16-tetraoxa-4-azanonadecan-19-oic acid with <b>30</b> gave <b>8</b> in 32% yield.</div><figure id="sch4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/medium/jm-2017-00736q_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0011.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of <b>8</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00736&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>tert</i>-butyl piperazine-1-carboxylate, RuPhos Pd G1 methyl <i>tert</i>-butyl ether adduct, RuPhos, Cs<sub>2</sub>CO<sub>3</sub>, THF, 85 °C, 4 h, 34% yield; (b) 95% TFA/H<sub>2</sub>O, 0 °C, 30 min, <b>30</b> carried through crude; (c) EDCI, 1-maleimido-3-oxo-7,10,13,16-tetraoxa-4-azanonadecan-19-oic acid, DCM, rt, 2 h, 32% yield.</p></p></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Antibody Conjugation</h3><div class="NLM_p">The maleimide PBD drug-linkers <b>6</b>, <b>7</b>, and <b>8</b> were conjugated to mutated anti-HER2 and anti-CD22 antibodies at position HC-A118C. Site specific cysteine engineered antibodies were chosen which contain engineered cysteines to give a theoretical drug/antibody ratio (DAR) of 2 for each ADC.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Average DAR, aggregation analysis, and percentage remaining free drug for the six ADCs are shown in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>. In summary, the maleimides were reacted in 6- to 8-fold molar excess with deblocked, reoxidized, cysteine engineered antibodies. The crude ADCs were then purified by cation exchange chromatography and characterized by UV spectroscopy to determine protein concentration. Analytical size-exclusion chromatography (SEC) was used for aggregation analysis and LC–MS determined DAR.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Analysis of ADCs</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">PBD</th><th class="colsep0 rowsep0" align="center">mAb</th><th class="colsep0 rowsep0" align="center" char=".">DAR<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">% monomer<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char=".">% free drug<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">anti-HER2<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">1.9</td><td class="colsep0 rowsep0" align="char" char=".">95.6</td><td class="colsep0 rowsep0" align="char" char="."><0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">anti-CD22<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">1.7</td><td class="colsep0 rowsep0" align="char" char=".">98.6</td><td class="colsep0 rowsep0" align="char" char="."><0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">anti-HER2<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">1.8</td><td class="colsep0 rowsep0" align="char" char=".">95.6</td><td class="colsep0 rowsep0" align="char" char="."><0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">anti-CD22<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">1.8</td><td class="colsep0 rowsep0" align="char" char=".">95.0</td><td class="colsep0 rowsep0" align="char" char="."><0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">anti-HER2<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">1.8</td><td class="colsep0 rowsep0" align="char" char=".">95.6</td><td class="colsep0 rowsep0" align="char" char="."><1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">anti-CD22<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="char" char=".">1.8</td><td class="colsep0 rowsep0" align="char" char=".">94.2</td><td class="colsep0 rowsep0" align="char" char="."><3.0</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">DAR = drug/antibody ratio determined by LC–MS.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Thio Hu anti-HER2 4D5 HC-A118C.</p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last">Thio Hu anti-CD22 10F4v3 HC-A118C.</p></div><div class="footnote" id="t1fn4"><sup>d</sup><p class="last">Determined by SEC.</p></div><div class="footnote" id="t1fn5"><sup>e</sup><p class="last">Determined by LC–MS.</p></div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> In Vitro Cytotoxicity</h3><div class="NLM_p">The anti-HER2 ADCs were evaluated for their in vitro cytotoxicity in three breast cancer cell lines with differing levels of HER2 expression based on immunohistochemistry: MCF7 (HER2 0), KPL-4 (HER2 3+), and SK-BR-3 (HER2 3+). As anticipated, the anti-HER2 ADCs displayed no activity in the HER2 0 MCF7 negative<a onclick="showRef(event, 'ref28 ref43'); return false;" href="javascript:void(0);" class="ref ref28 ref43">(28, 43)</a> control cell line (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>c, <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). <b>8</b> and <b>6</b> both showed good potency in HER2 3+ KPL-4 with IC<sub>50</sub> values of 28 ng/mL and 48 ng/mL, respectively; <b>7</b> was inactive in KPL-4 (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>b). All three anti-HER2 ADCs showed potent activity in HER2 3+ SK-BR-3 line with IC<sub>50</sub> values of 11, 15, and 23 ng/mL for <b>6</b>, <b>8</b>, and <b>7</b> (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>a), respectively. The control anti-CD22 ADC for <b>8</b> was inactive across all lines (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>a–c).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. In Vitro Cytotoxicity Data in HER2 Models</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">IC<sub>50</sub> (ng/mL)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">PBD</th><th class="colsep0 rowsep0" align="center">mAb</th><th class="colsep0 rowsep0" align="center">MCF7<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">KPL-4<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">SK-BR-3<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">anti-HER2<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">48.25</td><td class="colsep0 rowsep0" align="left">11.14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">anti-HER2<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">22.90</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">anti-HER2<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">28.20</td><td class="colsep0 rowsep0" align="left">15.00</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">anti-CD22<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">>10000</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">Thio Hu anti-HER2 4D5 HC-A118C.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">Thio Hu anti-CD22 10F4v3 HC-A118C.</p></div><div class="footnote" id="t2fn3"><sup>c</sup><p class="last">HER2 0.</p></div><div class="footnote" id="t2fn4"><sup>d</sup><p class="last">HER2 3+.</p></div></div></div><figure id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/medium/jm-2017-00736q_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0005.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. In vitro cytotoxicity data for the PBD ADCs in HER2 models (a) SK-BR-3, (b) KPL-4, and (c) MCF7.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00736&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Similarly, the anti-CD22 ADCs were tested in two CD22 3+ lymphatic lines (BJAB and WSU-DLCL2) and one CD22 0 hematological line (Jurkat). The anti-CD22 ADCs and anti-HER2 controls were inactive at low doses in the CD22 0 line Jurkat, which was as expected (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>c, <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). Anti-CD22 <b>6</b> and <b>8</b> gave IC<sub>50</sub> values of 0.10 and 0.18 μg/mL, respectively, in BJAB cells and 1.22 and 1.73 μg/mL, respectively, in WSU-DLCL2 cells (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>a,b). Anti-CD22 <b>7</b> and the control anti-HER2 ADCs did not show any activity in the CD22 3+ lines.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. In Vitro Cytotoxicity Data in CD22 Models</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">IC<sub>50</sub> (μg/mL)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">PBD</th><th class="colsep0 rowsep0" align="center">mAb</th><th class="colsep0 rowsep0" align="center">Jurkat<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">WSU-DLCL2<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">BJAB<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">anti-CD22<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">1.22</td><td class="colsep0 rowsep0" align="left">0.10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">anti-CD22<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">anti-CD222<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">1.73</td><td class="colsep0 rowsep0" align="left">0.18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">anti-HER2<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">anti-HER2<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">anti-HER2<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">>20</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">Thio Hu anti-CD22 10F4v3 HC-A118CThio.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">Hu anti-HER2 4D5 HC-A118C.</p></div><div class="footnote" id="t3fn3"><sup>c</sup><p class="last">CD22 0.</p></div><div class="footnote" id="t3fn4"><sup>d</sup><p class="last">CD22 3+.</p></div></div></div><figure id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/medium/jm-2017-00736q_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0006.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. In vitro cytotoxicity data for the PBD ADCs in CD22 models (a) BJAB, (b) WSU-DLCL2, and (c) Jurkat.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00736&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> In Vivo Efficacy</h3><div class="NLM_p">Investigation of the in vivo single-dose efficacy for the three noncleavable PBDs was performed in the Founder 5 (Fo5) mammary tumor transplant model (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>a–c, <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>) for the anti-HER2 conjugates and in the WSU-DLCL2 lymphoma xenograft model (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>d, <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>) for the anti-CD22 ADCs. The anti-CD22 ADCs acted as controls in the Fo5 experiments, and similarly the anti-HER2 compounds were used as negative controls for WSU-DLCL2. The three anti-HER2 ADCs showed good efficacy in the Fo5 model which was dose-responsive. Anti-HER2 <b>6</b> and <b>8</b> were tested at 0.3, 1, and 3 mg/kg, and the doses to give tumor stasis were 0.3–1 mg/kg and 1 mg/kg, respectively (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>a,b). In the cases of <b>6</b> and <b>8</b>, the control anti-CD22 ADCs at 3 mg/kg did show activity at a similar level to anti-HER2 <b>6</b> at 0.3 mg/kg and anti-HER2 <b>8</b> at 1 mg/kg. From the in vitro experiments, anti-HER2 <b>7</b> was less active, so it was tested at 3 and 6 mg/kg in Fo5 and the dose to give tumor stasis was 3–6 mg/kg; however, there was more of a differential from the control ADC at 6 mg/kg (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>c). Anti-CD22 <b>6</b> was tested at 0.5 and 2 mg/kg in WSU-DLCL2 and showed good efficacy at the higher dose level versus the anti-HER2 control at 2 mg/kg (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>d). Anti-CD22 <b>7</b> did not show any activity at 5 mg/kg; similarly anti-CD22 <b>8</b> did not show efficacy at 0.5 mg/kg in WSU-DLCL2.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. In Vivo Efficacy Summary</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">tumor stasis dose (mg/kg)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">PBD</th><th class="colsep0 rowsep0" align="center">Fo5<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">WSU-DLCL2<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">0.3–1</td><td class="colsep0 rowsep0" align="left">2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">3–6</td><td class="colsep0 rowsep0" align="left">>5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">>0.5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">Thio Hu anti-HER2 4D5 HC-A118C.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">Thio Hu anti-CD22 10F4v3 HC-A118C.</p></div></div></div><figure id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/medium/jm-2017-00736q_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0007.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. In vivo efficacy data for the PBD ADCs, single dose at day 0: (a) <b>6</b>, (b) <b>8</b>, and (c) <b>7</b> in the Fo5 model and (d) <b>6</b>, <b>7</b>, and <b>8</b> in the WSU-DLCL2 model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00736&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48435" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48435" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Noncleavable linkers in ADCs are known to change the active metabolite and thus can greatly influence the safety and efficacy profiles for this class of drugs. As the parameters that make up a successful ADC are currently not well-understood and are dependent on the antigen target and disease indication, the largest possible toolbox of linker types for a given drug class is of great value.</div><div class="NLM_p">Six examples of PBD dimer ADCs possessing noncleavable linkers were designed and successfully synthesized. Molecular modeling studies, with a 10-nucleotide long DNA duplex (5′-AACCATCGTT-3′), suggest that linking the antibodies through aryl tethers would not have a detrimental effect on the ability of the released PBD cysteine catabolites to bind in the minor groove of DNA. In vitro cytotoxicity evaluation showed the anti-HER2 PBD-ADCs to have potent activity in the HER2 3+ cell line SKBR-3 (IC<sub>50</sub> values of 11–23 ng/mL); however, a slight reduction in activity in HER2 3+ KPL-4 (IC<sub>50</sub> 28–48 ng/mL, <b>7</b> inactive) was observed. Complete abolition of cytotoxicity in the HER2 0 MCF7 line demonstrated selectivity in vitro with these ADCs for higher HER2-expressing cell lines. Similar results were obtained in the CD22 in vitro models for anti-CD22 <b>6</b> and <b>8</b> with IC<sub>50</sub> of 0.10–0.18 μg/mL in BJAB CD22 3+ cells and 1.22–1.73 μg/mL in WSU-DLCL2 CD22 3+ cells, while no activity was observed in the CD22 0 Jurkat line for anti-CD22 <b>6</b>, <b>7</b>, and <b>8</b> at low doses. Anti-CD22 <b>7</b> had poor activity against CD22 3+ expressing lines. For both HER2 and CD22 models, negative control ADCs did not display activity in the 3+ expressing cell lines.</div><div class="NLM_p">The anti-HER2 ADCs of the three compounds showed promising in vivo antitumor efficacy in the HER2-expressing Fo5 breast model. The rank order of potency from the in vitro studies was reflected in vivo with HER2 conjugates of <b>6</b> and <b>8</b> requiring similar doses to reach tumor stasis (0.3–1 mg/kg for <b>6</b> and 1 mg/kg for <b>8</b>), with <b>7</b> being less active (3–6 mg/kg). In vivo activity in the Fo5 model with the control anti-CD22 ADCs was more pronounced with <b>6</b> and <b>8</b> than <b>7</b>, which could simply be due to <b>7</b> being less efficacious. However, it should be noted that the targeted anti-HER2 ADC of <b>6</b> was active at about <sup>1</sup>/<sub>10</sub> the dose of control and in the case of <b>8</b> about <sup>1</sup>/<sub>3</sub> the dose of control. In the CD22 model WSU-DLCL2, only anti-CD22 <b>6</b> showed activity (2 mg/kg) compared to negative control HER2 (2 mg/kg) at the doses tested.</div><div class="NLM_p">Overall, the ADCs performed better in HER2 targeted models than CD22 in vitro and in vivo; for both targets ADCs derived from alkyne <b>6</b> and piperazine <b>8</b> were more potent than triazole <b>7</b>. Given the modeling suggests steric factors would be similar between the drug-linkers, we wondered whether polarity may explain the difference in activity for <b>7</b>. The calculated (MarvinSketch 15.1.12.0) log <i>D</i> values at pH 7.4 of the three drug-linkers were 3.49 (<b>7</b>), 1.72 (<b>6</b>), and 1.48 (<b>8</b>), which suggests <b>7</b> would penetrate cell membranes better than <b>6</b> and <b>8</b> and thus be more potent; however, the reverse was observed with <b>6</b> and <b>8</b> being the most active. The multifactorial nature of ADC constructs (e.g., linker type, polarity, warhead potency, internalization potential, ability to reach drug target, etc.) make it difficult to discriminate in terms of biological activity between three drug-linker molecules which broadly come in the same class. Structure–activity relationships of PBDs<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> have determined how to fine-tune PBD warhead activity, but the effects of the linking group from the aryl tether of a PBD-ADC on biological activity are not clearly understood at the present time.</div><div class="NLM_p">From a chemistry perspective, the syntheses of <b>7</b> and <b>8</b> were facile from the key iodoaryl intermediate <b>19</b>. The synthesis of <b>6</b> was the most challenging, and although the methodology was not ideal (unwanted partial secondary <i>N</i>-Boc cleavage), the recovery of material for antibody conjugation was respectable. Iodoaryl intermediates of type <b>19</b> are versatile and could be useful for the introduction of antibody linking groups using other palladium chemistries.</div><div class="NLM_p last">The data presented here support the molecular modeling hypothesis that noncleavable linking of an ADC through the aryl tether of a PBD dimer does not interfere with PBD-DNA binding and biological activity. Mode of action studies on this class of noncleavable PBD-ADCs are underway, and the results will be published elsewhere. Two PBD drug-linker molecules containing dipeptide cleavable linkers are currently being evaluated in the clinical setting.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> The work described here suggests that noncleavable PBD dimer ADCs show potential and warrant further evaluation for PBD-ADC toolbox inclusion.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08001" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08001" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Molecular Modeling</h3><div class="NLM_p last">Modeling was based on the solution structure of a PBD monomer covalently bound to a 10mer B-DNA duplex (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2KTT">2KTT</a><a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a>). The DNA sequence was mutated to 5′-AACCATCGTT-3′ to introduce two dG nucleotides at an appropriate configuration for alkylation with the PBD dimers. The C11(S) geometry was adopted for all PBD molecules studied, as this stereochemistry is known to lead to energetically favored adducts with the exocyclic C2-NH<sub>2</sub> group of an embedded guanine in the context of a B-DNA duplex. The length of the covalent bond between the C11 of the PBD and the exocylic amino N atom of deoxyguanine was constrained to a value between 1.47 and 1.49 Å, consistent with the observations from PBD structure <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2KTT">2KTT</a>. Local minimizations of the complex including the above constraints were performed in MOE (version 2015, Chemical Computing Group) using the default parameters. The models were visually examined, and manual adjustments were made as needed in MOE to correct some artifacts of the local minimization.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Synthesis of Compounds</h3><div class="NLM_p">Fine chemicals and reaction solvents were purchased from Sigma-Aldrich, and chromatography solvents were bought from Fisher Scientific. MAL-dPEG<sub>4</sub>-CO<sub>2</sub>H (1-maleimido-3-oxo-7,10,13,16-tetraoxa-4-azanonadecan-19-oic acid) and <i>t</i>-Boc-<i>N</i>-amido-dPEG<sub>4</sub>-acid (<b>20</b>, 2,2-dimethyl-4-oxo-3,8,11,14,17-pentaoxa-5-azaicosan-20-oic acid) were obtained from Quanta BioDesign, Ltd. Optical rotations were measured on an ADP 220 polarimeter (Bellingham Stanley Ltd.) and concentrations (<i>c</i>) are given in g/100 mL. IR spectra were recorded on a Bruker Alpha Platinum-ATR. <sup>1</sup>H and <sup>13</sup>C NMR spectra were acquired at 300 K using a Bruker Avance NMR spectrometer at 400 and 100 MHz, respectively. Chemical shifts are reported relative to TMS (δ = 0.0 ppm), and signals are designated as s (singlet), d (doublet), t (triplet), dd (doublet of doublets), or m (multiplet), with coupling constants given in hertz (Hz). TLC was performed on silica gel aluminum plates (Merck 60, F<sub>254</sub>), and flash chromatography utilized silica gel (Merck 60, 230–400 mesh).</div><div class="NLM_p">The LC–MS conditions for compounds in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a>, <a class="ref internalNav" href="#sch3" aria-label="3">3</a>, and <a class="ref internalNav" href="#sch4" aria-label="4">4</a> were as follows: Waters Alliance 2695 HPLC, Waters 2996 PDA, and Waters Micromass ZQ in electrospray mode using a mobile phase of water (A, 0.1% formic acid) and acetonitrile (B, 0.1% formic acid) with a Phenomenex Onyx Monolithic C18 50 mm × 4.60 mm column at 50 °C. Initial composition was 5% B for 1.0 min, then gradient from 5% B to 95% B over 3 min, held for 30 s at 95% B, then returned to 5% B in 18 s and held for 12 s; the total method run time was 5 min at a flow rate of 3.0 mL/min. Detection range was between 220 and 400 nm.</div><div class="NLM_p">The LC–MS conditions for compounds in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a> and <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a> were as follows: Shimadzu Nexera/Prominence LC–MS 2020 in electrospray mode using a mobile phase of water (A, 0.1% formic acid) and acetonitrile (B, 0.1% formic acid) with a Waters Acquity UPLC BEH Shield RP18 1.7 μm, 2.1 mm × 50 mm column at 50 °C. Initial composition was 5% B for 25 s, then gradient from 5% B to 100% B over 1 min 35 s, held for 50 s at 100% B, then returned to 5% B in 5 s and held for 5 s; the total method run time was 3.0 min at a flow rate of 0.8 mL/min. Detection was at 214 and 254 nm.</div><div class="NLM_p last">Accurate mass measurements were performed using a Q-Exactive Orbitrap (ThermoFisher Scientific) with mass spectrometry performed on a ThermoQuest Navigator (Thermo Electron). Electrospray spectra were obtained at 20–30 V using 50% acetonitrile in water and 0.1% formic acid as a solvent. The instrument was calibrated with [Glu<sup>1</sup>]-fibrinopeptide B immediately prior to measurement, and accurate mass calculations were performed using Xcalibur 3.1 software.</div></div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> <i>N</i>-(3-(3,5-Bis((((<i>S</i>)-7-methoxy-2-methylene-5-oxo-2,3,5,11a-tetrahydro-1<i>H</i>-pyrrolo[2,1-<i>c</i>][1,4]benzodiazepin-8-yl)oxy)methyl)phenyl)prop-2-yn-1-yl)-1-(3-(2,5-dioxo-2,5-dihydro-1<i>H</i>-pyrrol-1-yl)propanamido)-3,6,9,12-tetraoxapentadecan-15-amide (<b>6</b>)</h3><div class="NLM_p last">A solution of 95:5 v/v TFA/H<sub>2</sub>O (5 mL) was added to a crude sample of the Boc/THP-protected compound <b>24</b> (∼470 mg, 0.32 mmol) at 0 °C (ice/acetone). After stirring at 0 °C for 1 h, the reaction was deemed complete as judged by LC–MS, desired product peak at retention time 1.32 min (ES<sup>+</sup>) <i>m</i>/<i>z</i> 1070 [M + H]<sup>+•</sup>. The reaction mixture was kept cold and added dropwise to a chilled saturated aqueous solution of NaHCO<sub>3</sub> (120 mL). The mixture was extracted with DCM (3 × 40 mL), and the combined organic layers were washed with brine (50 mL), dried (MgSO<sub>4</sub>), filtered, and the solvent was removed by rotary evaporation under reduced pressure to provide the crude product. Purification by flash chromatography (100% CHCl<sub>3</sub> to 96% CHCl<sub>3</sub>/MeOH) gave <b>6</b> as an orange foam (204 mg, 0.19 mmol, 60% yield in four steps from <b>22</b>): [α]<sup>21</sup><sub>D</sub> +351° (<i>c</i> 0.47, CHCl<sub>3</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.66 (d, 2H, <i>J</i> = 4.4 Hz), 7.52 (s, 2H), 7.45–7.40 (m, 3H), 6.98–6.94 (m, 1H), 6.80 (s, 2H), 6.66 (s, 2H), 6.55–6.50 (m, 1H), 5.22–5.07 (m, 8H), 4.30–4.22 (m, 6H), 3.96 (s, 6H), 3.91–3.85 (m, 2H), 3.82 (t, 2H, <i>J</i> = 7.2 Hz), 3.76 (t, 2H, <i>J</i> = 5.8 Hz), 3.65–3.43 (m, 14H), 3.38 (dd, 2H, <i>J</i> = 5.3, 10.2 Hz), 3.16–3.08 (m, 2H), 2.94 (d, 2H, <i>J</i> = 15.7 Hz), 2.54–2.44 (m, 4H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 171.2, 170.5, 169.8, 164.6, 162.8, 150.3, 148.0, 141.6, 140.6, 137.1, 134.2, 130.2, 125.9, 123.7, 120.4, 111.7, 111.2, 109.4, 86.4, 82.2, 70.5, 70.3, 70.2, 70.1, 69.7, 67.1, 56.2, 53.8, 51.4, 39.3, 36.8, 35.5, 34.5, 34.3, 29.7; IR (CHCl<sub>3</sub>) 3311, 3082, 3004, 2868, 1706, 1653, 1623, 1601, 1507, 1453, 1433, 1375, 1245, 1094, 1003, 874, 827, 793, 695 cm<sup>–1</sup>; MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> (relative intensity) 1070 ([M + H]<sup>+•</sup>, 100). HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>57</sub>H<sub>63</sub>N<sub>7</sub>O<sub>14</sub> + H<sup>+</sup> [M + H<sup>+</sup>], 1070.450 58. Found: 1070.449 83.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> <i>N</i>-(2-(2-(2-(2-(4-(3,5-bBs((((<i>S</i>)-7-methoxy-2-methylene-5-oxo-2,3,5,11a-tetrahydro-1<i>H</i>-pyrrolo[2,1-<i>c</i>][1,4]benzodiazepin-8-yl)oxy)methyl)phenyl)-1<i>H</i>-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)ethyl)-6-(2,5-dioxo-2,5-dihydro-1<i>H</i>-pyrrol-1-yl)hexanamide (<b>7</b>)</h3><div class="NLM_p last">A solution of 95:5 v/v TFA/H<sub>2</sub>O (5 mL) was added to a sample of the Boc/THP-protected compound <b>28</b> (428 mg, 0.29 mmol) at 0 °C (ice/acetone). After stirring at 0 °C for 1 h, the reaction was deemed complete as judged by LC–MS, desired product peak at retention time 2.72 min (ES+) <i>m</i>/<i>z</i> 1055 [M + H]<sup>+•</sup>. The reaction mixture was kept cold and added dropwise to a chilled saturated aqueous solution of NaHCO<sub>3</sub> (100 mL). The mixture was extracted with DCM (3 × 30 mL), and the combined organic layers were washed with H<sub>2</sub>O (20 mL), brine (40 mL), dried (MgSO<sub>4</sub>), filtered, and the solvent was removed by rotary evaporation under reduced pressure to provide the crude product. Purification by flash chromatography (100% CHCl<sub>3</sub> to 96% CHCl<sub>3</sub>/MeOH) gave <b>7</b> as an orange foam (163 mg, 0.15 mmol, 53% yield): [α]<sup>21</sup><sub>D</sub> +441° (<i>c</i> 0.15, CHCl<sub>3</sub>); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 8.00 (s, 1H), 7.88 (d, 2H, <i>J</i> = 1.1 Hz), 7.65 (d, 2H, <i>J</i> = 4.4 Hz), 7.52 (s, 2H), 7.50 (br s, 1H), 6.85 (s, 2H), 6.66 (s, 2H), 6.10–6.05 (m, 1H), 5.27–5.16 (m, 8H), 4.59 (t, 2H, <i>J</i> = 5.0 Hz), 4.28 (s, 4H), 3.95–3.85 (m, 10H), 3.65–3.46 (m, 12H), 3.39–3.35 (m, 2H), 3.11 (dd, 2H, <i>J</i> = 9.1, 15.9 Hz), 2.93 (d, 2H, <i>J</i> = 15.8 Hz), 2.12 (t, 2H, <i>J</i> = 7.5 Hz), 1.66–1.53 (m, 4H), 1.32–1.24 (m, 2H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 172.7, 170.8, 164.7, 162.7, 150.5, 148.1, 147.0, 141.7, 140.6, 137.5, 134.0, 131.7, 125.8, 124.5, 121.3, 120.4, 111.7, 111.4, 109.4, 70.7, 70.6, 70.5 (x 2), 70.1, 69.8, 69.5, 56.2, 53.8, 51.4, 50.4, 39.1, 37.7, 36.3, 35.5, 28.3, 26.4, 25.1; IR (CHCl<sub>3</sub>) 3313, 3084, 2934, 2864, 1703, 1601, 1505, 1454, 1432, 1370, 1246, 1127, 1095, 1052, 1001, 875, 827, 793, 695 cm<sup>–1</sup>; MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> (relative intensity) 1055 ([M + H]<sup>+•</sup>, 60), 527 (100). HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>56</sub>H<sub>63</sub>N<sub>9</sub>O<sub>12</sub> + H<sup>+</sup> [M + H<sup>+</sup>], 1054.466 89. Found: 1054.466 19.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> <i>N</i>-(15-(4-(3,5-Bis((((<i>S</i>)-7-methoxy-2-methylene-5-oxo-2,3,5,11a-tetrahydro-1<i>H</i>-pyrrolo[2,1-<i>c</i>][1,4]benzodiazepin-8-yl)oxy)methyl)phenyl)piperazin-1-yl)-15-oxo-3,6,9,12-tetraoxapentadecyl)-3-(2,5-dioxo-2,5-dihydro-1<i>H</i>-pyrrol-1-yl)propanamide (<b>8</b>)</h3><div class="NLM_p last">EDCI (1.1 equiv, 35 mg, 0.18 mmol) was added to a solution of compound <b>30</b> (1.0 equiv, 116 mg, 0.165 mmol) and MAL-dPEG<sub>4</sub>-acid (1.0 equiv, 69 mg, 0.165 mmol) in anhydrous DCM (5 mL) under an argon atmosphere. The resultant solution was stirred at room temperature for 2 h where analysis by LC–MS showed formation of desired product at retention time 2.65 min (ES<sup>+</sup>) <i>m</i>/<i>z</i> 1101 [M + H]<sup>+•</sup>. The reaction mixture was diluted with DCM (50 mL), washed with water (100 mL), saturated aqueous NaHCO<sub>3</sub> solution (100 mL), water (100 mL), brine (100 mL), dried (MgSO<sub>4</sub>), filtered, and the solvent was removed by rotary evaporation under reduced pressure to give the crude product. Purification by flash chromatography (100% CHCl<sub>3</sub> to 95% CHCl<sub>3</sub>/MeOH) gave the product <b>8</b> as a yellow glass (58 mg, 0.053 mmol, 32% yield): [α]<sup>18</sup><sub>D</sub> +628° (<i>c</i> 0.25, CHCl<sub>3</sub>); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 7.66 (d, 2H, <i>J</i> = 4.4 Hz), 7.52 (s, 2H), 6.99 (s, 1H), 6.96–6.91 (m, 2H), 6.83 (s, 2H), 6.68 (s, 2H), 6.39–6.32 (m, 1H), 5.22–5.08 (m, 8H), 4.28 (s, 4H), 3.96 (s, 6H), 3.89–3.72 (m, 8H), 3.69–3.55 (m, 14H), 3.52 (t, 2H, <i>J</i> = 5.0 Hz), 3.43–3.37 (m, 2H), 3.28–3.08 (m, 6H), 2.94 (d, 2H, <i>J</i> = 15.8 Hz), 2.67 (t, 2H, <i>J</i> = 6.7 Hz), 2.50 (t, 2H, <i>J</i> = 7.3 Hz); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 170.5, 169.9, 169.5, 164.7, 162.6, 151.6, 150.6, 148.0, 141.6, 140.6, 137.8, 134.2, 120.2, 117.9, 114.8, 111.6, 111.3, 109.4, 71.0, 70.4, 70.1, 69.8, 67.4, 56.2, 53.8, 51.4, 49.3, 49.0, 45.5, 41.4, 39.2, 35.5, 34.5, 34.4, 33.5; IR (CHCl<sub>3</sub>) 3312, 3083, 3003, 2868, 1705, 1624, 1600, 1506, 1433, 1377, 1244, 1094, 995, 874, 827, 793, 695 cm<sup>–1</sup>; MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> (relative intensity) 1101 ([M + H]<sup>+•</sup>, 35), 551 (100). HRMS (ESI): <i>m</i>/<i>z</i> calculated for C<sub>58</sub>H<sub>68</sub>N<sub>8</sub>O<sub>14</sub> + H<sup>+</sup> [M + H<sup>+</sup>], 1101.492 78. Found: 1101.492 49.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> <i>N</i>-[4-Benzyloxy-5-methoxy-2-nitrobenzoyl]-(2<i>S</i>,4<i>R</i>)-[4-hydroxypyrrolidine-2-carboxylate] (<b>10</b>)</h3><div class="NLM_p last">A catalytic amount of dry DMF (2 drops) was added to a solution of acid <b>9</b> (1.0 equiv, 5 g, 16.4 mmol) in dry DCM (70 mL) and oxalyl chloride (1.1 equiv, 1.6 mL, 2.3 g, 18.1 mmol), and then the reaction mixture was stirred overnight under a nitrogen atmosphere. The resulting solution was added dropwise to a solution of the methyl (2<i>S</i>,4<i>R</i>)-4-hydroxypyrrolidine-2-carboxylate·HCl (1.1 equiv, 5.74 g, 18.1 mmol) and TEA (3.0 equiv, 6.84 mL, 4.96 g, 49.2 mmol) in dry DCM (100 mL) at −20 °C (ethylene glycol/dry ice). The reaction mixture was allowed to warm to room temperature and stirred overnight at which point TLC (EtOAc) revealed that the reaction was complete. The mixture was washed with 1 N HCl (50 mL), water (50 mL), saturated aqueous NaHCO<sub>3</sub> (50 mL), brine (50 mL), dried (MgSO<sub>4</sub>), and filtered. The solvents were removed by rotary evaporation under reduced pressure to leave a yellow solid which was triturated with cold EtOAc to yield pure ester <b>10</b> (4.84 g, 11.2 mmol, 68% yield): [α]<sup>28</sup><sub>D</sub> −57° (<i>c</i> 0.20, CHCl<sub>3</sub>); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) (rotamers) δ 7.69 (s, 1H), 7.46–7.32 (m, 5H), 6.85 (s, 1H), 6.80 (s, 1H), 5.20 (s, 2H), 4.83 (t, 1H, <i>J</i> = 8.0 Hz), 4.59–4.52 (m, 2H), 4.49–4.42 (m, 2H), 4.20–4.09 (m, 4H), 3.97 (s, 3H), 3.93 (s, 3H), 3.80 (s, 3H), 3.75–3.71 (m, 3H), 3.53–3.49 (m, 3H), 3.47 (s, 3H), 3.18–3.10 (m, 3H), 2.45–2.10 (m, 1H), 1.38–1.22 (m, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) (rotamers) δ 172.5, 172.4, 167.0, 166.7, 154.9, 154.5, 148.3, 148.2, 137.3, 135.3, 135.2, 128.8, 128.5, 127.6, 127.3, 126.5, 109.7, 109.1, 71.4, 70.0, 69.2, 59.0, 57.2, 56.8, 56.6, 56.3, 54.6, 52.5, 52.3, 39.4, 38.0; IR (neat) 3433, 2950, 1742, 1626, 1577, 1521, 1454, 1432, 1336, 1277, 1213, 1073, 750 cm<sup>–1</sup>; MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> (relative intensity) 431 ([M + H]<sup>+•</sup>, 100).</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> <i>N</i>-[4-Benzyloxy-5-methoxy-2-nitrobenzoyl]-(2<i>S</i>,4<i>R</i>)-[4-hydroxy-2-(hydroxymethyl)pyrrolidine] (<b>11</b>)</h3><div class="NLM_p last">A solution of the ester <b>10</b> (1.0 equiv, 3.8 g, 8.83 mmol) in THF (100 mL) was cooled to 0 °C and treated with LiBH<sub>4</sub> (1.5 equiv, 0.29 g, 13.25 mmol) in portions. After stirring for 30 min at 0 °C, the reaction mixture was allowed to warm to room temperature and stirred under a nitrogen atmosphere for 4 h at which time TLC (EtOAc) revealed complete consumption of ester <b>10</b>. The mixture was cooled to 0 °C again, and water (100 mL) was carefully added followed by 1 N HCl (250 mL) which provoked vigorous effervescence. After evaporation of the THF by rotary evaporation under reduced pressure, the residue was neutralized to pH 7 with 1 N NaOH. The aqueous solution was then extracted with EtOAc (4 × 70 mL), and the combined organic layers were washed with brine (50 mL), dried (MgSO<sub>4</sub>), filtered, and evaporated by rotary evaporation under reduced pressure to furnish the pure diol <b>11</b> (3.2 g, 7.96 mmol, 90% yield), which was used in the subsequent reaction without further purification: [α]<sup>29</sup><sub>D</sub> −96° (<i>c</i> 0.15, CHCl<sub>3</sub>); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 7.74 (s, 1H), 7.50–7.29 (m, 5H), 6.86 (s, 1H), 5.20 (m, 2H), 4.61–4.46 (m, 2H), 4.38–4.30 (m, 1H), 4.04–3.85 (m, 5H), 3.82–3.70 (m, 1H), 3.20–3.11 (m, 1H), 3.39–3.25 (m, 1H), 2.28–2.09 (m, 1H), 1.99–1.85 (m, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 155, 148.2, 137.2, 135.2, 128.8, 128.5, 127.7, 127.6, 109.3, 109.1, 71.4, 69.4, 65.0, 59.9, 56.9, 56.8, 37.1; IR (neat) 3357, 2938, 1614, 1576, 1520, 1454, 1434, 1333, 1276, 1220, 1069, 1048, 1006, 730, 698, 647 cm<sup>–1</sup>; MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> (relative intensity) 403 ([M + H]<sup>+•</sup>, 100).</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> <i>N</i>-[2-Amino-4-benzyloxy-5-methoxybenzoyl]-(2<i>S</i>,4<i>R</i>)-[4-hydroxy-2-(hydroxymethyl)pyrrolidine] (<b>12</b>)</h3><div class="NLM_p last">A mixture of diol <b>11</b> (1.0 equiv, 26 g, 64.6 mmol) and SnCl<sub>2</sub>·2H<sub>2</sub>O (5.0 equiv, 72.9 g, 323 mmol) in MeOH (300 mL) was heated at reflux and the progress of the reaction monitored by TLC (EtOAc). After 3 h, the MeOH was evaporated by rotary evaporation under reduced pressure and the resulting residue was cooled and treated carefully with saturated NaHCO<sub>3</sub> (400 mL). The mixture was diluted with EtOAc (800 mL), and after 12 h stirring at room temperature the inorganic precipitate was removed by filtration through Celite. The organic layer was separated, washed with brine (100 mL), dried (MgSO<sub>4</sub>), filtered, and evaporated by rotary evaporation under reduced pressure to give a brown solid <b>12</b> which was used in the next reaction without further purification: [α]<sup>29</sup><sub>D</sub> −69° (<i>c</i> 0.13, CHCl<sub>3</sub>); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 7.36–7.29 (m, 7H), 6.78 (s, 1H), 6.26 (s, 1H), 5.10 (s, 2H), 4.60–4.47 (m, 1H), 4.72–4.26 (m, 1H), 3.85–3.52 (m, 9H), 2.19–2.06 (m, 1H), 1.82–1.70 (m, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 172.8, 151.0, 141.9, 140.0, 136.5, 128.6, 128.0, 127.1, 112.9, 112.4, 103.4, 70.7, 69.4, 37.0, 66.2, 59.0, 58.5, 57.1; IR (neat) 3358, 2939, 1619, 1589, 1512, 1455, 1432, 1408, 1263, 1231, 1171, 1113, 1012, 787, 735, 698, 644 cm<sup>–1</sup>; MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> (relative intensity) 373 ([M + H]<sup>+•</sup>, 70), 256 (100).</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> <i>N</i>-[4-Benzyloxy-5-methoxy-2-(<i>tert</i>-butyloxycarbonylamino)benzoyl]-(2<i>S</i>,4<i>R</i>)-[4-hydroxy-2-(hydroxymethyl)pyrrolidine] (<b>13</b>)</h3><div class="NLM_p last">A solution of aniline <b>12</b> (1.0 equiv, 24 g, 64.6 mmol) and (Boc)<sub>2</sub>O (1.0 equiv, 14.1 g, 64.6 mmol) in THF (300 mL) was heated at reflux overnight. The reaction mixture was allowed to cool to room temperature and the THF was removed by rotary evaporation under reduced pressure to give the crude product. The residue was subjected to flash column chromatography (30% EtOAc/hexane) to afford the product <b>13</b> (18.3 g, 38.8 mmol, 60% yield) as a yellow oil: [α]<sup>25</sup><sub>D</sub> −46° (<i>c</i> 0.15, CHCl<sub>3</sub>); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 7.72 (s, 1H), 7.49–7.26 (m, 6H), 6.79 (s, 1H), 5.15 (d, 2H, <i>J</i> = 4.54 Hz), 4.43–4.26 (m, 1H), 3.94–3.77 (m, 4H), 3.76–3.54 (m, 3H), 2.78 (bs, 1H), 2.24–2.15 (m, 1H), 1.84–1.71 (m, 1H), 1.46 (s, 9H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 153.6, 150.1, 145.1, 136.2, 130.4, 128.6, 128.1, 127.6, 118.8, 111.5, 108.1, 80.8, 70.8, 69.7, 59.4, 56.7, 37.2, 28.3; IR (neat) 3358, 2971, 1717, 1597, 1519, 1454, 1432, 1404, 1367, 1241, 1157, 1118, 1016, 773, 698 cm<sup>–1</sup>; MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> (relative intensity) 473 ([M + H]<sup>+•</sup>, 100).</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> (11<i>S</i>,11a<i>S</i>)-8-Benzyloxy-10-(<i>tert</i>-butyloxycarbonyl)-11-hydroxy-7-methoxy-2-oxo-1,2,3,10,11,11a-hexahydro-5<i>H</i>-pyrrolo[2,1-<i>c</i>][1,4]benzodiazepine-5-one (<b>14</b>)</h3><div class="NLM_p last">BAIB (5.0 equiv, 17.0 g, 53.0 mmol) and TEMPO (0.1 equiv, 0.17 g, 1.05 mmol) were added to a solution of Boc protected aniline <b>13</b> (1.0 equiv, 5.0 g, 10.6 mmol) in DCM (50 mL), and the mixture was allowed to stir overnight. When the reaction was complete as indicated by TLC (50% EtOAc/hexane), the reaction mixture was diluted with DCM (100 mL) and washed with saturated Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (60 mL). The aqueous layer was extracted with DCM (2 × 50 mL), and the combined organic layers were washed with brine (50 mL) and dried (MgSO<sub>4</sub>). Filtration, followed by removal of solvent by rotary evaporation under reduced pressure, afforded a crude solid which was washed with cold EtOAc to give cyclized compound <b>14</b> (2.3 g, 4.9 mmol, 46% yield) as a white solid: [α]<sup>25</sup><sub>D</sub> +117° (<i>c</i> 0.14, CHCl<sub>3</sub>); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 7.45–7.33 (m, 5H), 7.23 (s, 1H), 6.68 (s, 1H), 5.69–5.55 (m, 1H), 5.26–5.03 (m, 2H), 4.46–4.22 (m, 1H), 4.01–3.75 (m, 6H), 3.02–2.90 (m, 1H), 2.73–2.68 (m, 1H), 1.28 (s, 9H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 207.9, 167.7, 150.5, 149.0, 136.2, 130.3, 129.1, 128.8, 128.6, 128.2, 127.0, 123.9, 114.6, 110.7, 86.0, 71.1, 56.6, 56.2, 52.6, 40.3, 28.0; IR (neat) 3389, 2978, 1762, 1700, 1637, 1603, 1511, 1456, 1431, 1368, 1329, 1256, 1221, 1157, 1118, 1059, 767 cm<sup>–1</sup>; MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> (relative intensity) 469 ([M + H]<sup>+•</sup>, 27), 413 (100).</div></div><div id="sec4_2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> (11<i>S</i>,11a<i>S</i>)-10-(<i>tert</i>-Butyloxycarbonyl)-8,11-dihydroxy-7-methoxy-2-oxo-1,2,3,10,11,11a-hexahydro-5<i>H</i>-pyrrolo[2,1-<i>c</i>][1,4]benzodiazepine-5-one (<b>15</b>)</h3><div class="NLM_p last">A catalytic amount of 10% w/w palladium on carbon (0.23 g) was added to a solution of cyclized compound <b>14</b> (2.3 g, 4.9 mmol) in absolute alcohol (50 mL). The reaction mixture was hydrogenated for 4 h at 30 psi. When the reaction was complete as indicated by TLC (50% EtOAc/hexane), the reaction mixture was filtered through Celite, and removal of solvent under reduced pressure afforded the phenol <b>15</b> (4.70 g, 2.64 mmol, 53% yield) as a white solid: [α]<sup>25</sup><sub>D</sub> +115° (<i>c</i> 0.10, MeOH); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 7.20 (s, 1H), 6.73 (s, 1H), 6.02 (s, 1H), 5.71–5.53 (m, 1H), 4.35–4.22 (m, 1H), 4.06–3.84 (m, 6H), 3.02–2.87 (m, 1H), 2.80–2.68 (m, 1H), 1.39 (s, 9H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 208.1, 167.8, 148.2, 145.9, 129.9, 123.1, 115.9, 110.1, 85.9, 56.7, 56.2, 52.6, 40.4, 28.1; IR (neat) 3355, 2977, 1760, 1685, 1606, 1515, 1469, 1415, 1369, 1332, 1297, 1212, 1162, 1132, 1042, 767 cm<sup>–1</sup>; MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> (relative intensity) 379 ([M + H]<sup>+•</sup>, 93), 364 (100).</div></div><div id="sec4_2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> (11<i>S</i>,11a<i>S</i>)-10-(<i>tert</i>-Butyloxycarbonyl)-7-methoxy-2-oxo-8,11-di(tetrahydroxypyran-2-yloxy)-1,2,3,10,11,11a-hexahydro-5<i>H</i>-pyrrolo[2,1-<i>c</i>][1,4]benzodiazepine-5-one (<b>16</b>)</h3><div class="NLM_p last">A catalytic amount of PTSA was added to a solution of DHP (10.0 equiv, 4.8 mL, 52.8 mmol) in EtOAc (10 mL) at 0 °C. After stirring for 10 min, the phenolic compound <b>15</b> (1.0 equiv, 2.0 g, 5.28 mmol) was added portionwise to the mixture and stirred until the disappearance of starting material was observed by TLC (50% EtOAc/hexane). The mixture was diluted with EtOAc (100 mL), washed with saturated NaHCO<sub>3</sub> (30 mL), brine (30 mL), and dried (MgSO<sub>4</sub>). Filtration, followed by removal of solvent under reduced pressure, afforded a crude solid which was subjected to flash column chromatography (30% EtOAc–hexane) to give the protected compound <b>16</b> (1.8 g, 3.4 mmol, 65% yield, mixture of diastereoisomers from THP): [α]<sup>24</sup><sub>D</sub> +110° (<i>c</i> 0.10, CHCl<sub>3</sub>); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 7.22–7.15 (3<i>s</i>, 3H), 6.90–6.86 (2<i>s</i>, 1H), 6.01–5.90 (m, 1H), 5.86–5.77 (m, 1H), 5.50–5.43 (m, 1H), 5.41–5.26 (m, 1H), 5.20–5.12 (m, 1H), 5.06–4.96 (m, 1H), 4.44–4.23 (m, 2H), 4.05–3.82 (m, 14H), 3.66–3.51 (m, 4H), 3.00–2.82 (m, 3H), 2.65–2.55 (m, 1H), 2.14–1.83 (m, 6H), 1.81–1.42 (m, 18H), 1.34 (s, 18H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 208.5, 208.3, 168.2, 168.1, 148.7, 148.6, 129.6, 129.5, 125.9, 118.2, 110.9, 110.5, 100.4, 96.6, 91.2, 88.3, 81.5, 64.7, 63.9, 63.6, 62.1, 62.0, 61.6, 57.0, 56.9, 56.2, 52.8, 52.7, 40.8, 40.4, 31.2, 31.1, 30.9, 30.6, 30.1, 30.0, 28.2, 28.1, 28.0, 27.9, 25.2 (×2), 25.1, 20.6, 20.2, 20.0, 18.8, 18.6, 18.2; IR (neat) 2941, 1762, 1702, 1649, 1604, 1508, 1454, 1429, 1393, 1367, 1324, 1256, 1197, 1162, 1115, 1072, 1021, 960, 904, 870, 731 cm<sup>–1</sup>; MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> (relative intensity) 547 ([M + H]<sup>+•</sup>, 56), 261 (100).</div></div><div id="sec4_2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> (11<i>S</i>,11a<i>S</i>)-10-(<i>tert</i>-Butyloxycarbonyl)-7-methoxy-2-methylidene-8,11-di(tetrahydroxypyran-2-yloxy)-1,2,3,10,11,11a-hexahydro-5<i>H</i>-pyrrolo[2,1-<i>c</i>][1,4]benzodiazepine-5-one (<b>17</b>)</h3><div class="NLM_p last">Potassium <i>tert</i>-butoxide (10.0 equiv, 4.1 g, 36 mmol) was added portionwise to a suspension of methyltriphenylphosphonium bromide (10.0 equiv, 12.8 g, 36 mmol) in THF (50 mL) at 0 °C, under a nitrogen atmosphere. After stirring for 2 h at 0 °C, a solution of the ketone <b>16</b> (1.0 equiv, 2.0 g, 3.6 mmol) was added dropwise and the mixture allowed to warm to room temperature. After stirring overnight, the reaction mixture was diluted with EtOAc (250 mL) and water (250 mL) and the organic layer separated, washed with brine, dried (MgSO<sub>4</sub>), filtered, and the solvent was removed by rotary evaporation under reduced pressure to give a dark red oil, which was shown to contain a mixture of several components by TLC (50% EtOAc/hexane). Purification by flash chromatography (30% EtOAc/hexane) isolated the pure olefin <b>17</b> as a white solid (1.4 g, 2.59 mmol, 72% yield, mixture of diastereoisomers from THP): [α]<sup>22</sup><sub>D</sub> +105° (<i>c</i> 0.20, CHCl<sub>3</sub>); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 7.20–7.10 (3s, 3H), 6.90–6.77 (2s, 1H), 5.87–5.75 (m, 1H), 5.71–5.62 (m, 1H), 5.48–5.22 (m, 2H), 5.19–4.96 (m, 6H), 4.38–4.23 (m, 2H), 1.32 (s, 18H), 4.18–4.04 (m, 2H), 4.03–3.82 (m, 10H), 3.72–3.51 (m, 6H), 2.95–2.69 (m, 3H), 2.59–2.50 (m, 1H), 2.14–1.83 (m, 6H), 1.81–1.40 (m, 18H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 168.2, 168.1, 155.2, 149.4, 148.8, 148.1, 147.9, 142.3, 129.8, 129.7, 129.6, 127.3, 120.3, 118.1, 110.7, 110.3, 109.5, 109.4, 100.3, 99.6, 98.4, 96.7, 96.5, 96.3, 96.0, 90.9, 88.0, 81.2, 81.1, 64.5, 63.6, 63.4, 62.1, 62.0, 61.6, 60.0, 59.8, 56.2, 50.7, 35.5, 35.1, 31.3, 31.2, 31.0, 30.7, 30.4, 30.2, 30.1, 28.2, 28.0, 27.9, 25.3, 25.2, 25.1, 20.6, 20.0, 19.9, 18.8, 18.7, 18.3; IR (neat) 2940, 2866, 1702, 1639, 1604, 1508, 1453, 1431, 1393, 1367, 1324, 1198, 1162, 1114, 1072, 1019, 960, 906, 870, 727, 644 cm<sup>–1</sup>; MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> (relative intensity) 545 ([M + H]<sup>+•</sup>, 38), 343 (100).</div></div><div id="sec4_2_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> (11<i>S</i>,11a<i>S</i>)-10-(<i>tert</i>-Butyloxycarbonyl)-8-hydroxy-7-methoxy-2-methylidene-11-(tetrahydroxypyran-2-yloxy)-1,2,3,10,11,11a-hexahydro-5<i>H</i>-pyrrolo[2,1-<i>c</i>][1,4]benzodiazepine-5-one (<b>18</b>)</h3><div class="NLM_p last">A solution of THF/AcOH/H<sub>2</sub>O (2:1:1, 5 mL) was added to the olefin <b>17</b> (1.8 g, 3.3 mmol), and the resulting mixture was stirred for 3 h at which point TLC (50% EtOAc/hexane) revealed the reaction was complete. The mixture was then neutralized with saturated NaHCO<sub>3</sub> and extracted with EtOAc (3 × 30 mL), and the combined organic layers were washed with brine (50 mL) and dried (MgSO<sub>4</sub>). Removal of solvent by rotary evaporation under reduced pressure gave the crude product. The residue was subjected to flash chromatography (50% EtOAc/hexane) to afford the product <b>18</b> as a white solid (1.34 g, 2.90 mmol, 87% yield, mixture of diastereoisomers from THP): [α]<sup>27</sup><sub>D</sub> +81° (<i>c</i> 0.16, CHCl<sub>3</sub>); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 7.21 (s, 1H), 7.17 (s, 1H), 6.92 (s, 1H), 6.63 (s, 1H), 6.00 (s, 1H), 5.97 (s, 1H), 5.88–5.75 (d, 1H), 5.72–5.65 (d, 1H), 5.19–4.96 (m, 6H), 4.38–4.23 (m, 2H), 4.18–4.04 (m, 2H), 4.00–3.87 (m, 8H), 3.67–3.51 (m, 4H), 2.96–2.84 (m, 2H), 2.80–2.68 (m, 1H), 2.58–2.50 (m, 1H), 1.84–1.66 (m, 4H), 1.64–1.45 (m, 8H), 1.32 (s, 18H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 167.5, 167.3, 147.7, 147.5, 146.0, 145.8, 142.0, 130.5, 130.3, 117.0, 116.4, 109.8, 109.4, 100.7, 96.1, 91.0, 88.0, 81.5, 64.6, 63.6, 60.0, 59.8, 56.2, 56.1, 50.7, 35.4, 35.1, 31.3, 30.8, 29.7, 28.1, 28.0, 25.2, 25.1, 20.7, 20.0; IR (neat) 2940, 2851, 1703, 1630, 1512, 1467, 1440, 1407, 1391, 1367, 1326, 1200, 1161, 1118, 1072, 1019, 910, 730 cm<sup>–1</sup>; MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> (relative intensity) 461 ([M + H]<sup>+•</sup>, 75), 259 (100).</div></div><div id="sec4_2_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> (11<i>S</i>,11a<i>S</i>,11′<i>S</i>,11a′<i>S</i>)-Di-<i>tert</i>-butyl 8,8′-(((5-Iodo-1,3-phenylene)bis(methylene))bis(oxy))bis(7-methoxy-2-methylene-5-oxo-11-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)-2,3,11,11a-tetrahydro-1<i>H</i>-pyrrolo[2,1-<i>c</i>][1,4]benzodiazepine-10(5<i>H</i>)-carboxylate) (<b>19</b>)</h3><div class="NLM_p last">1,3-Bis(bromomethyl)-5-iodobenzene (1 equiv, 2.00 g, 5.20 mmol) was added to a stirred solution of Boc/THP-protected PBD capping unit <b>18</b> (2 equiv, 4.75 g, 10.3 mmol), TBAI (0.1 equiv, 190 mg, 0.52 mmol), and K<sub>2</sub>CO<sub>3</sub> (2 equiv, 1.42 g, 10.3 mmol) in dry DMF (60 mL). The reaction mixture was heated to 60 °C and stirred under an argon atmosphere for 3 h at which point analysis by LC–MS revealed substantial product formation at retention time 4.15 min (ES<sup>+</sup>) <i>m</i>/<i>z</i> 1171 [M + Na]<sup>+•</sup>. The reaction mixture was allowed to cool to room temperature, and the DMF was removed by rotary evaporation under reduced pressure. The resulting residue was partitioned between water (50 mL) and EtOAc (50 mL), and the aqueous phase was extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with water (2 × 20 mL), brine (50 mL), dried (MgSO<sub>4</sub>), filtered, and the solvent was removed by rotary evaporation under reduced pressure to provide the crude product. Purification by flash chromatography (50% EtOAc/hexane to 80% EtOAc/hexane) gave the bis-ether <b>19</b> as a white foam (5.42 g, 4.72 mmol, 91% yield, mixture of diastereoisomers from THP): [α]<sup>21</sup><sub>D</sub> +44° (<i>c</i> 0.29, CHCl<sub>3</sub>); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 7.76 (s, 2H), 7.51 (br s, 1H), 7.25 (s, 1H), 7.21 (s, 1H), 6.87 (s, 1H), 6.53 (s, 1H), 5.81–5.78 (m, 1H), 5.68 (d, 1H, <i>J</i> = 9.3 Hz), 5.13–4.97 (m, 10H), 4.34–4.27 (m, 2H), 4.15–4.08 (m, 2H), 3.93–3.88 (m, 8H), 3.62–3.57 (m, 3H), 3.51–3.47 (m, 1H), 2.94–2.86 (m, 2H), 2.74 (d, 1H, <i>J</i> = 16.0 Hz), 2.54 (d, 1H, <i>J</i> = 16.1 Hz), 1.77–1.21 (m, 30H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 167.3, 167.1, 154.8, 149.7, 149.5, 149.3, 148.9, 142.1, 139.6, 139.4, 135.7, 135.6, 129.8, 129.6, 127.4, 126.8, 125.0, 116.0, 115.8, 110.9, 110.3, 109.6, 109.5, 100.8, 96.1, 94.8, 91.1, 88.3, 81.5, 81.0, 70.4, 70.0, 64.9, 63.5, 60.0, 59.9, 56.2, 56.1, 50.7, 35.5, 35.2, 31.4, 31.0, 28.2, 28.1, 25.3, 20.9, 20.1; IR (CHCl<sub>3</sub>) 2942, 2864, 1702, 1638, 1604, 1510, 1455, 1431, 1398, 1367, 1326, 1274, 1246, 1202, 1161, 1118, 1072, 1014, 965, 904, 858, 639 cm<sup>–1</sup>; MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> (relative intensity) 1171 ([M + Na]<sup>+•</sup>, 10), 947 (100).</div></div><div id="sec4_2_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> <i>tert</i>-Butyl (15-Oxo-3,6,9,12-tetraoxa-16-azanonadec-18-yn-1-yl)carbamate (<b>21</b>)</h3><div class="NLM_p last">EDCI (1 equiv, 263 mg, 1.37 mmol) was added to a stirred solution of <i>t</i>-Boc-<i>N</i>-amido-dPEG<sub>4</sub>-acid (<b>20</b>) (1 equiv, 500 mg, 1.37 mmol, Stratech Scientific Limited) and propargylamine (1 equiv, 88 μL, 76 mg, 1.37 mmol) in dry DCM (10 mL) at room temperature. The reaction mixture was stirred under an argon atmosphere for 16 h at which point analysis by LC–MS showed a substantial amount of desired product at retention time 1.26 min (ES<sup>+</sup>) <i>m</i>/<i>z</i> 403 [M + H]<sup>+•</sup>, 425 [M + Na]<sup>+•</sup>. Note that both starting material and product had weak UV absorption (214 and 254 nm) and were best detected on ES+ TIC. The reaction mixture was diluted with DCM (100 mL) and washed with H<sub>2</sub>O (30 mL), brine (40 mL), dried (MgSO<sub>4</sub>), filtered, and the solvent was removed by rotary evaporation under reduced pressure to provide the crude product. Purification by flash chromatography (100% DCM to 98% DCM/MeOH) gave the amide <b>21</b> as an oil (392 mg, 0.97 mmol, 71% yield): <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 6.99–6.83 (m, 1H), 5.09–4.96 (m, 1H), 4.04 (dd, 2H, <i>J</i> = 2.6, 5.4 Hz), 3.74 (t, 2H, <i>J</i> = 5.7 Hz), 3.70–3.59 (m, 12H), 3.54 (t, 2H, <i>J</i> = 5.1 Hz), 3.35–3.26 (m, 2H), 2.50 (t, 2H, <i>J</i> = 5.7 Hz), 2.21 (t, 1H, <i>J</i> = 2.5 Hz), 1.45 (s, 9H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 171.3, 156.0, 80.1, 79.2, 71.0, 70.6, 70.5, 70.3 (x 2), 70.2, 67.0, 40.4, 36.7, 28.9, 28.4; IR (CHCl<sub>3</sub>) 3307, 2870, 1696, 1657, 1526, 1454, 1391, 1365, 1272, 1249, 1169, 1093, 1042, 942, 862, 781, 650 cm<sup>–1</sup>; MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> (relative intensity) 425 ([M + Na]<sup>+•</sup>, 30), 403 ([M + H]<sup>+•</sup>, 40), 303 (100).</div></div><div id="sec4_2_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Di-<i>tert</i>-butyl 8,8′-(((5-(2,2-Dimethyl-4,20-dioxo-3,8,11,14,17-pentaoxa-5,21-diazatetracos-23-yn-24-yl)-1,3-phenylene)bis(methylene))bis(oxy))(11<i>S</i>,11a<i>S</i>,11′<i>S</i>,11a′<i>S</i>)-bis(7-methoxy-2-methylene-5-oxo-11-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)-2,3,11,11a-tetrahydro-1<i>H</i>-pyrrolo[2,1-<i>c</i>][1,4]benzodiazepine-10(5<i>H</i>)-carboxylate) (<b>22</b>)</h3><div class="NLM_p last">A catalytic amount of Pd(PPh<sub>3</sub>)<sub>4</sub> (0.02 equiv, 23.0 mg, 19.5 μmol) was added to a mixture of the iodoaryl compound <b>19</b> (1 equiv, 1.02 g, 0.89 mmol), Boc-acetylene <b>21</b> (1.1 equiv, 393 mg, 0.98 mmol), CuI (0.04 equiv, 7.4 mg, 39.1 μmol), diethylamine (22 equiv, 2.02 mL, 1.43 g, 19.5 mmol), and oven-dried 4 Å molecular sieve pellets in dry DMF (9 mL) in an oven-dried sealable vessel. The mixture was degassed in vacuo and flushed with argon 3 times and then heated in a microwave at 100 °C for 26 min at which point analysis by LC–MS revealed substantial product formation at retention time 1.89 min (ES<sup>+</sup>) <i>m</i>/<i>z</i> 1446 [M + Na]<sup>+•</sup>, 1424 [M + H]<sup>+•</sup>. The reaction mixture was allowed to cool to room temperature and was then filtered through a sinter to remove the sieves (washed with DMF). The filtrate was subjected to rotary evaporation under reduced pressure and the resulting residue dissolved in DCM (100 mL) and washed with H<sub>2</sub>O (20 mL), brine (30 mL), dried (MgSO<sub>4</sub>), filtered, and the solvent was removed by rotary evaporation under reduced pressure to give the crude product. Purification by flash chromatography (100% DCM to 97% DCM/MeOH) provided the alkyne <b>22</b> as a yellow foam (882 mg, 0.62 mmol, 70% yield, mixture of diastereoisomers from THP): [α]<sup>21</sup><sub>D</sub> +33° (<i>c</i> 0.24, CHCl<sub>3</sub>); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 7.54–7.49 (m, 1H), 7.47 (br s, 2H), 7.25 (s, 1H), 7.21 (s, 1H), 6.97–6.79 (m, 2H), 6.54 (br s, 1H), 5.85–5.74 (m, 1H), 5.69 (d, 1H, <i>J</i> = 9.2 Hz), 5.17–4.94 (m, 11H), 4.35–4.23 (m, 4H), 4.16–4.08 (m, 2H), 3.96–3.85 (m, 8H), 3.74 (t, 2H, <i>J</i> = 5.7 Hz), 3.68–3.56 (m, 15H), 3.55–3.44 (m, 3H), 3.34–3.24 (m, 2H), 2.96–2.84 (m, 2H), 2.74 (d, 1H, <i>J</i> = 15.9 Hz), 2.59–2.49 (m, 1H, obscured by t at 2.52), 2.52 (t, 2H, <i>J</i> = 5.7 Hz), 1.82–1.17 (m, 39H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 171.2, 167.3, 167.1, 156.0, 154.9, 149.6, 149.2, 148.8, 142.1, 137.5, 137.4, 130.1, 129.8, 129.6, 127.1, 126.6, 125.8, 123.9, 115.7, 115.5, 110.8, 110.2, 109.6, 100.8, 96.0, 91.1, 88.3, 86.4, 82.1, 81.5, 81.0, 79.2, 70.6 (x 2), 70.5, 70.4, 70.3 (×2), 70.2, 67.0, 64.9, 63.5, 60.0, 59.9, 56.1 (×2), 50.7, 40.4, 36.8, 35.5, 35.2, 31.4, 30.9, 29.6, 28.4, 28.2, 28.1, 25.3, 20.8, 20.0; IR (CHCl<sub>3</sub>) 3326, 2939, 2868, 1703, 1639, 1604, 1511, 1432, 1395, 1367, 1327, 1274, 1246, 1203, 1162, 1116, 1073, 1016, 965, 904, 860, 637 cm<sup>–1</sup>; MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> (relative intensity) 1446 ([M + Na]<sup>+•</sup>, 100), 1424 ([M + H]<sup>+•</sup>, 5).</div></div><div id="sec4_2_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Di-<i>tert</i>-butyl 8,8′-(((5-(1-Amino-15-oxo-3,6,9,12-tetraoxa-16-azanonadec-18-yn-19-yl)-1,3-phenylene)bis(methylene))bis(oxy))(11<i>S</i>,11a<i>S</i>,11′<i>S</i>,11a′<i>S</i>)-bis(7-methoxy-2-methylene-5-oxo-11-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)-2,3,11,11a-tetrahydro-1<i>H</i>-pyrrolo[2,1-<i>c</i>][1,4]benzodiazepine-10(5<i>H</i>)-carboxylate) (<b>23</b>)</h3><div class="NLM_p last">TBSOTf (10 equiv, 1.42 mL, 1.64 g, 6.20 mmol) was added to a stirred solution of the tri-Boc protected compound <b>22</b> (1 equiv, 882 mg, 0.62 mmol) and 2,6-lutidine (13 equiv, 0.96 mL, 883 mg, 8.25 mmol) in dry DCM (15 mL) at room temperature. The reaction mixture was allowed to stir under an argon atmosphere for 16 h during which time analysis by LC–MS revealed formation of the desired TBS carbamate at retention time 2.09 min (ES<sup>+</sup>) <i>m</i>/<i>z</i> 1504 [M + Na]<sup>+•</sup>. The reaction mixture was diluted with DCM (60 mL) and washed with saturated NH<sub>4</sub>Cl (2 × 20 mL), H<sub>2</sub>O (20 mL), brine (30 mL), dried (MgSO<sub>4</sub>), filtered, and the solvent was removed by rotary evaporation under reduced pressure to give the crude TBS carbamate. The product was redissolved in THF (15 mL) and treated with a solution of TBAF (1.2 equiv, 744 μL of a 1.0 M solution in THF, 0.744 mmol) at room temperature. The reaction mixture was allowed to stir for 1 h at room temperature at which point analysis by LC–MS revealed substantial formation of <b>23</b> at retention time 1.45 min (ES<sup>+</sup>) <i>m</i>/<i>z</i> 1324 [M + H]<sup>+•</sup> along with <b>23a</b> at retention time 1.29 min (ES<sup>+</sup>) <i>m</i>/<i>z</i> 1121 [M + H]<sup>+•</sup>, 1138 [M + H<sub>2</sub>O]<sup>+</sup> and <b>23b</b> at retention time 1.12 min (ES<sup>+</sup>) <i>m</i>/<i>z</i> 919 [M + H]<sup>+•</sup>, 937 [M + H<sub>2</sub>O]<sup>+•</sup>, 955 [M + 2H<sub>2</sub>O]<sup>+•</sup>. The THF was removed by rotary evaporation under reduced pressure and the resulting residue redissolved in DCM (60 mL) and washed with saturated NH<sub>4</sub>Cl (2 × 20 mL), H<sub>2</sub>O (20 mL), brine (30 mL), dried (MgSO<sub>4</sub>), filtered, and the solvent was removed by rotary evaporation under reduced pressure to give the key amine crude mixture <b>23</b>, <b>23a</b>, and <b>23b</b> as a pinkish foam (∼800 mg).</div></div><div id="sec4_2_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Di-<i>tert</i>-butyl 8,8′-(((5-(1-(2,5-Dioxo-2,5-dihydro-1<i>H</i>-pyrrol-1-yl)-3,19-dioxo-7,10,13,16-tetraoxa-4,20-diazatricos-22-yn-23-yl)-1,3-phenylene)bis(methylene))bis(oxy))(11<i>S</i>,11a<i>S</i>,11′<i>S</i>,11a′<i>S</i>)-bis(7-methoxy-2-methylene-5-oxo-11-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)-2,3,11,11a-tetrahydro-1<i>H</i>-pyrrolo[2,1-<i>c</i>][1,4]benzodiazepine-10(5<i>H</i>)-carboxylate (<b>24</b>)</h3><div class="NLM_p last">EDCI (1 equiv, 61 mg, 0.32 mmol) was added to a stirred solution of <i>N</i>-maleoyl-β-alanine (1 equiv, 53 mg, 0.32 mmol) and crude amine <b>23</b> (1 equiv, ∼418 mg, 0.32 mmol) in dry DCM (6 mL) at room temperature. The reaction mixture was stirred under an argon atmosphere for 3 h at which point analysis by LC–MS showed a substantial amount of <b>24</b> at retention time 1.80 min (ES<sup>+</sup>) <i>m</i>/<i>z</i> 1475 [M + H]<sup>+•</sup>, 1497 [M + Na]<sup>+•</sup>, along with <b>24a</b> at retention time 1.56 min (ES<sup>+</sup>) <i>m</i>/<i>z</i> 1273 [M + H]<sup>+•</sup>, 1295 [M + Na]<sup>+</sup> and <b>6</b> at retention time 1.31 min (ES<sup>+</sup> M<sup>+•</sup> not observed). The reaction mixture was diluted with DCM (30 mL) and washed with H<sub>2</sub>O (15 mL), brine (20 mL), dried (MgSO<sub>4</sub>), filtered, and the solvent was removed by rotary evaporation under reduced pressure to provide the crude mixture <b>24</b>, <b>24a</b>, and <b>6</b> as a foam (∼470 mg).</div></div><div id="sec4_2_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> (11<i>S</i>,11a<i>S</i>,11′<i>S</i>,11a′<i>S</i>)-Di-<i>tert</i>-butyl 8,8′-(((5-((Trimethylsilyl)ethynyl)-1,3-phenylene)bis(methylene))bis(oxy))bis(7-methoxy-2-methylene-5-oxo-11-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)-2,3,11,11a-tetrahydro-1<i>H</i>-pyrrolo[2,1-<i>c</i>][1,4]benzodiazepine-10(5<i>H</i>)-carboxylate) (<b>25</b>)</h3><div class="NLM_p last">A catalytic amount of Pd(PPh<sub>3</sub>)<sub>4</sub> (0.02 equiv, 15.0 mg, 13.1 μmol) was added to a mixture of the bis-ether <b>19</b> (1 equiv, 750 mg, 0.65 mmol), TMS-acetylene (3 equiv, 278 μL, 191 mg, 1.96 mmol), CuI (0.04 equiv, 5.0 mg, 26.1 μmol), diethylamine (20 equiv, 1.35 mL, 956 mg, 13.1 mmol), and oven-dried 4 Å molecular sieve pellets in dry DMF (5.6 mL) in an oven-dried sealable vessel. The mixture was degassed in vacuo and flushed with argon 3 times and then heated in a microwave at 100 °C for 30 min at which point analysis by LC–MS revealed complete consumption of starting material with formation of <b>19</b> at retention time 4.37 min (ES<sup>+</sup>) <i>m</i>/<i>z</i> 1142 [M + Na]<sup>+•</sup>. Peak at retention time 3.97 min (ES+) <i>m</i>/<i>z</i> 1069 [M + Na]<sup>+•</sup> observed which corresponds to TMS cleavage under LC–MS conditions. The reaction mixture was allowed to cool to room temperature and was then filtered through a sinter to remove the sieves (washed with DMF). The filtrate was subjected to rotary evaporation under reduced pressure and the resulting residue purified by flash chromatography (50% EtOAc/hexane to 80% EtOAc/hexane) to provide the TMS-acetylene <b>25</b> as a yellow foam (691 mg, 0.62 mmol, 95% yield, mixture of diastereoisomers from THP): [α]<sup>21</sup><sub>D</sub> +49° (<i>c</i> 0.23, CHCl<sub>3</sub>); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 7.55–7.46 (m, 3H), 7.24 (s, 1H), 7.20 (s, 1H), 6.88 (s, 1H), 6.53 (s, 1H), 5.80–5.78 (m, 1H), 5.67 (d, 1H, <i>J</i> = 9.4 Hz), 5.17–4.96 (m, 10H), 4.34–4.27 (m, 2H), 4.15–4.08 (m, 2H), 3.93–3.89 (m, 8H), 3.61–3.57 (m, 3H), 3.49–3.47 (m, 1H), 2.94–2.86 (m, 2H), 2.78–2.71 (m, 1H), 2.54 (d, 1H, <i>J</i> = 16.6 Hz), 1.77–1.19 (m, 30H), 0.24–0.22 (m, 9H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 167.4, 167.2, 154.9, 150.0, 149.8, 149.3, 149.0, 142.2, 137.8, 137.6, 132.3, 132.2, 132.0, 130.3, 129.9, 129.7, 128.7, 128.5, 127.3, 126.7, 125.9, 124.4, 116.0, 115.9, 115.8, 110.9, 110.3, 109.6, 109.5, 104.4, 101.0, 96.2, 95.4, 91.3, 88.4, 81.5, 81.1, 71.0, 70.6, 65.0, 63.7, 60.5, 60.1, 60.0, 56.2 (x 2), 50.8, 35.6, 35.3, 31.5, 31.1, 28.2 (×2), 25.4, 21.0, 20.2, 0.0; IR (CHCl<sub>3</sub>) 2942, 2864, 2155, 1703, 1643, 1604, 1510, 1454, 1430, 1397, 1367, 1326, 1275, 1248, 1202, 1162, 1118, 1072, 1016, 966, 904, 843, 795, 698 cm<sup>–1</sup>; MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> (relative intensity) 1142 ([M + Na]<sup>+•</sup>, 30), 918 (100).</div></div><div id="sec4_2_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> (11<i>S</i>,11a<i>S</i>,11′<i>S</i>,11a′<i>S</i>)-Di-<i>tert</i>-butyl 8,8′-(((5-Ethynyl-1,3-phenylene)bis(methylene))bis(oxy))bis(7-methoxy-2-methylene-5-oxo-11-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)-2,3,11,11a-tetrahydro-1<i>H</i>-pyrrolo[2,1-<i>c</i>][1,4]benzodiazepine-10(5<i>H</i>)-carboxylate) (<b>26</b>)</h3><div class="NLM_p last">Solid K<sub>2</sub>CO<sub>3</sub> (2 equiv, 383 mg, 2.77 mmol) was added to a stirred solution of the TMS-protected compound <b>25</b> (1 equiv, 1.55 g, 1.39 mmol) in MeOH (20 mL). After 3 h stirring at room temperature the reaction was deemed to be complete as judged by LC–MS, desired product peak at retention time 4.00 min (ES<sup>+</sup>) <i>m</i>/<i>z</i> 1047 [M + H]<sup>+•</sup>. The MeOH was removed by rotary evaporation under reduced pressure, and the resulting residue was partitioned between water (60 mL) and EtOAc (60 mL). The layers were separated, and the aqueous phase was extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with water (30 mL), brine (30 mL), dried (MgSO<sub>4</sub>), filtered, and the solvent was removed by rotary evaporation under reduced pressure to provide the crude product. Purification by flash chromatography (50% EtOAc/hexane to 80% EtOAc/hexane) gave the acetylene <b>26</b> as an orange foam (1.13 g, 1.08 mmol, 78% yield, mixture of diastereoisomers from THP): [α]<sup>22</sup><sub>D</sub> +91° (<i>c</i> 0.24, CHCl<sub>3</sub>); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 7.57–7.53 (m, 3H), 7.25 (s, 1H), 7.21 (s, 1H), 6.88 (s, 1H), 6.53 (s, 1H), 5.80–5.78 (m, 1H), 5.68 (d, 1H, <i>J</i> = 9.4 Hz), 5.17–4.96 (m, 10H), 4.34–4.27 (m, 2H), 4.15–4.08 (m, 2H), 3.93–3.88 (m, 8H), 3.62–3.57 (m, 3H), 3.51–3.47 (m, 1H), 3.09–3.08 (m, 1H), 2.94–2.86 (m, 2H), 2.74 (d, 1H, <i>J</i> = 16.1 Hz), 2.54 (d, 1H, <i>J</i> = 16.3 Hz), 1.76–1.08 (m, 30H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 167.3, 167.1, 154.9, 149.8, 149.6, 149.2, 148.9, 142.1, 137.8, 137.6, 132.2, 132.1, 131.9 (x 2), 130.4, 129.8, 129.6, 128.6, 128.4, 127.2, 126.7, 126.1, 123.2, 115.9, 115.7, 110.8, 110.3, 109.5, 109.4, 100.8, 96.1, 91.1, 88.3, 82.9, 81.4, 81.0, 78.0, 70.7, 70.4, 64.9, 63.6, 60.0, 59.9, 56.1 (x 2), 50.7, 35.5, 35.2, 31.4, 31.0, 28.1 (x 2), 25.3, 20.9, 20.0; IR (CHCl<sub>3</sub>) 3246, 2942, 2865, 1702, 1638, 1604, 1510, 1455, 1431, 1398, 1368, 1326, 1274, 1246, 1202, 1161, 1117, 1072, 1014, 965, 904, 861, 794 cm<sup>–1</sup>; MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> (relative intensity) 1069 ([M + Na]<sup>+•</sup>, 20), 845 (100).</div></div><div id="sec4_2_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> (11<i>S</i>,11a<i>S</i>,11′<i>S</i>,11a′<i>S</i>)-Di-<i>tert</i>-butyl 8,8′-(((5-(1-(2-(2-(2-(2-Aminoethoxy)ethoxy)ethoxy)ethyl)-1<i>H</i>-1,2,3-triazol-4-yl)-1,3-phenylene)bis(methylene))bis(oxy))bis(7-methoxy-2-methylene-5-oxo-11-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)-2,3,11,11a-tetrahydro-1<i>H</i>-pyrrolo[2,1-<i>c</i>][1,4]benzodiazepine-10(5<i>H</i>)-carboxylate) (<b>27</b>)</h3><div class="NLM_p last">Solid CuSO<sub>4</sub>·5H<sub>2</sub>O (0.05 equiv, 13.0 mg, 52.0 μmol) and (+)-sodium <span class="smallcaps smallerCapital">l</span>-ascorbate (0.20 equiv, 41.0 mg, 0.21 mmol) were added to a stirred solution of 11-azido-3,6,9-trioxaundecan-1-amine (1 equiv, 227 mg, 207 μL, 1.04 mmol) and the alkyne <b>26</b> (1 equiv, 1.09 g, 1.04 mmol) in <i>tert</i>-BuOH (6 mL) and H<sub>2</sub>O (6 mL) at room temperature. A color change from yellow to green was observed as the reaction progressed. After stirring for 16 h, analysis by LC–MS revealed a substantial of amount of desired product formed corresponding to peak at retention time 3.12 min (ES<sup>+</sup>) <i>m</i>/<i>z</i> 1266 [M + H]<sup>+•</sup>. [NOTE: On some occasions reaction progress stalled; however, the reaction was driven to completion upon addition of further CuSO<sub>4</sub>·5H<sub>2</sub>O (0.05 equiv) and (+)-sodium <span class="smallcaps smallerCapital">l</span>-ascorbate (0.20 equiv).] The reaction mixture was partitioned (without shaking of the separating funnel) between water (50 mL) and EtOAc (50 mL). The aqueous phase was extracted with EtOAc (3 × 15 mL), and the combined organic layers were washed with water (30 mL), brine (50 mL), dried (MgSO<sub>4</sub>), filtered, and the solvent was removed by rotary evaporation under reduced pressure to provide the crude product <b>27</b> as a green foam (1.32 g, 1.04 mmol, 100% crude yield). The crude product was carried through to the next step without further purification. [α]<sup>22</sup><sub>D</sub> +26° (<i>c</i> 0.31, CHCl<sub>3</sub>); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 8.11–7.83 (m, 3H), 7.57–7.53 (m, 1H), 7.25 (s, 1H), 7.21 (s, 1H), 6.94 (br s, 1H), 6.60 (br s, 1H), 5.80–5.75 (m, 1H), 5.68 (d, 1H, <i>J</i> = 8.1 Hz), 5.24–4.96 (m, 10H), 4.65–4.55 (m, 2H), 4.34–4.27 (m, 2H), 4.15–4.08 (m, 2H), 3.93–3.85 (m, 10H), 3.72–3.38 (m, 16H), 2.94–2.86 (m, 2H), 2.74 (d, 1H, <i>J</i> = 15.2 Hz), 2.54 (d, 1H, <i>J</i> = 15.6 Hz), 1.73–1.11 (m, 34H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 167.4, 167.2, 154.8, 150.0, 149.8, 149.2, 148.9, 142.1, 137.8, 132.2, 132.1, 131.9, 129.9, 129.6, 128.6, 128.4, 126.6, 125.4, 124.3, 115.8, 115.6, 110.8, 110.2, 109.5, 109.4, 100.7, 96.1, 91.1, 88.3, 81.4, 81.0, 71.2, 70.8, 70.6, 70.5, 69.7, 69.6, 69.2, 64.8, 63.6, 61.6, 60.0, 59.9, 56.2, 50.7, 50.4, 35.5, 35.2, 31.4, 31.0, 28.2, 28.1, 25.3, 20.8, 20.0; IR (CHCl<sub>3</sub>) 2932, 2858, 1704, 1635, 1602, 1511, 1454, 1432, 1404, 1368, 1327, 1272, 1255, 1203, 1163, 1116, 1073, 1017, 964, 904, 860, 837, 793 cm<sup>–1</sup>; MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> (relative intensity) 1266 ([M + H]<sup>+•</sup>, 80), 532 (100).</div></div><div id="sec4_2_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> (11<i>S</i>,11a<i>S</i>,11′<i>S</i>,11a′<i>S</i>)-Di-<i>tert</i>-butyl 8,8′-(((5-(1-(18-(2,5-Dioxo-2,5-dihydro-1<i>H</i>-pyrrol-1-yl)-13-oxo-3,6,9-trioxa-12-azaoctadecyl)-1<i>H</i>-1,2,3-triazol-4-yl)-1,3-phenylene)bis(methylene))bis(oxy))bis(7-methoxy-2-methylene-5-oxo-11-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)-2,3,11,11a-tetrahydro-1<i>H</i>-pyrrolo[2,1-<i>c</i>][1,4]benzodiazepine-10(5<i>H</i>)-carboxylate) (<b>28</b>)</h3><div class="NLM_p last">Solid 6-maleimidohexanoic acid <i>N</i>-hydroxysuccinimide ester (1.05 equiv, 327 mg, 1.06 mmol) was added to a stirred solution of the primary amine <b>27</b> (1 equiv, 1.28 g, 1.01 mmol) in dry DCM (30 mL) at room temperature. Progress was monitored by LC–MS and after 3 days stirring the reaction proceeded no further, a substantial amount of desired product was observed at retention time 3.65 min (ES<sup>+</sup>) <i>m</i>/<i>z</i> 1459 [M + H]<sup>+•</sup> accompanied by unreacted starting material at retention time 3.15 min. The reaction mixture was treated with silica gel, and the solvent was removed by rotary evaporation under reduced pressure. The resulting residue was subjected to flash chromatography (100% DCM to 97% DCM/MeOH) to give the maleimide <b>28</b> as a foam (658 mg, 0.45 mmol, 45% yield, mixture of diastereoisomers from THP): [α]<sup>22</sup><sub>D</sub> +41° (<i>c</i> 0.82, CHCl<sub>3</sub>); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 8.02 (s, 1H), 7.91 (br s, 2H), 7.57–7.54 (m, 1H), 7.26 (s, 1H), 7.22 (s, 1H), 6.95 (s, 1H), 6.67 (s, 2H), 6.61 (br s, 1H), 6.21 (br s, 1H), 5.80–5.78 (m, 1H), 5.69 (d, 1H, <i>J</i> = 9.2 Hz), 5.25–4.97 (m, 10H), 4.60 (t, 2H, <i>J</i> = 4.8 Hz), 4.34–4.27 (m, 2H), 4.16–4.08 (m, 2H), 3.96–3.89 (m, 10H), 3.69–3.54 (m, 11H), 3.49–3.41 (m, 5H), 3.39–3.37 (m, 2H), 2.95–2.86 (m, 2H), 2.74 (d, 1H, <i>J</i> = 15.7 Hz), 2.55 (d, 1H, <i>J</i> = 16.2 Hz), 2.15 (t, 2H, <i>J</i> = 7.5 Hz), 1.73–1.21 (m, 36H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 173.0, 170.8, 167.2, 154.9, 150.1, 149.8, 149.2, 148.9, 142.0, 137.9, 137.8, 134.1, 131.7, 129.9, 129.6, 127.0, 126.4, 125.5, 124.2, 121.3, 115.8, 115.5, 110.8, 110.2, 109.6, 109.5, 100.7, 96.0, 91.1, 88.3, 81.4, 81.0, 72.4, 71.1, 70.8, 70.6, 70.5 (×2), 70.4, 70.2, 70.1, 69.8, 69.5, 64.8, 63.5, 61.6, 60.1, 59.9, 56.2, 56.1, 50.7, 50.5, 39.2, 37.6, 36.3, 35.5, 35.1, 31.4, 30.9, 28.3, 28.1 (x 2), 26.4, 25.3, 25.1, 20.8, 20.0; IR (CHCl<sub>3</sub>) 3349, 2941, 2866, 1703, 1636, 1603, 1511, 1455, 1432, 1403, 1368, 1327, 1274, 1255, 1204, 1161, 1117, 1072, 1017, 965, 905, 869, 828, 793, 695 cm<sup>–1</sup>; MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> (relative intensity) 1459 ([M + H]<sup>+•</sup>, 30), 528 (100).</div></div><div id="sec4_2_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> (11<i>S</i>,11a<i>S</i>,11′<i>S</i>,11a′<i>S</i>)-Di-<i>tert</i>-butyl 8,8′-(((5-(4-(<i>tert</i>-Butoxycarbonyl)piperazin-1-yl)-1,3-phenylene)bis(methylene))bis(oxy))bis(7-methoxy-2-methylene-5-oxo-11-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)-2,3,11,11a-tetrahydro-1<i>H</i>-pyrrolo[2,1-<i>c</i>][1,4]benzodiazepine-10(5<i>H</i>)-carboxylate) (<b>29</b>)</h3><div class="NLM_p last">RuPhos (0.2 equiv, 18 mg, 38 μmol), RuPhos Pd G1 methyl <i>tert</i>-butyl ether adduct (0.12 equiv, 18 mg, 22 μmol), cesium carbonate (5.0 equiv, 0.36 g, 1.1 mmol), and iodo derivative <b>19</b> (1.0 equiv, 0.307 g, 0.27 mmol) were placed in a microwave vial which was evacuated and flushed with argon 3 times. Anhydrous THF (5 mL) was added followed by <i>tert</i>-butyl piperazine-1-carboxylate (1.1 equiv, 70 mg, 0.37 mmol), and the resulting mixture was heated at 85 °C for 4 h and then overnight at room temperature. LC–MS analysis showed desired product at retention time 4.12 min, (ES<sup>+</sup>) <i>m</i>/<i>z</i> 1208 [M + H]<sup>+•</sup>. The reaction mixture was diluted with saturated NaHCO<sub>3</sub> (100 mL) and extracted with EtOAc (3 × 100 mL). The combined EtOAc extracts were washed with brine (100 mL), dried (MgSO<sub>4</sub>), filtered, and the solvent was removed by rotary evaporation under reduced pressure. The crude product was purified by flash chromatography (100% CHCl<sub>3</sub> to 98.5% CHCl<sub>3</sub>/MeOH) to provide <b>29</b> as an orange film (111 mg, 0.09 mmol, 34% yield, mixture of diastereoisomers from THP): [α]<sup>22</sup><sub>D</sub> +49° (<i>c</i> 0.36, CHCl<sub>3</sub>); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz) δ 7.24 (s, 2H), 7.20 (s, 1H), 7.00 (s, 1H), 6.99–6.94 (m, 2H), 6.89 (s, 1H), 6.55 (s, 1H), 5.85–5.73 (m, 1H), 5.68 (d, 1H, <i>J</i> = 9.4 Hz), 5.17–4.93 (m, 10H), 4.35–4.24 (m, 2H), 4.17–4.06 (m, 2H), 3.99–3.83 (m, 8H), 3.65–3.52 (m, 7H), 3.51–3.43 (m, 1H), 3.19–3.08 (m, 4H), 2.96–2.84 (m, 2H), 2.74 (d, 1H, <i>J</i> = 16.1 Hz), 2.54 (d, 1H, <i>J</i> = 15.3 Hz), 1.82–1.15 (m, 39H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz) δ 167.3, 167.2, 154.9, 154.7, 152.1, 150.1, 149.8, 149.1, 148.8, 142.1, 138.1, 129.8, 129.6, 126.8, 126.4, 117.1, 115.7, 115.5, 114.7, 110.6, 110.1, 109.5 (×2), 100.5, 96.0, 91.1, 88.2, 81.3, 80.9, 80.0 (x 3), 71.5, 71.1, 64.6, 63.5, 60.0, 59.9, 56.1 (×2), 50.7, 49.1 (x 2), 49.0, 35.5, 35.2, 31.3, 30.9, 28.4, 28.1 (×2), 25.3 (×2), 20.7, 20.0; IR (CHCl<sub>3</sub>) 2975, 2939, 2856, 1699, 1640, 1602, 1510, 1454, 1430, 1393, 1367, 1326, 1273, 1246, 1202, 1161, 1118, 1072, 1015, 997, 965, 904, 861, 816, 792, 638 cm<sup>–1</sup>; MS (ES<sup>+</sup>) <i>m</i>/<i>z</i> (relative intensity) 1208 ([M + H]<sup>+•</sup>, 25), 483 (100).</div></div><div id="sec4_2_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> (11a<i>S</i>,11a′<i>S</i>)-8,8′-(((5-(Piperazin-1-yl)-1,3-phenylene)bis(methylene))bis(oxy))bis(7-methoxy-2-methylene-2,3-dihydro-1<i>H</i>-pyrrolo[2,1-<i>c</i>][1,4]benzodiazepin-5(11a<i>H</i>)-one) (<b>30</b>)</h3><div class="NLM_p last">A cold (ice bath) solution of 95:5 v/v TFA/H<sub>2</sub>O (4 mL) was added to compound <b>29</b> (0.2 g, 0.165 mmol) which had been cooled in an ice bath. The solution was stirred at 0 °C for 30 min when reaction was shown to be complete by LC–MS retention time 2.33 min (ES<sup>+</sup>) <i>m</i>/<i>z</i> 703 [M + H]<sup>+•</sup>. The reaction mixture was added dropwise to a mixture of ice and saturated NaHCO<sub>3</sub> solution to neutralize the TFA. The mixture was extracted with DCM (4 × 75 mL) and the combined extracts were washed with water (100 mL), saturated brine (100 mL), dried (MgSO<sub>4</sub>), filtered, and the solvent was removed by rotary evaporation under reduced pressure to give <b>30</b> as a yellow solid which was used without further purification (0.116 g, 0.165 mmol, 100% yield).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> Reduction/Oxidation of THIOMABs for Conjugation</h3><div class="NLM_p last">Full length cysteine engineered monoclonal antibodies<a onclick="showRef(event, 'ref42 ref44 ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref42 ref44 ref45 ref46">(42, 44-46)</a> (THIOMABs) were expressed in CHO cells as cysteine and glutathione capped intermediates. The engineered cysteines were made reactive by reduction with a 50-fold excess of DTT in 50 mM Tris, pH 7.5, with 2 mM EDTA for 3 h at 37 °C or overnight at room temperature.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> The reduced THIOMAB antibody was purified by cation exchange chromatography (SPHP resin, GE) using an AKTA Prime purification system. Samples were acidified by the addition of 10% acetic acid to a final concentration of 0.5% and then diluted 6-fold with 10 mM succinate, pH 5. The antibody was then loaded onto the column and washed with 10 column volumes of succinate buffer. The column was eluted with 50 mM Tris, pH 7.5, and 150 mM NaCl. The eluted, reduced THIOMAB antibody was treated with a 15-fold molar excess of dehydroascorbic acid (DHAA) to re-form the interchain disulfides. Reoxidation was complete in 2–3 h, as monitored by LC–MS. The reoxidized antibody was again purified by cation exchange chromatography using the conditions already described. The purified, reoxidized THIOMAB antibody was dialyzed into 20 mM sodium succinate, pH 5, 150 mM NaCl, 2 mM EDTA and stored frozen at −20 °C.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> Conjugation of THIOMAB Antibodies with Compounds to Prepare ADCs</h3><div class="NLM_p last">The deblocked, reoxidized THIOMAB antibodies were reacted with 2.5- to 6-fold molar excess of compounds <b>6</b>, <b>7</b>, and <b>8</b> (from a DMSO stock at a concentration of 20 mM) in 50 mM Tris, pH 8, with 10% DMSO v/v final, until the reaction was complete (1–16 h) as determined by LC–MS analysis of the reaction mixture. The crude ADCs were then applied to a cation exchange column after dilution with 20 mM histidine acetate, pH 5.5. The column was washed with at least 10 column volumes of 20 mM histidine acetate, pH 5.5, and the antibody was eluted with 20 mM histidine acetate, pH 5.5, and 300 mM NaCl. The ADCs were formulated into 20 mM histidine acetate, pH 5.5, with 240 mM sucrose using gel filtration columns (Sephacryl S200, GE), pooling the main monomer peak. The ADCs were characterized by UV spectroscopy to determine protein concentration, analytical SEC for aggregation analysis, and LC–MS before and after treatment with lysine C endopeptidase. SEC was performed using a Shodex KW802.5 column in 0.2 M potassium phosphate, pH 6.2, with 0.25 mM potassium chloride and 15% IPA at a flow rate of 0.75 mL/min. The aggregation state of the conjugate was determined by integration of eluted peak area absorbance at 280 nm. LC–MS analysis was performed using an Agilent quadrupole time-of-flight 6520 ESI instrument. As an example, an ADC generated using this chemistry was treated with 1:500 w/w endoproteinase Lys C (Promega) in Tris, pH 7.5, for 30 min at 37 °C. The resulting cleavage fragments were loaded onto a 1000 Å, 8 μm PLRP-S column heated to 80 °C and eluted with a mobile phase of water (A, 0.05% TFA) and acetonitrile (B, 0.04% TFA), gradient 30% B to 40% B in 5 min; the flow rate was 0.5 mL/min. Protein elution was monitored by UV absorbance detection at 280 nm prior to electrospray ionization and MS analysis. Chromatographic resolution of the unconjugated Fc fragment, residual unconjugated Fab, and drugged Fab was usually achieved. The obtained <i>m</i>/<i>z</i> spectra were deconvoluted using Mass Hunter software (Agilent Technologies) to calculate the mass of the antibody fragments and drug to antibody ratio (DAR).</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> In Vitro Cytotoxicity<a onclick="showRef(event, 'ref28 ref48'); return false;" href="javascript:void(0);" class="ref ref28 ref48">(28, 48)</a></h3><div class="NLM_p">Human breast tumor lines SK-BR-3 and MCF7 were obtained from the American Type Culture Collection. KPL-4 breast cancer cells were provided by Prof. Junichi Kurebayashi, Kawasaki Medical Hospital, Kurashiki, Okayama, Japan. Cells were plated in black-walled 96-well plates (4000 for SK-BR-3; 1300 for KPL-4; 5000 for MCF7) and allowed to adhere overnight at 37 °C in a humidified atmosphere containing 5% CO<sub>2</sub>. The medium was then removed and replaced by fresh culture medium containing different concentrations of each ADC. Cell Titer-Glo (Promega Corp.) was added to the wells at 5 days after ADC administration, and the luminescent signal was measured using EnVision multilabel plate reader (PerkinElmer).</div><div class="NLM_p last">BJAB, Jurkat, and WSU-DLCL2 cell lines were seeded at 4–7000 cells/well and grown on Corning 384-well flat clear bottom white polystyrene TC-treated microplates in cysteine-free RPMI or DMEM Ham’s F-12 media containing 10% FBS, 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine, and 0.015 g/L methionine supplemented with 50 μM fresh cystine to confluence. The ADCs were incubated for 4 days before cell viability was determined using Cell Titer-Glo (Promega Corp.) and the luminescent intensity measured on an EnVision multilabel plate reader (PerkinElmer).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> In Vivo Efficacy<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></h3><div class="NLM_p">The efficacy of anti-HER2 ADCs was investigated in an allograft model of MMTV-HER2 Fo5 mouse mammary tumors. The Fo5 model is a transgenic mouse model in which the human HER2 gene, under transcriptional regulation of the murine mammary tumor virus promoter (MMTV-HER2), is overexpressed in mammary epithelium. The overexpression causes spontaneous development of mammary tumors that overexpress the human HER2 receptor. The mammary tumor of one of the founder animals has been propagated in subsequent generations of FVB mice by serial transplantation of tumor fragments. Before being used for an in vivo efficacy study, the MMTV-HER2 Fo5 transgenic mammary tumor was surgically transplanted into the no. 2/3 mammary fat pad of nu/nu mice (Charles River Laboratories) in fragments that measured approximately 2 × 2 mm.</div><div class="NLM_p">The efficacy of anti-CD22 ADCs was evaluated in a xenograft model of WSU-DLCL2 human non-Hodgkin lymphoma (from DSMZ, German Collection of Microorganisms and Cell Cultures). Cells were maintained in RPMI 1640 supplemented with 10% FBS (Sigma) and 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine. To establish a subcutaneous xenograft model for an in vivo efficacy study, female C.B-17 SCID mice (from Charles River Laboratories) were each inoculated in the flank area with the tumor cells (20 million cells in 0.2 mL of Hank’s balanced salt solution; HyClone).</div><div class="NLM_p last">When tumors reached desired volumes, the tumor-bearing mice were randomized and given a single dose by iv injection of the ADC. Results were plotted as mean tumor volume ± SEM of each group over time.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i47"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00736">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81383" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81383" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b00736" class="ext-link">10.1021/acs.jmedchem.7b00736</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Atomic coordinates for models (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00736/suppl_file/jm7b00736_si_001.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00736/suppl_file/jm7b00736_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00736/suppl_file/jm7b00736_si_001.pdb">jm7b00736_si_001.pdb (103.93 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00736/suppl_file/jm7b00736_si_002.csv">jm7b00736_si_002.csv (0.94 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b00736" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78882" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78882" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephen J. Gregson</span> - <span class="hlFld-Affiliation affiliation">Spirogen, QMB Innovation Centre, 42 New Road, London E1 2AX, United Kingdom</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6859-9772" title="Orcid link">http://orcid.org/0000-0002-6859-9772</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#f394819694809c9d80b39e96979a9e9e869d96dd909c9e"><span class="__cf_email__" data-cfemail="bfd8cddad8ccd0d1ccffd2dadbd6d2d2cad1da91dcd0d2">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas H. Pillow</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#0c7c656060637b22786463616d7f4c6b696269226f6361"><span class="__cf_email__" data-cfemail="97e7fefbfbf8e0b9e3fff8faf6e4d7f0f2f9f2b9f4f8fa">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luke A. Masterson</span> - <span class="hlFld-Affiliation affiliation">Spirogen, QMB Innovation Centre, 42 New Road, London E1 2AX, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Binqing Wei</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Susan D. Spencer</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gyoung-Dong Kang</span> - <span class="hlFld-Affiliation affiliation">Spirogen, QMB Innovation Centre, 42 New Road, London E1 2AX, United Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shang-Fan Yu</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Helga Raab</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeffrey Lau</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guangmin Li</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gail D. Lewis Phillips</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Janet Gunzner-Toste</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian S. Safina</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rachana Ohri</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martine Darwish</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Katherine R. Kozak</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Josefa dela Cruz-Chuh</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew Polson</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John A. Flygare</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Philip W. Howard</span> - <span class="hlFld-Affiliation affiliation">Spirogen, QMB Innovation Centre, 42 New Road, London E1 2AX, United Kingdom</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): S.J.G., L.A.M., G.-D.K., and P.W.H. are employees of Spirogen (now owned by Medimmune Inc.). B.W., T.H.P., S.D.S., S.-F.Y., J.L., G.L., G.D.L.P., J.G.-T., B.S.S., R.O., M.D., K.R.K., J.d.C.-C., and A.P. are employees of Genentech Inc. J.A.F. and H.R. are former employees of Genentech Inc.<br /></br><p class="inlineNote">All animal studies were carried out in compliance with the National Institutes of Health guidelines for the care and use of laboratory animals and were approved by the Institutional Animal Care and Use Committee at Genentech, Inc.</p><br /></br><p class="inlineNote">Authors will release the atomic coordinates and experimental data upon article publication.</p></div></li></ul></div><div class="ack" id="ACK-d146e4546-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i52">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57787" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57787" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Neki Patel of Spirogen is thanked for editorial assistance on this manuscript.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i53" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i53"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i54" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i54"> Abbreviations Used</h2><tr><td class="NLM_term">AcOH</td><td class="NLM_def"><p class="first last">acetic acid</p></td></tr><tr><td class="NLM_term">ADC</td><td class="NLM_def"><p class="first last">antibody–drug conjugate</p></td></tr><tr><td class="NLM_term">(Boc)<sub>2</sub>O</td><td class="NLM_def"><p class="first last">di-<i>tert</i>-butyl dicarbonate</p></td></tr><tr><td class="NLM_term"><i>t</i>-Boc-<i>N</i>-amido-dPEG<sub>4</sub>-acid</td><td class="NLM_def"><p class="first last">2,2-dimethyl-4-oxo-3,8,11,14,17-pentaoxa-5-azaicosan-20-oic acid</p></td></tr><tr><td class="NLM_term">br s</td><td class="NLM_def"><p class="first last">broad singlet</p></td></tr><tr><td class="NLM_term">DAIB</td><td class="NLM_def"><p class="first last">(diacetoxyiodo)benzene</p></td></tr><tr><td class="NLM_term">DAR</td><td class="NLM_def"><p class="first last">drug/antibody ratio</p></td></tr><tr><td class="NLM_term">DHAA</td><td class="NLM_def"><p class="first last">dehydroascorbic acid</p></td></tr><tr><td class="NLM_term">DHP</td><td class="NLM_def"><p class="first last">3,4-dihydro-2<i>H</i>-pyran</p></td></tr><tr><td class="NLM_term">EDCI</td><td class="NLM_def"><p class="first last"><i>N</i>-(3-dimethylaminopropyl)-<i>N</i>′-ethylcarbodiimide hydrochloride</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">EtOH</td><td class="NLM_def"><p class="first last">ethanol</p></td></tr><tr><td class="NLM_term">Fo5</td><td class="NLM_def"><p class="first last">Founder 5</p></td></tr><tr><td class="NLM_term">FVB</td><td class="NLM_def"><p class="first last">Friend virus B</p></td></tr><tr><td class="NLM_term">HER2</td><td class="NLM_def"><p class="first last">human epidermal growth factor receptor 2</p></td></tr><tr><td class="NLM_term">IBD</td><td class="NLM_def"><p class="first last">indolobenzodiazepine</p></td></tr><tr><td class="NLM_term">IPA</td><td class="NLM_def"><p class="first last">propan-2-ol</p></td></tr><tr><td class="NLM_term">mAb</td><td class="NLM_def"><p class="first last">monoclonal antibody</p></td></tr><tr><td class="NLM_term">MAL-dPEG<sub>4</sub>-acid</td><td class="NLM_def"><p class="first last">1-maleimido-3-oxo-7,10,13,16-tetraoxa-4-azanonadecan-19-oic acid</p></td></tr><tr><td class="NLM_term">MeOH</td><td class="NLM_def"><p class="first last">methanol</p></td></tr><tr><td class="NLM_term">KO<i><sup>t</sup></i>Bu</td><td class="NLM_def"><p class="first last">potassium <i>tert</i>-butoxide</p></td></tr><tr><td class="NLM_term">PAB</td><td class="NLM_def"><p class="first last"><i>p</i>-aminobenzyl</p></td></tr><tr><td class="NLM_term">PBD</td><td class="NLM_def"><p class="first last">pyrrolobenzodiazepine</p></td></tr><tr><td class="NLM_term">RuPhos</td><td class="NLM_def"><p class="first last">2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl</p></td></tr><tr><td class="NLM_term">RuPhos Pd G1 methyl <i>tert</i>-butyl ether adduct</td><td class="NLM_def"><p class="first last">chloro-(2-dicyclohexylphosphino-2′,6′-diisopropoxy-1,1′-biphenyl)[2-(2-aminoethyl)phenyl]palladium(II)–methyl <i>tert</i>-butyl ether adduct</p></td></tr><tr><td class="NLM_term">SEC</td><td class="NLM_def"><p class="first last">size-exclusion chromatography</p></td></tr><tr><td class="NLM_term">TBAI</td><td class="NLM_def"><p class="first last">tetrabutylammonium iodide</p></td></tr><tr><td class="NLM_term">TBSOTf</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyldimethylsilyl trifluoromethanesulfonate</p></td></tr><tr><td class="NLM_term"><sup><i>t</i></sup>BuOH</td><td class="NLM_def"><p class="first last">2-methyl-2-propanol</p></td></tr><tr><td class="NLM_term">TCEP</td><td class="NLM_def"><p class="first last">tris(2-carboxyethyl)phosphine hydrochloride</p></td></tr><tr><td class="NLM_term">TEA</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr><tr><td class="NLM_term">TEMPO</td><td class="NLM_def"><p class="first last">2,2,6,6-tetramethyl-1-piperidinyloxy, free radical</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i55">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08761" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08761" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 48 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Thomas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teicher, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassan, R.</span><span> </span><span class="NLM_article-title">Antibody-drug conjugates for cancer therapy</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">e254</span><span class="NLM_x">–</span> <span class="NLM_lpage">262</span><span class="refDoi"> DOI: 10.1016/S1470-2045(16)30030-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1016%2FS1470-2045%2816%2930030-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=27299281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC28XptFCnsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=e254-262&issue=6&author=A.+Thomasauthor=B.+A.+Teicherauthor=R.+Hassan&title=Antibody-drug+conjugates+for+cancer+therapy&doi=10.1016%2FS1470-2045%2816%2930030-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-drug conjugates for cancer therapy</span></div><div class="casAuthors">Thomas, Anish; Teicher, Beverly A.; Hassan, Raffit</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e254-e262</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Antibody-drug conjugates are monoclonal antibodies conjugated to cytotoxic agents.  They use antibodies that are specific to tumor cell-surface proteins and, thus, have tumor specificity and potency not achievable with traditional drugs.  Design of effective antibody-drug conjugates for cancer therapy requires selection of an appropriate target, a monoclonal antibody against the target, potent cytotoxic effector mols., and conjugation of the monoclonal antibody to cytotoxic agents.  Substantial advances in all these aspects in the past decade have resulted in regulatory approval of ado-trastuzumab emtansine and brentuximab vedotin for clin. use.  Several promising antibody-drug conjugates are now in late-phase clin. testing.  Ongoing efforts are focused on identifying better targets, more effective cytotoxic payloads, and further improvements in antibody-drug linker technol.  Improved understanding of the mechanistic basis of antibody-drug conjugate activity will enable design of rational combination therapies with other agents, including immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5Z8wfiqGgZ7Vg90H21EOLACvtfcHk0lhOvquSNIZuhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptFCnsbc%253D&md5=375b381d7f5b23f36453aaa50d46f4b7</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2816%2930030-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252816%252930030-4%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DTeicher%26aufirst%3DB.%2BA.%26aulast%3DHassan%26aufirst%3DR.%26atitle%3DAntibody-drug%2520conjugates%2520for%2520cancer%2520therapy%26jtitle%3DLancet%2520Oncol.%26date%3D2016%26volume%3D17%26issue%3D6%26spage%3De254%26epage%3D262%26doi%3D10.1016%2FS1470-2045%2816%2930030-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Flygare, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pillow, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aristoff, P.</span><span> </span><span class="NLM_article-title">Antibody-drug conjugates for the treatment of cancer</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">113</span><span class="NLM_x">–</span> <span class="NLM_lpage">121</span><span class="refDoi"> DOI: 10.1111/cbdd.12085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1111%2Fcbdd.12085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=23253133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlt1yksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2013&pages=113-121&issue=1&author=J.+A.+Flygareauthor=T.+H.+Pillowauthor=P.+Aristoff&title=Antibody-drug+conjugates+for+the+treatment+of+cancer&doi=10.1111%2Fcbdd.12085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-drug conjugates for the treatment of cancer</span></div><div class="casAuthors">Flygare, John A.; Pillow, Thomas H.; Aristoff, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">113-121</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  With over 20 antibody-drug conjugates in clin. trials as well as a recently FDA-approved drug, it is clear that this is becoming an important and viable approach for selectively delivering highly cytotoxic agents to tumor cells while sparing normal tissue.  This review discusses the crit. aspects for this approach with an emphasis on the properties of the linker between the antibody and the cytotoxic payload that are required for an effective antibody-drug conjugate.  Different linkers are illustrated with attention focused on (i) the specifics of attachment to the antibody, (ii) the polarity of the linker, (iii) the trigger on the linker that initiates cleavage from the drug, and (iv) the self-immolative spacer that liberates the active payload.  Future directions in the field are proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBVlj709scT7Vg90H21EOLACvtfcHk0lhOvquSNIZuhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlt1yksA%253D%253D&md5=236ee3d312781e0b2ad27ad1f6c9365d</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1111%2Fcbdd.12085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcbdd.12085%26sid%3Dliteratum%253Aachs%26aulast%3DFlygare%26aufirst%3DJ.%2BA.%26aulast%3DPillow%26aufirst%3DT.%2BH.%26aulast%3DAristoff%26aufirst%3DP.%26atitle%3DAntibody-drug%2520conjugates%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2013%26volume%3D81%26issue%3D1%26spage%3D113%26epage%3D121%26doi%3D10.1111%2Fcbdd.12085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Lambert, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, C. Q.</span><span> </span><span class="NLM_article-title">Antibody-drug conjugates (ADCs) for personalized treatment of solid tumors: a review</span> <span class="citation_source-journal">Adv. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">1015</span><span class="NLM_x">–</span> <span class="NLM_lpage">1035</span><span class="refDoi"> DOI: 10.1007/s12325-017-0519-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1007%2Fs12325-017-0519-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=28361465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltl2isbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2017&pages=1015-1035&issue=5&author=J.+M.+Lambertauthor=C.+Q.+Morris&title=Antibody-drug+conjugates+%28ADCs%29+for+personalized+treatment+of+solid+tumors%3A+a+review&doi=10.1007%2Fs12325-017-0519-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review</span></div><div class="casAuthors">Lambert, John M.; Morris, Charles Q.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1015-1035</span>CODEN:
                <span class="NLM_cas:coden">ADTHE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-238X</span>.
    
            (<span class="NLM_cas:orgname">Springer Healthcare Ltd.</span>)
        </div><div class="casAbstract">Attaching a cytotoxic "payload" to an antibody to form an antibody-drug conjugate (ADC) provides a mechanism for selective delivery of the cytotoxic agent to cancer cells via the specific binding of the antibody to cancer-selective cell surface mols.  The first ADC to receive marketing authorization was gemtuzumab ozogamicin, which comprises an anti-CD33 antibody conjugated to a highly potent DNA-targeting antibiotic, calicheamicin, approved in 2000 for treating acute myeloid leukemia.  It was withdrawn from the US market in 2010 following an unsuccessful confirmatory trial.  The development of two classes of highly potent microtubule-disrupting agents, maytansinoids and auristatins, as payloads for ADCs resulted in approval of brentuximab vedotin in 2011 for treating Hodgkin lymphoma and anaplastic large cell lymphoma, and approval of ado-trastuzumab emtansine in 2013 for treating HER2-pos. breast cancer.  Their success stimulated much research into the ADC approach, with >60 ADCs currently in clin. evaluation, mostly targeting solid tumors.  Five ADCs have advanced into pivotal clin. trials for treating various solid tumors-platinum-resistant ovarian cancer, mesothelioma, triple-neg. breast cancer, glioblastoma, and small cell lung cancer.  The level of target expression is a key parameter in predicting the likelihood of patient benefit for all these ADCs, as well as for the approved compd., ado-trastuzumab emtansine.  The development of a patient selection strategy linked to target expression on the tumor is thus critically important for identifying the population appropriate for receiving treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFGOQG-cRY8bVg90H21EOLACvtfcHk0lhuPBdxZ1aRjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltl2isbk%253D&md5=42789949f7bbb6d2764af4072632f905</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1007%2Fs12325-017-0519-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12325-017-0519-6%26sid%3Dliteratum%253Aachs%26aulast%3DLambert%26aufirst%3DJ.%2BM.%26aulast%3DMorris%26aufirst%3DC.%2BQ.%26atitle%3DAntibody-drug%2520conjugates%2520%2528ADCs%2529%2520for%2520personalized%2520treatment%2520of%2520solid%2520tumors%253A%2520a%2520review%26jtitle%3DAdv.%2520Ther.%26date%3D2017%26volume%3D34%26issue%3D5%26spage%3D1015%26epage%3D1035%26doi%3D10.1007%2Fs12325-017-0519-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Beck, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goetsch, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumontet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corvaia, N.</span><span> </span><span class="NLM_article-title">Strategies and challenges for the next generation of antibody-drug conjugates</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">315</span><span class="NLM_x">–</span> <span class="NLM_lpage">337</span><span class="refDoi"> DOI: 10.1038/nrd.2016.268</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1038%2Fnrd.2016.268" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=28303026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkt1Onsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=315-337&issue=5&author=A.+Beckauthor=L.+Goetschauthor=C.+Dumontetauthor=N.+Corvaia&title=Strategies+and+challenges+for+the+next+generation+of+antibody-drug+conjugates&doi=10.1038%2Fnrd.2016.268"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies and challenges for the next generation of antibody-drug conjugates</span></div><div class="casAuthors">Beck, Alain; Goetsch, Liliane; Dumontet, Charles; Corvaia, Nathalie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">315-337</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Antibody-drug conjugates (ADCs) are one of the fastest growing classes of oncol. therapeutics.  After half a century of research, the approvals of brentuximab vedotin (in 2011) and trastuzumab emtansine (in 2013) have paved the way for ongoing clin. trials that are evaluating more than 60 further ADC candidates.  The limited success of first-generation ADCs (developed in the early 2000s) informed strategies to bring second-generation ADCs to the market, which have higher levels of cytotoxic drug conjugation, lower levels of naked antibodies and more-stable linkers between the drug and the antibody.  Furthermore, lessons learned during the past decade are now being used in the development of third-generation ADCs.  In this Review, we discuss strategies to select the best target antigens as well as suitable cytotoxic drugs; the design of optimized linkers; the discovery of bioorthogonal conjugation chemistries; and toxicity issues.  The selection and engineering of antibodies for site-specific drug conjugation, which will result in higher homogeneity and increased stability, as well as the quest for new conjugation chemistries and mechanisms of action, are priorities in ADC research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqP7lV63Ws8rbVg90H21EOLACvtfcHk0lhuPBdxZ1aRjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkt1Onsbc%253D&md5=7358b6080dd1aed1d21e98c078cd9ef1</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.268%26sid%3Dliteratum%253Aachs%26aulast%3DBeck%26aufirst%3DA.%26aulast%3DGoetsch%26aufirst%3DL.%26aulast%3DDumontet%26aufirst%3DC.%26aulast%3DCorvaia%26aufirst%3DN.%26atitle%3DStrategies%2520and%2520challenges%2520for%2520the%2520next%2520generation%2520of%2520antibody-drug%2520conjugates%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26issue%3D5%26spage%3D315%26epage%3D337%26doi%3D10.1038%2Fnrd.2016.268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Mantaj, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahman, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thurston, D. E.</span><span> </span><span class="NLM_article-title">From anthramycin to pyrrolobenzodiazepine (PBD)-containing antibody-drug conjugates (ADCs)</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">462</span><span class="NLM_x">–</span> <span class="NLM_lpage">488</span><span class="refDoi"> DOI: 10.1002/anie.201510610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1002%2Fanie.201510610" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=462-488&issue=2&author=J.+Mantajauthor=P.+J.+Jacksonauthor=K.+M.+Rahmanauthor=D.+E.+Thurston&title=From+anthramycin+to+pyrrolobenzodiazepine+%28PBD%29-containing+antibody-drug+conjugates+%28ADCs%29&doi=10.1002%2Fanie.201510610"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2Fanie.201510610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201510610%26sid%3Dliteratum%253Aachs%26aulast%3DMantaj%26aufirst%3DJ.%26aulast%3DJackson%26aufirst%3DP.%2BJ.%26aulast%3DRahman%26aufirst%3DK.%2BM.%26aulast%3DThurston%26aufirst%3DD.%2BE.%26atitle%3DFrom%2520anthramycin%2520to%2520pyrrolobenzodiazepine%2520%2528PBD%2529-containing%2520antibody-drug%2520conjugates%2520%2528ADCs%2529%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26issue%3D2%26spage%3D462%26epage%3D488%26doi%3D10.1002%2Fanie.201510610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Gerratana, B.</span><span> </span><span class="NLM_article-title">Biosynthesis, synthesis, and biological activities of pyrrolobenzodiazepines</span> <span class="citation_source-journal">Med. Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">254</span><span class="NLM_x">–</span> <span class="NLM_lpage">293</span><span class="refDoi"> DOI: 10.1002/med.20212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1002%2Fmed.20212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=20544978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtFyrsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2012&pages=254-293&issue=2&author=B.+Gerratana&title=Biosynthesis%2C+synthesis%2C+and+biological+activities+of+pyrrolobenzodiazepines&doi=10.1002%2Fmed.20212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Biosynthesis, synthesis, and biological activities of pyrrolobenzodiazepines</span></div><div class="casAuthors">Gerratana, Barbara</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">254-293</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Pyrrolobenzodiazepines (PBDs) are sequence selective DNA alkylating agents with remarkable antineoplastic activity.  They are either naturally produced by actinomycetes or synthetically produced.  The remarkable broad spectrum of activities of the naturally produced PBDs encouraged the synthesis of several PBDs, including dimeric and hybrid PBDs yielding to an improvement in the DNA-binding sequence specificity and in the potency of this class of compds.  However, limitation in the chem. synthesis prevented the testing of one of the most potent PBDs, sibiromycin, a naturally produced glycosylated PBDs.  Only recently, the biosynthetic gene clusters for PBDs have been identified opening the doors to the prodn. of glycosylated PBDs by mutasynthesis and biosynthetic engineering.  This review describes the recent studies on the biosynthesis of naturally produced pyrrolobenzodiazepines.  In addn., it provides an overview on the isolation and characterization of naturally produced PBDs, chem. synthesis of PBDs, mechanism of DNA alkylation, and DNA-binding affinity and cytotoxic properties of both naturally produced and synthetic pyrrolobenzodiazepines. © 2010 Wiley Periodicals, Inc.  Med Res Rev.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOmRcKrPImT7Vg90H21EOLACvtfcHk0lgsyFNlRv43Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtFyrsrg%253D&md5=52cbb58c773ff202f874514afc406fab</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1002%2Fmed.20212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20212%26sid%3Dliteratum%253Aachs%26aulast%3DGerratana%26aufirst%3DB.%26atitle%3DBiosynthesis%252C%2520synthesis%252C%2520and%2520biological%2520activities%2520of%2520pyrrolobenzodiazepines%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2012%26volume%3D32%26issue%3D2%26spage%3D254%26epage%3D293%26doi%3D10.1002%2Fmed.20212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Antonow, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thurston, D. E.</span><span> </span><span class="NLM_article-title">Synthesis of DNA-interactive pyrrolo[2,1-<i>c</i>][1,4]benzodiazepines (PBDs)</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">2815</span><span class="NLM_x">–</span> <span class="NLM_lpage">2864</span><span class="refDoi"> DOI: 10.1021/cr100120f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr100120f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFOqsb7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2011&pages=2815-2864&issue=4&author=D.+Antonowauthor=D.+E.+Thurston&title=Synthesis+of+DNA-interactive+pyrrolo%5B2%2C1-c%5D%5B1%2C4%5Dbenzodiazepines+%28PBDs%29&doi=10.1021%2Fcr100120f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of DNA-Interactive Pyrrolo[2,1-c][1,4]benzodiazepines (PBDs)</span></div><div class="casAuthors">Antonow, Dyeison; Thurston, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2815-2864</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) are an important class of sequence-selective DNA-interactive agents that bind covalently to guanine bases within the minor groove of DNA.  This review is organized around the crucial "B-ring cyclization" reaction that allows formation of the PBD skeleton.  Synthetic methodologies to PBD include ring-closing metathesis, the redn. of azides to amines for the cyclization of Me N-(2-azidobenzoyl)pyrrolidine-2-carboxylates, the bis(trifluoroacetoxy)iodobenzene (PIFA)-mediated cyclization of 1-benzoyl-N-methoxypyrrolidine-2-carboxamides, the intramol. cyclization of 1-benzoyl-N-methoxypyrrolidine-2-carboxamides, etc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRHM0E2GH6zLVg90H21EOLACvtfcHk0lgsyFNlRv43Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFOqsb7K&md5=52d2294bd331032316a5e604d43e1375</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fcr100120f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr100120f%26sid%3Dliteratum%253Aachs%26aulast%3DAntonow%26aufirst%3DD.%26aulast%3DThurston%26aufirst%3DD.%2BE.%26atitle%3DSynthesis%2520of%2520DNA-interactive%2520pyrrolo%255B2%252C1-c%255D%255B1%252C4%255Dbenzodiazepines%2520%2528PBDs%2529%26jtitle%3DChem.%2520Rev.%26date%3D2011%26volume%3D111%26issue%3D4%26spage%3D2815%26epage%3D2864%26doi%3D10.1021%2Fcr100120f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Hartley, J. A.</span><span> </span><span class="NLM_article-title">The development of pyrrolobenzodiazepines as antitumour agents</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">733</span><span class="NLM_x">–</span> <span class="NLM_lpage">744</span><span class="refDoi"> DOI: 10.1517/13543784.2011.573477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1517%2F13543784.2011.573477" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=733-744&issue=6&author=J.+A.+Hartley&title=The+development+of+pyrrolobenzodiazepines+as+antitumour+agents&doi=10.1517%2F13543784.2011.573477"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1517%2F13543784.2011.573477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2011.573477%26sid%3Dliteratum%253Aachs%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520development%2520of%2520pyrrolobenzodiazepines%2520as%2520antitumour%2520agents%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2011%26volume%3D20%26issue%3D6%26spage%3D733%26epage%3D744%26doi%3D10.1517%2F13543784.2011.573477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Jeffrey, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyon, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sussman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leiske, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyamoto, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholas, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okeley, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanderson, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, I. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregson, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masterson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiberghien, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thurston, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Law, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span> </span><span class="NLM_article-title">A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">1256</span><span class="NLM_x">–</span> <span class="NLM_lpage">1263</span><span class="refDoi"> DOI: 10.1021/bc400217g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc400217g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptFKjs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=1256-1263&issue=7&author=S.+C.+Jeffreyauthor=P.+J.+Burkeauthor=R.+P.+Lyonauthor=D.+W.+Meyerauthor=D.+Sussmanauthor=M.+Andersonauthor=J.+H.+Hunterauthor=C.+I.+Leiskeauthor=J.+B.+Miyamotoauthor=N.+D.+Nicholasauthor=N.+M.+Okeleyauthor=R.+J.+Sandersonauthor=I.+J.+Stoneauthor=W.+Zengauthor=S.+J.+Gregsonauthor=L.+Mastersonauthor=A.+C.+Tiberghienauthor=P.+W.+Howardauthor=D.+E.+Thurstonauthor=C.+L.+Lawauthor=P.+D.+Senter&title=A+potent+anti-CD70+antibody-drug+conjugate+combining+a+dimeric+pyrrolobenzodiazepine+drug+with+site-specific+conjugation+technology&doi=10.1021%2Fbc400217g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">A Potent Anti-CD70 Antibody-Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology</span></div><div class="casAuthors">Jeffrey, Scott C.; Burke, Patrick J.; Lyon, Robert P.; Meyer, David W.; Sussman, Django; Anderson, Martha; Hunter, Joshua H.; Leiske, Chris I.; Miyamoto, Jamie B.; Nicholas, Nicole D.; Okeley, Nicole M.; Sanderson, Russell J.; Stone, Ivan J.; Zeng, Weiping; Gregson, Stephen J.; Masterson, Luke; Tiberghien, Arnaud C.; Howard, Philip W.; Thurston, David E.; Law, Che-Leung; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1256-1263</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A highly cytotoxic DNA crosslinking pyrrolobenzodiazepine (PBD) dimer with a valine-alanine dipeptide linker was conjugated to the anti-CD70 h1F6 mAb either through endogenous interchain cysteines or, site-specifically, through engineered cysteines at position 239 of the heavy chains.  The h1F6239C-PBD conjugation strategy proved to be superior to interchain cysteine conjugation, affording an antibody-drug conjugate (ADC) with high uniformity in drug-loading and low levels of aggregation.  In vitro cytotoxicity expts. demonstrated that the h1F6239C-PBD was potent and immunol. specific on CD70-pos. renal cell carcinoma (RCC) and non-Hodgkin lymphoma (NHL) cell lines.  The conjugate was resistant to drug loss in plasma and in circulation, and had a pharmacokinetic profile closely matching that of the parental h1F6239C antibody capped with N-ethylmaleimide (NEM).  Evaluation in CD70-pos. RCC and NHL mouse xenograft models showed pronounced antitumor activities at single or weekly doses as low as 0.1 mg/kg of ADC.  The ADC was tolerated at 2.5 mg/kg.  These results demonstrate that PBDs can be effectively used for antibody-targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVruNGtWHpsbVg90H21EOLACvtfcHk0lgsyFNlRv43Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptFKjs7c%253D&md5=31841b0267e41ae861eaf05240c97b15</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fbc400217g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc400217g%26sid%3Dliteratum%253Aachs%26aulast%3DJeffrey%26aufirst%3DS.%2BC.%26aulast%3DBurke%26aufirst%3DP.%2BJ.%26aulast%3DLyon%26aufirst%3DR.%2BP.%26aulast%3DMeyer%26aufirst%3DD.%2BW.%26aulast%3DSussman%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DM.%26aulast%3DHunter%26aufirst%3DJ.%2BH.%26aulast%3DLeiske%26aufirst%3DC.%2BI.%26aulast%3DMiyamoto%26aufirst%3DJ.%2BB.%26aulast%3DNicholas%26aufirst%3DN.%2BD.%26aulast%3DOkeley%26aufirst%3DN.%2BM.%26aulast%3DSanderson%26aufirst%3DR.%2BJ.%26aulast%3DStone%26aufirst%3DI.%2BJ.%26aulast%3DZeng%26aufirst%3DW.%26aulast%3DGregson%26aufirst%3DS.%2BJ.%26aulast%3DMasterson%26aufirst%3DL.%26aulast%3DTiberghien%26aufirst%3DA.%2BC.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26aulast%3DThurston%26aufirst%3DD.%2BE.%26aulast%3DLaw%26aufirst%3DC.%2BL.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DA%2520potent%2520anti-CD70%2520antibody-drug%2520conjugate%2520combining%2520a%2520dimeric%2520pyrrolobenzodiazepine%2520drug%2520with%2520site-specific%2520conjugation%2520technology%26jtitle%3DBioconjugate%2520Chem.%26date%3D2013%26volume%3D24%26issue%3D7%26spage%3D1256%26epage%3D1263%26doi%3D10.1021%2Fbc400217g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Kung Sutherland, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffrey, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kostner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sussman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyon, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrington, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klussman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westendorf, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernstein, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benjamin, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drachman, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McEarchern, J. A.</span><span> </span><span class="NLM_article-title">SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">1455</span><span class="NLM_x">–</span> <span class="NLM_lpage">1463</span><span class="refDoi"> DOI: 10.1182/blood-2013-03-491506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1182%2Fblood-2013-03-491506" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2013&pages=1455-1463&issue=8&author=M.+S.+Kung+Sutherlandauthor=R.+B.+Walterauthor=S.+C.+Jeffreyauthor=P.+J.+Burkeauthor=C.+Yuauthor=H.+Kostnerauthor=I.+Stoneauthor=M.+C.+Ryanauthor=D.+Sussmanauthor=R.+P.+Lyonauthor=W.+Zengauthor=K.+H.+Harringtonauthor=K.+Klussmanauthor=L.+Westendorfauthor=D.+Meyerauthor=I.+D.+Bernsteinauthor=P.+D.+Senterauthor=D.+R.+Benjaminauthor=J.+G.+Drachmanauthor=J.+A.+McEarchern&title=SGN-CD33A%3A+a+novel+CD33-targeting+antibody-drug+conjugate+using+a+pyrrolobenzodiazepine+dimer+is+active+in+models+of+drug-resistant+AML&doi=10.1182%2Fblood-2013-03-491506"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-03-491506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-03-491506%26sid%3Dliteratum%253Aachs%26aulast%3DKung%2BSutherland%26aufirst%3DM.%2BS.%26aulast%3DWalter%26aufirst%3DR.%2BB.%26aulast%3DJeffrey%26aufirst%3DS.%2BC.%26aulast%3DBurke%26aufirst%3DP.%2BJ.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DKostner%26aufirst%3DH.%26aulast%3DStone%26aufirst%3DI.%26aulast%3DRyan%26aufirst%3DM.%2BC.%26aulast%3DSussman%26aufirst%3DD.%26aulast%3DLyon%26aufirst%3DR.%2BP.%26aulast%3DZeng%26aufirst%3DW.%26aulast%3DHarrington%26aufirst%3DK.%2BH.%26aulast%3DKlussman%26aufirst%3DK.%26aulast%3DWestendorf%26aufirst%3DL.%26aulast%3DMeyer%26aufirst%3DD.%26aulast%3DBernstein%26aufirst%3DI.%2BD.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26aulast%3DBenjamin%26aufirst%3DD.%2BR.%26aulast%3DDrachman%26aufirst%3DJ.%2BG.%26aulast%3DMcEarchern%26aufirst%3DJ.%2BA.%26atitle%3DSGN-CD33A%253A%2520a%2520novel%2520CD33-targeting%2520antibody-drug%2520conjugate%2520using%2520a%2520pyrrolobenzodiazepine%2520dimer%2520is%2520active%2520in%2520models%2520of%2520drug-resistant%2520AML%26jtitle%3DBlood%26date%3D2013%26volume%3D122%26issue%3D8%26spage%3D1455%26epage%3D1463%26doi%3D10.1182%2Fblood-2013-03-491506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Tiberghien, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masterson, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, N. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbett, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, P. W.</span><span> </span><span class="NLM_article-title">Design and synthesis of tesirine, a clinical antibody-drug conjugate pyrrolobenzodiazepine dimer payload</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">983</span><span class="NLM_x">–</span> <span class="NLM_lpage">987</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00062</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00062" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC28XosFSgu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=983-987&issue=11&author=A.+C.+Tiberghienauthor=J.+N.+Levyauthor=L.+A.+Mastersonauthor=N.+V.+Patelauthor=L.+R.+Adamsauthor=S.+Corbettauthor=D.+G.+Williamsauthor=J.+A.+Hartleyauthor=P.+W.+Howard&title=Design+and+synthesis+of+tesirine%2C+a+clinical+antibody-drug+conjugate+pyrrolobenzodiazepine+dimer+payload&doi=10.1021%2Facsmedchemlett.6b00062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Tesirine, a Clinical Antibody-Drug Conjugate Pyrrolobenzodiazepine Dimer Payload</span></div><div class="casAuthors">Tiberghien, Arnaud C.; Levy, Jean-Noel; Masterson, Luke A.; Patel, Neki V.; Adams, Lauren R.; Corbett, Simon; Williams, David G.; Hartley, John A.; Howard, Philip W.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">983-987</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pyrrolobenzodiazepine dimers are an emerging class of warhead in the field of antibody-drug conjugates (ADCs).  Tesirine (SG3249) was designed to combine potent antitumor activity with desirable physicochem. properties such as favorable hydrophobicity and improved conjugation characteristics.  One of the reactive imines was capped with a cathepsin B-cleavable valine-alanine linker.  A robust synthetic route was developed to allow the prodn. of tesirine on clin. scale, employing a flexible, convergent strategy.  Tesirine was evaluated in vitro both in stochastic and engineered ADC constructs and was confirmed as a potent and versatile payload.  The conjugation of tesirine to anti-DLL3 rovalpituzumab has resulted in rovalpituzumab-tesirine (Rova-T), currently under evaluation for the treatment of small cell lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYid7RNts7s7Vg90H21EOLACvtfcHk0lix6xuq9xwcfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosFSgu70%253D&md5=7e4bbdd55b944ff712f01d31d58c0d13</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00062%26sid%3Dliteratum%253Aachs%26aulast%3DTiberghien%26aufirst%3DA.%2BC.%26aulast%3DLevy%26aufirst%3DJ.%2BN.%26aulast%3DMasterson%26aufirst%3DL.%2BA.%26aulast%3DPatel%26aufirst%3DN.%2BV.%26aulast%3DAdams%26aufirst%3DL.%2BR.%26aulast%3DCorbett%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DD.%2BG.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520tesirine%252C%2520a%2520clinical%2520antibody-drug%2520conjugate%2520pyrrolobenzodiazepine%2520dimer%2520payload%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26issue%3D11%26spage%3D983%26epage%3D987%26doi%3D10.1021%2Facsmedchemlett.6b00062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Saunders, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bankovich, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aujay, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bheddah, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Escarpe, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hampl, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laysang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Molina, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pysz, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slingerland, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torgov, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foord, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jassem, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badzio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czapiewski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harpole, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowlati, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massion, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Travis, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietanza, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirier, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudin, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stull, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dylla, S. J.</span><span> </span><span class="NLM_article-title">A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells <i>in vivo</i></span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">302</span><span class="NLM_x">) </span> <span class="NLM_fpage">302ra136</span><span class="refDoi"> DOI: 10.1126/scitranslmed.aac9459</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1126%2Fscitranslmed.aac9459" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=26311731" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=302ra136&issue=302&author=L.+R.+Saundersauthor=A.+J.+Bankovichauthor=W.+C.+Andersonauthor=M.+A.+Aujayauthor=S.+Bheddahauthor=K.+Blackauthor=R.+Desaiauthor=P.+A.+Escarpeauthor=J.+Hamplauthor=A.+Laysangauthor=D.+Liuauthor=J.+Lopez-Molinaauthor=M.+Miltonauthor=A.+Parkauthor=M.+A.+Pyszauthor=H.+Shaoauthor=B.+Slingerlandauthor=M.+Torgovauthor=S.+A.+Williamsauthor=O.+Foordauthor=P.+Howardauthor=J.+Jassemauthor=A.+Badzioauthor=P.+Czapiewskiauthor=D.+H.+Harpoleauthor=A.+Dowlatiauthor=P.+P.+Massionauthor=W.+D.+Travisauthor=M.+C.+Pietanzaauthor=J.+T.+Poirierauthor=C.+M.+Rudinauthor=R.+A.+Stullauthor=S.+J.+Dylla&title=A+DLL3-targeted+antibody-drug+conjugate+eradicates+high-grade+pulmonary+neuroendocrine+tumor-initiating+cells+in+vivo&doi=10.1126%2Fscitranslmed.aac9459"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aac9459&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aac9459%26sid%3Dliteratum%253Aachs%26aulast%3DSaunders%26aufirst%3DL.%2BR.%26aulast%3DBankovich%26aufirst%3DA.%2BJ.%26aulast%3DAnderson%26aufirst%3DW.%2BC.%26aulast%3DAujay%26aufirst%3DM.%2BA.%26aulast%3DBheddah%26aufirst%3DS.%26aulast%3DBlack%26aufirst%3DK.%26aulast%3DDesai%26aufirst%3DR.%26aulast%3DEscarpe%26aufirst%3DP.%2BA.%26aulast%3DHampl%26aufirst%3DJ.%26aulast%3DLaysang%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DLopez-Molina%26aufirst%3DJ.%26aulast%3DMilton%26aufirst%3DM.%26aulast%3DPark%26aufirst%3DA.%26aulast%3DPysz%26aufirst%3DM.%2BA.%26aulast%3DShao%26aufirst%3DH.%26aulast%3DSlingerland%26aufirst%3DB.%26aulast%3DTorgov%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DS.%2BA.%26aulast%3DFoord%26aufirst%3DO.%26aulast%3DHoward%26aufirst%3DP.%26aulast%3DJassem%26aufirst%3DJ.%26aulast%3DBadzio%26aufirst%3DA.%26aulast%3DCzapiewski%26aufirst%3DP.%26aulast%3DHarpole%26aufirst%3DD.%2BH.%26aulast%3DDowlati%26aufirst%3DA.%26aulast%3DMassion%26aufirst%3DP.%2BP.%26aulast%3DTravis%26aufirst%3DW.%2BD.%26aulast%3DPietanza%26aufirst%3DM.%2BC.%26aulast%3DPoirier%26aufirst%3DJ.%2BT.%26aulast%3DRudin%26aufirst%3DC.%2BM.%26aulast%3DStull%26aufirst%3DR.%2BA.%26aulast%3DDylla%26aufirst%3DS.%2BJ.%26atitle%3DA%2520DLL3-targeted%2520antibody-drug%2520conjugate%2520eradicates%2520high-grade%2520pulmonary%2520neuroendocrine%2520tumor-initiating%2520cells%2520in%2520vivo%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2015%26volume%3D7%26issue%3D302%26spage%3D302ra136%26doi%3D10.1126%2Fscitranslmed.aac9459" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Flynn, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zammarchi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyrer, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akarca, A. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janghra, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Britten, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Havenith, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiberghien, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masterson, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Hooge, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marafioti, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parren, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Berkel, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartley, J. A.</span><span> </span><span class="NLM_article-title">ADCT-301, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting CD25-expressing hematological malignancies</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">2709</span><span class="NLM_x">–</span> <span class="NLM_lpage">2721</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1158%2F1535-7163.MCT-16-0233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=27535974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC2sXovVOqsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=2709-2721&issue=11&author=M.+J.+Flynnauthor=F.+Zammarchiauthor=P.+C.+Tyrerauthor=A.+U.+Akarcaauthor=N.+Janghraauthor=C.+E.+Brittenauthor=C.+E.+Havenithauthor=J.+N.+Levyauthor=A.+Tiberghienauthor=L.+A.+Mastersonauthor=C.+Barryauthor=F.+D%E2%80%99Hoogeauthor=T.+Marafiotiauthor=P.+W.+Parrenauthor=D.+G.+Williamsauthor=P.+W.+Howardauthor=P.+H.+van+Berkelauthor=J.+A.+Hartley&title=ADCT-301%2C+a+pyrrolobenzodiazepine+%28PBD%29+dimer-containing+antibody-drug+conjugate+%28ADC%29+targeting+CD25-expressing+hematological+malignancies&doi=10.1158%2F1535-7163.MCT-16-0233"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">ADCT-301, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting CD25-expressing hematological malignancies</span></div><div class="casAuthors">Flynn, Michael J.; Zammarchi, Francesca; Tyrer, Peter C.; Akarca, Ayse U.; Janghra, Narinder; Britten, Charles E.; Havenith, Carin E. G.; Levy, Jean-Noel; Tiberghien, Arnaud; Masterson, Luke A.; Barry, Conor; D'Hooge, Francois; Marafioti, Teresa; Parren, Paul W. H. I.; Williams, David G.; Howard, Philip W.; van Berkel, Patrick H.; Hartley, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2709-2721</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Despite the many advances in the treatment of hematol. malignancies over the past decade, outcomes in refractory lymphomas remain poor.  One potential strategy in this patient population is the specific targeting of IL2R-α (CD25), which is overexpressed on many lymphoma and leukemic cells, using antibody-drug conjugates (ADC).  ADCT-301 is an ADC composed of human IgG1 HuMax-TAC against CD25, stochastically conjugated through a dipeptide cleavable linker to a pyrrolobenzodiazepine (PBD) dimer warhead with a drug-antibody ratio (DAR) of 2.3.  ADCT-301 binds human CD25 with picomolar affinity.  ADCT-301 has highly potent and selective cytotoxicity against a panel of CD25-expressing human lymphoma cell lines.  Once internalized, the released warhead binds in the DNA minor groove and exerts its potent cytotoxic action via the formation of DNA interstrand cross-links.  A strong correlation between loss of viability and DNA cross-link formation is demonstrated.  DNA damage persists, resulting in phosphorylation of histone H2AX, cell-cycle arrest in G2-M, and apoptosis Bystander killing of CD25-neg. cells by ADCT-301 is also obsd.  In vivo, a single dose of ADCT-301 results in dose-dependent and targeted antitumor activity against both s.c. and disseminated CD25-pos. lymphoma models.  In xenografts of Karpas 299, which expressed both CD25 and CD30, marked superiority over brentuximab vedotin (Adcetris) is obsd.  Dose-dependent increases in DNA crosslinking, γ-H2AX, and PBD payload staining were obsd. in tumors in vivo indicating a role as relevant pharmacodynamic assays.  Together, these data support the clin. testing of this novel ADC in patients with CD25-expressing tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOYRWJCTYK9rVg90H21EOLACvtfcHk0lhULXhSkZWNqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXovVOqsro%253D&md5=f43190787d13ef897602016b3a607bc3</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0233%26sid%3Dliteratum%253Aachs%26aulast%3DFlynn%26aufirst%3DM.%2BJ.%26aulast%3DZammarchi%26aufirst%3DF.%26aulast%3DTyrer%26aufirst%3DP.%2BC.%26aulast%3DAkarca%26aufirst%3DA.%2BU.%26aulast%3DJanghra%26aufirst%3DN.%26aulast%3DBritten%26aufirst%3DC.%2BE.%26aulast%3DHavenith%26aufirst%3DC.%2BE.%26aulast%3DLevy%26aufirst%3DJ.%2BN.%26aulast%3DTiberghien%26aufirst%3DA.%26aulast%3DMasterson%26aufirst%3DL.%2BA.%26aulast%3DBarry%26aufirst%3DC.%26aulast%3DD%25E2%2580%2599Hooge%26aufirst%3DF.%26aulast%3DMarafioti%26aufirst%3DT.%26aulast%3DParren%26aufirst%3DP.%2BW.%26aulast%3DWilliams%26aufirst%3DD.%2BG.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26aulast%3Dvan%2BBerkel%26aufirst%3DP.%2BH.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26atitle%3DADCT-301%252C%2520a%2520pyrrolobenzodiazepine%2520%2528PBD%2529%2520dimer-containing%2520antibody-drug%2520conjugate%2520%2528ADC%2529%2520targeting%2520CD25-expressing%2520hematological%2520malignancies%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26issue%3D11%26spage%3D2709%26epage%3D2721%26doi%3D10.1158%2F1535-7163.MCT-16-0233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Rudin, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietanza, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ready, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgensztern, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glisson, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byers, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burris, H. A.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bheddah, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theiss, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathur, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vennapusa, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zayed, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lally, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strickland, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Govindan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dylla, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spigel, D. R.</span><span> </span><span class="NLM_article-title">Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">42</span><span class="NLM_x">–</span> <span class="NLM_lpage">51</span><span class="refDoi"> DOI: 10.1016/S1470-2045(16)30565-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1016%2FS1470-2045%2816%2930565-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=27932068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVSqs7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=42-51&issue=1&author=C.+M.+Rudinauthor=M.+C.+Pietanzaauthor=T.+M.+Bauerauthor=N.+Readyauthor=D.+Morgenszternauthor=B.+S.+Glissonauthor=L.+A.+Byersauthor=M.+L.+Johnsonauthor=H.+A.+Burrisauthor=F.+Robertauthor=T.+H.+Hanauthor=S.+Bheddahauthor=N.+Theissauthor=S.+Watsonauthor=D.+Mathurauthor=B.+Vennapusaauthor=H.+Zayedauthor=S.+Lallyauthor=D.+K.+Stricklandauthor=R.+Govindanauthor=S.+J.+Dyllaauthor=S.+L.+Pengauthor=D.+R.+Spigel&title=Rovalpituzumab+tesirine%2C+a+DLL3-targeted+antibody-drug+conjugate%2C+in+recurrent+small-cell+lung+cancer%3A+a+first-in-human%2C+first-in-class%2C+open-label%2C+phase+1+study&doi=10.1016%2FS1470-2045%2816%2930565-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study</span></div><div class="casAuthors">Rudin, Charles M.; Pietanza, M. Catherine; Bauer, Todd M.; Ready, Neal; Morgensztern, Daniel; Glisson, Bonnie S.; Byers, Lauren A.; Johnson, Melissa L.; Burris, Howard A. III; Robert, Francisco; Han, Tae H.; Bheddah, Sheila; Theiss, Noah; Watson, Sky; Mathur, Deepan; Vennapusa, Bharathi; Zayed, Hany; Lally, Satwant; Strickland, Donald K.; Govindan, Ramaswamy; Dylla, Scott J.; Peng, Stanford L.; Spigel, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">42-51</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Rovalpituzumab tesirine is a first-in-class antibody-drug conjugate directed against delta-like protein 3 (DLL3), a novel target identified in tumor-initiating cells and expressed in more than 80% of patients with small-cell lung cancer.  We aimed to assess the safety and activity of rovalpituzumab tesirine in patients who progressed after one or more previous regimen.  We conducted a phase 1 open-label study at ten cancer centers in the USA.  Eligible patients were aged 18 years or older and had histol. or cytol. confirmed small-cell lung cancer or large-cell neuroendocrine tumors with progressive measurable disease (according to Response Evaluation Criteria in Solid Tumors [RECIST], version 1.1) previously treated with one or two chemotherapeutic regimens, including a platinum-based regimen.  We assigned patients to dose-escalation or expansion cohorts, ranging from 0·05 mg/kg to 0·8 mg/kg rovalpituzumab tesirine i.v. every 3 wk or every 6 wk, followed by investigation of the dose schedules 0·3 mg/kg and 0·4 mg/kg every 6 wk and 0·2 mg/kg every 3 wk.  Primary objectives were to assess the safety of rovalpituzumab tesirine, including the max. tolerated dose and dose-limiting toxic effects.  The primary activity endpoint was objective response by intention-to-treat anal.  This study is registered with ClinicalTrials.gov, no. NCT01901653.  The study is closed to enrollment; this report focuses on the cohort with small-cell lung cancer.  Between July 22, 2013, and Aug 10, 2015, 82 patients were enrolled, including 74 patients with small-cell lung cancer and eight with large-cell neuroendocrine carcinoma, all of whom received at least one dose of rovalpituzumab tesirine.  Dose-limiting toxic effects of rovalpituzumab tesirine occurred at a dose of 0·8 mg/kg every 3 wk, including grade 4 thrombocytopenia (in two of two patients at that dose level) and grade 4 liver function test abnormalities (in one patient).  The most frequent grade 3 or worse treatment-related adverse events in 74 patients with small-cell lung cancer were thrombocytopenia (eight [11%]), pleural effusion (six [8%]), and increased lipase (five [7%]).  Drug-related serious adverse events occurred in 28 (38%) of 74 patients.  The max. tolerated dose of rovalpituzumab tesirine was 0·4 mg/kg every 3 wk; the recommended phase 2 dose and schedule is 0·3 mg/kg every 6 wk.  At active doses of rovalpituzumab tesirine (0·2 mg/kg or 0·4 mg/kg every 3 wk or 0·3 mg/kg or 0·4 mg/kg every 6 wk), 11 (18%) of 60 assessable patients had a confirmed objective response. 11 (18%) of 60 assessable patients had a confirmed objective response, including ten (38%) of 26 patients confirmed to have high DLL3 expression (expression in 50% or more of tumor cells).  Rovalpituzumab tesirine shows encouraging single-agent antitumor activity with a manageable safety profile.  Further development of rovalpituzumab tesirine in DLL3-expressing malignant diseases is warranted.Stemcentrx Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYPf4wkohCNrVg90H21EOLACvtfcHk0lhULXhSkZWNqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVSqs7zN&md5=0c8b51f422fb0973c2e9eb13641dfaf3</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2816%2930565-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252816%252930565-4%26sid%3Dliteratum%253Aachs%26aulast%3DRudin%26aufirst%3DC.%2BM.%26aulast%3DPietanza%26aufirst%3DM.%2BC.%26aulast%3DBauer%26aufirst%3DT.%2BM.%26aulast%3DReady%26aufirst%3DN.%26aulast%3DMorgensztern%26aufirst%3DD.%26aulast%3DGlisson%26aufirst%3DB.%2BS.%26aulast%3DByers%26aufirst%3DL.%2BA.%26aulast%3DJohnson%26aufirst%3DM.%2BL.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DRobert%26aufirst%3DF.%26aulast%3DHan%26aufirst%3DT.%2BH.%26aulast%3DBheddah%26aufirst%3DS.%26aulast%3DTheiss%26aufirst%3DN.%26aulast%3DWatson%26aufirst%3DS.%26aulast%3DMathur%26aufirst%3DD.%26aulast%3DVennapusa%26aufirst%3DB.%26aulast%3DZayed%26aufirst%3DH.%26aulast%3DLally%26aufirst%3DS.%26aulast%3DStrickland%26aufirst%3DD.%2BK.%26aulast%3DGovindan%26aufirst%3DR.%26aulast%3DDylla%26aufirst%3DS.%2BJ.%26aulast%3DPeng%26aufirst%3DS.%2BL.%26aulast%3DSpigel%26aufirst%3DD.%2BR.%26atitle%3DRovalpituzumab%2520tesirine%252C%2520a%2520DLL3-targeted%2520antibody-drug%2520conjugate%252C%2520in%2520recurrent%2520small-cell%2520lung%2520cancer%253A%2520a%2520first-in-human%252C%2520first-in-class%252C%2520open-label%252C%2520phase%25201%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2017%26volume%3D18%26issue%3D1%26spage%3D42%26epage%3D51%26doi%3D10.1016%2FS1470-2045%2816%2930565-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Bauer, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spigel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ready, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgensztern, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glisson, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byers, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burris, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strickland, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietanza, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Govindan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dylla, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudin, C.</span><span> </span><span class="NLM_article-title">ORAL02.01: Safety and efficacy of single-agent rovalpituzumab tesirine, a DLL3-targeted ADC, in recurrent or refractory SCLC</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">11S</span><span class="NLM_x">) </span> <span class="NLM_fpage">S252</span><span class="NLM_x">–</span> <span class="NLM_lpage">S253</span><span class="refDoi"> DOI: 10.1016/j.jtho.2016.09.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1016%2Fj.jtho.2016.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=27969444" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=S252-S253&issue=11S&author=T.+M.+Bauerauthor=D.+Spigelauthor=N.+Readyauthor=D.+Morgenszternauthor=B.+S.+Glissonauthor=L.+A.+Byersauthor=H.+Burrisauthor=F.+Robertauthor=D.+K.+Stricklandauthor=M.+C.+Pietanzaauthor=R.+Govindanauthor=S.+J.+Dyllaauthor=S.+Pengauthor=C.+Rudin&title=ORAL02.01%3A+Safety+and+efficacy+of+single-agent+rovalpituzumab+tesirine%2C+a+DLL3-targeted+ADC%2C+in+recurrent+or+refractory+SCLC&doi=10.1016%2Fj.jtho.2016.09.010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2016.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2016.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DBauer%26aufirst%3DT.%2BM.%26aulast%3DSpigel%26aufirst%3DD.%26aulast%3DReady%26aufirst%3DN.%26aulast%3DMorgensztern%26aufirst%3DD.%26aulast%3DGlisson%26aufirst%3DB.%2BS.%26aulast%3DByers%26aufirst%3DL.%2BA.%26aulast%3DBurris%26aufirst%3DH.%26aulast%3DRobert%26aufirst%3DF.%26aulast%3DStrickland%26aufirst%3DD.%2BK.%26aulast%3DPietanza%26aufirst%3DM.%2BC.%26aulast%3DGovindan%26aufirst%3DR.%26aulast%3DDylla%26aufirst%3DS.%2BJ.%26aulast%3DPeng%26aufirst%3DS.%26aulast%3DRudin%26aufirst%3DC.%26atitle%3DORAL02.01%253A%2520Safety%2520and%2520efficacy%2520of%2520single-agent%2520rovalpituzumab%2520tesirine%252C%2520a%2520DLL3-targeted%2520ADC%252C%2520in%2520recurrent%2520or%2520refractory%2520SCLC%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2016%26volume%3D11%26issue%3D11S%26spage%3DS252%26epage%3DS253%26doi%3D10.1016%2Fj.jtho.2016.09.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Bixby, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fathi, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovacsovics, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erba, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lancet, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jillella, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravandi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faderl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeAngelo, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Meara, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voellinger, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Advani, A.</span><span> </span><span class="NLM_article-title">Vadastuximab talirine monotherapy in older patients with treatment naive CD33-positive acute myeloid leukemia (AML)</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">128</span><span class="NLM_x"> (</span><span class="NLM_issue">22</span><span class="NLM_x">) </span> <span class="NLM_fpage">590</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2016&pages=590&issue=22&author=D.+L.+Bixbyauthor=A.+S.+Steinauthor=A.+T.+Fathiauthor=T.+J.+Kovacsovicsauthor=M.+Y.+Levyauthor=H.+P.+Erbaauthor=J.+E.+Lancetauthor=A.+P.+Jillellaauthor=F.+Ravandiauthor=R.+B.+Walterauthor=E.+M.+Steinauthor=S.+Faderlauthor=D.+J.+DeAngeloauthor=P.+Hoauthor=M.+M.+O%E2%80%99Mearaauthor=J.+L.+Voellingerauthor=A.+Advani&title=Vadastuximab+talirine+monotherapy+in+older+patients+with+treatment+naive+CD33-positive+acute+myeloid+leukemia+%28AML%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBixby%26aufirst%3DD.%2BL.%26aulast%3DStein%26aufirst%3DA.%2BS.%26aulast%3DFathi%26aufirst%3DA.%2BT.%26aulast%3DKovacsovics%26aufirst%3DT.%2BJ.%26aulast%3DLevy%26aufirst%3DM.%2BY.%26aulast%3DErba%26aufirst%3DH.%2BP.%26aulast%3DLancet%26aufirst%3DJ.%2BE.%26aulast%3DJillella%26aufirst%3DA.%2BP.%26aulast%3DRavandi%26aufirst%3DF.%26aulast%3DWalter%26aufirst%3DR.%2BB.%26aulast%3DStein%26aufirst%3DE.%2BM.%26aulast%3DFaderl%26aufirst%3DS.%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DHo%26aufirst%3DP.%26aulast%3DO%25E2%2580%2599Meara%26aufirst%3DM.%2BM.%26aulast%3DVoellinger%26aufirst%3DJ.%2BL.%26aulast%3DAdvani%26aufirst%3DA.%26atitle%3DVadastuximab%2520talirine%2520monotherapy%2520in%2520older%2520patients%2520with%2520treatment%2520naive%2520CD33-positive%2520acute%2520myeloid%2520leukemia%2520%2528AML%2529%26jtitle%3DBlood%26date%3D2016%26volume%3D128%26issue%3D22%26spage%3D590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Erba, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fathi, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maris, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Advani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faderl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donnellan, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voellinger, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravandi, F.</span><span> </span><span class="NLM_article-title">A phase 1b study of vadastuximab talirine in combination with 7+3 induction therapy for patients with newly diagnosed acute myeloid leukemia (AML)</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">128</span><span class="NLM_x"> (</span><span class="NLM_issue">22</span><span class="NLM_x">) </span> <span class="NLM_fpage">211</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2016&pages=211&issue=22&author=H.+P.+Erbaauthor=M.+Y.+Levyauthor=S.+Vasuauthor=A.+S.+Steinauthor=A.+T.+Fathiauthor=M.+B.+Marisauthor=A.+Advaniauthor=S.+Faderlauthor=S.+E.+Smithauthor=B.+L.+Woodauthor=R.+B.+Walterauthor=J.+Yangauthor=W.+B.+Donnellanauthor=E.+J.+Feldmanauthor=J.+L.+Voellingerauthor=F.+Ravandi&title=A+phase+1b+study+of+vadastuximab+talirine+in+combination+with+7%2B3+induction+therapy+for+patients+with+newly+diagnosed+acute+myeloid+leukemia+%28AML%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DErba%26aufirst%3DH.%2BP.%26aulast%3DLevy%26aufirst%3DM.%2BY.%26aulast%3DVasu%26aufirst%3DS.%26aulast%3DStein%26aufirst%3DA.%2BS.%26aulast%3DFathi%26aufirst%3DA.%2BT.%26aulast%3DMaris%26aufirst%3DM.%2BB.%26aulast%3DAdvani%26aufirst%3DA.%26aulast%3DFaderl%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DS.%2BE.%26aulast%3DWood%26aufirst%3DB.%2BL.%26aulast%3DWalter%26aufirst%3DR.%2BB.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DDonnellan%26aufirst%3DW.%2BB.%26aulast%3DFeldman%26aufirst%3DE.%2BJ.%26aulast%3DVoellinger%26aufirst%3DJ.%2BL.%26aulast%3DRavandi%26aufirst%3DF.%26atitle%3DA%2520phase%25201b%2520study%2520of%2520vadastuximab%2520talirine%2520in%2520combination%2520with%25207%252B3%2520induction%2520therapy%2520for%2520patients%2520with%2520newly%2520diagnosed%2520acute%2520myeloid%2520leukemia%2520%2528AML%2529%26jtitle%3DBlood%26date%3D2016%26volume%3D128%26issue%3D22%26spage%3D211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Fathi, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erba, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lancet, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravandi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faderl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Advani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeAngelo, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovacsovics, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jillella, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bixby, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Meara, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, A. S.</span><span> </span><span class="NLM_article-title">Vadastuximab talirine plus hypomethylating agents: a well-tolerated regimen with high remission rate in frontline older patients with acute myeloid leukemia (AML)</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">128</span><span class="NLM_x"> (</span><span class="NLM_issue">22</span><span class="NLM_x">) </span> <span class="NLM_fpage">591</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2016&pages=591&issue=22&author=A.+T.+Fathiauthor=H.+P.+Erbaauthor=J.+E.+Lancetauthor=E.+M.+Steinauthor=F.+Ravandiauthor=S.+Faderlauthor=R.+B.+Walterauthor=A.+Advaniauthor=D.+J.+DeAngeloauthor=T.+J.+Kovacsovicsauthor=A.+P.+Jillellaauthor=D.+L.+Bixbyauthor=M.+Y.+Levyauthor=M.+M.+O%E2%80%99Mearaauthor=P.+Hoauthor=A.+S.+Stein&title=Vadastuximab+talirine+plus+hypomethylating+agents%3A+a+well-tolerated+regimen+with+high+remission+rate+in+frontline+older+patients+with+acute+myeloid+leukemia+%28AML%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFathi%26aufirst%3DA.%2BT.%26aulast%3DErba%26aufirst%3DH.%2BP.%26aulast%3DLancet%26aufirst%3DJ.%2BE.%26aulast%3DStein%26aufirst%3DE.%2BM.%26aulast%3DRavandi%26aufirst%3DF.%26aulast%3DFaderl%26aufirst%3DS.%26aulast%3DWalter%26aufirst%3DR.%2BB.%26aulast%3DAdvani%26aufirst%3DA.%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DKovacsovics%26aufirst%3DT.%2BJ.%26aulast%3DJillella%26aufirst%3DA.%2BP.%26aulast%3DBixby%26aufirst%3DD.%2BL.%26aulast%3DLevy%26aufirst%3DM.%2BY.%26aulast%3DO%25E2%2580%2599Meara%26aufirst%3DM.%2BM.%26aulast%3DHo%26aufirst%3DP.%26aulast%3DStein%26aufirst%3DA.%2BS.%26atitle%3DVadastuximab%2520talirine%2520plus%2520hypomethylating%2520agents%253A%2520a%2520well-tolerated%2520regimen%2520with%2520high%2520remission%2520rate%2520in%2520frontline%2520older%2520patients%2520with%2520acute%2520myeloid%2520leukemia%2520%2528AML%2529%26jtitle%3DBlood%26date%3D2016%26volume%3D128%26issue%3D22%26spage%3D591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravandi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Advani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faderl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erba, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fathi, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donnellan, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voellinger, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maris, M. B.</span><span> </span><span class="NLM_article-title">A phase 1b study of vadastuximab talirine as maintenance and in combination with standard consolidation for patients with acute myeloid leukemia (AML)</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">128</span><span class="NLM_x"> (</span><span class="NLM_issue">22</span><span class="NLM_x">) </span> <span class="NLM_fpage">340</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2016&pages=340&issue=22&author=J.+Yangauthor=F.+Ravandiauthor=A.+Advaniauthor=S.+Vasuauthor=R.+B.+Walterauthor=S.+Faderlauthor=A.+S.+Steinauthor=H.+P.+Erbaauthor=A.+T.+Fathiauthor=W.+B.+Donnellanauthor=M.+Y.+Levyauthor=S.+E.+Smithauthor=B.+L.+Woodauthor=E.+J.+Feldmanauthor=J.+L.+Voellingerauthor=M.+B.+Maris&title=A+phase+1b+study+of+vadastuximab+talirine+as+maintenance+and+in+combination+with+standard+consolidation+for+patients+with+acute+myeloid+leukemia+%28AML%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DRavandi%26aufirst%3DF.%26aulast%3DAdvani%26aufirst%3DA.%26aulast%3DVasu%26aufirst%3DS.%26aulast%3DWalter%26aufirst%3DR.%2BB.%26aulast%3DFaderl%26aufirst%3DS.%26aulast%3DStein%26aufirst%3DA.%2BS.%26aulast%3DErba%26aufirst%3DH.%2BP.%26aulast%3DFathi%26aufirst%3DA.%2BT.%26aulast%3DDonnellan%26aufirst%3DW.%2BB.%26aulast%3DLevy%26aufirst%3DM.%2BY.%26aulast%3DSmith%26aufirst%3DS.%2BE.%26aulast%3DWood%26aufirst%3DB.%2BL.%26aulast%3DFeldman%26aufirst%3DE.%2BJ.%26aulast%3DVoellinger%26aufirst%3DJ.%2BL.%26aulast%3DMaris%26aufirst%3DM.%2BB.%26atitle%3DA%2520phase%25201b%2520study%2520of%2520vadastuximab%2520talirine%2520as%2520maintenance%2520and%2520in%2520combination%2520with%2520standard%2520consolidation%2520for%2520patients%2520with%2520acute%2520myeloid%2520leukemia%2520%2528AML%2529%26jtitle%3DBlood%26date%3D2016%26volume%3D128%26issue%3D22%26spage%3D340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Miller, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fishkin, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whiteman, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovtun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reid, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Archer, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maloney, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Audette, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayo, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilhelm, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modafferi, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinkas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldmacher, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chari, R. V.</span><span> </span><span class="NLM_article-title">A new class of antibody-drug conjugates with potent DNA alkylating activity</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">1870</span><span class="NLM_x">–</span> <span class="NLM_lpage">1878</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1158%2F1535-7163.MCT-16-0184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=27216304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Oks77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=1870-1878&issue=8&author=M.+L.+Millerauthor=N.+E.+Fishkinauthor=W.+Liauthor=K.+R.+Whitemanauthor=Y.+Kovtunauthor=E.+E.+Reidauthor=K.+E.+Archerauthor=E.+K.+Maloneyauthor=C.+A.+Audetteauthor=M.+F.+Mayoauthor=A.+Wilhelmauthor=H.+A.+Modafferiauthor=R.+Singhauthor=J.+Pinkasauthor=V.+Goldmacherauthor=J.+M.+Lambertauthor=R.+V.+Chari&title=A+new+class+of+antibody-drug+conjugates+with+potent+DNA+alkylating+activity&doi=10.1158%2F1535-7163.MCT-16-0184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating Activity</span></div><div class="casAuthors">Miller, Michael L.; Fishkin, Nathan E.; Li, Wei; Whiteman, Kathleen R.; Kovtun, Yelena; Reid, Emily E.; Archer, Katie E.; Maloney, Erin K.; Audette, Charlene A.; Mayo, Michele F.; Wilhelm, Alan; Modafferi, Holly A.; Singh, Rajeeva; Pinkas, Jan; Goldmacher, Victor; Lambert, John M.; Chari, Ravi V. J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1870-1878</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The promise of tumor-selective delivery of cytotoxic agents in the form of antibody-drug conjugates (ADC) has now been realized, evidenced by the approval of two ADCs, both of which incorporate highly cytotoxic tubulin-interacting agents, for cancer therapy.  An ongoing challenge remains in identifying potent agents with alternative mechanisms of cell killing that can provide ADCs with high therapeutic indexes and favorable tolerability.  Here, we describe the development of a new class of potent DNA alkylating agents that meets these objectives.  Through chem. design, we changed the mechanism of action of our novel DNA crosslinking agent to a monofunctional DNA alkylator.  This modification, coupled with linker optimization, generated ADCs that were well tolerated in mice and demonstrated robust antitumor activity in multiple tumor models at doses 1.5% to 3.5% of maximally tolerated levels.  These properties underscore the considerable potential of these purpose-created, unique DNA-interacting conjugates for broadening the clin. application of ADC technol.  Mol Cancer Ther; 15(8); 1870-8. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt5MUcMyl9MbVg90H21EOLACvtfcHk0lgB3QmfBOmOFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Oks77F&md5=39217fa47540ea33e2c7c25d57daa19c</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0184%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DM.%2BL.%26aulast%3DFishkin%26aufirst%3DN.%2BE.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DWhiteman%26aufirst%3DK.%2BR.%26aulast%3DKovtun%26aufirst%3DY.%26aulast%3DReid%26aufirst%3DE.%2BE.%26aulast%3DArcher%26aufirst%3DK.%2BE.%26aulast%3DMaloney%26aufirst%3DE.%2BK.%26aulast%3DAudette%26aufirst%3DC.%2BA.%26aulast%3DMayo%26aufirst%3DM.%2BF.%26aulast%3DWilhelm%26aufirst%3DA.%26aulast%3DModafferi%26aufirst%3DH.%2BA.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DPinkas%26aufirst%3DJ.%26aulast%3DGoldmacher%26aufirst%3DV.%26aulast%3DLambert%26aufirst%3DJ.%2BM.%26aulast%3DChari%26aufirst%3DR.%2BV.%26atitle%3DA%2520new%2520class%2520of%2520antibody-drug%2520conjugates%2520with%2520potent%2520DNA%2520alkylating%2520activity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26issue%3D8%26spage%3D1870%26epage%3D1878%26doi%3D10.1158%2F1535-7163.MCT-16-0184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Polakis, P.</span><span> </span><span class="NLM_article-title">Antibody drug conjugates for cancer therapy</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">19</span><span class="refDoi"> DOI: 10.1124/pr.114.009373</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1124%2Fpr.114.009373" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=26589413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVagtbfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2016&pages=3-19&issue=1&author=P.+Polakis&title=Antibody+drug+conjugates+for+cancer+therapy&doi=10.1124%2Fpr.114.009373"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody drug conjugates for cancer therapy</span></div><div class="casAuthors">Polakis, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-19</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Antibody drug conjugates (ADCs) constitute a family of cancer therapeutics designed to preferentially direct a cytotoxic drug to cells expressing a cell-surface antigen recognized by an antibody.  The antibody and drug are linked through chemistries that enable release of the cytotoxic drug or drug adduct upon internalization and digestion of the ADC by the cell.  Over 40 distinct ADCs, targeting an array of antigens and utilizing a variety of drugs and linkers, are undergoing clin. evaluation.  This review primarily covers ADCs that have advanced to clin. investigation with a particular emphasis on how the individual targets, linker chemistries, and appended drugs influence their behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohI1JS8kX1ZLVg90H21EOLACvtfcHk0ljm5cS-0BOK1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVagtbfM&md5=0f0e52f1481854a86485ebbbc15f1c20</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1124%2Fpr.114.009373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.114.009373%26sid%3Dliteratum%253Aachs%26aulast%3DPolakis%26aufirst%3DP.%26atitle%3DAntibody%2520drug%2520conjugates%2520for%2520cancer%2520therapy%26jtitle%3DPharmacol.%2520Rev.%26date%3D2016%26volume%3D68%26issue%3D1%26spage%3D3%26epage%3D19%26doi%3D10.1124%2Fpr.114.009373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Dorywalska, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dushin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moine, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farias, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navaratnam, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasa-Moreno, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casas, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaria, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foletti, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pons, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shelton, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajpal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strop, P.</span><span> </span><span class="NLM_article-title">Molecular basis of valine-citrulline-PABC linker instability in site-specific ADCs and its mitigation by linker design</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">958</span><span class="NLM_x">–</span> <span class="NLM_lpage">970</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-15-1004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1158%2F1535-7163.MCT-15-1004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=26944918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC28Xnt12rs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=958-970&issue=5&author=M.+Dorywalskaauthor=R.+Dushinauthor=L.+Moineauthor=S.+E.+Fariasauthor=D.+Zhouauthor=T.+Navaratnamauthor=V.+Luiauthor=A.+Hasa-Morenoauthor=M.+G.+Casasauthor=T.+T.+Tranauthor=K.+Delariaauthor=S.+H.+Liuauthor=D.+Folettiauthor=C.+J.+O%E2%80%99Donnellauthor=J.+Ponsauthor=D.+L.+Sheltonauthor=A.+Rajpalauthor=P.+Strop&title=Molecular+basis+of+valine-citrulline-PABC+linker+instability+in+site-specific+ADCs+and+its+mitigation+by+linker+design&doi=10.1158%2F1535-7163.MCT-15-1004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design</span></div><div class="casAuthors">Dorywalska, Magdalena; Dushin, Russell; Moine, Ludivine; Farias, Santiago E.; Zhou, Dahui; Navaratnam, Thayalan; Lui, Victor; Hasa-Moreno, Adela; Casas, Meritxell Galindo; Tran, Thomas-Toan; Delaria, Kathy; Liu, Shu-Hui; Foletti, Davide; O'Donnell, Christopher J.; Pons, Jaume; Shelton, David L.; Rajpal, Arvind; Strop, Pavel</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">958-970</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The degree of stability of antibody-drug linkers in systemic circulation, and the rate of their intracellular processing within target cancer cells are among the key factors detg. the efficacy of antibody-drug conjugates (ADC) in vivo.  Previous studies demonstrated the susceptibility of cleavable linkers, as well as auristatin-based payloads, to enzymic cleavage in rodent plasma.  Here, we identify Carboxylesterase 1C as the enzyme responsible for the extracellular hydrolysis of valine-citrulline-p-aminocarbamate (VC-PABC)-based linkers in mouse plasma.  We further show that the activity of Carboxylesterase 1C towards VC-PABC-based linkers, and consequently the stability of ADCs in mouse plasma, can be effectively modulated by small chem. modifications to the linker.  While the introduced modifications can protect the VC-PABC-based linkers from extracellular cleavage, they do not significantly alter the intracellular linker processing by the lysosomal protease Cathepsin B. The distinct substrate preference of the serum Carboxylesterase 1C offers the opportunity to modulate the extracellular stability of cleavable ADCs without diminishing the intracellular payload release required for ADC efficacy.  Mol Cancer Ther; 15(5); 958-70. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9idQSKwDGcLVg90H21EOLACvtfcHk0ljm5cS-0BOK1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xnt12rs7k%253D&md5=b96d577fd0e19bfc5eb42a5ae0edec5e</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-1004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-1004%26sid%3Dliteratum%253Aachs%26aulast%3DDorywalska%26aufirst%3DM.%26aulast%3DDushin%26aufirst%3DR.%26aulast%3DMoine%26aufirst%3DL.%26aulast%3DFarias%26aufirst%3DS.%2BE.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DNavaratnam%26aufirst%3DT.%26aulast%3DLui%26aufirst%3DV.%26aulast%3DHasa-Moreno%26aufirst%3DA.%26aulast%3DCasas%26aufirst%3DM.%2BG.%26aulast%3DTran%26aufirst%3DT.%2BT.%26aulast%3DDelaria%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DS.%2BH.%26aulast%3DFoletti%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DPons%26aufirst%3DJ.%26aulast%3DShelton%26aufirst%3DD.%2BL.%26aulast%3DRajpal%26aufirst%3DA.%26aulast%3DStrop%26aufirst%3DP.%26atitle%3DMolecular%2520basis%2520of%2520valine-citrulline-PABC%2520linker%2520instability%2520in%2520site-specific%2520ADCs%2520and%2520its%2520mitigation%2520by%2520linker%2520design%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26issue%3D5%26spage%3D958%26epage%3D970%26doi%3D10.1158%2F1535-7163.MCT-15-1004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Ogitani, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagihara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harada, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soma, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oitate, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arakawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atsumi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayakawa, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agatsuma, T.</span><span> </span><span class="NLM_article-title">DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x"> (</span><span class="NLM_issue">20</span><span class="NLM_x">) </span> <span class="NLM_fpage">5097</span><span class="NLM_x">–</span> <span class="NLM_lpage">5108</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-2822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1158%2F1078-0432.CCR-15-2822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=27026201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslOhs77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=5097-5108&issue=20&author=Y.+Ogitaniauthor=T.+Aidaauthor=K.+Hagiharaauthor=J.+Yamaguchiauthor=C.+Ishiiauthor=N.+Haradaauthor=M.+Somaauthor=H.+Okamotoauthor=M.+Oitateauthor=S.+Arakawaauthor=T.+Hiraiauthor=R.+Atsumiauthor=T.+Nakadaauthor=I.+Hayakawaauthor=Y.+Abeauthor=T.+Agatsuma&title=DS-8201a%2C+a+novel+HER2-targeting+ADC+with+a+novel+DNA+topoisomerase+I+inhibitor%2C+demonstrates+a+promising+antitumor+efficacy+with+differentiation+from+T-DM1&doi=10.1158%2F1078-0432.CCR-15-2822"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1</span></div><div class="casAuthors">Ogitani, Yusuke; Aida, Tetsuo; Hagihara, Katsunobu; Yamaguchi, Junko; Ishii, Chiaki; Harada, Naoya; Soma, Masako; Okamoto, Hiromi; Oitate, Masataka; Arakawa, Shingo; Hirai, Takehiro; Atsumi, Ryo; Nakada, Takashi; Hayakawa, Ichiro; Abe, Yuki; Agatsuma, Toshinori</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5097-5108</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">An anti-HER2 antibody-drug conjugate with a novel topoisomerase I inhibitor, DS-8201a, was generated as a new antitumor drug candidate, and its preclin. pharmacol. profile was assessed.  In vitro and in vivo pharmacol. activities of DS-8201a were evaluated and compared with T-DM1 in several HER2-pos. cell lines and patient-derived xenograft (PDX) models.  The mechanism of action for the efficacy was also evaluated.  Pharmacokinetics in cynomolgus monkeys and the safety profiles in rats and cynomolgus monkeys were assessed.  DS-8201a exhibited a HER2 expression-dependent cell growth-inhibitory activity and induced tumor regression with a single dosing at more than 1 mg/kg in a HER2-pos. gastric cancer NCI-N87 model.  Binding activity to HER2 and ADCC activity of DS-8201a were comparable with unconjugated anti-HER2 antibody.  DS-8201a also showed an inhibitory activity to Akt phosphorylation.  DS-8201a induced phosphorylation of Chk1 and Histone H2A.X, the markers of DNA damage.  Pharmacokinetics and safety profiles of DS-8201a were favorable and the highest non-severely toxic dose was 30 mg/kg in cynomolgus monkeys, supporting DS-8201a as being well tolerated in humans.  DS-8201a was effective in a T-DM1-insensitive PDX model with high HER2 expression.  DS-8201a, but not T-DM1, demonstrated antitumor efficacy against several breast cancer PDX models with low HER2 expression.  DS-8201a exhibited a potent antitumor activity in a broad selection of HER2-pos. models and favorable pharmacokinetics and safety profiles.  The results demonstrate that DS-8201a will be a valuable therapy with a great potential to respond to T-DM1-insensitive HER2-pos. cancers and low HER2-expressing cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCZitEmBAqAbVg90H21EOLACvtfcHk0lgmgABoPTdO2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslOhs77F&md5=3fc9a072b2ba05c80929713c843df3f5</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-2822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-2822%26sid%3Dliteratum%253Aachs%26aulast%3DOgitani%26aufirst%3DY.%26aulast%3DAida%26aufirst%3DT.%26aulast%3DHagihara%26aufirst%3DK.%26aulast%3DYamaguchi%26aufirst%3DJ.%26aulast%3DIshii%26aufirst%3DC.%26aulast%3DHarada%26aufirst%3DN.%26aulast%3DSoma%26aufirst%3DM.%26aulast%3DOkamoto%26aufirst%3DH.%26aulast%3DOitate%26aufirst%3DM.%26aulast%3DArakawa%26aufirst%3DS.%26aulast%3DHirai%26aufirst%3DT.%26aulast%3DAtsumi%26aufirst%3DR.%26aulast%3DNakada%26aufirst%3DT.%26aulast%3DHayakawa%26aufirst%3DI.%26aulast%3DAbe%26aufirst%3DY.%26aulast%3DAgatsuma%26aufirst%3DT.%26atitle%3DDS-8201a%252C%2520a%2520novel%2520HER2-targeting%2520ADC%2520with%2520a%2520novel%2520DNA%2520topoisomerase%2520I%2520inhibitor%252C%2520demonstrates%2520a%2520promising%2520antitumor%2520efficacy%2520with%2520differentiation%2520from%2520T-DM1%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26issue%3D20%26spage%3D5097%26epage%3D5108%26doi%3D10.1158%2F1078-0432.CCR-15-2822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Menderes, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonazzoli, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellone, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altwerger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masserdotti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettinella, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zammataro, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buza, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hui, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Litkouhi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratner, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silasi, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azodi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santin, A. D.</span><span> </span><span class="NLM_article-title">SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression</span> <span class="citation_source-journal">Gynecol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">146</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">179</span><span class="NLM_x">–</span> <span class="NLM_lpage">186</span><span class="refDoi"> DOI: 10.1016/j.ygyno.2017.04.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1016%2Fj.ygyno.2017.04.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=28473206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntVShu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2017&pages=179-186&issue=1&author=G.+Menderesauthor=E.+Bonazzoliauthor=S.+Belloneauthor=J.+Blackauthor=G.+Altwergerauthor=A.+Masserdottiauthor=F.+Pettinellaauthor=L.+Zammataroauthor=N.+Buzaauthor=P.+Huiauthor=S.+Wongauthor=B.+Litkouhiauthor=E.+Ratnerauthor=D.+A.+Silasiauthor=G.+S.+Huangauthor=M.+Azodiauthor=P.+E.+Schwartzauthor=A.+D.+Santin&title=SYD985%2C+a+novel+duocarmycin-based+HER2-targeting+antibody-drug+conjugate%2C+shows+promising+antitumor+activity+in+epithelial+ovarian+carcinoma+with+HER2%2FNeu+expression&doi=10.1016%2Fj.ygyno.2017.04.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression</span></div><div class="casAuthors">Menderes, Gulden; Bonazzoli, Elena; Bellone, Stefania; Black, Jonathan; Altwerger, Gary; Masserdotti, Alice; Pettinella, Francesca; Zammataro, Luca; Buza, Natalia; Hui, Pei; Wong, Serena; Litkouhi, Babak; Ratner, Elena; Silasi, Dan-Arin; Huang, Gloria S.; Azodi, Masoud; Schwartz, Peter E.; Santin, Alessandro D.</div><div class="citationInfo"><span class="NLM_cas:title">Gynecologic Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">179-186</span>CODEN:
                <span class="NLM_cas:coden">GYNOA3</span>;
        ISSN:<span class="NLM_cas:issn">0090-8258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Epithelial ovarian cancer (EOC) is an aggressive and heterogeneous disease. < 10% of EOC demonstrate HER2/neu 3 + receptor over-expression.  However, moderate to low (i.e., 2 + and 1 +) HER2/neu expression is reported in up to 50% of EOC.  The objective of this study was to compare the anti-tumor activity of SYD985, a novel HER2-targeting antibody-drug conjugate (ADC), to trastuzumab emtansine (T-DM1) in EOC models with differential HER2/neu expression.  The cytotoxicity of SYD985 and T-DM1 was evaluated using ten primary EOC cell lines with 0/1 +, 2 +, and 3 + HER2/neu expression in antibody-dependent cellular cytotoxicity (ADCC), proliferation, viability and bystander killing expts.  Finally, the in vivo activity of SYD985 and T-DM1 was also studied in ovarian cancer xenografts.  SYD985 and T-DM1 induced similar ADCC in the presence of peripheral blood lymphocytes (PBL) against EOC cell lines with differential HER2/neu expression.  In contrast, SYD985 was 3 to 42 fold more cytotoxic in the absence of PBL when compared to T-DM1 (p < 0.0001).  Unlike T-DM1, SYD985 induced efficient bystander killing of HER2/neu 0/1 + tumor cells when admixed with HER2/neu 3 + EOC cells.  In vivo studies confirmed that SYD985 is significantly more active than T-DM1 against HER2/neu 3 + EOC xenografts.  SYD985 is a novel ADC with remarkable activity against EOC with strong (3 +) as well as moderate to low (i.e., 2 + and 1 +) HER2/neu expression.  SYD985 is more potent than T-DM1 in comparative expts. and unlike T-DM1, it is active against EOC demonstrating moderate/low or heterogeneous HER2/neu expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7He1TDKs0sbVg90H21EOLACvtfcHk0lgmgABoPTdO2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntVShu7k%253D&md5=84d1f52781c732605cf38594f5024de0</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.ygyno.2017.04.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ygyno.2017.04.023%26sid%3Dliteratum%253Aachs%26aulast%3DMenderes%26aufirst%3DG.%26aulast%3DBonazzoli%26aufirst%3DE.%26aulast%3DBellone%26aufirst%3DS.%26aulast%3DBlack%26aufirst%3DJ.%26aulast%3DAltwerger%26aufirst%3DG.%26aulast%3DMasserdotti%26aufirst%3DA.%26aulast%3DPettinella%26aufirst%3DF.%26aulast%3DZammataro%26aufirst%3DL.%26aulast%3DBuza%26aufirst%3DN.%26aulast%3DHui%26aufirst%3DP.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DLitkouhi%26aufirst%3DB.%26aulast%3DRatner%26aufirst%3DE.%26aulast%3DSilasi%26aufirst%3DD.%2BA.%26aulast%3DHuang%26aufirst%3DG.%2BS.%26aulast%3DAzodi%26aufirst%3DM.%26aulast%3DSchwartz%26aufirst%3DP.%2BE.%26aulast%3DSantin%26aufirst%3DA.%2BD.%26atitle%3DSYD985%252C%2520a%2520novel%2520duocarmycin-based%2520HER2-targeting%2520antibody-drug%2520conjugate%252C%2520shows%2520promising%2520antitumor%2520activity%2520in%2520epithelial%2520ovarian%2520carcinoma%2520with%2520HER2%252FNeu%2520expression%26jtitle%3DGynecol.%2520Oncol.%26date%3D2017%26volume%3D146%26issue%3D1%26spage%3D179%26epage%3D186%26doi%3D10.1016%2Fj.ygyno.2017.04.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Li, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muniz-Medina, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetzel, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rebelatto, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinrichs, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bezabeh, B. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleming, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimasi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toader, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, A. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dixit, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osbourn, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coats, S. R.</span><span> </span><span class="NLM_article-title">A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">117</span><span class="NLM_x">–</span> <span class="NLM_lpage">129</span><span class="refDoi"> DOI: 10.1016/j.ccell.2015.12.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1016%2Fj.ccell.2015.12.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=26766593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC28Xmsl2lsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=117-129&issue=1&author=J.+Y.+Liauthor=S.+R.+Perryauthor=V.+Muniz-Medinaauthor=X.+Wangauthor=L.+K.+Wetzelauthor=M.+C.+Rebelattoauthor=M.+J.+Hinrichsauthor=B.+Z.+Bezabehauthor=R.+L.+Flemingauthor=N.+Dimasiauthor=H.+Fengauthor=D.+Toaderauthor=A.+Q.+Yuanauthor=L.+Xuauthor=J.+Linauthor=C.+Gaoauthor=H.+Wuauthor=R.+Dixitauthor=J.+K.+Osbournauthor=S.+R.+Coats&title=A+biparatopic+HER2-targeting+antibody-drug+conjugate+induces+tumor+regression+in+primary+models+refractory+to+or+ineligible+for+HER2-targeted+therapy&doi=10.1016%2Fj.ccell.2015.12.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy</span></div><div class="casAuthors">Li, John Y.; Perry, Samuel R.; Muniz-Medina, Vanessa; Wang, Xinzhong; Wetzel, Leslie K.; Rebelatto, Marlon C.; Hinrichs, Mary Jane Masson; Bezabeh, Binyam Z.; Fleming, Ryan L.; Dimasi, Nazzareno; Feng, Hui; Toader, Dorin; Yuan, Andy Q.; Xu, Lan; Lin, Jia; Gao, Changshou; Wu, Herren; Dixit, Rakesh; Osbourn, Jane K.; Coats, Steven R.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">117-129</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Antibody-drug conjugate (ADC) which delivers cytotoxic drugs specifically into targeted cells through internalization and lysosomal trafficking has emerged as an effective cancer therapy.  We show that a bivalent biparatopic antibody targeting two non-overlapping epitopes on HER2 can induce HER2 receptor clustering, which in turn promotes robust internalization, lysosomal trafficking, and degrdn.  When conjugated with a tubulysin-based microtubule inhibitor, the biparatopic ADC demonstrates superior anti-tumor activity over ado-trastuzumab emtansine (T-DM1) in tumor models representing various patient subpopulations, including T-DM1 eligible, T-DM1 ineligible, and T-DM1 relapsed/refractory.  Our findings indicate that this biparatopic ADC has promising potential as an effective therapy for metastatic breast cancer and a broader patient population may benefit from this unique HER2-targeting ADC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp18b-9TGTzUbVg90H21EOLACvtfcHk0lgmgABoPTdO2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xmsl2lsA%253D%253D&md5=bbd94b53427de32f8d636b63507dd139</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2015.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2015.12.008%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%2BY.%26aulast%3DPerry%26aufirst%3DS.%2BR.%26aulast%3DMuniz-Medina%26aufirst%3DV.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWetzel%26aufirst%3DL.%2BK.%26aulast%3DRebelatto%26aufirst%3DM.%2BC.%26aulast%3DHinrichs%26aufirst%3DM.%2BJ.%26aulast%3DBezabeh%26aufirst%3DB.%2BZ.%26aulast%3DFleming%26aufirst%3DR.%2BL.%26aulast%3DDimasi%26aufirst%3DN.%26aulast%3DFeng%26aufirst%3DH.%26aulast%3DToader%26aufirst%3DD.%26aulast%3DYuan%26aufirst%3DA.%2BQ.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DDixit%26aufirst%3DR.%26aulast%3DOsbourn%26aufirst%3DJ.%2BK.%26aulast%3DCoats%26aufirst%3DS.%2BR.%26atitle%3DA%2520biparatopic%2520HER2-targeting%2520antibody-drug%2520conjugate%2520induces%2520tumor%2520regression%2520in%2520primary%2520models%2520refractory%2520to%2520or%2520ineligible%2520for%2520HER2-targeted%2520therapy%26jtitle%3DCancer%2520Cell%26date%3D2016%26volume%3D29%26issue%3D1%26spage%3D117%26epage%3D129%26doi%3D10.1016%2Fj.ccell.2015.12.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Kantarjian, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeAngelo, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stelljes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liedtke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stock, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gokbuget, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paccagnella, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sleight, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandendries, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Advani, A. S.</span><span> </span><span class="NLM_article-title">Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">375</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">740</span><span class="NLM_x">–</span> <span class="NLM_lpage">753</span><span class="refDoi"> DOI: 10.1056/NEJMoa1509277</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1056%2FNEJMoa1509277" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=27292104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2ks7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2016&pages=740-753&issue=8&author=H.+M.+Kantarjianauthor=D.+J.+DeAngeloauthor=M.+Stelljesauthor=G.+Martinelliauthor=M.+Liedtkeauthor=W.+Stockauthor=N.+Gokbugetauthor=S.+O%E2%80%99Brienauthor=K.+Wangauthor=T.+Wangauthor=M.+L.+Paccagnellaauthor=B.+Sleightauthor=E.+Vandendriesauthor=A.+S.+Advani&title=Inotuzumab+ozogamicin+versus+standard+therapy+for+acute+lymphoblastic+leukemia&doi=10.1056%2FNEJMoa1509277"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia</span></div><div class="casAuthors">Kantarjian, Hagop M.; DeAngelo, Daniel J.; Stelljes, Matthias; Martinelli, Giovanni; Liedtke, Michaela; Stock, Wendy; Goekbuget, Nicola; O'Brien, Susan; Wang, Kongming; Wang, Tao; Paccagnella, M. Luisa; Sleight, Barbara; Vandendries, Erik; Advani, Anjali S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">740-753</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: The prognosis for adults with relapsed acute lymphoblastic leukemia is poor.  We sought to det. whether inotuzumab ozogamicin, an anti-CD22 antibody conjugated to calicheamicin, results in better outcomes in patients with relapsed or refractory acute lymphoblastic leukemia than does std. therapy.  METHODS: In this phase 3 trial, we randomly assigned adults with relapsed or refractory acute lymphoblastic leukemia to receive either inotuzumab ozogamicin (inotuzumab ozogamicin group) or std. intensive chemotherapy (std.-therapy group).  The primary end points were complete remission (including complete remission with incomplete hematol. recovery) and overall survival.  RESULTS: Of the 326 patients who underwent randomization, the first 218 (109 in each group) were included in the primary intention-to-treat anal. of complete remission.  The rate of complete remission was significantly higher in the inotuzumab ozogamicin group than in the std.-therapy group (80.7% [95% confidence interval {CI}, 72.1 to 87.7] vs. 29.4% [95% CI, 21.0 to 38.8], P<0.001).  Among the patients who had complete remission, a higher percentage in the inotuzumab ozogamicin group had results below the threshold for minimal residual disease (0.01% marrow blasts) (78.4% vs. 28.1%, P<0.001); the duration of remission was longer in the inotuzumab ozogamicin group (median, 4.6 mo [95% CI, 3.9 to 5.4] vs. 3.1 mo [95% CI, 1.4 to 4.9]; hazard ratio, 0.55 [95% CI, 0.31 to 0.96]; P = 0.03).  In the survival anal., which included all 326 patients, progression- free survival was significantly longer in the inotuzumab ozogamicin group (median, 5.0 mo [95% CI, 3.7 to 5.6] vs. 1.8 mo [95% CI, 1.5 to 2.2]; hazard ratio, 0.45 [97.5% CI, 0.34 to 0.61]; P<0.001); the median overall survival was 7.7 mo (95% CI, 6.0 to 9.2) vs. 6.7 mo (95% CI, 4.9 to 8.3), and the hazard ratio was 0.77 (97.5% CI, 0.58 to 1.03) (P = 0.04).  In the safety population, the most frequent grade 3 or higher nonhematol. adverse events with inotuzumab ozogamicin were liver-related.  Veno-occlusive liver disease of any grade occurred in 15 patients (11%) who received inotuzumab ozogamicin and in 1 patient (1%) who received std. therapy.  CONCLUSIONS: The rate of complete remission was higher with inotuzumab ozogamicin than with std. therapy, and a higher percentage of patients in the inotuzumab ozogamicin group had results below the threshold for minimal residual disease.  Both progression-free and overall survival were longer with inotuzumab ozogamicin.  Veno-occlusive liver disease was a major adverse event assocd. with inotuzumab ozogamicin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPWFX8IdaUIrVg90H21EOLACvtfcHk0lhATLKaZ5UhFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2ks7%252FI&md5=f36fe4d8eaad5ed2107d4394efa29181</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1509277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1509277%26sid%3Dliteratum%253Aachs%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DStelljes%26aufirst%3DM.%26aulast%3DMartinelli%26aufirst%3DG.%26aulast%3DLiedtke%26aufirst%3DM.%26aulast%3DStock%26aufirst%3DW.%26aulast%3DGokbuget%26aufirst%3DN.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DPaccagnella%26aufirst%3DM.%2BL.%26aulast%3DSleight%26aufirst%3DB.%26aulast%3DVandendries%26aufirst%3DE.%26aulast%3DAdvani%26aufirst%3DA.%2BS.%26atitle%3DInotuzumab%2520ozogamicin%2520versus%2520standard%2520therapy%2520for%2520acute%2520lymphoblastic%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D375%26issue%3D8%26spage%3D740%26epage%3D753%26doi%3D10.1056%2FNEJMoa1509277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Shen, B. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bumbaca, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saad, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yue, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pastuskovas, C. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khojasteh, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibbitts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaur, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, Y. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoRusso, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girish, S.</span><span> </span><span class="NLM_article-title">Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">901</span><span class="NLM_x">–</span> <span class="NLM_lpage">910</span><span class="refDoi"> DOI: 10.2174/138920012802138598</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.2174%2F138920012802138598" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=22475269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1OlurrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=901-910&issue=7&author=B.+Q.+Shenauthor=D.+Bumbacaauthor=O.+Saadauthor=Q.+Yueauthor=C.+V.+Pastuskovasauthor=S.+C.+Khojastehauthor=J.+Tibbittsauthor=S.+Kaurauthor=B.+Wangauthor=Y.+W.+Chuauthor=P.+M.+LoRussoauthor=S.+Girish&title=Catabolic+fate+and+pharmacokinetic+characterization+of+trastuzumab+emtansine+%28T-DM1%29%3A+an+emphasis+on+preclinical+and+clinical+catabolism&doi=10.2174%2F138920012802138598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism</span></div><div class="casAuthors">Shen, Ben-Quan; Bumbaca, Daniela; Saad, Ola; Yue, Qin; Pastuskovas, Cinthia V.; Khojasteh, S. Cyrus; Tibbitts, Jay; Kaur, Surinder; Wang, Bei; Chu, Yu-Waye; LoRusso, Patricia M.; Girish, Sandhya</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">901-910</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate in clin. development for the treatment of human epidermal growth factor receptor 2 (HER2)-pos. cancers.  Herein, we describe a series of studies to assess T-DM1 absorption, distribution, metab., and excretion (ADME) in rats as well as to assess human exposure to T-DM1 catabolites.  Following administration of unlabeled and radiolabeled T-DM1 in female Sprague Dawley rats as a single dose, plasma, urine, bile and feces were assessed for mass balance, profiling and identification of catabolites.  In rats, the major circulating species in plasma was T-DM1, while DM1 concns. were low (1.08 to 15.6 ng/mL).  The major catabolites found circulating in rat plasma were DM1, [N-maleimidomethyl] cyclohexane-1-carboxylate-DM1 (MCC-DM1), and Lysine-MCC-DM1.  These catabolites identified in rats were also detected in plasma samples from patients with HER2-pos. metastatic breast cancer who received single-agent T-DM1 (3.6 mg/kg every 3 wk) in a phase 2 clin. study.  There was no evidence of tissue accumulation in rats or catabolite accumulation in human plasma following multiple dosing.  In rats, T-DM1 was distributed nonspecifically to the organs without accumulation.  The major pathway of DM1-contg. catabolite elimination in rats was the fecal/biliary route, with up to 80% of radioactivity recovered in the feces and 50% in the bile.  The rat T-DM1 ADME profile is likely similar to the human profile, although there may be differences since trastuzumab does not bind the rat HER2- like receptor.  Further research is necessary to more fully understand the T-DM1 ADME profile in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDuHn1EbzEhLVg90H21EOLACvtfcHk0lhATLKaZ5UhFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1OlurrN&md5=faf70e5692e4d6a5a7789a0510705837</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.2174%2F138920012802138598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920012802138598%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DB.%2BQ.%26aulast%3DBumbaca%26aufirst%3DD.%26aulast%3DSaad%26aufirst%3DO.%26aulast%3DYue%26aufirst%3DQ.%26aulast%3DPastuskovas%26aufirst%3DC.%2BV.%26aulast%3DKhojasteh%26aufirst%3DS.%2BC.%26aulast%3DTibbitts%26aufirst%3DJ.%26aulast%3DKaur%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DChu%26aufirst%3DY.%2BW.%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26aulast%3DGirish%26aufirst%3DS.%26atitle%3DCatabolic%2520fate%2520and%2520pharmacokinetic%2520characterization%2520of%2520trastuzumab%2520emtansine%2520%2528T-DM1%2529%253A%2520an%2520emphasis%2520on%2520preclinical%2520and%2520clinical%2520catabolism%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2012%26volume%3D13%26issue%3D7%26spage%3D901%26epage%3D910%26doi%3D10.2174%2F138920012802138598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Lewis Phillips, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dugger, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crocker, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mai, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blattler, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chari, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeppen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwall, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenkare-Mitra, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span> </span><span class="NLM_article-title">Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x"> (</span><span class="NLM_issue">22</span><span class="NLM_x">) </span> <span class="NLM_fpage">9280</span><span class="NLM_x">–</span> <span class="NLM_lpage">9290</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-1776</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1158%2F0008-5472.CAN-08-1776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=19010901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlOmt7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=9280-9290&issue=22&author=G.+D.+Lewis+Phillipsauthor=G.+Liauthor=D.+L.+Duggerauthor=L.+M.+Crockerauthor=K.+L.+Parsonsauthor=E.+Maiauthor=W.+A.+Blattlerauthor=J.+M.+Lambertauthor=R.+V.+Chariauthor=R.+J.+Lutzauthor=W.+L.+Wongauthor=F.+S.+Jacobsonauthor=H.+Koeppenauthor=R.+H.+Schwallauthor=S.+R.+Kenkare-Mitraauthor=S.+D.+Spencerauthor=M.+X.+Sliwkowski&title=Targeting+HER2-positive+breast+cancer+with+trastuzumab-DM1%2C+an+antibody-cytotoxic+drug+conjugate&doi=10.1158%2F0008-5472.CAN-08-1776"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate</span></div><div class="casAuthors">Lewis Phillips, Gail D.; Li, Guangmin; Dugger, Debra L.; Crocker, Lisa M.; Parsons, Kathryn L.; Mai, Elaine; Blaettler, Walter A.; Lambert, John M.; Chari, Ravi V. J.; Lutz, Robert J.; Wong, Wai Lee T.; Jacobson, Frederic S.; Koeppen, Hartmut; Schwall, Ralph H.; Kenkare-Mitra, Sara R.; Spencer, Susan D.; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9280-9290</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">HER2 is a validated target in breast cancer therapy.  Two drugs are currently approved for HER2-pos. breast cancer: trastuzumab (Herceptin), introduced in 1998, and lapatinib (Tykerb), in 2007.  Despite these advances, some patients progress through therapy and succumb to their disease.  A variation on antibody-targeted therapy is utilization of antibodies to deliver cytotoxic agents specifically to antigen-expressing tumors.  We detd. in vitro and in vivo efficacy, pharmacokinetics, and toxicity of trastuzumab-maytansinoid (microtubule-depolymg. agents) conjugates using disulfide and thioether linkers.  Antiproliferative effects of trastuzumab-maytansinoid conjugates were evaluated on cultured normal and tumor cells.  In vivo activity was detd. in mouse breast cancer models, and toxicity was assessed in rats as measured by body wt. loss.  Surprisingly, trastuzumab linked to DM1 through a nonreducible thioether linkage (SMCC), displayed superior activity compared with unconjugated trastuzumab or trastuzumab linked to other maytansinoids through disulfide linkers.  Serum concns. of trastuzumab-MCC-DM1 remained elevated compared with other conjugates, and toxicity in rats was negligible compared with free DM1 or trastuzumab linked to DM1 through a reducible linker.  Potent activity was obsd. on all HER2-overexpressing tumor cells, whereas nontransformed cells and tumor cell lines with normal HER2 expression were unaffected.  In addn., trastuzumab-DM1 was active on HER2-overexpressing, trastuzumab-refractory tumors.  In summary, trastuzumab-DM1 shows greater activity compared with nonconjugated trastuzumab while maintaining selectivity for HER2-overexpressing tumor cells.  Because trastuzumab linked to DM1 through a nonreducible linker offers improved efficacy and pharmacokinetics and reduced toxicity over the reducible disulfide linkers evaluated, trastuzumab-MCC-DM1 was selected for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpP5fkJnRorrVg90H21EOLACvtfcHk0lhATLKaZ5UhFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlOmt7rK&md5=e86e8687d5f8884f8e28514299dcbbf1</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-1776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-1776%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%2BPhillips%26aufirst%3DG.%2BD.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DDugger%26aufirst%3DD.%2BL.%26aulast%3DCrocker%26aufirst%3DL.%2BM.%26aulast%3DParsons%26aufirst%3DK.%2BL.%26aulast%3DMai%26aufirst%3DE.%26aulast%3DBlattler%26aufirst%3DW.%2BA.%26aulast%3DLambert%26aufirst%3DJ.%2BM.%26aulast%3DChari%26aufirst%3DR.%2BV.%26aulast%3DLutz%26aufirst%3DR.%2BJ.%26aulast%3DWong%26aufirst%3DW.%2BL.%26aulast%3DJacobson%26aufirst%3DF.%2BS.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DSchwall%26aufirst%3DR.%2BH.%26aulast%3DKenkare-Mitra%26aufirst%3DS.%2BR.%26aulast%3DSpencer%26aufirst%3DS.%2BD.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DTargeting%2520HER2-positive%2520breast%2520cancer%2520with%2520trastuzumab-DM1%252C%2520an%2520antibody-cytotoxic%2520drug%2520conjugate%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26issue%3D22%26spage%3D9280%26epage%3D9290%26doi%3D10.1158%2F0008-5472.CAN-08-1776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Doronina, S. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendelsohn, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bovee, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerveny, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alley, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oflazoglu, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toki, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanderson, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zabinski, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahl, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span> </span><span class="NLM_article-title">Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">114</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span><span class="refDoi"> DOI: 10.1021/bc0502917</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc0502917" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlars7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=114-124&issue=1&author=S.+O.+Doroninaauthor=B.+A.+Mendelsohnauthor=T.+D.+Boveeauthor=C.+G.+Cervenyauthor=S.+C.+Alleyauthor=D.+L.+Meyerauthor=E.+Oflazogluauthor=B.+E.+Tokiauthor=R.+J.+Sandersonauthor=R.+F.+Zabinskiauthor=A.+F.+Wahlauthor=P.+D.+Senter&title=Enhanced+activity+of+monomethylauristatin+F+through+monoclonal+antibody+delivery%3A+effects+of+linker+technology+on+efficacy+and+toxicity&doi=10.1021%2Fbc0502917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and Toxicity</span></div><div class="casAuthors">Doronina, Svetlana O.; Mendelsohn, Brian A.; Bovee, Tim D.; Cerveny, Charles G.; Alley, Stephen C.; Meyer, Damon L.; Oflazoglu, Ezogelin; Toki, Brian E.; Sanderson, Russell J.; Zabinski, Roger F.; Wahl, Alan F.; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">114-124</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have previously shown that antibody-drug conjugates (ADCs) consisting of cAC10 (anti-CD30) linked to the antimitotic agent monomethylauristatin E (MMAE) lead to potent in vitro and in vivo activities against antigen pos. tumor models.  MMAF is a new antimitotic auristatin deriv. with a charged C-terminal phenylalanine residue that attenuates its cytotoxic activity compared to its uncharged counterpart, MMAE, most likely due to impaired intracellular access.  In vitro cytotoxicity studies indicated that mAb-maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl-MMAF (mAb-L1-MMAF) conjugates were >2200-fold more potent than free MMAF on a large panel of CD30 pos. hematol. cell lines.  As with cAC10-L1-MMAE, the corresponding MMAF ADC induced cures and regressions of established xenograft tumors at well tolerated doses.  To further optimize the ADC, several new linkers were generated in which various components within the L1 linker were either altered or deleted.  One of the most promising linkers contained a noncleavable maleimidocaproyl (L4) spacer between the drug and the mAb.  CAC10-L4-MMAF was approx. as potent in vitro as cAC10-L1-MMAF against a large panel of cell lines and was equally potent in vivo.  Importantly, cAC10-L4-MMAF was tolerated at >3 times the MTD of cAC10-L1-MMAF.  LCMS studies indicated that drug released from cAC10-L4-MMAF was the cysteine-L4-MMAF adduct, which likely arises from mAb degrdn. within the lysosomes of target cells.  This new linker technol. appears to be ideally suited for drugs that are both relatively cell-impermeable and tolerant of substitution with amino acids.  Thus, alterations of the linker have pronounced impacts on toxicity and lead to new ADCs with greatly improved therapeutic indexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfwQJyn8sp0LVg90H21EOLACvtfcHk0ljw_TbfavHCuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlars7%252FL&md5=92da0266f0a83c7680006ef94956c879</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fbc0502917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc0502917%26sid%3Dliteratum%253Aachs%26aulast%3DDoronina%26aufirst%3DS.%2BO.%26aulast%3DMendelsohn%26aufirst%3DB.%2BA.%26aulast%3DBovee%26aufirst%3DT.%2BD.%26aulast%3DCerveny%26aufirst%3DC.%2BG.%26aulast%3DAlley%26aufirst%3DS.%2BC.%26aulast%3DMeyer%26aufirst%3DD.%2BL.%26aulast%3DOflazoglu%26aufirst%3DE.%26aulast%3DToki%26aufirst%3DB.%2BE.%26aulast%3DSanderson%26aufirst%3DR.%2BJ.%26aulast%3DZabinski%26aufirst%3DR.%2BF.%26aulast%3DWahl%26aufirst%3DA.%2BF.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DEnhanced%2520activity%2520of%2520monomethylauristatin%2520F%2520through%2520monoclonal%2520antibody%2520delivery%253A%2520effects%2520of%2520linker%2520technology%2520on%2520efficacy%2520and%2520toxicity%26jtitle%3DBioconjugate%2520Chem.%26date%3D2006%26volume%3D17%26issue%3D1%26spage%3D114%26epage%3D124%26doi%3D10.1021%2Fbc0502917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Gregson, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelland, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thurston, D. E.</span><span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">737</span><span class="NLM_x">–</span> <span class="NLM_lpage">748</span><span class="refDoi"> DOI: 10.1021/jm001064n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm001064n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=737-748&issue=5&author=S.+J.+Gregsonauthor=P.+W.+Howardauthor=J.+A.+Hartleyauthor=N.+A.+Brooksauthor=L.+J.+Adamsauthor=T.+C.+Jenkinsauthor=L.+R.+Kellandauthor=D.+E.+Thurston&title=Design%2C+synthesis%2C+and+evaluation+of+a+novel+pyrrolobenzodiazepine+DNA-interactive+agent+with+highly+efficient+cross-linking+ability+and+potent+cytotoxicity&doi=10.1021%2Fjm001064n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm001064n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm001064n%26sid%3Dliteratum%253Aachs%26aulast%3DGregson%26aufirst%3DS.%2BJ.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3DBrooks%26aufirst%3DN.%2BA.%26aulast%3DAdams%26aufirst%3DL.%2BJ.%26aulast%3DJenkins%26aufirst%3DT.%2BC.%26aulast%3DKelland%26aufirst%3DL.%2BR.%26aulast%3DThurston%26aufirst%3DD.%2BE.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520a%2520novel%2520pyrrolobenzodiazepine%2520DNA-interactive%2520agent%2520with%2520highly%2520efficient%2520cross-linking%2520ability%2520and%2520potent%2520cytotoxicity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26issue%3D5%26spage%3D737%26epage%3D748%26doi%3D10.1021%2Fjm001064n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Gregson, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gullick, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamaguchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corcoran, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guille, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thurston, D. E.</span><span> </span><span class="NLM_article-title">Linker length modulates DNA cross-linking reactivity and cytotoxic potency of C8/C8′ ether-linked C2-exo-unsaturated pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimers</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">1161</span><span class="NLM_x">–</span> <span class="NLM_lpage">1174</span><span class="refDoi"> DOI: 10.1021/jm030897l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030897l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1161-1174&issue=5&author=S.+J.+Gregsonauthor=P.+W.+Howardauthor=D.+R.+Gullickauthor=A.+Hamaguchiauthor=K.+E.+Corcoranauthor=N.+A.+Brooksauthor=J.+A.+Hartleyauthor=T.+C.+Jenkinsauthor=S.+Patelauthor=M.+J.+Guilleauthor=D.+E.+Thurston&title=Linker+length+modulates+DNA+cross-linking+reactivity+and+cytotoxic+potency+of+C8%2FC8%E2%80%B2+ether-linked+C2-exo-unsaturated+pyrrolo%5B2%2C1-c%5D%5B1%2C4%5Dbenzodiazepine+%28PBD%29+dimers&doi=10.1021%2Fjm030897l"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm030897l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030897l%26sid%3Dliteratum%253Aachs%26aulast%3DGregson%26aufirst%3DS.%2BJ.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26aulast%3DGullick%26aufirst%3DD.%2BR.%26aulast%3DHamaguchi%26aufirst%3DA.%26aulast%3DCorcoran%26aufirst%3DK.%2BE.%26aulast%3DBrooks%26aufirst%3DN.%2BA.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3DJenkins%26aufirst%3DT.%2BC.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DGuille%26aufirst%3DM.%2BJ.%26aulast%3DThurston%26aufirst%3DD.%2BE.%26atitle%3DLinker%2520length%2520modulates%2520DNA%2520cross-linking%2520reactivity%2520and%2520cytotoxic%2520potency%2520of%2520C8%252FC8%25E2%2580%25B2%2520ether-linked%2520C2-exo-unsaturated%2520pyrrolo%255B2%252C1-c%255D%255B1%252C4%255Dbenzodiazepine%2520%2528PBD%2529%2520dimers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26issue%3D5%26spage%3D1161%26epage%3D1174%26doi%3D10.1021%2Fjm030897l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Hartley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamaguchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suggitt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregson, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thurston, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, P. W.</span><span> </span><span class="NLM_article-title">DNA interstrand cross-linking and <i>in vivo</i> antitumor activity of the extended pyrrolo[2,1-c][1,4]benzodiazepine dimer SG2057</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">950</span><span class="NLM_x">–</span> <span class="NLM_lpage">958</span><span class="refDoi"> DOI: 10.1007/s10637-011-9647-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1007%2Fs10637-011-9647-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=21384134" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvFamtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=950-958&issue=3&author=J.+A.+Hartleyauthor=A.+Hamaguchiauthor=M.+Suggittauthor=S.+J.+Gregsonauthor=D.+E.+Thurstonauthor=P.+W.+Howard&title=DNA+interstrand+cross-linking+and+in+vivo+antitumor+activity+of+the+extended+pyrrolo%5B2%2C1-c%5D%5B1%2C4%5Dbenzodiazepine+dimer+SG2057&doi=10.1007%2Fs10637-011-9647-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">DNA interstrand cross-linking and in vivo antitumor activity of the extended pyrrolo[2,1-c][1,4]benzodiazepine dimer SG2057</span></div><div class="casAuthors">Hartley, John A.; Hamaguchi, Anzu; Suggitt, Marie; Gregson, Stephen J.; Thurston, David E.; Howard, Philip W.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">950-958</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The pyrrolobenzodiazepines (PBDs) are naturally occurring antitumor antibiotics and a PBD dimer (SJG-136, SG2000) is in Phase II trials.  SG2000 is a propyldioxy linked PBD dimer which binds sequence selectively in the minor groove of DNA forming DNA interstrand and intrastrand cross-linked adducts, and also mono-adducts depending on sequence.  SG2057 is the corresponding dimer contg. a pentyldioxy linkage.  SG2057 has multilog differential in vitro cytotoxicity against a panel of human tumor cell lines with a mean GI50 of 212 pM.  The agent is highly efficient at producing DNA interstrand cross-links in cells which form rapidly and persist over a 48 h period.  Significant antitumor activity was demonstrated in several human tumor xenograft models.  Cures were obtained in a LOX-IMVI melanoma model following a single administration and dose-dependent activity, including regression responses, obsd. in SKOV-3 ovarian and HL-60 promyelocytic leukemia models following repeat dose schedules.  In the advanced stage LS174T model, SG2057 administered either as a single dose, or in two repeat dose schedules, was superior to irinotecan.  SG2057 is therefore a highly active antitumor agent, with more potent in vitro activity and superior in vivo activity to SG2000, warranting further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXu8VuTWqyI7Vg90H21EOLACvtfcHk0lgn1WQvTL-tnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvFamtLk%253D&md5=083b09bc0bf01b580e479e50e3c9080e</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1007%2Fs10637-011-9647-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-011-9647-z%26sid%3Dliteratum%253Aachs%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3DHamaguchi%26aufirst%3DA.%26aulast%3DSuggitt%26aufirst%3DM.%26aulast%3DGregson%26aufirst%3DS.%2BJ.%26aulast%3DThurston%26aufirst%3DD.%2BE.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26atitle%3DDNA%2520interstrand%2520cross-linking%2520and%2520in%2520vivo%2520antitumor%2520activity%2520of%2520the%2520extended%2520pyrrolo%255B2%252C1-c%255D%255B1%252C4%255Dbenzodiazepine%2520dimer%2520SG2057%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2012%26volume%3D30%26issue%3D3%26spage%3D950%26epage%3D958%26doi%3D10.1007%2Fs10637-011-9647-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Rettig, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weingarth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langel, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisz, K.</span><span> </span><span class="NLM_article-title">Solution structure of a covalently bound pyrrolo[2,1-c][1,4]benzodiazepine-benzimidazole hybrid to a 10mer DNA duplex</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x"> (</span><span class="NLM_issue">51</span><span class="NLM_x">) </span> <span class="NLM_fpage">12223</span><span class="NLM_x">–</span> <span class="NLM_lpage">12232</span><span class="refDoi"> DOI: 10.1021/bi901655t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi901655t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=12223-12232&issue=51&author=M.+Rettigauthor=M.+Weingarthauthor=W.+Langelauthor=A.+Kamalauthor=P.+P.+Kumarauthor=K.+Weisz&title=Solution+structure+of+a+covalently+bound+pyrrolo%5B2%2C1-c%5D%5B1%2C4%5Dbenzodiazepine-benzimidazole+hybrid+to+a+10mer+DNA+duplex&doi=10.1021%2Fbi901655t"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fbi901655t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi901655t%26sid%3Dliteratum%253Aachs%26aulast%3DRettig%26aufirst%3DM.%26aulast%3DWeingarth%26aufirst%3DM.%26aulast%3DLangel%26aufirst%3DW.%26aulast%3DKamal%26aufirst%3DA.%26aulast%3DKumar%26aufirst%3DP.%2BP.%26aulast%3DWeisz%26aufirst%3DK.%26atitle%3DSolution%2520structure%2520of%2520a%2520covalently%2520bound%2520pyrrolo%255B2%252C1-c%255D%255B1%252C4%255Dbenzodiazepine-benzimidazole%2520hybrid%2520to%2520a%252010mer%2520DNA%2520duplex%26jtitle%3DBiochemistry%26date%3D2009%26volume%3D48%26issue%3D51%26spage%3D12223%26epage%3D12232%26doi%3D10.1021%2Fbi901655t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Harder, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grunze, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahint, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitesides, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laibinis, P. E.</span><span> </span><span class="NLM_article-title">Molecular conformation in oligo(ethylene glycol)-terminated self-assembled monolayers on gold and silver surfaces determines their ability to resist protein adsorption</span> <span class="citation_source-journal">J. Phys. Chem. B</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">426</span><span class="NLM_x">–</span> <span class="NLM_lpage">436</span><span class="refDoi"> DOI: 10.1021/jp972635z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jp972635z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADyaK1cXksFWgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=1998&pages=426-436&issue=2&author=P.+Harderauthor=M.+Grunzeauthor=R.+Dahintauthor=G.+M.+Whitesidesauthor=P.+E.+Laibinis&title=Molecular+conformation+in+oligo%28ethylene+glycol%29-terminated+self-assembled+monolayers+on+gold+and+silver+surfaces+determines+their+ability+to+resist+protein+adsorption&doi=10.1021%2Fjp972635z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Conformation in Oligo(ethylene glycol)-Terminated Self-Assembled Monolayers on Gold and Silver Surfaces Determines Their Ability To Resist Protein Adsorption</span></div><div class="casAuthors">Harder, P.; Grunze, M.; Dahint, R.; Whitesides, G. M.; Laibinis, P. E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry B</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">426-436</span>CODEN:
                <span class="NLM_cas:coden">JPCBFK</span>;
        ISSN:<span class="NLM_cas:issn">1089-5647</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Data from IR absorption (FTIR) and X-ray photoelectron spectroscopies that correlate the mol. conformation of oligo(ethylene glycol) (OEG)-terminated self-assembled alkanethiolate monolayers (SAMs) with the ability of these films to resist protein adsorption was reported.  Three different SAMs of alkanethiolates on evapd. Au and Ag surfaces.  The SAMs were formed from substituted 1-undecanethiols with either a hydroxyl-terminated hexa(ethylene glycol) (EG6-OH) or a methoxy-terminated tri(ethylene glycol) (EG3-OMe) end group, or a substituted 1-tridecanethiol chain with a methoxy-terminated tri(ethylene glycol) end group and a -CH2OCH3 side chain at the C-12 atom (EG[3,1]-OMe).  The IR data of EG6-OH-terminated SAMs on both Au and Ag surfaces reveal the presence of a cryst. helical OEG phase, coexisting with amorphous OEG moieties; the EG[3,1]-OMe-terminated alkanethiolates on Au and Ag show a lower abs. coverage and greater disorder than the two other compds.  The mol. conformation of the methoxy-terminated tri(ethylene glycol) (EG3-OMe) is different on Au and Ag surfaces due to the different lateral densities of SAMs on these substrates: on Au we find a conformation similar to that of EG6-OH alkanethiolates, whereas on Ag the IR spectra indicate a densely packed film with trans conformation around the C-C bonds of the glycol units.  The resistance of these OEG-functionalized alkanethiolate SAMs to adsorption of fibrinogen from a buffered soln. correlates with the mol. conformation of the OEG moieties.  The predominantly cryst. helical and the amorphous forms of OEG on gold substrates are resistant to adsorption of proteins, while a densely packed "all-trans" form of EG3-OMe present on silver surfaces adsorbs protein.  The exptl. observations are compatible with the hypothesis that binding of interfacial water by the OEG moieties is important in their ability to resist protein adsorption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3ZjvnsVdbXbVg90H21EOLACvtfcHk0ljKvAG9HZOYHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXksFWgug%253D%253D&md5=159b7b18ae2b544412935b075d2d2868</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjp972635z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjp972635z%26sid%3Dliteratum%253Aachs%26aulast%3DHarder%26aufirst%3DP.%26aulast%3DGrunze%26aufirst%3DM.%26aulast%3DDahint%26aufirst%3DR.%26aulast%3DWhitesides%26aufirst%3DG.%2BM.%26aulast%3DLaibinis%26aufirst%3DP.%2BE.%26atitle%3DMolecular%2520conformation%2520in%2520oligo%2528ethylene%2520glycol%2529-terminated%2520self-assembled%2520monolayers%2520on%2520gold%2520and%2520silver%2520surfaces%2520determines%2520their%2520ability%2520to%2520resist%2520protein%2520adsorption%26jtitle%3DJ.%2520Phys.%2520Chem.%2520B%26date%3D1998%26volume%3D102%26issue%3D2%26spage%3D426%26epage%3D436%26doi%3D10.1021%2Fjp972635z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Althuis, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hess, H. J.</span><span> </span><span class="NLM_article-title">Synthesis and identification of the major metabolites of prazosin formed in dog and rat</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">146</span><span class="NLM_x">–</span> <span class="NLM_lpage">149</span><span class="refDoi"> DOI: 10.1021/jm00211a031</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00211a031" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1977&pages=146-149&issue=1&author=T.+H.+Althuisauthor=H.+J.+Hess&title=Synthesis+and+identification+of+the+major+metabolites+of+prazosin+formed+in+dog+and+rat&doi=10.1021%2Fjm00211a031"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm00211a031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00211a031%26sid%3Dliteratum%253Aachs%26aulast%3DAlthuis%26aufirst%3DT.%2BH.%26aulast%3DHess%26aufirst%3DH.%2BJ.%26atitle%3DSynthesis%2520and%2520identification%2520of%2520the%2520major%2520metabolites%2520of%2520prazosin%2520formed%2520in%2520dog%2520and%2520rat%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1977%26volume%3D20%26issue%3D1%26spage%3D146%26epage%3D149%26doi%3D10.1021%2Fjm00211a031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Tercel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stribbling, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheppard, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siim, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pullen, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botting, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Unsymmetrical DNA cross-linking agents: combination of the CBI and PBD pharmacophores</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">2132</span><span class="NLM_x">–</span> <span class="NLM_lpage">2151</span><span class="refDoi"> DOI: 10.1021/jm020526p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020526p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=2132-2151&issue=11&author=M.+Tercelauthor=S.+M.+Stribblingauthor=H.+Sheppardauthor=B.+G.+Siimauthor=K.+Wuauthor=S.+M.+Pullenauthor=K.+J.+Bottingauthor=W.+R.+Wilsonauthor=W.+A.+Denny&title=Unsymmetrical+DNA+cross-linking+agents%3A+combination+of+the+CBI+and+PBD+pharmacophores&doi=10.1021%2Fjm020526p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm020526p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020526p%26sid%3Dliteratum%253Aachs%26aulast%3DTercel%26aufirst%3DM.%26aulast%3DStribbling%26aufirst%3DS.%2BM.%26aulast%3DSheppard%26aufirst%3DH.%26aulast%3DSiim%26aufirst%3DB.%2BG.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DPullen%26aufirst%3DS.%2BM.%26aulast%3DBotting%26aufirst%3DK.%2BJ.%26aulast%3DWilson%26aufirst%3DW.%2BR.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DUnsymmetrical%2520DNA%2520cross-linking%2520agents%253A%2520combination%2520of%2520the%2520CBI%2520and%2520PBD%2520pharmacophores%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26issue%3D11%26spage%3D2132%26epage%3D2151%26doi%3D10.1021%2Fjm020526p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Wells, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sands, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laughton, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiberghien, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masterson, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephenson, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shnyder, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loadman, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waring, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thurston, D. E.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biophysical and biological evaluation of a series of pyrrolobenzodiazepine-poly(<i>N</i>-methylpyrrole) conjugates</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x"> (</span><span class="NLM_issue">18</span><span class="NLM_x">) </span> <span class="NLM_fpage">5442</span><span class="NLM_x">–</span> <span class="NLM_lpage">5461</span><span class="refDoi"> DOI: 10.1021/jm051199z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm051199z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5442-5461&issue=18&author=G.+Wellsauthor=C.+R.+Martinauthor=P.+W.+Howardauthor=Z.+A.+Sandsauthor=C.+A.+Laughtonauthor=A.+Tiberghienauthor=C.+K.+Wooauthor=L.+A.+Mastersonauthor=M.+J.+Stephensonauthor=J.+A.+Hartleyauthor=T.+C.+Jenkinsauthor=S.+D.+Shnyderauthor=P.+M.+Loadmanauthor=M.+J.+Waringauthor=D.+E.+Thurston&title=Design%2C+synthesis%2C+and+biophysical+and+biological+evaluation+of+a+series+of+pyrrolobenzodiazepine-poly%28N-methylpyrrole%29+conjugates&doi=10.1021%2Fjm051199z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm051199z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm051199z%26sid%3Dliteratum%253Aachs%26aulast%3DWells%26aufirst%3DG.%26aulast%3DMartin%26aufirst%3DC.%2BR.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26aulast%3DSands%26aufirst%3DZ.%2BA.%26aulast%3DLaughton%26aufirst%3DC.%2BA.%26aulast%3DTiberghien%26aufirst%3DA.%26aulast%3DWoo%26aufirst%3DC.%2BK.%26aulast%3DMasterson%26aufirst%3DL.%2BA.%26aulast%3DStephenson%26aufirst%3DM.%2BJ.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3DJenkins%26aufirst%3DT.%2BC.%26aulast%3DShnyder%26aufirst%3DS.%2BD.%26aulast%3DLoadman%26aufirst%3DP.%2BM.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DThurston%26aufirst%3DD.%2BE.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biophysical%2520and%2520biological%2520evaluation%2520of%2520a%2520series%2520of%2520pyrrolobenzodiazepine-poly%2528N-methylpyrrole%2529%2520conjugates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26issue%3D18%26spage%3D5442%26epage%3D5461%26doi%3D10.1021%2Fjm051199z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Alberico, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lautens, M.</span><span> </span><span class="NLM_article-title">Synthesis of tricyclic heterocycles via a tandem aryl alkylation/Heck coupling sequence</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">775</span><span class="NLM_x">–</span> <span class="NLM_lpage">781</span><span class="refDoi"> DOI: 10.1021/jo0617868</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo0617868" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2007&pages=775-781&issue=3&author=D.+Albericoauthor=A.+Rudolphauthor=M.+Lautens&title=Synthesis+of+tricyclic+heterocycles+via+a+tandem+aryl+alkylation%2FHeck+coupling+sequence&doi=10.1021%2Fjo0617868"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjo0617868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0617868%26sid%3Dliteratum%253Aachs%26aulast%3DAlberico%26aufirst%3DD.%26aulast%3DRudolph%26aufirst%3DA.%26aulast%3DLautens%26aufirst%3DM.%26atitle%3DSynthesis%2520of%2520tricyclic%2520heterocycles%2520via%2520a%2520tandem%2520aryl%2520alkylation%252FHeck%2520coupling%2520sequence%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2007%26volume%3D72%26issue%3D3%26spage%3D775%26epage%3D781%26doi%3D10.1021%2Fjo0617868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Peterle, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ringler, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayor, M.</span><span> </span><span class="NLM_article-title">Gold nanoparticles stabilized by acetylene-functionalized multidentate thioether ligands: building blocks for nanoparticle superstructures</span> <span class="citation_source-journal">Adv. Funct. Mater.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x"> (</span><span class="NLM_issue">21</span><span class="NLM_x">) </span> <span class="NLM_fpage">3497</span><span class="NLM_x">–</span> <span class="NLM_lpage">3506</span><span class="refDoi"> DOI: 10.1002/adfm.200901410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1002%2Fadfm.200901410" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=3497-3506&issue=21&author=T.+Peterleauthor=P.+Ringlerauthor=M.+Mayor&title=Gold+nanoparticles+stabilized+by+acetylene-functionalized+multidentate+thioether+ligands%3A+building+blocks+for+nanoparticle+superstructures&doi=10.1002%2Fadfm.200901410"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fadfm.200901410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fadfm.200901410%26sid%3Dliteratum%253Aachs%26aulast%3DPeterle%26aufirst%3DT.%26aulast%3DRingler%26aufirst%3DP.%26aulast%3DMayor%26aufirst%3DM.%26atitle%3DGold%2520nanoparticles%2520stabilized%2520by%2520acetylene-functionalized%2520multidentate%2520thioether%2520ligands%253A%2520building%2520blocks%2520for%2520nanoparticle%2520superstructures%26jtitle%3DAdv.%2520Funct.%2520Mater.%26date%3D2009%26volume%3D19%26issue%3D21%26spage%3D3497%26epage%3D3506%26doi%3D10.1002%2Fadfm.200901410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Sakaitani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohfune, Y.</span><span> </span><span class="NLM_article-title">Selective transformation of <i>N</i>-<i>t</i>-butoxycarbonyl group into <i>N</i>-alkoxy-carbonyl group <i>via N</i>-carboxylate ion equivalent</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x"> (</span><span class="NLM_issue">45</span><span class="NLM_x">) </span> <span class="NLM_fpage">5543</span><span class="NLM_x">–</span> <span class="NLM_lpage">5546</span><span class="refDoi"> DOI: 10.1016/S0040-4039(01)80883-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1016%2FS0040-4039%2801%2980883-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1985&pages=5543-5546&issue=45&author=M.+Sakaitaniauthor=Y.+Ohfune&title=Selective+transformation+of+N-t-butoxycarbonyl+group+into+N-alkoxy-carbonyl+group+via+N-carboxylate+ion+equivalent&doi=10.1016%2FS0040-4039%2801%2980883-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2801%2980883-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252801%252980883-2%26sid%3Dliteratum%253Aachs%26aulast%3DSakaitani%26aufirst%3DM.%26aulast%3DOhfune%26aufirst%3DY.%26atitle%3DSelective%2520transformation%2520of%2520N-t-butoxycarbonyl%2520group%2520into%2520N-alkoxy-carbonyl%2520group%2520via%2520N-carboxylate%2520ion%2520equivalent%26jtitle%3DTetrahedron%2520Lett.%26date%3D1985%26volume%3D26%26issue%3D45%26spage%3D5543%26epage%3D5546%26doi%3D10.1016%2FS0040-4039%2801%2980883-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Maiti, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fors, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henderson, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchwald, S. L.</span><span> </span><span class="NLM_article-title">Palladium-catalyzed coupling of functionalized primary and secondary amines with aryl and heteroaryl halides: two ligands suffice in most cases</span> <span class="citation_source-journal">Chem. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">57</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span><span class="refDoi"> DOI: 10.1039/C0SC00330A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1039%2FC0SC00330A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=22384311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFWqsbjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=57-68&issue=1&author=D.+Maitiauthor=B.+P.+Forsauthor=J.+L.+Hendersonauthor=Y.+Nakamuraauthor=S.+L.+Buchwald&title=Palladium-catalyzed+coupling+of+functionalized+primary+and+secondary+amines+with+aryl+and+heteroaryl+halides%3A+two+ligands+suffice+in+most+cases&doi=10.1039%2FC0SC00330A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-catalyzed coupling of functionalized primary and secondary amines with aryl and heteroaryl halides: two ligands suffice in most cases</span></div><div class="casAuthors">Maiti, Debabrata; Fors, Brett P.; Henderson, Jaclyn L.; Nakamura, Yoshinori; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-68</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A study on the use of two catalyst systems is reported here.  The ligands used in this study were BrettPhos [i.e., dicyclohexyl[3,6-dimethoxy-2',4',6'-tris(1-methylethyl)[1,1'-biphenyl]-2-yl]phosphine] and RuPhos [i.e., [2',6'-bis(1-methylethoxy)[1,1'-biphenyl]-2-yl]dicyclohexylphosphine].  These ligands provide a wide scope for Pd-catalyzed C-N cross-coupling reactions.  Often low catalyst loadings and short reaction times can be used with functionalized aryl and heteroaryl coupling partners.  The reactions are highly robust and can be set up and performed without the use of a glove box.  These catalysts should find wide application in the synthesis of complex mols. including pharmaceuticals, natural products and functional materials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7MMWmsn65tLVg90H21EOLACvtfcHk0lgJepnAjTkOTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFWqsbjF&md5=217f0d978b9cc44b2b3c468fd291c2b2</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1039%2FC0SC00330A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC0SC00330A%26sid%3Dliteratum%253Aachs%26aulast%3DMaiti%26aufirst%3DD.%26aulast%3DFors%26aufirst%3DB.%2BP.%26aulast%3DHenderson%26aufirst%3DJ.%2BL.%26aulast%3DNakamura%26aufirst%3DY.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DPalladium-catalyzed%2520coupling%2520of%2520functionalized%2520primary%2520and%2520secondary%2520amines%2520with%2520aryl%2520and%2520heteroaryl%2520halides%253A%2520two%2520ligands%2520suffice%2520in%2520most%2520cases%26jtitle%3DChem.%2520Sci.%26date%3D2011%26volume%3D2%26issue%3D1%26spage%3D57%26epage%3D68%26doi%3D10.1039%2FC0SC00330A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Junutula, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raab, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhakta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leipold, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weir, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simpson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dennis, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, Y. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duenas, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorrell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katta, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDorman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flagella, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venook, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee Wong, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowman, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandlen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheller, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polakis, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallet, W.</span><span> </span><span class="NLM_article-title">Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">925</span><span class="NLM_x">–</span> <span class="NLM_lpage">932</span><span class="refDoi"> DOI: 10.1038/nbt.1480</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1038%2Fnbt.1480" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=18641636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1Wmu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=925-932&issue=8&author=J.+R.+Junutulaauthor=H.+Raabauthor=S.+Clarkauthor=S.+Bhaktaauthor=D.+D.+Leipoldauthor=S.+Weirauthor=Y.+Chenauthor=M.+Simpsonauthor=S.+P.+Tsaiauthor=M.+S.+Dennisauthor=Y.+Luauthor=Y.+G.+Mengauthor=C.+Ngauthor=J.+Yangauthor=C.+C.+Leeauthor=E.+Duenasauthor=J.+Gorrellauthor=V.+Kattaauthor=A.+Kimauthor=K.+McDormanauthor=K.+Flagellaauthor=R.+Venookauthor=S.+Rossauthor=S.+D.+Spencerauthor=W.+Lee+Wongauthor=H.+B.+Lowmanauthor=R.+Vandlenauthor=M.+X.+Sliwkowskiauthor=R.+H.+Schellerauthor=P.+Polakisauthor=W.+Mallet&title=Site-specific+conjugation+of+a+cytotoxic+drug+to+an+antibody+improves+the+therapeutic+index&doi=10.1038%2Fnbt.1480"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index</span></div><div class="casAuthors">Junutula, Jagath R.; Raab, Helga; Clark, Suzanna; Bhakta, Sunil; Leipold, Douglas D.; Weir, Sylvia; Chen, Yvonne; Simpson, Michelle; Tsai, Siao Ping; Dennis, Mark S.; Lu, Yanmei; Meng, Y. Gloria; Ng, Carl; Yang, Jihong; Lee, Chien C.; Duenas, Eileen; Gorrell, Jeffrey; Katta, Viswanatham; Kim, Amy; McDorman, Kevin; Flagella, Kelly; Venook, Rayna; Ross, Sarajane; Spencer, Susan D.; Wong, Wai Lee; Lowman, Henry B.; Vandlen, Richard; Sliwkowski, Mark X.; Scheller, Richard H.; Polakis, Paul; Mallet, William</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">925-932</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Antibody-drug conjugates enhance the antitumor effects of antibodies and reduce adverse systemic effects of potent cytotoxic drugs.  However, conventional drug conjugation strategies yield heterogeneous conjugates with relatively narrow therapeutic index (max. tolerated dose/curative dose).  Using leads from the authors' previously described phage display-based method to predict suitable conjugation sites, the authors engineered cysteine substitutions at positions on light and heavy chains that provide reactive thiol groups and do not perturb Ig folding and assembly, or alter antigen binding.  When conjugated to monomethyl auristatin E, an antibody against the ovarian cancer antigen MUC16 is as efficacious as a conventional conjugate in mouse xenograft models.  Moreover, it is tolerated at higher doses in rats and cynomolgus monkeys than the same conjugate prepd. by conventional approaches.  The favorable in vivo properties of the near-homogeneous compn. of this conjugate suggest that this strategy offers a general approach to retaining the antitumor efficacy of antibody-drug conjugates, while minimizing their systemic toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4HIiPBABzRLVg90H21EOLACvtfcHk0lhq1ru8WLNmqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1Wmu7s%253D&md5=d55f59594fb6349d0337dfed2783e83c</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1480&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1480%26sid%3Dliteratum%253Aachs%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26aulast%3DRaab%26aufirst%3DH.%26aulast%3DClark%26aufirst%3DS.%26aulast%3DBhakta%26aufirst%3DS.%26aulast%3DLeipold%26aufirst%3DD.%2BD.%26aulast%3DWeir%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DSimpson%26aufirst%3DM.%26aulast%3DTsai%26aufirst%3DS.%2BP.%26aulast%3DDennis%26aufirst%3DM.%2BS.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DMeng%26aufirst%3DY.%2BG.%26aulast%3DNg%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DDuenas%26aufirst%3DE.%26aulast%3DGorrell%26aufirst%3DJ.%26aulast%3DKatta%26aufirst%3DV.%26aulast%3DKim%26aufirst%3DA.%26aulast%3DMcDorman%26aufirst%3DK.%26aulast%3DFlagella%26aufirst%3DK.%26aulast%3DVenook%26aufirst%3DR.%26aulast%3DRoss%26aufirst%3DS.%26aulast%3DSpencer%26aufirst%3DS.%2BD.%26aulast%3DLee%2BWong%26aufirst%3DW.%26aulast%3DLowman%26aufirst%3DH.%2BB.%26aulast%3DVandlen%26aufirst%3DR.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DScheller%26aufirst%3DR.%2BH.%26aulast%3DPolakis%26aufirst%3DP.%26aulast%3DMallet%26aufirst%3DW.%26atitle%3DSite-specific%2520conjugation%2520of%2520a%2520cytotoxic%2520drug%2520to%2520an%2520antibody%2520improves%2520the%2520therapeutic%2520index%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26issue%3D8%26spage%3D925%26epage%3D932%26doi%3D10.1038%2Fnbt.1480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Verma, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pillow, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DePalatis, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raab, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, B.</span><span> </span><span class="NLM_article-title">The cryptophycins as potent payloads for antibody drug conjugates</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">864</span><span class="NLM_x">–</span> <span class="NLM_lpage">868</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2014.12.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1016%2Fj.bmcl.2014.12.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=25613677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVOitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=864-868&issue=4&author=V.+A.+Vermaauthor=T.+H.+Pillowauthor=L.+DePalatisauthor=G.+Liauthor=G.+L.+Phillipsauthor=A.+G.+Polsonauthor=H.+E.+Raabauthor=S.+Spencerauthor=B.+Zheng&title=The+cryptophycins+as+potent+payloads+for+antibody+drug+conjugates&doi=10.1016%2Fj.bmcl.2014.12.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">The cryptophycins as potent payloads for antibody drug conjugates</span></div><div class="casAuthors">Verma, Vishal A.; Pillow, Thomas H.; DePalatis, Laura; Li, Guangmin; Phillips, Gail Lewis; Polson, Andrew G.; Raab, Helga E.; Spencer, Susan; Zheng, Bing</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">864-868</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The cryptophycins are a potent class of cytotoxic agents that were evaluated as antibody drug conjugate (ADC) payloads.  Free cryptophycin analog (I) displayed cell activity an order of magnitude more potent than approved ADC payloads MMAE and DM1.  This potency increase was also reflected in the activity of the cryptophycin ADCs, attached via a either cleavable or non-cleavable linker.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMHocqt_vwd7Vg90H21EOLACvtfcHk0lhq1ru8WLNmqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVOitQ%253D%253D&md5=6074661a1ad89ae71f88401f24c45ec7</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.12.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.12.070%26sid%3Dliteratum%253Aachs%26aulast%3DVerma%26aufirst%3DV.%2BA.%26aulast%3DPillow%26aufirst%3DT.%2BH.%26aulast%3DDePalatis%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DPhillips%26aufirst%3DG.%2BL.%26aulast%3DPolson%26aufirst%3DA.%2BG.%26aulast%3DRaab%26aufirst%3DH.%2BE.%26aulast%3DSpencer%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DB.%26atitle%3DThe%2520cryptophycins%2520as%2520potent%2520payloads%2520for%2520antibody%2520drug%2520conjugates%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26issue%3D4%26spage%3D864%26epage%3D868%26doi%3D10.1016%2Fj.bmcl.2014.12.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Dornan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dennis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eaton, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elkins, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">French, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Go, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jack, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Junutula, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeppen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBride, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rawstron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yue, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebens, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polson, A. G.</span><span> </span><span class="NLM_article-title">Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x"> (</span><span class="NLM_issue">13</span><span class="NLM_x">) </span> <span class="NLM_fpage">2721</span><span class="NLM_x">–</span> <span class="NLM_lpage">2729</span><span class="refDoi"> DOI: 10.1182/blood-2009-02-205500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1182%2Fblood-2009-02-205500" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=19633198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1eit7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=2721-2729&issue=13&author=D.+Dornanauthor=F.+Bennettauthor=Y.+Chenauthor=M.+Dennisauthor=D.+Eatonauthor=K.+Elkinsauthor=D.+Frenchauthor=M.+A.+Goauthor=A.+Jackauthor=J.+R.+Junutulaauthor=H.+Koeppenauthor=J.+Lauauthor=J.+McBrideauthor=A.+Rawstronauthor=X.+Shiauthor=N.+Yuauthor=S.+F.+Yuauthor=P.+Yueauthor=B.+Zhengauthor=A.+Ebensauthor=A.+G.+Polson&title=Therapeutic+potential+of+an+anti-CD79b+antibody-drug+conjugate%2C+anti-CD79b-vc-MMAE%2C+for+the+treatment+of+non-Hodgkin+lymphoma&doi=10.1182%2Fblood-2009-02-205500"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma</span></div><div class="casAuthors">Dornan, David; Bennett, Fiona; Chen, Yvonne; Dennis, Mark; Eaton, Dan; Elkins, Kristi; French, Dorothy; Go, Mary Ann T.; Jack, Andrew; Junutula, Jagath R.; Koeppen, Hartmut; Lau, Jeffrey; McBride, Jacqueline; Rawstron, Andy; Shi, Xiaoyan; Yu, Nancy; Yu, Shang-Fan; Yue, Peng; Zheng, Bing; Ebens, Allen; Polson, Andrew G.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2721-2729</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Here we describe the generation of an antibody-drug conjugate (ADC) consisting of a humanized anti-CD79b antibody that is conjugated to monomethylauristatin E (MMAE) through engineered cysteines (THIOMABs) by a protease cleavable linker.  By using flow cytometry, we detected the surface expression of CD79b in almost all non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia patients, suggesting that anti-CD79b-vcMMAE could be widely used in these malignancies.  By using NHL cell lines to simulate a patient population we discovered that a minimal cell-surface expression level of CD79b was required for in vitro activity.  Within the subpopulation of cell lines above this minimal threshold, we found that sensitivity to free MMAE, mutation of cancer genes, and cell doubling time were poorly correlated with in vitro activity; however, the expression level of BCL-XL was correlated with reduced sensitivity to anti-CD79b-vcMMAE.  This observation was supported by in vivo data showing that a Bcl-2 family inhibitor, ABT-263, strikingly enhanced the activity of anti-CD79b-vcMMAE.  Furthermore, anti-CD79b-vcMMAE was significantly more effective than a std.-of-care regimen, R-CHOP (ie, rituximab with a single i.v. injection of 30 mg/kg cyclophosphamide, 2.475 mg/kg doxorubicin, 0.375 mg/kg vincristine, and oral dosing of 0.15 mg/kg prednisone once a day for 5 days), in 3 xenograft models of NHL.  Together, these data suggest that anti-CD79b-vcMMAE could be broadly efficacious for the treatment of NHL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvpWja1X5Ce7Vg90H21EOLACvtfcHk0lhq1ru8WLNmqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1eit7jO&md5=02b943d887958c47dd2e5d1a3d490371</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-02-205500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-02-205500%26sid%3Dliteratum%253Aachs%26aulast%3DDornan%26aufirst%3DD.%26aulast%3DBennett%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDennis%26aufirst%3DM.%26aulast%3DEaton%26aufirst%3DD.%26aulast%3DElkins%26aufirst%3DK.%26aulast%3DFrench%26aufirst%3DD.%26aulast%3DGo%26aufirst%3DM.%2BA.%26aulast%3DJack%26aufirst%3DA.%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DLau%26aufirst%3DJ.%26aulast%3DMcBride%26aufirst%3DJ.%26aulast%3DRawstron%26aufirst%3DA.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DN.%26aulast%3DYu%26aufirst%3DS.%2BF.%26aulast%3DYue%26aufirst%3DP.%26aulast%3DZheng%26aufirst%3DB.%26aulast%3DEbens%26aufirst%3DA.%26aulast%3DPolson%26aufirst%3DA.%2BG.%26atitle%3DTherapeutic%2520potential%2520of%2520an%2520anti-CD79b%2520antibody-drug%2520conjugate%252C%2520anti-CD79b-vc-MMAE%252C%2520for%2520the%2520treatment%2520of%2520non-Hodgkin%2520lymphoma%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26issue%3D13%26spage%3D2721%26epage%3D2729%26doi%3D10.1182%2Fblood-2009-02-205500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Shen, B.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raab, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhakta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenrick, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons-Reponte, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tien, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, S.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mai, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibbitts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baudys, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saad, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scales, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hass, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solis, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuji, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flagella, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khawli, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebens, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandlen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaur, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheller, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polakis, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Junutula, J. R.</span><span> </span><span class="NLM_article-title">Conjugation site modulates the <i>in vivo</i> stability and therapeutic activity of antibody-drug conjugates</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">184</span><span class="NLM_x">–</span> <span class="NLM_lpage">189</span><span class="refDoi"> DOI: 10.1038/nbt.2108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1038%2Fnbt.2108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=22267010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVGqtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=184-189&issue=2&author=B.-Q.+Shenauthor=K.+Xuauthor=L.+Liuauthor=H.+Raabauthor=S.+Bhaktaauthor=M.+Kenrickauthor=K.+L.+Parsons-Reponteauthor=J.+Tienauthor=S.-F.+Yuauthor=E.+Maiauthor=D.+Liauthor=J.+Tibbittsauthor=J.+Baudysauthor=O.+M.+Saadauthor=S.+J.+Scalesauthor=P.+J.+McDonaldauthor=P.+E.+Hassauthor=C.+Eigenbrotauthor=T.+Nguyenauthor=W.+A.+Solisauthor=R.+N.+Fujiauthor=K.+M.+Flagellaauthor=D.+Patelauthor=S.+D.+Spencerauthor=L.+A.+Khawliauthor=A.+Ebensauthor=W.+L.+Wongauthor=R.+Vandlenauthor=S.+Kaurauthor=M.+X.+Sliwkowskiauthor=R.+H.+Schellerauthor=P.+Polakisauthor=J.+R.+Junutula&title=Conjugation+site+modulates+the+in+vivo+stability+and+therapeutic+activity+of+antibody-drug+conjugates&doi=10.1038%2Fnbt.2108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates</span></div><div class="casAuthors">Shen, Ben-Quan; Xu, Keyang; Liu, Luna; Raab, Helga; Bhakta, Sunil; Kenrick, Margaret; Parsons-Reponte, Kathryn L.; Tien, Janet; Yu, Shang-Fan; Mai, Elaine; Li, Dongwei; Tibbitts, Jay; Baudys, Jakub; Saad, Ola M.; Scales, Suzie J.; McDonald, Paul J.; Hass, Philip E.; Eigenbrot, Charles; Nguyen, Trung; Solis, Willy A.; Fuji, Reina N.; Flagella, Kelly M.; Patel, Darshana; Spencer, Susan D.; Khawli, Leslie A.; Ebens, Allen; Wong, Wai Lee; Vandlen, Richard; Kaur, Surinder; Sliwkowski, Mark X.; Scheller, Richard H.; Polakis, Paul; Junutula, Jagath R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">184-189</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The reactive thiol in cysteine is used for coupling maleimide linkers in the generation of antibody conjugates.  To assess the impact of the conjugation site, we engineered cysteines into a therapeutic HER2/neu antibody at three sites differing in solvent accessibility and local charge.  The highly solvent-accessible site rapidly lost conjugated thiol-reactive linkers in plasma owing to maleimide exchange with reactive thiols in albumin, free cysteine or glutathione.  In contrast, a partially accessible site with a pos. charged environment promoted hydrolysis of the succinimide ring in the linker, thereby preventing this exchange reaction.  The site with partial solvent-accessibility and neutral charge displayed both properties.  In a mouse mammary tumor model, the stability and therapeutic activity of the antibody conjugate were affected pos. by succinimide ring hydrolysis and neg. by maleimide exchange with thiol-reactive constituents in plasma.  Thus, the chem. and structural dynamics of the conjugation site can influence antibody conjugate performance by modulating the stability of the antibody-linker interface.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkINkMwQTMFrVg90H21EOLACvtfcHk0ljS4Lib425o7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVGqtLg%253D&md5=c647fc5bdfe93dfdabb15ca40934837f</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2108%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DB.-Q.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DRaab%26aufirst%3DH.%26aulast%3DBhakta%26aufirst%3DS.%26aulast%3DKenrick%26aufirst%3DM.%26aulast%3DParsons-Reponte%26aufirst%3DK.%2BL.%26aulast%3DTien%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DS.-F.%26aulast%3DMai%26aufirst%3DE.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DTibbitts%26aufirst%3DJ.%26aulast%3DBaudys%26aufirst%3DJ.%26aulast%3DSaad%26aufirst%3DO.%2BM.%26aulast%3DScales%26aufirst%3DS.%2BJ.%26aulast%3DMcDonald%26aufirst%3DP.%2BJ.%26aulast%3DHass%26aufirst%3DP.%2BE.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DSolis%26aufirst%3DW.%2BA.%26aulast%3DFuji%26aufirst%3DR.%2BN.%26aulast%3DFlagella%26aufirst%3DK.%2BM.%26aulast%3DPatel%26aufirst%3DD.%26aulast%3DSpencer%26aufirst%3DS.%2BD.%26aulast%3DKhawli%26aufirst%3DL.%2BA.%26aulast%3DEbens%26aufirst%3DA.%26aulast%3DWong%26aufirst%3DW.%2BL.%26aulast%3DVandlen%26aufirst%3DR.%26aulast%3DKaur%26aufirst%3DS.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DScheller%26aufirst%3DR.%2BH.%26aulast%3DPolakis%26aufirst%3DP.%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26atitle%3DConjugation%2520site%2520modulates%2520the%2520in%2520vivo%2520stability%2520and%2520therapeutic%2520activity%2520of%2520antibody-drug%2520conjugates%26jtitle%3DNat.%2520Biotechnol.%26date%3D2012%26volume%3D30%26issue%3D2%26spage%3D184%26epage%3D189%26doi%3D10.1038%2Fnbt.2108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Junutula, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhakta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raab, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ervin, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandlen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheller, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowman, H. B.</span><span> </span><span class="NLM_article-title">Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs</span> <span class="citation_source-journal">J. Immunol. Methods</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">332</span><span class="NLM_x"> (</span><span class="NLM_issue">1–2</span><span class="NLM_x">) </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">52</span><span class="refDoi"> DOI: 10.1016/j.jim.2007.12.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1016%2Fj.jim.2007.12.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=18230399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtlygur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=332&publication_year=2008&pages=41-52&issue=1%E2%80%932&author=J.+R.+Junutulaauthor=S.+Bhaktaauthor=H.+Raabauthor=K.+E.+Ervinauthor=C.+Eigenbrotauthor=R.+Vandlenauthor=R.+H.+Schellerauthor=H.+B.+Lowman&title=Rapid+identification+of+reactive+cysteine+residues+for+site-specific+labeling+of+antibody-Fabs&doi=10.1016%2Fj.jim.2007.12.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs</span></div><div class="casAuthors">Junutula, Jagath R.; Bhakta, Sunil; Raab, Helga; Ervin, Karen E.; Eigenbrot, Charles; Vandlen, Richard; Scheller, Richard H.; Lowman, Henry B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunological Methods</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">332</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">41-52</span>CODEN:
                <span class="NLM_cas:coden">JIMMBG</span>;
        ISSN:<span class="NLM_cas:issn">0022-1759</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Cysteines with reactive thiol groups are attractive tools for site-specific labeling of proteins.  Engineering a reactive cysteine residue into proteins with multiple disulfide bonds is often a challenging task as it may interfere with structural and functional properties of the protein.  Here we developed a phage display-based biochem. assay, PHESELECTOR (Phage ELISA for Selection of Reactive Thiols) to rapidly screen reactive thiol groups on antibody fragments without interfering with their antigen binding, using trastuzumab-Fab (hu4D5Fab) as a model system.  The solvent accessibility values for all the amino acid residues in the hu4D5Fab were calcd. using available crystal structure information.  Serine, alanine and valine residues with highest solvent accessibility values were selected and tested to compare structure-based design with the PHESELECTOR biochem. method.  Cysteine substitutions at partially solvent-accessible alanine or valine residues exhibited better thiol reactivity values than substitutions at serine residues.  The poor correlation between fractional solvent accessibility and thiol reactivity of the engineered hu4D5Fab variants indicated the value of PHESELECTOR biochem. assay to identify reactive thiol groups on the antibody-Fab surface.  Mass spectrometric anal. of biotinylated ThioFab (Fab with engineered cysteine) variants confirmed that conjugation occurred only at the engineered cysteine thiols of either light or heavy chains.  ThioFabs with engineered cysteine residues in the const. domains (CL and CH1) should allow universal application for site-specific conjugation of antibody-Fabs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw4ofIVb0hO7Vg90H21EOLACvtfcHk0ljS4Lib425o7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtlygur0%253D&md5=55f3c07ff74193fa1160aafc99e02c50</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.jim.2007.12.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jim.2007.12.011%26sid%3Dliteratum%253Aachs%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26aulast%3DBhakta%26aufirst%3DS.%26aulast%3DRaab%26aufirst%3DH.%26aulast%3DErvin%26aufirst%3DK.%2BE.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DVandlen%26aufirst%3DR.%26aulast%3DScheller%26aufirst%3DR.%2BH.%26aulast%3DLowman%26aufirst%3DH.%2BB.%26atitle%3DRapid%2520identification%2520of%2520reactive%2520cysteine%2520residues%2520for%2520site-specific%2520labeling%2520of%2520antibody-Fabs%26jtitle%3DJ.%2520Immunol.%2520Methods%26date%3D2008%26volume%3D332%26issue%3D1%25E2%2580%25932%26spage%3D41%26epage%3D52%26doi%3D10.1016%2Fj.jim.2007.12.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Getz, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakrabarty, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selvin, P. R.</span><span> </span><span class="NLM_article-title">A comparison between the sulfhydryl reductants tris(2-carboxyethyl)phosphine and dithiothreitol for use in protein biochemistry</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">273</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">73</span><span class="NLM_x">–</span> <span class="NLM_lpage">80</span><span class="refDoi"> DOI: 10.1006/abio.1999.4203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1006%2Fabio.1999.4203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10452801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADyaK1MXlt1Wktbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1999&pages=73-80&issue=1&author=E.+B.+Getzauthor=M.+Xiaoauthor=T.+Chakrabartyauthor=R.+Cookeauthor=P.+R.+Selvin&title=A+comparison+between+the+sulfhydryl+reductants+tris%282-carboxyethyl%29phosphine+and+dithiothreitol+for+use+in+protein+biochemistry&doi=10.1006%2Fabio.1999.4203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">A Comparison between the Sulfhydryl Reductants Tris(2-carboxyethyl)phosphine and Dithiothreitol for Use in Protein Biochemistry</span></div><div class="casAuthors">Getz, Elise Burmeister; Xiao, Ming; Chakrabarty, Tania; Cooke, Roger; Selvin, Paul R.</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">273</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">73-80</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">The newly introduced sulfhydryl reductant tris(2-carboxyethyl)phosphine (TCEP) is a potentially attractive alternative to commonly used dithiothreitol (DTT).  We compare properties of DTT and TCEP important in protein biochem., using the motor enzyme myosin as an example protein.  The reductants equally preserve myosin's enzymic activity, which is sensitive to sulfhydryl oxidn.  When labeling with extrinsic probes, DTT inhibits maleimide attachment to myosin and must be removed before labeling.  In contrast, maleimide attachment to myosin was achieved in the presence of TCEP, although with less efficiency than no reductant.  Surprisingly, iodoacetamide attachment to myosin was nearly unaffected by either reductant at low (0.1 mM) concns.  In ESR (EPR) spectroscopy utilizing nitroxide spin labels, TCEP is highly advantageous: spin labels are two to four times more stable in TCEP than DTT, thereby alleviating a long-standing problem in EPR.  During protein purifn., Ni2+ concns. contaminating proteins eluted from Ni2+ affinity columns cause rapid oxidn. of DTT without affecting TCEP.  For long-term storage of proteins, TCEP is significantly more stable than DTT without metal chelates such as EGTA in the buffer, whereas DTT is more stable if metal chelates are present.  Thus TCEP has advantages over DTT, although the choice of reductant is application specific.  (c) 1999 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdtHBL1_btC7Vg90H21EOLACvtfcHk0ljS4Lib425o7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlt1Wktbg%253D&md5=7cef8b931982ecbdddf2c92774c438ee</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1006%2Fabio.1999.4203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fabio.1999.4203%26sid%3Dliteratum%253Aachs%26aulast%3DGetz%26aufirst%3DE.%2BB.%26aulast%3DXiao%26aufirst%3DM.%26aulast%3DChakrabarty%26aufirst%3DT.%26aulast%3DCooke%26aufirst%3DR.%26aulast%3DSelvin%26aufirst%3DP.%2BR.%26atitle%3DA%2520comparison%2520between%2520the%2520sulfhydryl%2520reductants%2520tris%25282-carboxyethyl%2529phosphine%2520and%2520dithiothreitol%2520for%2520use%2520in%2520protein%2520biochemistry%26jtitle%3DAnal.%2520Biochem.%26date%3D1999%26volume%3D273%26issue%3D1%26spage%3D73%26epage%3D80%26doi%3D10.1006%2Fabio.1999.4203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Zhang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pillow, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cruz-Chuh, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozak, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadowsky, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis Phillips, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darwish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hop, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khojasteh, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span> </span><span class="NLM_article-title">Linker immolation determines cell killing activity of disulfide-linked pyrrolobenzodiazepine antibody-drug conjugates</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">988</span><span class="NLM_x">–</span> <span class="NLM_lpage">993</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00233</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00233" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=988-993&issue=11&author=D.+Zhangauthor=T.+H.+Pillowauthor=Y.+Maauthor=J.+D.+Cruz-Chuhauthor=K.+R.+Kozakauthor=J.+D.+Sadowskyauthor=G.+D.+Lewis+Phillipsauthor=J.+Guoauthor=M.+Darwishauthor=P.+Fanauthor=J.+Chenauthor=C.+Heauthor=T.+Wangauthor=H.+Yaoauthor=Z.+Xuauthor=J.+Chenauthor=J.+Waiauthor=Z.+Peiauthor=C.+E.+Hopauthor=S.+C.+Khojastehauthor=P.+S.+Dragovich&title=Linker+immolation+determines+cell+killing+activity+of+disulfide-linked+pyrrolobenzodiazepine+antibody-drug+conjugates&doi=10.1021%2Facsmedchemlett.6b00233"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00233%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DPillow%26aufirst%3DT.%2BH.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DCruz-Chuh%26aufirst%3DJ.%2BD.%26aulast%3DKozak%26aufirst%3DK.%2BR.%26aulast%3DSadowsky%26aufirst%3DJ.%2BD.%26aulast%3DLewis%2BPhillips%26aufirst%3DG.%2BD.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DDarwish%26aufirst%3DM.%26aulast%3DFan%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DWai%26aufirst%3DJ.%26aulast%3DPei%26aufirst%3DZ.%26aulast%3DHop%26aufirst%3DC.%2BE.%26aulast%3DKhojasteh%26aufirst%3DS.%2BC.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26atitle%3DLinker%2520immolation%2520determines%2520cell%2520killing%2520activity%2520of%2520disulfide-linked%2520pyrrolobenzodiazepine%2520antibody-drug%2520conjugates%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26issue%3D11%26spage%3D988%26epage%3D993%26doi%3D10.1021%2Facsmedchemlett.6b00233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 19 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Leanna R. Staben, Jinhua Chen, Josefa dela Cruz-Chuh, Geoff del Rosario, Mary Ann Go, Jun Guo, S. Cyrus Khojasteh, Katherine R. Kozak, Guangmin Li, Carl Ng, Gail D. Lewis Phillips, Thomas H. Pillow, Rebecca K. Rowntree, John Wai, BinQing Wei, Keyang Xu, Zijin Xu, Shang-Fan Yu, Donglu Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Peter S. Dragovich</span>. </span><span class="cited-content_cbyCitation_article-title">Systematic Variation of Pyrrolobenzodiazepine (PBD)-Dimer Payload Physicochemical Properties Impacts Efficacy and Tolerability of the Corresponding Antibody–Drug Conjugates. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (17)
                                     , 9603-9622. <a href="https://doi.org/10.1021/acs.jmedchem.0c00691" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00691</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00691%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSystematic%252BVariation%252Bof%252BPyrrolobenzodiazepine%252B%252528PBD%252529-Dimer%252BPayload%252BPhysicochemical%252BProperties%252BImpacts%252BEfficacy%252Band%252BTolerability%252Bof%252Bthe%252BCorresponding%252BAntibody%2525E2%252580%252593Drug%252BConjugates%26aulast%3DStaben%26aufirst%3DLeanna%2BR.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D06052020%26date%3D18082020%26date%3D31072020%26volume%3D63%26issue%3D17%26spage%3D9603%26epage%3D9622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="NLM_string-name hlFld-ContribAuthor">Tanaji T. Talele</span>. </span><span class="cited-content_cbyCitation_article-title">Acetylene Group, Friend or Foe in Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (11)
                                     , 5625-5663. <a href="https://doi.org/10.1021/acs.jmedchem.9b01617" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01617</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01617%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAcetylene%252BGroup%25252C%252BFriend%252Bor%252BFoe%252Bin%252BMedicinal%252BChemistry%26aulast%3DTalele%26aufirst%3DTanaji%2BT.%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D29092019%26date%3D19022020%26date%3D07022020%26volume%3D63%26issue%3D11%26spage%3D5625%26epage%3D5663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Silvia Sonzini, Maria Laura Greco, Thais Cailleau, Lauren Adams, Luke Masterson, Balakumar Vijayakrishnan, Conor Barry, Phillip Howard, Peter Ravn, <span class="NLM_string-name hlFld-ContribAuthor">Christopher F. van der Walle</span>. </span><span class="cited-content_cbyCitation_article-title">Improved Physical Stability of an Antibody–Drug Conjugate Using Host–Guest Chemistry. </span><span class="cited-content_cbyCitation_journal-name">Bioconjugate Chemistry</span><span> <strong>2020,</strong> <em>31 </em>
                                    (1)
                                     , 123-129. <a href="https://doi.org/10.1021/acs.bioconjchem.9b00809" title="DOI URL">https://doi.org/10.1021/acs.bioconjchem.9b00809</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.bioconjchem.9b00809&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.bioconjchem.9b00809%26sid%3Dliteratum%253Aachs%26jtitle%3DBioconjugate%2520Chemistry%26atitle%3DImproved%252BPhysical%252BStability%252Bof%252Ban%252BAntibody%2525E2%252580%252593Drug%252BConjugate%252BUsing%252BHost%2525E2%252580%252593Guest%252BChemistry%26aulast%3DSonzini%26aufirst%3DSilvia%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D02122019%26date%3D03122019%26date%3D16122019%26date%3D03122019%26volume%3D31%26issue%3D1%26spage%3D123%26epage%3D129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vesela  Kostova</span>, <span class="hlFld-ContribAuthor ">Patrice  Désos</span>, <span class="hlFld-ContribAuthor ">Jérôme-Benoît  Starck</span>, <span class="hlFld-ContribAuthor ">Andras  Kotschy</span>. </span><span class="cited-content_cbyCitation_article-title">The Chemistry Behind ADCs. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2021,</strong> <em>14 </em>
                                    (5)
                                     , 442. <a href="https://doi.org/10.3390/ph14050442" title="DOI URL">https://doi.org/10.3390/ph14050442</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph14050442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph14050442%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3DThe%252BChemistry%252BBehind%252BADCs%26aulast%3DKostova%26aufirst%3DVesela%26date%3D2021%26date%3D2021%26volume%3D14%26issue%3D5%26spage%3D442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zheng  Su</span>, <span class="hlFld-ContribAuthor ">Dian  Xiao</span>, <span class="hlFld-ContribAuthor ">Fei  Xie</span>, <span class="hlFld-ContribAuthor ">Lianqi  Liu</span>, <span class="hlFld-ContribAuthor ">Yanming  Wang</span>, <span class="hlFld-ContribAuthor ">Shiyong  Fan</span>, <span class="hlFld-ContribAuthor ">Xinbo  Zhou</span>, <span class="hlFld-ContribAuthor ">Song  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody–drug conjugates: Recent advances in linker chemistry. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2021,</strong> <em>8 </em><a href="https://doi.org/10.1016/j.apsb.2021.03.042" title="DOI URL">https://doi.org/10.1016/j.apsb.2021.03.042</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2021.03.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2021.03.042%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DAntibody%2525E2%252580%252593drug%252Bconjugates%25253A%252BRecent%252Badvances%252Bin%252Blinker%252Bchemistry%26aulast%3DSu%26aufirst%3DZheng%26date%3D2021%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mariana  Segovia-Mendoza</span>, <span class="hlFld-ContribAuthor ">Cristina  Lemini</span>, <span class="hlFld-ContribAuthor ">Rocio  García-Becerra</span>, <span class="hlFld-ContribAuthor ">Jorge  Morales-Montor</span>. </span><span class="cited-content_cbyCitation_article-title">Immunoconjugates as immune canoes to kill breast cancer cells. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 11-31. <a href="https://doi.org/10.1016/B978-0-12-822028-3.00006-6" title="DOI URL">https://doi.org/10.1016/B978-0-12-822028-3.00006-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-822028-3.00006-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-822028-3.00006-6%26sid%3Dliteratum%253Aachs%26atitle%3DImmunoconjugates%252Bas%252Bimmune%252Bcanoes%252Bto%252Bkill%252Bbreast%252Bcancer%252Bcells%26aulast%3DSegovia-Mendoza%26aufirst%3DMariana%26date%3D2021%26spage%3D11%26epage%3D31%26pub%3DElsevier%26atitle%3DImmunotherapy%252Bin%252BResistant%252BCancer%25253A%252BFrom%252Bthe%252BLab%252BBench%252BWork%252Bto%252BIts%252BClinical%252BPerspectives%26date%3D2021%26volume%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rong  Huang</span>, <span class="hlFld-ContribAuthor ">Yao  Sheng</span>, <span class="hlFld-ContribAuthor ">Ding  Wei</span>, <span class="hlFld-ContribAuthor ">Jianghui  Yu</span>, <span class="hlFld-ContribAuthor ">Hongli  Chen</span>, <span class="hlFld-ContribAuthor ">Biao  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Bis(vinylsulfonyl)piperazines as efficient linkers for highly homogeneous antibody-drug conjugates. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>190 </em>, 112080. <a href="https://doi.org/10.1016/j.ejmech.2020.112080" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112080</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112080%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DBis%252528vinylsulfonyl%252529piperazines%252Bas%252Befficient%252Blinkers%252Bfor%252Bhighly%252Bhomogeneous%252Bantibody-drug%252Bconjugates%26aulast%3DHuang%26aufirst%3DRong%26date%3D2020%26volume%3D190%26spage%3D112080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nafsika  Forte</span>, <span class="hlFld-ContribAuthor ">Irene  Benni</span>, <span class="hlFld-ContribAuthor ">Kersti  Karu</span>, <span class="hlFld-ContribAuthor ">Vijay  Chudasama</span>, <span class="hlFld-ContribAuthor ">James R.  Baker</span>. </span><span class="cited-content_cbyCitation_article-title">Cysteine-to-lysine transfer antibody fragment conjugation. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2019,</strong> <em>10 </em>
                                    (47)
                                     , 10919-10924. <a href="https://doi.org/10.1039/C9SC03825F" title="DOI URL">https://doi.org/10.1039/C9SC03825F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9SC03825F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9SC03825F%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DCysteine-to-lysine%252Btransfer%252Bantibody%252Bfragment%252Bconjugation%26aulast%3DForte%26aufirst%3DNafsika%26date%3D2019%26date%3D2019%26volume%3D10%26issue%3D47%26spage%3D10919%26epage%3D10924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stephen J.  Gregson</span>, <span class="hlFld-ContribAuthor ">Allison M.  Barrett</span>, <span class="hlFld-ContribAuthor ">Neki V.  Patel</span>, <span class="hlFld-ContribAuthor ">Gyoung-Dong  Kang</span>, <span class="hlFld-ContribAuthor ">Davide  Schiavone</span>, <span class="hlFld-ContribAuthor ">Erin  Sult</span>, <span class="hlFld-ContribAuthor ">Conor S.  Barry</span>, <span class="hlFld-ContribAuthor ">Balakumar  Vijayakrishnan</span>, <span class="hlFld-ContribAuthor ">Lauren R.  Adams</span>, <span class="hlFld-ContribAuthor ">Luke A.  Masterson</span>, <span class="hlFld-ContribAuthor ">Francois  D'Hooge</span>, <span class="hlFld-ContribAuthor ">Mike  Snaith</span>, <span class="hlFld-ContribAuthor ">Jay  Harper</span>, <span class="hlFld-ContribAuthor ">John A.  Hartley</span>, <span class="hlFld-ContribAuthor ">Philip W.  Howard</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and evaluation of pyrrolobenzodiazepine dimer antibody-drug conjugates with dual β-glucuronide and dipeptide triggers. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>179 </em>, 591-607. <a href="https://doi.org/10.1016/j.ejmech.2019.06.044" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.06.044</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.06.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.06.044%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bevaluation%252Bof%252Bpyrrolobenzodiazepine%252Bdimer%252Bantibody-drug%252Bconjugates%252Bwith%252Bdual%252B%2525CE%2525B2-glucuronide%252Band%252Bdipeptide%252Btriggers%26aulast%3DGregson%26aufirst%3DStephen%2BJ.%26date%3D2019%26volume%3D179%26spage%3D591%26epage%3D607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kanwen  Yang</span>, <span class="hlFld-ContribAuthor ">Bo  Chen</span>, <span class="hlFld-ContribAuthor ">Diego A.  Gianolio</span>, <span class="hlFld-ContribAuthor ">James E.  Stefano</span>, <span class="hlFld-ContribAuthor ">Michelle  Busch</span>, <span class="hlFld-ContribAuthor ">Charlene  Manning</span>, <span class="hlFld-ContribAuthor ">Kim  Alving</span>, <span class="hlFld-ContribAuthor ">Richard C.  Gregory</span>, <span class="hlFld-ContribAuthor ">William H.  Brondyk</span>, <span class="hlFld-ContribAuthor ">Robert J.  Miller</span>, <span class="hlFld-ContribAuthor ">Pradeep K.  Dhal</span>. </span><span class="cited-content_cbyCitation_article-title">Convergent synthesis of hydrophilic monomethyl dolastatin 10 based drug linkers for antibody–drug conjugation. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2019,</strong> <em>17 </em>
                                    (35)
                                     , 8115-8124. <a href="https://doi.org/10.1039/C9OB01639B" title="DOI URL">https://doi.org/10.1039/C9OB01639B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9OB01639B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9OB01639B%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DConvergent%252Bsynthesis%252Bof%252Bhydrophilic%252Bmonomethyl%252Bdolastatin%252B10%252Bbased%252Bdrug%252Blinkers%252Bfor%252Bantibody%2525E2%252580%252593drug%252Bconjugation%26aulast%3DYang%26aufirst%3DKanwen%26date%3D2019%26date%3D2019%26volume%3D17%26issue%3D35%26spage%3D8115%26epage%3D8124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brent A.  Williams</span>, <span class="hlFld-ContribAuthor ">Arjun  Law</span>, <span class="hlFld-ContribAuthor ">Judit  Hunyadkurti</span>, <span class="hlFld-ContribAuthor ">Stephanie  Desilets</span>, <span class="hlFld-ContribAuthor ">Jeffrey V.  Leyton</span>, <span class="hlFld-ContribAuthor ">Armand  Keating</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody Therapies for Acute Myeloid Leukemia: Unconjugated, Toxin-Conjugated, Radio-Conjugated and Multivalent Formats. </span><span class="cited-content_cbyCitation_journal-name">Journal of Clinical Medicine</span><span> <strong>2019,</strong> <em>8 </em>
                                    (8)
                                     , 1261. <a href="https://doi.org/10.3390/jcm8081261" title="DOI URL">https://doi.org/10.3390/jcm8081261</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/jcm8081261&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fjcm8081261%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Clinical%2520Medicine%26atitle%3DAntibody%252BTherapies%252Bfor%252BAcute%252BMyeloid%252BLeukemia%25253A%252BUnconjugated%25252C%252BToxin-Conjugated%25252C%252BRadio-Conjugated%252Band%252BMultivalent%252BFormats%26aulast%3DWilliams%26aufirst%3DBrent%2BA.%26date%3D2019%26date%3D2019%26volume%3D8%26issue%3D8%26spage%3D1261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paula  MacGregor</span>, <span class="hlFld-ContribAuthor ">Andrea L.  Gonzalez-Munoz</span>, <span class="hlFld-ContribAuthor ">Fatoumatta  Jobe</span>, <span class="hlFld-ContribAuthor ">Martin C.  Taylor</span>, <span class="hlFld-ContribAuthor ">Steven  Rust</span>, <span class="hlFld-ContribAuthor ">Alan M.  Sandercock</span>, <span class="hlFld-ContribAuthor ">Olivia J. S.  Macleod</span>, <span class="hlFld-ContribAuthor ">Katrien  Van Bocxlaer</span>, <span class="hlFld-ContribAuthor ">Amanda F.  Francisco</span>, <span class="hlFld-ContribAuthor ">Francois  D’Hooge</span>, <span class="hlFld-ContribAuthor ">Arnaud  Tiberghien</span>, <span class="hlFld-ContribAuthor ">Conor S.  Barry</span>, <span class="hlFld-ContribAuthor ">Philip  Howard</span>, <span class="hlFld-ContribAuthor ">Matthew K.  Higgins</span>, <span class="hlFld-ContribAuthor ">Tristan J.  Vaughan</span>, <span class="hlFld-ContribAuthor ">Ralph  Minter</span>, <span class="hlFld-ContribAuthor ">Mark  Carrington</span>, . </span><span class="cited-content_cbyCitation_article-title">A single dose of antibody-drug conjugate cures a stage 1 model of African trypanosomiasis. </span><span class="cited-content_cbyCitation_journal-name">PLOS Neglected Tropical Diseases</span><span> <strong>2019,</strong> <em>13 </em>
                                    (5)
                                     , e0007373. <a href="https://doi.org/10.1371/journal.pntd.0007373" title="DOI URL">https://doi.org/10.1371/journal.pntd.0007373</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pntd.0007373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pntd.0007373%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520Neglected%2520Tropical%2520Diseases%26atitle%3DA%252Bsingle%252Bdose%252Bof%252Bantibody-drug%252Bconjugate%252Bcures%252Ba%252Bstage%252B1%252Bmodel%252Bof%252BAfrican%252Btrypanosomiasis%26aulast%3DMacGregor%26aufirst%3DPaula%26date%3D2019%26date%3D2019%26volume%3D13%26issue%3D5%26spage%3De0007373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anil  Vasudevan</span>, <span class="hlFld-ContribAuthor ">Maria A.  Argiriadi</span>, <span class="hlFld-ContribAuthor ">Aleksandra  Baranczak</span>, <span class="hlFld-ContribAuthor ">Michael M.  Friedman</span>, <span class="hlFld-ContribAuthor ">Julia  Gavrilyuk</span>, <span class="hlFld-ContribAuthor ">Adrian D.  Hobson</span>, <span class="hlFld-ContribAuthor ">Jonathan J.  Hulce</span>, <span class="hlFld-ContribAuthor ">Sami  Osman</span>, <span class="hlFld-ContribAuthor ">Noel S.  Wilson</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent binders in drug discovery. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 1-62. <a href="https://doi.org/10.1016/bs.pmch.2018.12.002" title="DOI URL">https://doi.org/10.1016/bs.pmch.2018.12.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.pmch.2018.12.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.pmch.2018.12.002%26sid%3Dliteratum%253Aachs%26atitle%3DCovalent%252Bbinders%252Bin%252Bdrug%252Bdiscovery%26aulast%3DVasudevan%26aufirst%3DAnil%26date%3D2019%26spage%3D1%26epage%3D62%26pub%3DElsevier%26date%3D2019%26volume%3D58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Krista  Kinneer</span>, <span class="hlFld-ContribAuthor ">John  Meekin</span>, <span class="hlFld-ContribAuthor ">Arnaud C.  Tiberghien</span>, <span class="hlFld-ContribAuthor ">Yu-Tzu  Tai</span>, <span class="hlFld-ContribAuthor ">Sandrina  Phipps</span>, <span class="hlFld-ContribAuthor ">Christine Mione  Kiefer</span>, <span class="hlFld-ContribAuthor ">Marlon C.  Rebelatto</span>, <span class="hlFld-ContribAuthor ">Nazzareno  Dimasi</span>, <span class="hlFld-ContribAuthor ">Alyssa  Moriarty</span>, <span class="hlFld-ContribAuthor ">Kyriakos P.  Papadopoulos</span>, <span class="hlFld-ContribAuthor ">Sriram  Sridhar</span>, <span class="hlFld-ContribAuthor ">Stephen J.  Gregson</span>, <span class="hlFld-ContribAuthor ">Michael J.  Wick</span>, <span class="hlFld-ContribAuthor ">Luke  Masterson</span>, <span class="hlFld-ContribAuthor ">Kenneth C.  Anderson</span>, <span class="hlFld-ContribAuthor ">Ronald  Herbst</span>, <span class="hlFld-ContribAuthor ">Philip W.  Howard</span>, <span class="hlFld-ContribAuthor ">David A.  Tice</span>. </span><span class="cited-content_cbyCitation_article-title">SLC46A3 as a Potential Predictive Biomarker for Antibody–Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2018,</strong> <em>24 </em>
                                    (24)
                                     , 6570-6582. <a href="https://doi.org/10.1158/1078-0432.CCR-18-1300" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-18-1300</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-18-1300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-18-1300%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DSLC46A3%252Bas%252Ba%252BPotential%252BPredictive%252BBiomarker%252Bfor%252BAntibody%2525E2%252580%252593Drug%252BConjugates%252BBearing%252BNoncleavable%252BLinked%252BMaytansinoid%252Band%252BPyrrolobenzodiazepine%252BWarheads%26aulast%3DKinneer%26aufirst%3DKrista%26date%3D2018%26date%3D2018%26volume%3D24%26issue%3D24%26spage%3D6570%26epage%3D6582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nafsika  Forte</span>, <span class="hlFld-ContribAuthor ">Vijay  Chudasama</span>, <span class="hlFld-ContribAuthor ">James R.  Baker</span>. </span><span class="cited-content_cbyCitation_article-title">Homogeneous antibody-drug conjugates via site-selective disulfide bridging. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today: Technologies</span><span> <strong>2018,</strong> <em>30 </em>, 11-20. <a href="https://doi.org/10.1016/j.ddtec.2018.09.004" title="DOI URL">https://doi.org/10.1016/j.ddtec.2018.09.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ddtec.2018.09.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ddtec.2018.09.004%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Technologies%26atitle%3DHomogeneous%252Bantibody-drug%252Bconjugates%252Bvia%252Bsite-selective%252Bdisulfide%252Bbridging%26aulast%3DForte%26aufirst%3DNafsika%26date%3D2018%26volume%3D30%26spage%3D11%26epage%3D20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yasuaki  Anami</span>, <span class="hlFld-ContribAuthor ">Chisato M.  Yamazaki</span>, <span class="hlFld-ContribAuthor ">Wei  Xiong</span>, <span class="hlFld-ContribAuthor ">Xun  Gui</span>, <span class="hlFld-ContribAuthor ">Ningyan  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhiqiang  An</span>, <span class="hlFld-ContribAuthor ">Kyoji  Tsuchikama</span>. </span><span class="cited-content_cbyCitation_article-title">Glutamic acid–valine–citrulline linkers ensure stability and efficacy of antibody–drug conjugates in mice. </span><span class="cited-content_cbyCitation_journal-name">Nature Communications</span><span> <strong>2018,</strong> <em>9 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41467-018-04982-3" title="DOI URL">https://doi.org/10.1038/s41467-018-04982-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41467-018-04982-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41467-018-04982-3%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Communications%26atitle%3DGlutamic%252Bacid%2525E2%252580%252593valine%2525E2%252580%252593citrulline%252Blinkers%252Bensure%252Bstability%252Band%252Befficacy%252Bof%252Bantibody%2525E2%252580%252593drug%252Bconjugates%252Bin%252Bmice%26aulast%3DAnami%26aufirst%3DYasuaki%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tiago  Rodrigues</span>, <span class="hlFld-ContribAuthor ">Gonçalo J. L.  Bernardes</span>. </span><span class="cited-content_cbyCitation_article-title">Antikörpergerichtete Therapien: Quo vadis?. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2018,</strong> <em>130 </em>
                                    (8)
                                     , 2050-2052. <a href="https://doi.org/10.1002/ange.201712185" title="DOI URL">https://doi.org/10.1002/ange.201712185</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.201712185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.201712185%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DAntik%2525C3%2525B6rpergerichtete%252BTherapien%25253A%252BQuo%252Bvadis%25253F%26aulast%3DRodrigues%26aufirst%3DTiago%26date%3D2018%26date%3D2018%26volume%3D130%26issue%3D8%26spage%3D2050%26epage%3D2052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tiago  Rodrigues</span>, <span class="hlFld-ContribAuthor ">Gonçalo J. L.  Bernardes</span>. </span><span class="cited-content_cbyCitation_article-title">Development of Antibody-Directed Therapies:
              Quo Vadis
              ?. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2018,</strong> <em>57 </em>
                                    (8)
                                     , 2032-2034. <a href="https://doi.org/10.1002/anie.201712185" title="DOI URL">https://doi.org/10.1002/anie.201712185</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.201712185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.201712185%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DDevelopment%252Bof%252BAntibody-Directed%252BTherapies%25253A%252BQuo%252BVadis%252B%25253F%26aulast%3DRodrigues%26aufirst%3DTiago%26date%3D2018%26date%3D2018%26volume%3D57%26issue%3D8%26spage%3D2032%26epage%3D2034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">R.  Christie</span>, <span class="hlFld-ContribAuthor ">Arnaud  Tiberghien</span>, <span class="hlFld-ContribAuthor ">Qun  Du</span>, <span class="hlFld-ContribAuthor ">Binyam  Bezabeh</span>, <span class="hlFld-ContribAuthor ">Ryan  Fleming</span>, <span class="hlFld-ContribAuthor ">Amanda  Shannon</span>, <span class="hlFld-ContribAuthor ">Shenlan  Mao</span>, <span class="hlFld-ContribAuthor ">Shannon  Breen</span>, <span class="hlFld-ContribAuthor ">Jing  Zhang</span>, <span class="hlFld-ContribAuthor ">Haihong  Zhong</span>, <span class="hlFld-ContribAuthor ">Jay  Harper</span>, <span class="hlFld-ContribAuthor ">Herren  Wu</span>, <span class="hlFld-ContribAuthor ">Philip  Howard</span>, <span class="hlFld-ContribAuthor ">Changshou  Gao</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrrolobenzodiazepine Antibody-Drug Conjugates Designed for Stable Thiol Conjugation. </span><span class="cited-content_cbyCitation_journal-name">Antibodies</span><span> <strong>2017,</strong> <em>6 </em>
                                    (4)
                                     , 20. <a href="https://doi.org/10.3390/antib6040020" title="DOI URL">https://doi.org/10.3390/antib6040020</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/antib6040020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fantib6040020%26sid%3Dliteratum%253Aachs%26jtitle%3DAntibodies%26atitle%3DPyrrolobenzodiazepine%252BAntibody-Drug%252BConjugates%252BDesigned%252Bfor%252BStable%252BThiol%252BConjugation%26aulast%3DChristie%26aufirst%3DR.%26date%3D2017%26date%3D2017%26volume%3D6%26issue%3D4%26spage%3D20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/medium/jm-2017-00736q_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00736&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/medium/jm-2017-00736q_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0001.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of marketed ADC drug-linkers trastuzumab emtansine (<b>1</b>) and brentuximab vedotin (<b>2</b>) and a standalone PBD dimer and PBD (<b>3</b> and <b>4</b>)/IBD (<b>5</b>) ADC drug-linkers in clinical trials and development. Notable PBD atom numbers are shown in <b>3</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00736&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/medium/jm-2017-00736q_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0002.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. PBD dimer ADCs evaluated in this study. The drugs were conjugated to either anti-HER2 (thio Hu anti-HER2 4D5 HC-A118C) or anti-CD22 (thio Hu anti-CD22 10F4v3 HC-A118C) cysteine engineered antibodies.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00736&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/medium/jm-2017-00736q_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0003.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (a) Structure of pentyldioxy tethered PBD dimer <b>4a</b>. (b) Schematic representation of an aryl tether PBD dimer bound to 10-nucleotide long DNA duplex (5′-AACCATCGTT-3′). (c) Model of <b>6</b> (carbon atoms in cyan) bound in the DNA minor groove, where the molecular surface of the drug-linker cysteine adduct is shown in yellow. (d) Alternative view of the same complex with <b>6</b> looking down the minor groove. The covalent bonds between C11/C11′ of the PBD and the exocyclic N2 atom of two deoxyguanines are marked by solid lines and labeled with the bond length values (in Å), and potential hydrogen bonds between N10/N10′ of the PBD and an adjacent DNA base are marked by dashed lines. (e) Model of <b>7</b> (carbon atoms in brown) bound in the DNA minor groove. (f) Model of <b>8</b> (carbon atoms in green) bound in the DNA minor groove.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00736&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/medium/jm-2017-00736q_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0008.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <b>19</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00736&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (1) (COCl)<sub>2</sub>, DCM, DMF, rt, 16 h; (2) methyl (2<i>S</i>,4<i>R</i>)-4-hydroxypyrrolidine-2-carboxylate·HCl, DCM, TEA, −20 °C, 16 h, 68% yield; (b) LiBH<sub>4</sub>, THF, 0 °C, 4 h, 90% yield; (c) SnCl<sub>2</sub>, MeOH, reflux, 3 h, <b>12</b> carried through crude; (d) (Boc)<sub>2</sub>O, THF, reflux, 16 h, 60% yield; (e) TEMPO, DAIB, DCM, rt, 16 h, 46% yield; (f) 10% w/<i>w</i> Pd–C, EtOH, rt, 4 h, 53% yield; (g) DHP, PTSA, EtOAc, rt, 1 h, 65% yield; (h) PPh<sub>3</sub>CH<sub>3</sub>Br, KO<sup><i>t</i></sup>Bu, THF, 0 °C to rt, 18 h, 72% yield; (i) THF, AcOH, H<sub>2</sub>O, rt, 3 h, 87% yield; (j) 1,3-bis(bromomethyl)-5-iodobenzene, K<sub>2</sub>CO<sub>3</sub>, TBAI, DMF, 60 °C, 3 h, 91% yield.</p></p></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/medium/jm-2017-00736q_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0009.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <b>6</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00736&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) propargylamine, EDCI, DCM, rt, 16 h, 71% yield; (b) <b>19</b>, Pd(PPh<sub>3</sub>)<sub>4</sub>, CuI, diethylamine, DMF, 4 Å molecular sieves, microwave at 100 °C, 26 min, 70% yield; (c) (1) TBSOTf, 2,6-lutidine, DCM, rt, 16 h; (2) TBAF, THF, rt, 1 h, <b>23</b> carried through crude; (d) EDCI, <i>N</i>-maleoyl-β-alanine, DCM, rt, 3 h, <b>24</b> carried through crude; (e) 95% TFA/H<sub>2</sub>O, 0 °C, 1 h, 60% yield from <b>22</b> (in 4 steps).</p></p></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/medium/jm-2017-00736q_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0004.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Structures of compounds to assist discussion of <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00736&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/medium/jm-2017-00736q_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0010.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of <b>7</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00736&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) TMS-acetylene, Pd(PPh<sub>3</sub>)<sub>4</sub>, CuI, diethylamine, DMF, microwave at 100 °C, 30 min, 95% yield; (b) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt, 3 h, 78% yield; (c) 11-azido-3,6,9-trioxaundecan-1-amine, CuSO<sub>4</sub>·5H<sub>2</sub>O, sodium ascorbate, <i><sup>t</sup></i>BuOH, H<sub>2</sub>O, rt, 16 h, <b>27</b> carried through crude; (d) 6-maleimidohexanoic acid <i>N</i>-hydroxysuccinimide ester, DCM, rt, 3 d, 45% yield; (e) 95% TFA/H<sub>2</sub>O, 0 °C, 1 h, 53% yield.</p></p></figure><figure data-id="sch4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/medium/jm-2017-00736q_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0011.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of <b>8</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00736&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>tert</i>-butyl piperazine-1-carboxylate, RuPhos Pd G1 methyl <i>tert</i>-butyl ether adduct, RuPhos, Cs<sub>2</sub>CO<sub>3</sub>, THF, 85 °C, 4 h, 34% yield; (b) 95% TFA/H<sub>2</sub>O, 0 °C, 30 min, <b>30</b> carried through crude; (c) EDCI, 1-maleimido-3-oxo-7,10,13,16-tetraoxa-4-azanonadecan-19-oic acid, DCM, rt, 2 h, 32% yield.</p></p></figure><figure data-id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/medium/jm-2017-00736q_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0005.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. In vitro cytotoxicity data for the PBD ADCs in HER2 models (a) SK-BR-3, (b) KPL-4, and (c) MCF7.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00736&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/medium/jm-2017-00736q_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0006.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. In vitro cytotoxicity data for the PBD ADCs in CD22 models (a) BJAB, (b) WSU-DLCL2, and (c) Jurkat.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00736&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/medium/jm-2017-00736q_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0007.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. In vivo efficacy data for the PBD ADCs, single dose at day 0: (a) <b>6</b>, (b) <b>8</b>, and (c) <b>7</b> in the Fo5 model and (d) <b>6</b>, <b>7</b>, and <b>8</b> in the WSU-DLCL2 model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b00736/20171208/images/large/jm-2017-00736q_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00736&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i55">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43086" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43086" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 48 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Thomas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teicher, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassan, R.</span><span> </span><span class="NLM_article-title">Antibody-drug conjugates for cancer therapy</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">e254</span><span class="NLM_x">–</span> <span class="NLM_lpage">262</span><span class="refDoi"> DOI: 10.1016/S1470-2045(16)30030-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1016%2FS1470-2045%2816%2930030-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=27299281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC28XptFCnsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=e254-262&issue=6&author=A.+Thomasauthor=B.+A.+Teicherauthor=R.+Hassan&title=Antibody-drug+conjugates+for+cancer+therapy&doi=10.1016%2FS1470-2045%2816%2930030-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-drug conjugates for cancer therapy</span></div><div class="casAuthors">Thomas, Anish; Teicher, Beverly A.; Hassan, Raffit</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e254-e262</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Antibody-drug conjugates are monoclonal antibodies conjugated to cytotoxic agents.  They use antibodies that are specific to tumor cell-surface proteins and, thus, have tumor specificity and potency not achievable with traditional drugs.  Design of effective antibody-drug conjugates for cancer therapy requires selection of an appropriate target, a monoclonal antibody against the target, potent cytotoxic effector mols., and conjugation of the monoclonal antibody to cytotoxic agents.  Substantial advances in all these aspects in the past decade have resulted in regulatory approval of ado-trastuzumab emtansine and brentuximab vedotin for clin. use.  Several promising antibody-drug conjugates are now in late-phase clin. testing.  Ongoing efforts are focused on identifying better targets, more effective cytotoxic payloads, and further improvements in antibody-drug linker technol.  Improved understanding of the mechanistic basis of antibody-drug conjugate activity will enable design of rational combination therapies with other agents, including immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5Z8wfiqGgZ7Vg90H21EOLACvtfcHk0ljM6ghEdRpe5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptFCnsbc%253D&md5=375b381d7f5b23f36453aaa50d46f4b7</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2816%2930030-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252816%252930030-4%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DTeicher%26aufirst%3DB.%2BA.%26aulast%3DHassan%26aufirst%3DR.%26atitle%3DAntibody-drug%2520conjugates%2520for%2520cancer%2520therapy%26jtitle%3DLancet%2520Oncol.%26date%3D2016%26volume%3D17%26issue%3D6%26spage%3De254%26epage%3D262%26doi%3D10.1016%2FS1470-2045%2816%2930030-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Flygare, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pillow, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aristoff, P.</span><span> </span><span class="NLM_article-title">Antibody-drug conjugates for the treatment of cancer</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">81</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">113</span><span class="NLM_x">–</span> <span class="NLM_lpage">121</span><span class="refDoi"> DOI: 10.1111/cbdd.12085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1111%2Fcbdd.12085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=23253133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlt1yksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2013&pages=113-121&issue=1&author=J.+A.+Flygareauthor=T.+H.+Pillowauthor=P.+Aristoff&title=Antibody-drug+conjugates+for+the+treatment+of+cancer&doi=10.1111%2Fcbdd.12085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-drug conjugates for the treatment of cancer</span></div><div class="casAuthors">Flygare, John A.; Pillow, Thomas H.; Aristoff, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">113-121</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  With over 20 antibody-drug conjugates in clin. trials as well as a recently FDA-approved drug, it is clear that this is becoming an important and viable approach for selectively delivering highly cytotoxic agents to tumor cells while sparing normal tissue.  This review discusses the crit. aspects for this approach with an emphasis on the properties of the linker between the antibody and the cytotoxic payload that are required for an effective antibody-drug conjugate.  Different linkers are illustrated with attention focused on (i) the specifics of attachment to the antibody, (ii) the polarity of the linker, (iii) the trigger on the linker that initiates cleavage from the drug, and (iv) the self-immolative spacer that liberates the active payload.  Future directions in the field are proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBVlj709scT7Vg90H21EOLACvtfcHk0lhUHPsVByABmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlt1yksA%253D%253D&md5=236ee3d312781e0b2ad27ad1f6c9365d</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1111%2Fcbdd.12085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcbdd.12085%26sid%3Dliteratum%253Aachs%26aulast%3DFlygare%26aufirst%3DJ.%2BA.%26aulast%3DPillow%26aufirst%3DT.%2BH.%26aulast%3DAristoff%26aufirst%3DP.%26atitle%3DAntibody-drug%2520conjugates%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2013%26volume%3D81%26issue%3D1%26spage%3D113%26epage%3D121%26doi%3D10.1111%2Fcbdd.12085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Lambert, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, C. Q.</span><span> </span><span class="NLM_article-title">Antibody-drug conjugates (ADCs) for personalized treatment of solid tumors: a review</span> <span class="citation_source-journal">Adv. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">1015</span><span class="NLM_x">–</span> <span class="NLM_lpage">1035</span><span class="refDoi"> DOI: 10.1007/s12325-017-0519-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1007%2Fs12325-017-0519-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=28361465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltl2isbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2017&pages=1015-1035&issue=5&author=J.+M.+Lambertauthor=C.+Q.+Morris&title=Antibody-drug+conjugates+%28ADCs%29+for+personalized+treatment+of+solid+tumors%3A+a+review&doi=10.1007%2Fs12325-017-0519-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review</span></div><div class="casAuthors">Lambert, John M.; Morris, Charles Q.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1015-1035</span>CODEN:
                <span class="NLM_cas:coden">ADTHE7</span>;
        ISSN:<span class="NLM_cas:issn">0741-238X</span>.
    
            (<span class="NLM_cas:orgname">Springer Healthcare Ltd.</span>)
        </div><div class="casAbstract">Attaching a cytotoxic "payload" to an antibody to form an antibody-drug conjugate (ADC) provides a mechanism for selective delivery of the cytotoxic agent to cancer cells via the specific binding of the antibody to cancer-selective cell surface mols.  The first ADC to receive marketing authorization was gemtuzumab ozogamicin, which comprises an anti-CD33 antibody conjugated to a highly potent DNA-targeting antibiotic, calicheamicin, approved in 2000 for treating acute myeloid leukemia.  It was withdrawn from the US market in 2010 following an unsuccessful confirmatory trial.  The development of two classes of highly potent microtubule-disrupting agents, maytansinoids and auristatins, as payloads for ADCs resulted in approval of brentuximab vedotin in 2011 for treating Hodgkin lymphoma and anaplastic large cell lymphoma, and approval of ado-trastuzumab emtansine in 2013 for treating HER2-pos. breast cancer.  Their success stimulated much research into the ADC approach, with >60 ADCs currently in clin. evaluation, mostly targeting solid tumors.  Five ADCs have advanced into pivotal clin. trials for treating various solid tumors-platinum-resistant ovarian cancer, mesothelioma, triple-neg. breast cancer, glioblastoma, and small cell lung cancer.  The level of target expression is a key parameter in predicting the likelihood of patient benefit for all these ADCs, as well as for the approved compd., ado-trastuzumab emtansine.  The development of a patient selection strategy linked to target expression on the tumor is thus critically important for identifying the population appropriate for receiving treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFGOQG-cRY8bVg90H21EOLACvtfcHk0lhUHPsVByABmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltl2isbk%253D&md5=42789949f7bbb6d2764af4072632f905</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1007%2Fs12325-017-0519-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12325-017-0519-6%26sid%3Dliteratum%253Aachs%26aulast%3DLambert%26aufirst%3DJ.%2BM.%26aulast%3DMorris%26aufirst%3DC.%2BQ.%26atitle%3DAntibody-drug%2520conjugates%2520%2528ADCs%2529%2520for%2520personalized%2520treatment%2520of%2520solid%2520tumors%253A%2520a%2520review%26jtitle%3DAdv.%2520Ther.%26date%3D2017%26volume%3D34%26issue%3D5%26spage%3D1015%26epage%3D1035%26doi%3D10.1007%2Fs12325-017-0519-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Beck, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goetsch, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumontet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corvaia, N.</span><span> </span><span class="NLM_article-title">Strategies and challenges for the next generation of antibody-drug conjugates</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">315</span><span class="NLM_x">–</span> <span class="NLM_lpage">337</span><span class="refDoi"> DOI: 10.1038/nrd.2016.268</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1038%2Fnrd.2016.268" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=28303026" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkt1Onsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=315-337&issue=5&author=A.+Beckauthor=L.+Goetschauthor=C.+Dumontetauthor=N.+Corvaia&title=Strategies+and+challenges+for+the+next+generation+of+antibody-drug+conjugates&doi=10.1038%2Fnrd.2016.268"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies and challenges for the next generation of antibody-drug conjugates</span></div><div class="casAuthors">Beck, Alain; Goetsch, Liliane; Dumontet, Charles; Corvaia, Nathalie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">315-337</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Antibody-drug conjugates (ADCs) are one of the fastest growing classes of oncol. therapeutics.  After half a century of research, the approvals of brentuximab vedotin (in 2011) and trastuzumab emtansine (in 2013) have paved the way for ongoing clin. trials that are evaluating more than 60 further ADC candidates.  The limited success of first-generation ADCs (developed in the early 2000s) informed strategies to bring second-generation ADCs to the market, which have higher levels of cytotoxic drug conjugation, lower levels of naked antibodies and more-stable linkers between the drug and the antibody.  Furthermore, lessons learned during the past decade are now being used in the development of third-generation ADCs.  In this Review, we discuss strategies to select the best target antigens as well as suitable cytotoxic drugs; the design of optimized linkers; the discovery of bioorthogonal conjugation chemistries; and toxicity issues.  The selection and engineering of antibodies for site-specific drug conjugation, which will result in higher homogeneity and increased stability, as well as the quest for new conjugation chemistries and mechanisms of action, are priorities in ADC research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqP7lV63Ws8rbVg90H21EOLACvtfcHk0lhUHPsVByABmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkt1Onsbc%253D&md5=7358b6080dd1aed1d21e98c078cd9ef1</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.268%26sid%3Dliteratum%253Aachs%26aulast%3DBeck%26aufirst%3DA.%26aulast%3DGoetsch%26aufirst%3DL.%26aulast%3DDumontet%26aufirst%3DC.%26aulast%3DCorvaia%26aufirst%3DN.%26atitle%3DStrategies%2520and%2520challenges%2520for%2520the%2520next%2520generation%2520of%2520antibody-drug%2520conjugates%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26issue%3D5%26spage%3D315%26epage%3D337%26doi%3D10.1038%2Fnrd.2016.268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Mantaj, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahman, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thurston, D. E.</span><span> </span><span class="NLM_article-title">From anthramycin to pyrrolobenzodiazepine (PBD)-containing antibody-drug conjugates (ADCs)</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">462</span><span class="NLM_x">–</span> <span class="NLM_lpage">488</span><span class="refDoi"> DOI: 10.1002/anie.201510610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1002%2Fanie.201510610" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=462-488&issue=2&author=J.+Mantajauthor=P.+J.+Jacksonauthor=K.+M.+Rahmanauthor=D.+E.+Thurston&title=From+anthramycin+to+pyrrolobenzodiazepine+%28PBD%29-containing+antibody-drug+conjugates+%28ADCs%29&doi=10.1002%2Fanie.201510610"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2Fanie.201510610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201510610%26sid%3Dliteratum%253Aachs%26aulast%3DMantaj%26aufirst%3DJ.%26aulast%3DJackson%26aufirst%3DP.%2BJ.%26aulast%3DRahman%26aufirst%3DK.%2BM.%26aulast%3DThurston%26aufirst%3DD.%2BE.%26atitle%3DFrom%2520anthramycin%2520to%2520pyrrolobenzodiazepine%2520%2528PBD%2529-containing%2520antibody-drug%2520conjugates%2520%2528ADCs%2529%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26issue%3D2%26spage%3D462%26epage%3D488%26doi%3D10.1002%2Fanie.201510610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Gerratana, B.</span><span> </span><span class="NLM_article-title">Biosynthesis, synthesis, and biological activities of pyrrolobenzodiazepines</span> <span class="citation_source-journal">Med. Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">254</span><span class="NLM_x">–</span> <span class="NLM_lpage">293</span><span class="refDoi"> DOI: 10.1002/med.20212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1002%2Fmed.20212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=20544978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtFyrsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2012&pages=254-293&issue=2&author=B.+Gerratana&title=Biosynthesis%2C+synthesis%2C+and+biological+activities+of+pyrrolobenzodiazepines&doi=10.1002%2Fmed.20212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Biosynthesis, synthesis, and biological activities of pyrrolobenzodiazepines</span></div><div class="casAuthors">Gerratana, Barbara</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">254-293</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Pyrrolobenzodiazepines (PBDs) are sequence selective DNA alkylating agents with remarkable antineoplastic activity.  They are either naturally produced by actinomycetes or synthetically produced.  The remarkable broad spectrum of activities of the naturally produced PBDs encouraged the synthesis of several PBDs, including dimeric and hybrid PBDs yielding to an improvement in the DNA-binding sequence specificity and in the potency of this class of compds.  However, limitation in the chem. synthesis prevented the testing of one of the most potent PBDs, sibiromycin, a naturally produced glycosylated PBDs.  Only recently, the biosynthetic gene clusters for PBDs have been identified opening the doors to the prodn. of glycosylated PBDs by mutasynthesis and biosynthetic engineering.  This review describes the recent studies on the biosynthesis of naturally produced pyrrolobenzodiazepines.  In addn., it provides an overview on the isolation and characterization of naturally produced PBDs, chem. synthesis of PBDs, mechanism of DNA alkylation, and DNA-binding affinity and cytotoxic properties of both naturally produced and synthetic pyrrolobenzodiazepines. © 2010 Wiley Periodicals, Inc.  Med Res Rev.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOmRcKrPImT7Vg90H21EOLACvtfcHk0lhT5TXqtfMcDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtFyrsrg%253D&md5=52cbb58c773ff202f874514afc406fab</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1002%2Fmed.20212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20212%26sid%3Dliteratum%253Aachs%26aulast%3DGerratana%26aufirst%3DB.%26atitle%3DBiosynthesis%252C%2520synthesis%252C%2520and%2520biological%2520activities%2520of%2520pyrrolobenzodiazepines%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2012%26volume%3D32%26issue%3D2%26spage%3D254%26epage%3D293%26doi%3D10.1002%2Fmed.20212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Antonow, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thurston, D. E.</span><span> </span><span class="NLM_article-title">Synthesis of DNA-interactive pyrrolo[2,1-<i>c</i>][1,4]benzodiazepines (PBDs)</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">2815</span><span class="NLM_x">–</span> <span class="NLM_lpage">2864</span><span class="refDoi"> DOI: 10.1021/cr100120f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr100120f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFOqsb7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2011&pages=2815-2864&issue=4&author=D.+Antonowauthor=D.+E.+Thurston&title=Synthesis+of+DNA-interactive+pyrrolo%5B2%2C1-c%5D%5B1%2C4%5Dbenzodiazepines+%28PBDs%29&doi=10.1021%2Fcr100120f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of DNA-Interactive Pyrrolo[2,1-c][1,4]benzodiazepines (PBDs)</span></div><div class="casAuthors">Antonow, Dyeison; Thurston, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2815-2864</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) are an important class of sequence-selective DNA-interactive agents that bind covalently to guanine bases within the minor groove of DNA.  This review is organized around the crucial "B-ring cyclization" reaction that allows formation of the PBD skeleton.  Synthetic methodologies to PBD include ring-closing metathesis, the redn. of azides to amines for the cyclization of Me N-(2-azidobenzoyl)pyrrolidine-2-carboxylates, the bis(trifluoroacetoxy)iodobenzene (PIFA)-mediated cyclization of 1-benzoyl-N-methoxypyrrolidine-2-carboxamides, the intramol. cyclization of 1-benzoyl-N-methoxypyrrolidine-2-carboxamides, etc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRHM0E2GH6zLVg90H21EOLACvtfcHk0lhT5TXqtfMcDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFOqsb7K&md5=52d2294bd331032316a5e604d43e1375</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fcr100120f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr100120f%26sid%3Dliteratum%253Aachs%26aulast%3DAntonow%26aufirst%3DD.%26aulast%3DThurston%26aufirst%3DD.%2BE.%26atitle%3DSynthesis%2520of%2520DNA-interactive%2520pyrrolo%255B2%252C1-c%255D%255B1%252C4%255Dbenzodiazepines%2520%2528PBDs%2529%26jtitle%3DChem.%2520Rev.%26date%3D2011%26volume%3D111%26issue%3D4%26spage%3D2815%26epage%3D2864%26doi%3D10.1021%2Fcr100120f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Hartley, J. A.</span><span> </span><span class="NLM_article-title">The development of pyrrolobenzodiazepines as antitumour agents</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">733</span><span class="NLM_x">–</span> <span class="NLM_lpage">744</span><span class="refDoi"> DOI: 10.1517/13543784.2011.573477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1517%2F13543784.2011.573477" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=733-744&issue=6&author=J.+A.+Hartley&title=The+development+of+pyrrolobenzodiazepines+as+antitumour+agents&doi=10.1517%2F13543784.2011.573477"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1517%2F13543784.2011.573477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2011.573477%26sid%3Dliteratum%253Aachs%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26atitle%3DThe%2520development%2520of%2520pyrrolobenzodiazepines%2520as%2520antitumour%2520agents%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2011%26volume%3D20%26issue%3D6%26spage%3D733%26epage%3D744%26doi%3D10.1517%2F13543784.2011.573477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Jeffrey, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyon, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sussman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leiske, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyamoto, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholas, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okeley, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanderson, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, I. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregson, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masterson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiberghien, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thurston, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Law, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span> </span><span class="NLM_article-title">A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">1256</span><span class="NLM_x">–</span> <span class="NLM_lpage">1263</span><span class="refDoi"> DOI: 10.1021/bc400217g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc400217g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptFKjs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=1256-1263&issue=7&author=S.+C.+Jeffreyauthor=P.+J.+Burkeauthor=R.+P.+Lyonauthor=D.+W.+Meyerauthor=D.+Sussmanauthor=M.+Andersonauthor=J.+H.+Hunterauthor=C.+I.+Leiskeauthor=J.+B.+Miyamotoauthor=N.+D.+Nicholasauthor=N.+M.+Okeleyauthor=R.+J.+Sandersonauthor=I.+J.+Stoneauthor=W.+Zengauthor=S.+J.+Gregsonauthor=L.+Mastersonauthor=A.+C.+Tiberghienauthor=P.+W.+Howardauthor=D.+E.+Thurstonauthor=C.+L.+Lawauthor=P.+D.+Senter&title=A+potent+anti-CD70+antibody-drug+conjugate+combining+a+dimeric+pyrrolobenzodiazepine+drug+with+site-specific+conjugation+technology&doi=10.1021%2Fbc400217g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">A Potent Anti-CD70 Antibody-Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology</span></div><div class="casAuthors">Jeffrey, Scott C.; Burke, Patrick J.; Lyon, Robert P.; Meyer, David W.; Sussman, Django; Anderson, Martha; Hunter, Joshua H.; Leiske, Chris I.; Miyamoto, Jamie B.; Nicholas, Nicole D.; Okeley, Nicole M.; Sanderson, Russell J.; Stone, Ivan J.; Zeng, Weiping; Gregson, Stephen J.; Masterson, Luke; Tiberghien, Arnaud C.; Howard, Philip W.; Thurston, David E.; Law, Che-Leung; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1256-1263</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A highly cytotoxic DNA crosslinking pyrrolobenzodiazepine (PBD) dimer with a valine-alanine dipeptide linker was conjugated to the anti-CD70 h1F6 mAb either through endogenous interchain cysteines or, site-specifically, through engineered cysteines at position 239 of the heavy chains.  The h1F6239C-PBD conjugation strategy proved to be superior to interchain cysteine conjugation, affording an antibody-drug conjugate (ADC) with high uniformity in drug-loading and low levels of aggregation.  In vitro cytotoxicity expts. demonstrated that the h1F6239C-PBD was potent and immunol. specific on CD70-pos. renal cell carcinoma (RCC) and non-Hodgkin lymphoma (NHL) cell lines.  The conjugate was resistant to drug loss in plasma and in circulation, and had a pharmacokinetic profile closely matching that of the parental h1F6239C antibody capped with N-ethylmaleimide (NEM).  Evaluation in CD70-pos. RCC and NHL mouse xenograft models showed pronounced antitumor activities at single or weekly doses as low as 0.1 mg/kg of ADC.  The ADC was tolerated at 2.5 mg/kg.  These results demonstrate that PBDs can be effectively used for antibody-targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVruNGtWHpsbVg90H21EOLACvtfcHk0lhT5TXqtfMcDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptFKjs7c%253D&md5=31841b0267e41ae861eaf05240c97b15</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fbc400217g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc400217g%26sid%3Dliteratum%253Aachs%26aulast%3DJeffrey%26aufirst%3DS.%2BC.%26aulast%3DBurke%26aufirst%3DP.%2BJ.%26aulast%3DLyon%26aufirst%3DR.%2BP.%26aulast%3DMeyer%26aufirst%3DD.%2BW.%26aulast%3DSussman%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DM.%26aulast%3DHunter%26aufirst%3DJ.%2BH.%26aulast%3DLeiske%26aufirst%3DC.%2BI.%26aulast%3DMiyamoto%26aufirst%3DJ.%2BB.%26aulast%3DNicholas%26aufirst%3DN.%2BD.%26aulast%3DOkeley%26aufirst%3DN.%2BM.%26aulast%3DSanderson%26aufirst%3DR.%2BJ.%26aulast%3DStone%26aufirst%3DI.%2BJ.%26aulast%3DZeng%26aufirst%3DW.%26aulast%3DGregson%26aufirst%3DS.%2BJ.%26aulast%3DMasterson%26aufirst%3DL.%26aulast%3DTiberghien%26aufirst%3DA.%2BC.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26aulast%3DThurston%26aufirst%3DD.%2BE.%26aulast%3DLaw%26aufirst%3DC.%2BL.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DA%2520potent%2520anti-CD70%2520antibody-drug%2520conjugate%2520combining%2520a%2520dimeric%2520pyrrolobenzodiazepine%2520drug%2520with%2520site-specific%2520conjugation%2520technology%26jtitle%3DBioconjugate%2520Chem.%26date%3D2013%26volume%3D24%26issue%3D7%26spage%3D1256%26epage%3D1263%26doi%3D10.1021%2Fbc400217g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Kung Sutherland, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffrey, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kostner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stone, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sussman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyon, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrington, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klussman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westendorf, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernstein, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benjamin, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drachman, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McEarchern, J. A.</span><span> </span><span class="NLM_article-title">SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">1455</span><span class="NLM_x">–</span> <span class="NLM_lpage">1463</span><span class="refDoi"> DOI: 10.1182/blood-2013-03-491506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1182%2Fblood-2013-03-491506" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2013&pages=1455-1463&issue=8&author=M.+S.+Kung+Sutherlandauthor=R.+B.+Walterauthor=S.+C.+Jeffreyauthor=P.+J.+Burkeauthor=C.+Yuauthor=H.+Kostnerauthor=I.+Stoneauthor=M.+C.+Ryanauthor=D.+Sussmanauthor=R.+P.+Lyonauthor=W.+Zengauthor=K.+H.+Harringtonauthor=K.+Klussmanauthor=L.+Westendorfauthor=D.+Meyerauthor=I.+D.+Bernsteinauthor=P.+D.+Senterauthor=D.+R.+Benjaminauthor=J.+G.+Drachmanauthor=J.+A.+McEarchern&title=SGN-CD33A%3A+a+novel+CD33-targeting+antibody-drug+conjugate+using+a+pyrrolobenzodiazepine+dimer+is+active+in+models+of+drug-resistant+AML&doi=10.1182%2Fblood-2013-03-491506"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-03-491506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-03-491506%26sid%3Dliteratum%253Aachs%26aulast%3DKung%2BSutherland%26aufirst%3DM.%2BS.%26aulast%3DWalter%26aufirst%3DR.%2BB.%26aulast%3DJeffrey%26aufirst%3DS.%2BC.%26aulast%3DBurke%26aufirst%3DP.%2BJ.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DKostner%26aufirst%3DH.%26aulast%3DStone%26aufirst%3DI.%26aulast%3DRyan%26aufirst%3DM.%2BC.%26aulast%3DSussman%26aufirst%3DD.%26aulast%3DLyon%26aufirst%3DR.%2BP.%26aulast%3DZeng%26aufirst%3DW.%26aulast%3DHarrington%26aufirst%3DK.%2BH.%26aulast%3DKlussman%26aufirst%3DK.%26aulast%3DWestendorf%26aufirst%3DL.%26aulast%3DMeyer%26aufirst%3DD.%26aulast%3DBernstein%26aufirst%3DI.%2BD.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26aulast%3DBenjamin%26aufirst%3DD.%2BR.%26aulast%3DDrachman%26aufirst%3DJ.%2BG.%26aulast%3DMcEarchern%26aufirst%3DJ.%2BA.%26atitle%3DSGN-CD33A%253A%2520a%2520novel%2520CD33-targeting%2520antibody-drug%2520conjugate%2520using%2520a%2520pyrrolobenzodiazepine%2520dimer%2520is%2520active%2520in%2520models%2520of%2520drug-resistant%2520AML%26jtitle%3DBlood%26date%3D2013%26volume%3D122%26issue%3D8%26spage%3D1455%26epage%3D1463%26doi%3D10.1182%2Fblood-2013-03-491506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Tiberghien, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masterson, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, N. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbett, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, P. W.</span><span> </span><span class="NLM_article-title">Design and synthesis of tesirine, a clinical antibody-drug conjugate pyrrolobenzodiazepine dimer payload</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">983</span><span class="NLM_x">–</span> <span class="NLM_lpage">987</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00062</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00062" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC28XosFSgu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=983-987&issue=11&author=A.+C.+Tiberghienauthor=J.+N.+Levyauthor=L.+A.+Mastersonauthor=N.+V.+Patelauthor=L.+R.+Adamsauthor=S.+Corbettauthor=D.+G.+Williamsauthor=J.+A.+Hartleyauthor=P.+W.+Howard&title=Design+and+synthesis+of+tesirine%2C+a+clinical+antibody-drug+conjugate+pyrrolobenzodiazepine+dimer+payload&doi=10.1021%2Facsmedchemlett.6b00062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Tesirine, a Clinical Antibody-Drug Conjugate Pyrrolobenzodiazepine Dimer Payload</span></div><div class="casAuthors">Tiberghien, Arnaud C.; Levy, Jean-Noel; Masterson, Luke A.; Patel, Neki V.; Adams, Lauren R.; Corbett, Simon; Williams, David G.; Hartley, John A.; Howard, Philip W.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">983-987</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pyrrolobenzodiazepine dimers are an emerging class of warhead in the field of antibody-drug conjugates (ADCs).  Tesirine (SG3249) was designed to combine potent antitumor activity with desirable physicochem. properties such as favorable hydrophobicity and improved conjugation characteristics.  One of the reactive imines was capped with a cathepsin B-cleavable valine-alanine linker.  A robust synthetic route was developed to allow the prodn. of tesirine on clin. scale, employing a flexible, convergent strategy.  Tesirine was evaluated in vitro both in stochastic and engineered ADC constructs and was confirmed as a potent and versatile payload.  The conjugation of tesirine to anti-DLL3 rovalpituzumab has resulted in rovalpituzumab-tesirine (Rova-T), currently under evaluation for the treatment of small cell lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYid7RNts7s7Vg90H21EOLACvtfcHk0lgzR9O7qyWMKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosFSgu70%253D&md5=7e4bbdd55b944ff712f01d31d58c0d13</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00062%26sid%3Dliteratum%253Aachs%26aulast%3DTiberghien%26aufirst%3DA.%2BC.%26aulast%3DLevy%26aufirst%3DJ.%2BN.%26aulast%3DMasterson%26aufirst%3DL.%2BA.%26aulast%3DPatel%26aufirst%3DN.%2BV.%26aulast%3DAdams%26aufirst%3DL.%2BR.%26aulast%3DCorbett%26aufirst%3DS.%26aulast%3DWilliams%26aufirst%3DD.%2BG.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520tesirine%252C%2520a%2520clinical%2520antibody-drug%2520conjugate%2520pyrrolobenzodiazepine%2520dimer%2520payload%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26issue%3D11%26spage%3D983%26epage%3D987%26doi%3D10.1021%2Facsmedchemlett.6b00062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Saunders, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bankovich, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aujay, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bheddah, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Escarpe, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hampl, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laysang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Molina, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pysz, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slingerland, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torgov, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foord, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jassem, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badzio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czapiewski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harpole, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowlati, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massion, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Travis, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietanza, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirier, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudin, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stull, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dylla, S. J.</span><span> </span><span class="NLM_article-title">A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells <i>in vivo</i></span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">302</span><span class="NLM_x">) </span> <span class="NLM_fpage">302ra136</span><span class="refDoi"> DOI: 10.1126/scitranslmed.aac9459</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1126%2Fscitranslmed.aac9459" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=26311731" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=302ra136&issue=302&author=L.+R.+Saundersauthor=A.+J.+Bankovichauthor=W.+C.+Andersonauthor=M.+A.+Aujayauthor=S.+Bheddahauthor=K.+Blackauthor=R.+Desaiauthor=P.+A.+Escarpeauthor=J.+Hamplauthor=A.+Laysangauthor=D.+Liuauthor=J.+Lopez-Molinaauthor=M.+Miltonauthor=A.+Parkauthor=M.+A.+Pyszauthor=H.+Shaoauthor=B.+Slingerlandauthor=M.+Torgovauthor=S.+A.+Williamsauthor=O.+Foordauthor=P.+Howardauthor=J.+Jassemauthor=A.+Badzioauthor=P.+Czapiewskiauthor=D.+H.+Harpoleauthor=A.+Dowlatiauthor=P.+P.+Massionauthor=W.+D.+Travisauthor=M.+C.+Pietanzaauthor=J.+T.+Poirierauthor=C.+M.+Rudinauthor=R.+A.+Stullauthor=S.+J.+Dylla&title=A+DLL3-targeted+antibody-drug+conjugate+eradicates+high-grade+pulmonary+neuroendocrine+tumor-initiating+cells+in+vivo&doi=10.1126%2Fscitranslmed.aac9459"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aac9459&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aac9459%26sid%3Dliteratum%253Aachs%26aulast%3DSaunders%26aufirst%3DL.%2BR.%26aulast%3DBankovich%26aufirst%3DA.%2BJ.%26aulast%3DAnderson%26aufirst%3DW.%2BC.%26aulast%3DAujay%26aufirst%3DM.%2BA.%26aulast%3DBheddah%26aufirst%3DS.%26aulast%3DBlack%26aufirst%3DK.%26aulast%3DDesai%26aufirst%3DR.%26aulast%3DEscarpe%26aufirst%3DP.%2BA.%26aulast%3DHampl%26aufirst%3DJ.%26aulast%3DLaysang%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DLopez-Molina%26aufirst%3DJ.%26aulast%3DMilton%26aufirst%3DM.%26aulast%3DPark%26aufirst%3DA.%26aulast%3DPysz%26aufirst%3DM.%2BA.%26aulast%3DShao%26aufirst%3DH.%26aulast%3DSlingerland%26aufirst%3DB.%26aulast%3DTorgov%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DS.%2BA.%26aulast%3DFoord%26aufirst%3DO.%26aulast%3DHoward%26aufirst%3DP.%26aulast%3DJassem%26aufirst%3DJ.%26aulast%3DBadzio%26aufirst%3DA.%26aulast%3DCzapiewski%26aufirst%3DP.%26aulast%3DHarpole%26aufirst%3DD.%2BH.%26aulast%3DDowlati%26aufirst%3DA.%26aulast%3DMassion%26aufirst%3DP.%2BP.%26aulast%3DTravis%26aufirst%3DW.%2BD.%26aulast%3DPietanza%26aufirst%3DM.%2BC.%26aulast%3DPoirier%26aufirst%3DJ.%2BT.%26aulast%3DRudin%26aufirst%3DC.%2BM.%26aulast%3DStull%26aufirst%3DR.%2BA.%26aulast%3DDylla%26aufirst%3DS.%2BJ.%26atitle%3DA%2520DLL3-targeted%2520antibody-drug%2520conjugate%2520eradicates%2520high-grade%2520pulmonary%2520neuroendocrine%2520tumor-initiating%2520cells%2520in%2520vivo%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2015%26volume%3D7%26issue%3D302%26spage%3D302ra136%26doi%3D10.1126%2Fscitranslmed.aac9459" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Flynn, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zammarchi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyrer, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akarca, A. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janghra, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Britten, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Havenith, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiberghien, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masterson, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barry, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Hooge, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marafioti, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parren, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Berkel, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartley, J. A.</span><span> </span><span class="NLM_article-title">ADCT-301, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting CD25-expressing hematological malignancies</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">2709</span><span class="NLM_x">–</span> <span class="NLM_lpage">2721</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1158%2F1535-7163.MCT-16-0233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=27535974" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC2sXovVOqsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=2709-2721&issue=11&author=M.+J.+Flynnauthor=F.+Zammarchiauthor=P.+C.+Tyrerauthor=A.+U.+Akarcaauthor=N.+Janghraauthor=C.+E.+Brittenauthor=C.+E.+Havenithauthor=J.+N.+Levyauthor=A.+Tiberghienauthor=L.+A.+Mastersonauthor=C.+Barryauthor=F.+D%E2%80%99Hoogeauthor=T.+Marafiotiauthor=P.+W.+Parrenauthor=D.+G.+Williamsauthor=P.+W.+Howardauthor=P.+H.+van+Berkelauthor=J.+A.+Hartley&title=ADCT-301%2C+a+pyrrolobenzodiazepine+%28PBD%29+dimer-containing+antibody-drug+conjugate+%28ADC%29+targeting+CD25-expressing+hematological+malignancies&doi=10.1158%2F1535-7163.MCT-16-0233"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">ADCT-301, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting CD25-expressing hematological malignancies</span></div><div class="casAuthors">Flynn, Michael J.; Zammarchi, Francesca; Tyrer, Peter C.; Akarca, Ayse U.; Janghra, Narinder; Britten, Charles E.; Havenith, Carin E. G.; Levy, Jean-Noel; Tiberghien, Arnaud; Masterson, Luke A.; Barry, Conor; D'Hooge, Francois; Marafioti, Teresa; Parren, Paul W. H. I.; Williams, David G.; Howard, Philip W.; van Berkel, Patrick H.; Hartley, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2709-2721</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Despite the many advances in the treatment of hematol. malignancies over the past decade, outcomes in refractory lymphomas remain poor.  One potential strategy in this patient population is the specific targeting of IL2R-α (CD25), which is overexpressed on many lymphoma and leukemic cells, using antibody-drug conjugates (ADC).  ADCT-301 is an ADC composed of human IgG1 HuMax-TAC against CD25, stochastically conjugated through a dipeptide cleavable linker to a pyrrolobenzodiazepine (PBD) dimer warhead with a drug-antibody ratio (DAR) of 2.3.  ADCT-301 binds human CD25 with picomolar affinity.  ADCT-301 has highly potent and selective cytotoxicity against a panel of CD25-expressing human lymphoma cell lines.  Once internalized, the released warhead binds in the DNA minor groove and exerts its potent cytotoxic action via the formation of DNA interstrand cross-links.  A strong correlation between loss of viability and DNA cross-link formation is demonstrated.  DNA damage persists, resulting in phosphorylation of histone H2AX, cell-cycle arrest in G2-M, and apoptosis Bystander killing of CD25-neg. cells by ADCT-301 is also obsd.  In vivo, a single dose of ADCT-301 results in dose-dependent and targeted antitumor activity against both s.c. and disseminated CD25-pos. lymphoma models.  In xenografts of Karpas 299, which expressed both CD25 and CD30, marked superiority over brentuximab vedotin (Adcetris) is obsd.  Dose-dependent increases in DNA crosslinking, γ-H2AX, and PBD payload staining were obsd. in tumors in vivo indicating a role as relevant pharmacodynamic assays.  Together, these data support the clin. testing of this novel ADC in patients with CD25-expressing tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOYRWJCTYK9rVg90H21EOLACvtfcHk0lhF88kRuGAmjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXovVOqsro%253D&md5=f43190787d13ef897602016b3a607bc3</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0233%26sid%3Dliteratum%253Aachs%26aulast%3DFlynn%26aufirst%3DM.%2BJ.%26aulast%3DZammarchi%26aufirst%3DF.%26aulast%3DTyrer%26aufirst%3DP.%2BC.%26aulast%3DAkarca%26aufirst%3DA.%2BU.%26aulast%3DJanghra%26aufirst%3DN.%26aulast%3DBritten%26aufirst%3DC.%2BE.%26aulast%3DHavenith%26aufirst%3DC.%2BE.%26aulast%3DLevy%26aufirst%3DJ.%2BN.%26aulast%3DTiberghien%26aufirst%3DA.%26aulast%3DMasterson%26aufirst%3DL.%2BA.%26aulast%3DBarry%26aufirst%3DC.%26aulast%3DD%25E2%2580%2599Hooge%26aufirst%3DF.%26aulast%3DMarafioti%26aufirst%3DT.%26aulast%3DParren%26aufirst%3DP.%2BW.%26aulast%3DWilliams%26aufirst%3DD.%2BG.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26aulast%3Dvan%2BBerkel%26aufirst%3DP.%2BH.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26atitle%3DADCT-301%252C%2520a%2520pyrrolobenzodiazepine%2520%2528PBD%2529%2520dimer-containing%2520antibody-drug%2520conjugate%2520%2528ADC%2529%2520targeting%2520CD25-expressing%2520hematological%2520malignancies%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26issue%3D11%26spage%3D2709%26epage%3D2721%26doi%3D10.1158%2F1535-7163.MCT-16-0233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Rudin, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietanza, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ready, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgensztern, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glisson, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byers, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burris, H. A.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bheddah, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theiss, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathur, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vennapusa, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zayed, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lally, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strickland, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Govindan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dylla, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spigel, D. R.</span><span> </span><span class="NLM_article-title">Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">42</span><span class="NLM_x">–</span> <span class="NLM_lpage">51</span><span class="refDoi"> DOI: 10.1016/S1470-2045(16)30565-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1016%2FS1470-2045%2816%2930565-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=27932068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVSqs7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=42-51&issue=1&author=C.+M.+Rudinauthor=M.+C.+Pietanzaauthor=T.+M.+Bauerauthor=N.+Readyauthor=D.+Morgenszternauthor=B.+S.+Glissonauthor=L.+A.+Byersauthor=M.+L.+Johnsonauthor=H.+A.+Burrisauthor=F.+Robertauthor=T.+H.+Hanauthor=S.+Bheddahauthor=N.+Theissauthor=S.+Watsonauthor=D.+Mathurauthor=B.+Vennapusaauthor=H.+Zayedauthor=S.+Lallyauthor=D.+K.+Stricklandauthor=R.+Govindanauthor=S.+J.+Dyllaauthor=S.+L.+Pengauthor=D.+R.+Spigel&title=Rovalpituzumab+tesirine%2C+a+DLL3-targeted+antibody-drug+conjugate%2C+in+recurrent+small-cell+lung+cancer%3A+a+first-in-human%2C+first-in-class%2C+open-label%2C+phase+1+study&doi=10.1016%2FS1470-2045%2816%2930565-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study</span></div><div class="casAuthors">Rudin, Charles M.; Pietanza, M. Catherine; Bauer, Todd M.; Ready, Neal; Morgensztern, Daniel; Glisson, Bonnie S.; Byers, Lauren A.; Johnson, Melissa L.; Burris, Howard A. III; Robert, Francisco; Han, Tae H.; Bheddah, Sheila; Theiss, Noah; Watson, Sky; Mathur, Deepan; Vennapusa, Bharathi; Zayed, Hany; Lally, Satwant; Strickland, Donald K.; Govindan, Ramaswamy; Dylla, Scott J.; Peng, Stanford L.; Spigel, David R.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">42-51</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Rovalpituzumab tesirine is a first-in-class antibody-drug conjugate directed against delta-like protein 3 (DLL3), a novel target identified in tumor-initiating cells and expressed in more than 80% of patients with small-cell lung cancer.  We aimed to assess the safety and activity of rovalpituzumab tesirine in patients who progressed after one or more previous regimen.  We conducted a phase 1 open-label study at ten cancer centers in the USA.  Eligible patients were aged 18 years or older and had histol. or cytol. confirmed small-cell lung cancer or large-cell neuroendocrine tumors with progressive measurable disease (according to Response Evaluation Criteria in Solid Tumors [RECIST], version 1.1) previously treated with one or two chemotherapeutic regimens, including a platinum-based regimen.  We assigned patients to dose-escalation or expansion cohorts, ranging from 0·05 mg/kg to 0·8 mg/kg rovalpituzumab tesirine i.v. every 3 wk or every 6 wk, followed by investigation of the dose schedules 0·3 mg/kg and 0·4 mg/kg every 6 wk and 0·2 mg/kg every 3 wk.  Primary objectives were to assess the safety of rovalpituzumab tesirine, including the max. tolerated dose and dose-limiting toxic effects.  The primary activity endpoint was objective response by intention-to-treat anal.  This study is registered with ClinicalTrials.gov, no. NCT01901653.  The study is closed to enrollment; this report focuses on the cohort with small-cell lung cancer.  Between July 22, 2013, and Aug 10, 2015, 82 patients were enrolled, including 74 patients with small-cell lung cancer and eight with large-cell neuroendocrine carcinoma, all of whom received at least one dose of rovalpituzumab tesirine.  Dose-limiting toxic effects of rovalpituzumab tesirine occurred at a dose of 0·8 mg/kg every 3 wk, including grade 4 thrombocytopenia (in two of two patients at that dose level) and grade 4 liver function test abnormalities (in one patient).  The most frequent grade 3 or worse treatment-related adverse events in 74 patients with small-cell lung cancer were thrombocytopenia (eight [11%]), pleural effusion (six [8%]), and increased lipase (five [7%]).  Drug-related serious adverse events occurred in 28 (38%) of 74 patients.  The max. tolerated dose of rovalpituzumab tesirine was 0·4 mg/kg every 3 wk; the recommended phase 2 dose and schedule is 0·3 mg/kg every 6 wk.  At active doses of rovalpituzumab tesirine (0·2 mg/kg or 0·4 mg/kg every 3 wk or 0·3 mg/kg or 0·4 mg/kg every 6 wk), 11 (18%) of 60 assessable patients had a confirmed objective response. 11 (18%) of 60 assessable patients had a confirmed objective response, including ten (38%) of 26 patients confirmed to have high DLL3 expression (expression in 50% or more of tumor cells).  Rovalpituzumab tesirine shows encouraging single-agent antitumor activity with a manageable safety profile.  Further development of rovalpituzumab tesirine in DLL3-expressing malignant diseases is warranted.Stemcentrx Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYPf4wkohCNrVg90H21EOLACvtfcHk0lhF88kRuGAmjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVSqs7zN&md5=0c8b51f422fb0973c2e9eb13641dfaf3</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2816%2930565-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252816%252930565-4%26sid%3Dliteratum%253Aachs%26aulast%3DRudin%26aufirst%3DC.%2BM.%26aulast%3DPietanza%26aufirst%3DM.%2BC.%26aulast%3DBauer%26aufirst%3DT.%2BM.%26aulast%3DReady%26aufirst%3DN.%26aulast%3DMorgensztern%26aufirst%3DD.%26aulast%3DGlisson%26aufirst%3DB.%2BS.%26aulast%3DByers%26aufirst%3DL.%2BA.%26aulast%3DJohnson%26aufirst%3DM.%2BL.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DRobert%26aufirst%3DF.%26aulast%3DHan%26aufirst%3DT.%2BH.%26aulast%3DBheddah%26aufirst%3DS.%26aulast%3DTheiss%26aufirst%3DN.%26aulast%3DWatson%26aufirst%3DS.%26aulast%3DMathur%26aufirst%3DD.%26aulast%3DVennapusa%26aufirst%3DB.%26aulast%3DZayed%26aufirst%3DH.%26aulast%3DLally%26aufirst%3DS.%26aulast%3DStrickland%26aufirst%3DD.%2BK.%26aulast%3DGovindan%26aufirst%3DR.%26aulast%3DDylla%26aufirst%3DS.%2BJ.%26aulast%3DPeng%26aufirst%3DS.%2BL.%26aulast%3DSpigel%26aufirst%3DD.%2BR.%26atitle%3DRovalpituzumab%2520tesirine%252C%2520a%2520DLL3-targeted%2520antibody-drug%2520conjugate%252C%2520in%2520recurrent%2520small-cell%2520lung%2520cancer%253A%2520a%2520first-in-human%252C%2520first-in-class%252C%2520open-label%252C%2520phase%25201%2520study%26jtitle%3DLancet%2520Oncol.%26date%3D2017%26volume%3D18%26issue%3D1%26spage%3D42%26epage%3D51%26doi%3D10.1016%2FS1470-2045%2816%2930565-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Bauer, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spigel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ready, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgensztern, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glisson, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byers, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burris, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strickland, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pietanza, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Govindan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dylla, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudin, C.</span><span> </span><span class="NLM_article-title">ORAL02.01: Safety and efficacy of single-agent rovalpituzumab tesirine, a DLL3-targeted ADC, in recurrent or refractory SCLC</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">11S</span><span class="NLM_x">) </span> <span class="NLM_fpage">S252</span><span class="NLM_x">–</span> <span class="NLM_lpage">S253</span><span class="refDoi"> DOI: 10.1016/j.jtho.2016.09.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1016%2Fj.jtho.2016.09.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=27969444" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=S252-S253&issue=11S&author=T.+M.+Bauerauthor=D.+Spigelauthor=N.+Readyauthor=D.+Morgenszternauthor=B.+S.+Glissonauthor=L.+A.+Byersauthor=H.+Burrisauthor=F.+Robertauthor=D.+K.+Stricklandauthor=M.+C.+Pietanzaauthor=R.+Govindanauthor=S.+J.+Dyllaauthor=S.+Pengauthor=C.+Rudin&title=ORAL02.01%3A+Safety+and+efficacy+of+single-agent+rovalpituzumab+tesirine%2C+a+DLL3-targeted+ADC%2C+in+recurrent+or+refractory+SCLC&doi=10.1016%2Fj.jtho.2016.09.010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2016.09.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2016.09.010%26sid%3Dliteratum%253Aachs%26aulast%3DBauer%26aufirst%3DT.%2BM.%26aulast%3DSpigel%26aufirst%3DD.%26aulast%3DReady%26aufirst%3DN.%26aulast%3DMorgensztern%26aufirst%3DD.%26aulast%3DGlisson%26aufirst%3DB.%2BS.%26aulast%3DByers%26aufirst%3DL.%2BA.%26aulast%3DBurris%26aufirst%3DH.%26aulast%3DRobert%26aufirst%3DF.%26aulast%3DStrickland%26aufirst%3DD.%2BK.%26aulast%3DPietanza%26aufirst%3DM.%2BC.%26aulast%3DGovindan%26aufirst%3DR.%26aulast%3DDylla%26aufirst%3DS.%2BJ.%26aulast%3DPeng%26aufirst%3DS.%26aulast%3DRudin%26aufirst%3DC.%26atitle%3DORAL02.01%253A%2520Safety%2520and%2520efficacy%2520of%2520single-agent%2520rovalpituzumab%2520tesirine%252C%2520a%2520DLL3-targeted%2520ADC%252C%2520in%2520recurrent%2520or%2520refractory%2520SCLC%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2016%26volume%3D11%26issue%3D11S%26spage%3DS252%26epage%3DS253%26doi%3D10.1016%2Fj.jtho.2016.09.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Bixby, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fathi, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovacsovics, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erba, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lancet, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jillella, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravandi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faderl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeAngelo, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Meara, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voellinger, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Advani, A.</span><span> </span><span class="NLM_article-title">Vadastuximab talirine monotherapy in older patients with treatment naive CD33-positive acute myeloid leukemia (AML)</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">128</span><span class="NLM_x"> (</span><span class="NLM_issue">22</span><span class="NLM_x">) </span> <span class="NLM_fpage">590</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2016&pages=590&issue=22&author=D.+L.+Bixbyauthor=A.+S.+Steinauthor=A.+T.+Fathiauthor=T.+J.+Kovacsovicsauthor=M.+Y.+Levyauthor=H.+P.+Erbaauthor=J.+E.+Lancetauthor=A.+P.+Jillellaauthor=F.+Ravandiauthor=R.+B.+Walterauthor=E.+M.+Steinauthor=S.+Faderlauthor=D.+J.+DeAngeloauthor=P.+Hoauthor=M.+M.+O%E2%80%99Mearaauthor=J.+L.+Voellingerauthor=A.+Advani&title=Vadastuximab+talirine+monotherapy+in+older+patients+with+treatment+naive+CD33-positive+acute+myeloid+leukemia+%28AML%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBixby%26aufirst%3DD.%2BL.%26aulast%3DStein%26aufirst%3DA.%2BS.%26aulast%3DFathi%26aufirst%3DA.%2BT.%26aulast%3DKovacsovics%26aufirst%3DT.%2BJ.%26aulast%3DLevy%26aufirst%3DM.%2BY.%26aulast%3DErba%26aufirst%3DH.%2BP.%26aulast%3DLancet%26aufirst%3DJ.%2BE.%26aulast%3DJillella%26aufirst%3DA.%2BP.%26aulast%3DRavandi%26aufirst%3DF.%26aulast%3DWalter%26aufirst%3DR.%2BB.%26aulast%3DStein%26aufirst%3DE.%2BM.%26aulast%3DFaderl%26aufirst%3DS.%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DHo%26aufirst%3DP.%26aulast%3DO%25E2%2580%2599Meara%26aufirst%3DM.%2BM.%26aulast%3DVoellinger%26aufirst%3DJ.%2BL.%26aulast%3DAdvani%26aufirst%3DA.%26atitle%3DVadastuximab%2520talirine%2520monotherapy%2520in%2520older%2520patients%2520with%2520treatment%2520naive%2520CD33-positive%2520acute%2520myeloid%2520leukemia%2520%2528AML%2529%26jtitle%3DBlood%26date%3D2016%26volume%3D128%26issue%3D22%26spage%3D590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Erba, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fathi, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maris, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Advani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faderl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donnellan, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voellinger, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravandi, F.</span><span> </span><span class="NLM_article-title">A phase 1b study of vadastuximab talirine in combination with 7+3 induction therapy for patients with newly diagnosed acute myeloid leukemia (AML)</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">128</span><span class="NLM_x"> (</span><span class="NLM_issue">22</span><span class="NLM_x">) </span> <span class="NLM_fpage">211</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2016&pages=211&issue=22&author=H.+P.+Erbaauthor=M.+Y.+Levyauthor=S.+Vasuauthor=A.+S.+Steinauthor=A.+T.+Fathiauthor=M.+B.+Marisauthor=A.+Advaniauthor=S.+Faderlauthor=S.+E.+Smithauthor=B.+L.+Woodauthor=R.+B.+Walterauthor=J.+Yangauthor=W.+B.+Donnellanauthor=E.+J.+Feldmanauthor=J.+L.+Voellingerauthor=F.+Ravandi&title=A+phase+1b+study+of+vadastuximab+talirine+in+combination+with+7%2B3+induction+therapy+for+patients+with+newly+diagnosed+acute+myeloid+leukemia+%28AML%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DErba%26aufirst%3DH.%2BP.%26aulast%3DLevy%26aufirst%3DM.%2BY.%26aulast%3DVasu%26aufirst%3DS.%26aulast%3DStein%26aufirst%3DA.%2BS.%26aulast%3DFathi%26aufirst%3DA.%2BT.%26aulast%3DMaris%26aufirst%3DM.%2BB.%26aulast%3DAdvani%26aufirst%3DA.%26aulast%3DFaderl%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DS.%2BE.%26aulast%3DWood%26aufirst%3DB.%2BL.%26aulast%3DWalter%26aufirst%3DR.%2BB.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DDonnellan%26aufirst%3DW.%2BB.%26aulast%3DFeldman%26aufirst%3DE.%2BJ.%26aulast%3DVoellinger%26aufirst%3DJ.%2BL.%26aulast%3DRavandi%26aufirst%3DF.%26atitle%3DA%2520phase%25201b%2520study%2520of%2520vadastuximab%2520talirine%2520in%2520combination%2520with%25207%252B3%2520induction%2520therapy%2520for%2520patients%2520with%2520newly%2520diagnosed%2520acute%2520myeloid%2520leukemia%2520%2528AML%2529%26jtitle%3DBlood%26date%3D2016%26volume%3D128%26issue%3D22%26spage%3D211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Fathi, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erba, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lancet, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravandi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faderl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Advani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeAngelo, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovacsovics, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jillella, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bixby, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Meara, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, A. S.</span><span> </span><span class="NLM_article-title">Vadastuximab talirine plus hypomethylating agents: a well-tolerated regimen with high remission rate in frontline older patients with acute myeloid leukemia (AML)</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">128</span><span class="NLM_x"> (</span><span class="NLM_issue">22</span><span class="NLM_x">) </span> <span class="NLM_fpage">591</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2016&pages=591&issue=22&author=A.+T.+Fathiauthor=H.+P.+Erbaauthor=J.+E.+Lancetauthor=E.+M.+Steinauthor=F.+Ravandiauthor=S.+Faderlauthor=R.+B.+Walterauthor=A.+Advaniauthor=D.+J.+DeAngeloauthor=T.+J.+Kovacsovicsauthor=A.+P.+Jillellaauthor=D.+L.+Bixbyauthor=M.+Y.+Levyauthor=M.+M.+O%E2%80%99Mearaauthor=P.+Hoauthor=A.+S.+Stein&title=Vadastuximab+talirine+plus+hypomethylating+agents%3A+a+well-tolerated+regimen+with+high+remission+rate+in+frontline+older+patients+with+acute+myeloid+leukemia+%28AML%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFathi%26aufirst%3DA.%2BT.%26aulast%3DErba%26aufirst%3DH.%2BP.%26aulast%3DLancet%26aufirst%3DJ.%2BE.%26aulast%3DStein%26aufirst%3DE.%2BM.%26aulast%3DRavandi%26aufirst%3DF.%26aulast%3DFaderl%26aufirst%3DS.%26aulast%3DWalter%26aufirst%3DR.%2BB.%26aulast%3DAdvani%26aufirst%3DA.%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DKovacsovics%26aufirst%3DT.%2BJ.%26aulast%3DJillella%26aufirst%3DA.%2BP.%26aulast%3DBixby%26aufirst%3DD.%2BL.%26aulast%3DLevy%26aufirst%3DM.%2BY.%26aulast%3DO%25E2%2580%2599Meara%26aufirst%3DM.%2BM.%26aulast%3DHo%26aufirst%3DP.%26aulast%3DStein%26aufirst%3DA.%2BS.%26atitle%3DVadastuximab%2520talirine%2520plus%2520hypomethylating%2520agents%253A%2520a%2520well-tolerated%2520regimen%2520with%2520high%2520remission%2520rate%2520in%2520frontline%2520older%2520patients%2520with%2520acute%2520myeloid%2520leukemia%2520%2528AML%2529%26jtitle%3DBlood%26date%3D2016%26volume%3D128%26issue%3D22%26spage%3D591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravandi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Advani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faderl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erba, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fathi, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donnellan, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voellinger, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maris, M. B.</span><span> </span><span class="NLM_article-title">A phase 1b study of vadastuximab talirine as maintenance and in combination with standard consolidation for patients with acute myeloid leukemia (AML)</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">128</span><span class="NLM_x"> (</span><span class="NLM_issue">22</span><span class="NLM_x">) </span> <span class="NLM_fpage">340</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2016&pages=340&issue=22&author=J.+Yangauthor=F.+Ravandiauthor=A.+Advaniauthor=S.+Vasuauthor=R.+B.+Walterauthor=S.+Faderlauthor=A.+S.+Steinauthor=H.+P.+Erbaauthor=A.+T.+Fathiauthor=W.+B.+Donnellanauthor=M.+Y.+Levyauthor=S.+E.+Smithauthor=B.+L.+Woodauthor=E.+J.+Feldmanauthor=J.+L.+Voellingerauthor=M.+B.+Maris&title=A+phase+1b+study+of+vadastuximab+talirine+as+maintenance+and+in+combination+with+standard+consolidation+for+patients+with+acute+myeloid+leukemia+%28AML%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DRavandi%26aufirst%3DF.%26aulast%3DAdvani%26aufirst%3DA.%26aulast%3DVasu%26aufirst%3DS.%26aulast%3DWalter%26aufirst%3DR.%2BB.%26aulast%3DFaderl%26aufirst%3DS.%26aulast%3DStein%26aufirst%3DA.%2BS.%26aulast%3DErba%26aufirst%3DH.%2BP.%26aulast%3DFathi%26aufirst%3DA.%2BT.%26aulast%3DDonnellan%26aufirst%3DW.%2BB.%26aulast%3DLevy%26aufirst%3DM.%2BY.%26aulast%3DSmith%26aufirst%3DS.%2BE.%26aulast%3DWood%26aufirst%3DB.%2BL.%26aulast%3DFeldman%26aufirst%3DE.%2BJ.%26aulast%3DVoellinger%26aufirst%3DJ.%2BL.%26aulast%3DMaris%26aufirst%3DM.%2BB.%26atitle%3DA%2520phase%25201b%2520study%2520of%2520vadastuximab%2520talirine%2520as%2520maintenance%2520and%2520in%2520combination%2520with%2520standard%2520consolidation%2520for%2520patients%2520with%2520acute%2520myeloid%2520leukemia%2520%2528AML%2529%26jtitle%3DBlood%26date%3D2016%26volume%3D128%26issue%3D22%26spage%3D340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Miller, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fishkin, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whiteman, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovtun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reid, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Archer, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maloney, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Audette, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayo, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilhelm, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modafferi, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinkas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldmacher, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chari, R. V.</span><span> </span><span class="NLM_article-title">A new class of antibody-drug conjugates with potent DNA alkylating activity</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">1870</span><span class="NLM_x">–</span> <span class="NLM_lpage">1878</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1158%2F1535-7163.MCT-16-0184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=27216304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Oks77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=1870-1878&issue=8&author=M.+L.+Millerauthor=N.+E.+Fishkinauthor=W.+Liauthor=K.+R.+Whitemanauthor=Y.+Kovtunauthor=E.+E.+Reidauthor=K.+E.+Archerauthor=E.+K.+Maloneyauthor=C.+A.+Audetteauthor=M.+F.+Mayoauthor=A.+Wilhelmauthor=H.+A.+Modafferiauthor=R.+Singhauthor=J.+Pinkasauthor=V.+Goldmacherauthor=J.+M.+Lambertauthor=R.+V.+Chari&title=A+new+class+of+antibody-drug+conjugates+with+potent+DNA+alkylating+activity&doi=10.1158%2F1535-7163.MCT-16-0184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating Activity</span></div><div class="casAuthors">Miller, Michael L.; Fishkin, Nathan E.; Li, Wei; Whiteman, Kathleen R.; Kovtun, Yelena; Reid, Emily E.; Archer, Katie E.; Maloney, Erin K.; Audette, Charlene A.; Mayo, Michele F.; Wilhelm, Alan; Modafferi, Holly A.; Singh, Rajeeva; Pinkas, Jan; Goldmacher, Victor; Lambert, John M.; Chari, Ravi V. J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1870-1878</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The promise of tumor-selective delivery of cytotoxic agents in the form of antibody-drug conjugates (ADC) has now been realized, evidenced by the approval of two ADCs, both of which incorporate highly cytotoxic tubulin-interacting agents, for cancer therapy.  An ongoing challenge remains in identifying potent agents with alternative mechanisms of cell killing that can provide ADCs with high therapeutic indexes and favorable tolerability.  Here, we describe the development of a new class of potent DNA alkylating agents that meets these objectives.  Through chem. design, we changed the mechanism of action of our novel DNA crosslinking agent to a monofunctional DNA alkylator.  This modification, coupled with linker optimization, generated ADCs that were well tolerated in mice and demonstrated robust antitumor activity in multiple tumor models at doses 1.5% to 3.5% of maximally tolerated levels.  These properties underscore the considerable potential of these purpose-created, unique DNA-interacting conjugates for broadening the clin. application of ADC technol.  Mol Cancer Ther; 15(8); 1870-8. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt5MUcMyl9MbVg90H21EOLACvtfcHk0lhuYVuwZY39DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Oks77F&md5=39217fa47540ea33e2c7c25d57daa19c</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0184%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DM.%2BL.%26aulast%3DFishkin%26aufirst%3DN.%2BE.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DWhiteman%26aufirst%3DK.%2BR.%26aulast%3DKovtun%26aufirst%3DY.%26aulast%3DReid%26aufirst%3DE.%2BE.%26aulast%3DArcher%26aufirst%3DK.%2BE.%26aulast%3DMaloney%26aufirst%3DE.%2BK.%26aulast%3DAudette%26aufirst%3DC.%2BA.%26aulast%3DMayo%26aufirst%3DM.%2BF.%26aulast%3DWilhelm%26aufirst%3DA.%26aulast%3DModafferi%26aufirst%3DH.%2BA.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DPinkas%26aufirst%3DJ.%26aulast%3DGoldmacher%26aufirst%3DV.%26aulast%3DLambert%26aufirst%3DJ.%2BM.%26aulast%3DChari%26aufirst%3DR.%2BV.%26atitle%3DA%2520new%2520class%2520of%2520antibody-drug%2520conjugates%2520with%2520potent%2520DNA%2520alkylating%2520activity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26issue%3D8%26spage%3D1870%26epage%3D1878%26doi%3D10.1158%2F1535-7163.MCT-16-0184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Polakis, P.</span><span> </span><span class="NLM_article-title">Antibody drug conjugates for cancer therapy</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">19</span><span class="refDoi"> DOI: 10.1124/pr.114.009373</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1124%2Fpr.114.009373" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=26589413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVagtbfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2016&pages=3-19&issue=1&author=P.+Polakis&title=Antibody+drug+conjugates+for+cancer+therapy&doi=10.1124%2Fpr.114.009373"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody drug conjugates for cancer therapy</span></div><div class="casAuthors">Polakis, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-19</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Antibody drug conjugates (ADCs) constitute a family of cancer therapeutics designed to preferentially direct a cytotoxic drug to cells expressing a cell-surface antigen recognized by an antibody.  The antibody and drug are linked through chemistries that enable release of the cytotoxic drug or drug adduct upon internalization and digestion of the ADC by the cell.  Over 40 distinct ADCs, targeting an array of antigens and utilizing a variety of drugs and linkers, are undergoing clin. evaluation.  This review primarily covers ADCs that have advanced to clin. investigation with a particular emphasis on how the individual targets, linker chemistries, and appended drugs influence their behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohI1JS8kX1ZLVg90H21EOLACvtfcHk0lhuYVuwZY39DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVagtbfM&md5=0f0e52f1481854a86485ebbbc15f1c20</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1124%2Fpr.114.009373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.114.009373%26sid%3Dliteratum%253Aachs%26aulast%3DPolakis%26aufirst%3DP.%26atitle%3DAntibody%2520drug%2520conjugates%2520for%2520cancer%2520therapy%26jtitle%3DPharmacol.%2520Rev.%26date%3D2016%26volume%3D68%26issue%3D1%26spage%3D3%26epage%3D19%26doi%3D10.1124%2Fpr.114.009373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Dorywalska, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dushin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moine, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farias, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navaratnam, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lui, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasa-Moreno, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casas, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaria, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foletti, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pons, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shelton, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajpal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strop, P.</span><span> </span><span class="NLM_article-title">Molecular basis of valine-citrulline-PABC linker instability in site-specific ADCs and its mitigation by linker design</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">958</span><span class="NLM_x">–</span> <span class="NLM_lpage">970</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-15-1004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1158%2F1535-7163.MCT-15-1004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=26944918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC28Xnt12rs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=958-970&issue=5&author=M.+Dorywalskaauthor=R.+Dushinauthor=L.+Moineauthor=S.+E.+Fariasauthor=D.+Zhouauthor=T.+Navaratnamauthor=V.+Luiauthor=A.+Hasa-Morenoauthor=M.+G.+Casasauthor=T.+T.+Tranauthor=K.+Delariaauthor=S.+H.+Liuauthor=D.+Folettiauthor=C.+J.+O%E2%80%99Donnellauthor=J.+Ponsauthor=D.+L.+Sheltonauthor=A.+Rajpalauthor=P.+Strop&title=Molecular+basis+of+valine-citrulline-PABC+linker+instability+in+site-specific+ADCs+and+its+mitigation+by+linker+design&doi=10.1158%2F1535-7163.MCT-15-1004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design</span></div><div class="casAuthors">Dorywalska, Magdalena; Dushin, Russell; Moine, Ludivine; Farias, Santiago E.; Zhou, Dahui; Navaratnam, Thayalan; Lui, Victor; Hasa-Moreno, Adela; Casas, Meritxell Galindo; Tran, Thomas-Toan; Delaria, Kathy; Liu, Shu-Hui; Foletti, Davide; O'Donnell, Christopher J.; Pons, Jaume; Shelton, David L.; Rajpal, Arvind; Strop, Pavel</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">958-970</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The degree of stability of antibody-drug linkers in systemic circulation, and the rate of their intracellular processing within target cancer cells are among the key factors detg. the efficacy of antibody-drug conjugates (ADC) in vivo.  Previous studies demonstrated the susceptibility of cleavable linkers, as well as auristatin-based payloads, to enzymic cleavage in rodent plasma.  Here, we identify Carboxylesterase 1C as the enzyme responsible for the extracellular hydrolysis of valine-citrulline-p-aminocarbamate (VC-PABC)-based linkers in mouse plasma.  We further show that the activity of Carboxylesterase 1C towards VC-PABC-based linkers, and consequently the stability of ADCs in mouse plasma, can be effectively modulated by small chem. modifications to the linker.  While the introduced modifications can protect the VC-PABC-based linkers from extracellular cleavage, they do not significantly alter the intracellular linker processing by the lysosomal protease Cathepsin B. The distinct substrate preference of the serum Carboxylesterase 1C offers the opportunity to modulate the extracellular stability of cleavable ADCs without diminishing the intracellular payload release required for ADC efficacy.  Mol Cancer Ther; 15(5); 958-70. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9idQSKwDGcLVg90H21EOLACvtfcHk0lhuYVuwZY39DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xnt12rs7k%253D&md5=b96d577fd0e19bfc5eb42a5ae0edec5e</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-15-1004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-15-1004%26sid%3Dliteratum%253Aachs%26aulast%3DDorywalska%26aufirst%3DM.%26aulast%3DDushin%26aufirst%3DR.%26aulast%3DMoine%26aufirst%3DL.%26aulast%3DFarias%26aufirst%3DS.%2BE.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DNavaratnam%26aufirst%3DT.%26aulast%3DLui%26aufirst%3DV.%26aulast%3DHasa-Moreno%26aufirst%3DA.%26aulast%3DCasas%26aufirst%3DM.%2BG.%26aulast%3DTran%26aufirst%3DT.%2BT.%26aulast%3DDelaria%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DS.%2BH.%26aulast%3DFoletti%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DPons%26aufirst%3DJ.%26aulast%3DShelton%26aufirst%3DD.%2BL.%26aulast%3DRajpal%26aufirst%3DA.%26aulast%3DStrop%26aufirst%3DP.%26atitle%3DMolecular%2520basis%2520of%2520valine-citrulline-PABC%2520linker%2520instability%2520in%2520site-specific%2520ADCs%2520and%2520its%2520mitigation%2520by%2520linker%2520design%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26issue%3D5%26spage%3D958%26epage%3D970%26doi%3D10.1158%2F1535-7163.MCT-15-1004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Ogitani, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagihara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harada, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soma, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oitate, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arakawa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atsumi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayakawa, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abe, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agatsuma, T.</span><span> </span><span class="NLM_article-title">DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x"> (</span><span class="NLM_issue">20</span><span class="NLM_x">) </span> <span class="NLM_fpage">5097</span><span class="NLM_x">–</span> <span class="NLM_lpage">5108</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-2822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1158%2F1078-0432.CCR-15-2822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=27026201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslOhs77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=5097-5108&issue=20&author=Y.+Ogitaniauthor=T.+Aidaauthor=K.+Hagiharaauthor=J.+Yamaguchiauthor=C.+Ishiiauthor=N.+Haradaauthor=M.+Somaauthor=H.+Okamotoauthor=M.+Oitateauthor=S.+Arakawaauthor=T.+Hiraiauthor=R.+Atsumiauthor=T.+Nakadaauthor=I.+Hayakawaauthor=Y.+Abeauthor=T.+Agatsuma&title=DS-8201a%2C+a+novel+HER2-targeting+ADC+with+a+novel+DNA+topoisomerase+I+inhibitor%2C+demonstrates+a+promising+antitumor+efficacy+with+differentiation+from+T-DM1&doi=10.1158%2F1078-0432.CCR-15-2822"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1</span></div><div class="casAuthors">Ogitani, Yusuke; Aida, Tetsuo; Hagihara, Katsunobu; Yamaguchi, Junko; Ishii, Chiaki; Harada, Naoya; Soma, Masako; Okamoto, Hiromi; Oitate, Masataka; Arakawa, Shingo; Hirai, Takehiro; Atsumi, Ryo; Nakada, Takashi; Hayakawa, Ichiro; Abe, Yuki; Agatsuma, Toshinori</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5097-5108</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">An anti-HER2 antibody-drug conjugate with a novel topoisomerase I inhibitor, DS-8201a, was generated as a new antitumor drug candidate, and its preclin. pharmacol. profile was assessed.  In vitro and in vivo pharmacol. activities of DS-8201a were evaluated and compared with T-DM1 in several HER2-pos. cell lines and patient-derived xenograft (PDX) models.  The mechanism of action for the efficacy was also evaluated.  Pharmacokinetics in cynomolgus monkeys and the safety profiles in rats and cynomolgus monkeys were assessed.  DS-8201a exhibited a HER2 expression-dependent cell growth-inhibitory activity and induced tumor regression with a single dosing at more than 1 mg/kg in a HER2-pos. gastric cancer NCI-N87 model.  Binding activity to HER2 and ADCC activity of DS-8201a were comparable with unconjugated anti-HER2 antibody.  DS-8201a also showed an inhibitory activity to Akt phosphorylation.  DS-8201a induced phosphorylation of Chk1 and Histone H2A.X, the markers of DNA damage.  Pharmacokinetics and safety profiles of DS-8201a were favorable and the highest non-severely toxic dose was 30 mg/kg in cynomolgus monkeys, supporting DS-8201a as being well tolerated in humans.  DS-8201a was effective in a T-DM1-insensitive PDX model with high HER2 expression.  DS-8201a, but not T-DM1, demonstrated antitumor efficacy against several breast cancer PDX models with low HER2 expression.  DS-8201a exhibited a potent antitumor activity in a broad selection of HER2-pos. models and favorable pharmacokinetics and safety profiles.  The results demonstrate that DS-8201a will be a valuable therapy with a great potential to respond to T-DM1-insensitive HER2-pos. cancers and low HER2-expressing cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCZitEmBAqAbVg90H21EOLACvtfcHk0liZgC01Ippg4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslOhs77F&md5=3fc9a072b2ba05c80929713c843df3f5</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-2822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-2822%26sid%3Dliteratum%253Aachs%26aulast%3DOgitani%26aufirst%3DY.%26aulast%3DAida%26aufirst%3DT.%26aulast%3DHagihara%26aufirst%3DK.%26aulast%3DYamaguchi%26aufirst%3DJ.%26aulast%3DIshii%26aufirst%3DC.%26aulast%3DHarada%26aufirst%3DN.%26aulast%3DSoma%26aufirst%3DM.%26aulast%3DOkamoto%26aufirst%3DH.%26aulast%3DOitate%26aufirst%3DM.%26aulast%3DArakawa%26aufirst%3DS.%26aulast%3DHirai%26aufirst%3DT.%26aulast%3DAtsumi%26aufirst%3DR.%26aulast%3DNakada%26aufirst%3DT.%26aulast%3DHayakawa%26aufirst%3DI.%26aulast%3DAbe%26aufirst%3DY.%26aulast%3DAgatsuma%26aufirst%3DT.%26atitle%3DDS-8201a%252C%2520a%2520novel%2520HER2-targeting%2520ADC%2520with%2520a%2520novel%2520DNA%2520topoisomerase%2520I%2520inhibitor%252C%2520demonstrates%2520a%2520promising%2520antitumor%2520efficacy%2520with%2520differentiation%2520from%2520T-DM1%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26issue%3D20%26spage%3D5097%26epage%3D5108%26doi%3D10.1158%2F1078-0432.CCR-15-2822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Menderes, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonazzoli, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellone, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altwerger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masserdotti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettinella, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zammataro, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buza, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hui, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Litkouhi, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratner, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silasi, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azodi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santin, A. D.</span><span> </span><span class="NLM_article-title">SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression</span> <span class="citation_source-journal">Gynecol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">146</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">179</span><span class="NLM_x">–</span> <span class="NLM_lpage">186</span><span class="refDoi"> DOI: 10.1016/j.ygyno.2017.04.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1016%2Fj.ygyno.2017.04.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=28473206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntVShu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2017&pages=179-186&issue=1&author=G.+Menderesauthor=E.+Bonazzoliauthor=S.+Belloneauthor=J.+Blackauthor=G.+Altwergerauthor=A.+Masserdottiauthor=F.+Pettinellaauthor=L.+Zammataroauthor=N.+Buzaauthor=P.+Huiauthor=S.+Wongauthor=B.+Litkouhiauthor=E.+Ratnerauthor=D.+A.+Silasiauthor=G.+S.+Huangauthor=M.+Azodiauthor=P.+E.+Schwartzauthor=A.+D.+Santin&title=SYD985%2C+a+novel+duocarmycin-based+HER2-targeting+antibody-drug+conjugate%2C+shows+promising+antitumor+activity+in+epithelial+ovarian+carcinoma+with+HER2%2FNeu+expression&doi=10.1016%2Fj.ygyno.2017.04.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression</span></div><div class="casAuthors">Menderes, Gulden; Bonazzoli, Elena; Bellone, Stefania; Black, Jonathan; Altwerger, Gary; Masserdotti, Alice; Pettinella, Francesca; Zammataro, Luca; Buza, Natalia; Hui, Pei; Wong, Serena; Litkouhi, Babak; Ratner, Elena; Silasi, Dan-Arin; Huang, Gloria S.; Azodi, Masoud; Schwartz, Peter E.; Santin, Alessandro D.</div><div class="citationInfo"><span class="NLM_cas:title">Gynecologic Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">179-186</span>CODEN:
                <span class="NLM_cas:coden">GYNOA3</span>;
        ISSN:<span class="NLM_cas:issn">0090-8258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Epithelial ovarian cancer (EOC) is an aggressive and heterogeneous disease. < 10% of EOC demonstrate HER2/neu 3 + receptor over-expression.  However, moderate to low (i.e., 2 + and 1 +) HER2/neu expression is reported in up to 50% of EOC.  The objective of this study was to compare the anti-tumor activity of SYD985, a novel HER2-targeting antibody-drug conjugate (ADC), to trastuzumab emtansine (T-DM1) in EOC models with differential HER2/neu expression.  The cytotoxicity of SYD985 and T-DM1 was evaluated using ten primary EOC cell lines with 0/1 +, 2 +, and 3 + HER2/neu expression in antibody-dependent cellular cytotoxicity (ADCC), proliferation, viability and bystander killing expts.  Finally, the in vivo activity of SYD985 and T-DM1 was also studied in ovarian cancer xenografts.  SYD985 and T-DM1 induced similar ADCC in the presence of peripheral blood lymphocytes (PBL) against EOC cell lines with differential HER2/neu expression.  In contrast, SYD985 was 3 to 42 fold more cytotoxic in the absence of PBL when compared to T-DM1 (p < 0.0001).  Unlike T-DM1, SYD985 induced efficient bystander killing of HER2/neu 0/1 + tumor cells when admixed with HER2/neu 3 + EOC cells.  In vivo studies confirmed that SYD985 is significantly more active than T-DM1 against HER2/neu 3 + EOC xenografts.  SYD985 is a novel ADC with remarkable activity against EOC with strong (3 +) as well as moderate to low (i.e., 2 + and 1 +) HER2/neu expression.  SYD985 is more potent than T-DM1 in comparative expts. and unlike T-DM1, it is active against EOC demonstrating moderate/low or heterogeneous HER2/neu expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7He1TDKs0sbVg90H21EOLACvtfcHk0liZgC01Ippg4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntVShu7k%253D&md5=84d1f52781c732605cf38594f5024de0</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.ygyno.2017.04.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ygyno.2017.04.023%26sid%3Dliteratum%253Aachs%26aulast%3DMenderes%26aufirst%3DG.%26aulast%3DBonazzoli%26aufirst%3DE.%26aulast%3DBellone%26aufirst%3DS.%26aulast%3DBlack%26aufirst%3DJ.%26aulast%3DAltwerger%26aufirst%3DG.%26aulast%3DMasserdotti%26aufirst%3DA.%26aulast%3DPettinella%26aufirst%3DF.%26aulast%3DZammataro%26aufirst%3DL.%26aulast%3DBuza%26aufirst%3DN.%26aulast%3DHui%26aufirst%3DP.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DLitkouhi%26aufirst%3DB.%26aulast%3DRatner%26aufirst%3DE.%26aulast%3DSilasi%26aufirst%3DD.%2BA.%26aulast%3DHuang%26aufirst%3DG.%2BS.%26aulast%3DAzodi%26aufirst%3DM.%26aulast%3DSchwartz%26aufirst%3DP.%2BE.%26aulast%3DSantin%26aufirst%3DA.%2BD.%26atitle%3DSYD985%252C%2520a%2520novel%2520duocarmycin-based%2520HER2-targeting%2520antibody-drug%2520conjugate%252C%2520shows%2520promising%2520antitumor%2520activity%2520in%2520epithelial%2520ovarian%2520carcinoma%2520with%2520HER2%252FNeu%2520expression%26jtitle%3DGynecol.%2520Oncol.%26date%3D2017%26volume%3D146%26issue%3D1%26spage%3D179%26epage%3D186%26doi%3D10.1016%2Fj.ygyno.2017.04.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Li, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muniz-Medina, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetzel, L. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rebelatto, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinrichs, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bezabeh, B. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleming, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dimasi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toader, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, A. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dixit, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osbourn, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coats, S. R.</span><span> </span><span class="NLM_article-title">A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">117</span><span class="NLM_x">–</span> <span class="NLM_lpage">129</span><span class="refDoi"> DOI: 10.1016/j.ccell.2015.12.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1016%2Fj.ccell.2015.12.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=26766593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC28Xmsl2lsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=117-129&issue=1&author=J.+Y.+Liauthor=S.+R.+Perryauthor=V.+Muniz-Medinaauthor=X.+Wangauthor=L.+K.+Wetzelauthor=M.+C.+Rebelattoauthor=M.+J.+Hinrichsauthor=B.+Z.+Bezabehauthor=R.+L.+Flemingauthor=N.+Dimasiauthor=H.+Fengauthor=D.+Toaderauthor=A.+Q.+Yuanauthor=L.+Xuauthor=J.+Linauthor=C.+Gaoauthor=H.+Wuauthor=R.+Dixitauthor=J.+K.+Osbournauthor=S.+R.+Coats&title=A+biparatopic+HER2-targeting+antibody-drug+conjugate+induces+tumor+regression+in+primary+models+refractory+to+or+ineligible+for+HER2-targeted+therapy&doi=10.1016%2Fj.ccell.2015.12.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy</span></div><div class="casAuthors">Li, John Y.; Perry, Samuel R.; Muniz-Medina, Vanessa; Wang, Xinzhong; Wetzel, Leslie K.; Rebelatto, Marlon C.; Hinrichs, Mary Jane Masson; Bezabeh, Binyam Z.; Fleming, Ryan L.; Dimasi, Nazzareno; Feng, Hui; Toader, Dorin; Yuan, Andy Q.; Xu, Lan; Lin, Jia; Gao, Changshou; Wu, Herren; Dixit, Rakesh; Osbourn, Jane K.; Coats, Steven R.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">117-129</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Antibody-drug conjugate (ADC) which delivers cytotoxic drugs specifically into targeted cells through internalization and lysosomal trafficking has emerged as an effective cancer therapy.  We show that a bivalent biparatopic antibody targeting two non-overlapping epitopes on HER2 can induce HER2 receptor clustering, which in turn promotes robust internalization, lysosomal trafficking, and degrdn.  When conjugated with a tubulysin-based microtubule inhibitor, the biparatopic ADC demonstrates superior anti-tumor activity over ado-trastuzumab emtansine (T-DM1) in tumor models representing various patient subpopulations, including T-DM1 eligible, T-DM1 ineligible, and T-DM1 relapsed/refractory.  Our findings indicate that this biparatopic ADC has promising potential as an effective therapy for metastatic breast cancer and a broader patient population may benefit from this unique HER2-targeting ADC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp18b-9TGTzUbVg90H21EOLACvtfcHk0liZgC01Ippg4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xmsl2lsA%253D%253D&md5=bbd94b53427de32f8d636b63507dd139</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2015.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2015.12.008%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%2BY.%26aulast%3DPerry%26aufirst%3DS.%2BR.%26aulast%3DMuniz-Medina%26aufirst%3DV.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWetzel%26aufirst%3DL.%2BK.%26aulast%3DRebelatto%26aufirst%3DM.%2BC.%26aulast%3DHinrichs%26aufirst%3DM.%2BJ.%26aulast%3DBezabeh%26aufirst%3DB.%2BZ.%26aulast%3DFleming%26aufirst%3DR.%2BL.%26aulast%3DDimasi%26aufirst%3DN.%26aulast%3DFeng%26aufirst%3DH.%26aulast%3DToader%26aufirst%3DD.%26aulast%3DYuan%26aufirst%3DA.%2BQ.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DDixit%26aufirst%3DR.%26aulast%3DOsbourn%26aufirst%3DJ.%2BK.%26aulast%3DCoats%26aufirst%3DS.%2BR.%26atitle%3DA%2520biparatopic%2520HER2-targeting%2520antibody-drug%2520conjugate%2520induces%2520tumor%2520regression%2520in%2520primary%2520models%2520refractory%2520to%2520or%2520ineligible%2520for%2520HER2-targeted%2520therapy%26jtitle%3DCancer%2520Cell%26date%3D2016%26volume%3D29%26issue%3D1%26spage%3D117%26epage%3D129%26doi%3D10.1016%2Fj.ccell.2015.12.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Kantarjian, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeAngelo, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stelljes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinelli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liedtke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stock, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gokbuget, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paccagnella, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sleight, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandendries, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Advani, A. S.</span><span> </span><span class="NLM_article-title">Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">375</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">740</span><span class="NLM_x">–</span> <span class="NLM_lpage">753</span><span class="refDoi"> DOI: 10.1056/NEJMoa1509277</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1056%2FNEJMoa1509277" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=27292104" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvF2ks7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=375&publication_year=2016&pages=740-753&issue=8&author=H.+M.+Kantarjianauthor=D.+J.+DeAngeloauthor=M.+Stelljesauthor=G.+Martinelliauthor=M.+Liedtkeauthor=W.+Stockauthor=N.+Gokbugetauthor=S.+O%E2%80%99Brienauthor=K.+Wangauthor=T.+Wangauthor=M.+L.+Paccagnellaauthor=B.+Sleightauthor=E.+Vandendriesauthor=A.+S.+Advani&title=Inotuzumab+ozogamicin+versus+standard+therapy+for+acute+lymphoblastic+leukemia&doi=10.1056%2FNEJMoa1509277"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia</span></div><div class="casAuthors">Kantarjian, Hagop M.; DeAngelo, Daniel J.; Stelljes, Matthias; Martinelli, Giovanni; Liedtke, Michaela; Stock, Wendy; Goekbuget, Nicola; O'Brien, Susan; Wang, Kongming; Wang, Tao; Paccagnella, M. Luisa; Sleight, Barbara; Vandendries, Erik; Advani, Anjali S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">375</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">740-753</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: The prognosis for adults with relapsed acute lymphoblastic leukemia is poor.  We sought to det. whether inotuzumab ozogamicin, an anti-CD22 antibody conjugated to calicheamicin, results in better outcomes in patients with relapsed or refractory acute lymphoblastic leukemia than does std. therapy.  METHODS: In this phase 3 trial, we randomly assigned adults with relapsed or refractory acute lymphoblastic leukemia to receive either inotuzumab ozogamicin (inotuzumab ozogamicin group) or std. intensive chemotherapy (std.-therapy group).  The primary end points were complete remission (including complete remission with incomplete hematol. recovery) and overall survival.  RESULTS: Of the 326 patients who underwent randomization, the first 218 (109 in each group) were included in the primary intention-to-treat anal. of complete remission.  The rate of complete remission was significantly higher in the inotuzumab ozogamicin group than in the std.-therapy group (80.7% [95% confidence interval {CI}, 72.1 to 87.7] vs. 29.4% [95% CI, 21.0 to 38.8], P<0.001).  Among the patients who had complete remission, a higher percentage in the inotuzumab ozogamicin group had results below the threshold for minimal residual disease (0.01% marrow blasts) (78.4% vs. 28.1%, P<0.001); the duration of remission was longer in the inotuzumab ozogamicin group (median, 4.6 mo [95% CI, 3.9 to 5.4] vs. 3.1 mo [95% CI, 1.4 to 4.9]; hazard ratio, 0.55 [95% CI, 0.31 to 0.96]; P = 0.03).  In the survival anal., which included all 326 patients, progression- free survival was significantly longer in the inotuzumab ozogamicin group (median, 5.0 mo [95% CI, 3.7 to 5.6] vs. 1.8 mo [95% CI, 1.5 to 2.2]; hazard ratio, 0.45 [97.5% CI, 0.34 to 0.61]; P<0.001); the median overall survival was 7.7 mo (95% CI, 6.0 to 9.2) vs. 6.7 mo (95% CI, 4.9 to 8.3), and the hazard ratio was 0.77 (97.5% CI, 0.58 to 1.03) (P = 0.04).  In the safety population, the most frequent grade 3 or higher nonhematol. adverse events with inotuzumab ozogamicin were liver-related.  Veno-occlusive liver disease of any grade occurred in 15 patients (11%) who received inotuzumab ozogamicin and in 1 patient (1%) who received std. therapy.  CONCLUSIONS: The rate of complete remission was higher with inotuzumab ozogamicin than with std. therapy, and a higher percentage of patients in the inotuzumab ozogamicin group had results below the threshold for minimal residual disease.  Both progression-free and overall survival were longer with inotuzumab ozogamicin.  Veno-occlusive liver disease was a major adverse event assocd. with inotuzumab ozogamicin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPWFX8IdaUIrVg90H21EOLACvtfcHk0lh7ys0C11teHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvF2ks7%252FI&md5=f36fe4d8eaad5ed2107d4394efa29181</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1509277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1509277%26sid%3Dliteratum%253Aachs%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DStelljes%26aufirst%3DM.%26aulast%3DMartinelli%26aufirst%3DG.%26aulast%3DLiedtke%26aufirst%3DM.%26aulast%3DStock%26aufirst%3DW.%26aulast%3DGokbuget%26aufirst%3DN.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DPaccagnella%26aufirst%3DM.%2BL.%26aulast%3DSleight%26aufirst%3DB.%26aulast%3DVandendries%26aufirst%3DE.%26aulast%3DAdvani%26aufirst%3DA.%2BS.%26atitle%3DInotuzumab%2520ozogamicin%2520versus%2520standard%2520therapy%2520for%2520acute%2520lymphoblastic%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D375%26issue%3D8%26spage%3D740%26epage%3D753%26doi%3D10.1056%2FNEJMoa1509277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Shen, B. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bumbaca, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saad, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yue, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pastuskovas, C. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khojasteh, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibbitts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaur, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, Y. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoRusso, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girish, S.</span><span> </span><span class="NLM_article-title">Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x"> (</span><span class="NLM_issue">7</span><span class="NLM_x">) </span> <span class="NLM_fpage">901</span><span class="NLM_x">–</span> <span class="NLM_lpage">910</span><span class="refDoi"> DOI: 10.2174/138920012802138598</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.2174%2F138920012802138598" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=22475269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1OlurrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=901-910&issue=7&author=B.+Q.+Shenauthor=D.+Bumbacaauthor=O.+Saadauthor=Q.+Yueauthor=C.+V.+Pastuskovasauthor=S.+C.+Khojastehauthor=J.+Tibbittsauthor=S.+Kaurauthor=B.+Wangauthor=Y.+W.+Chuauthor=P.+M.+LoRussoauthor=S.+Girish&title=Catabolic+fate+and+pharmacokinetic+characterization+of+trastuzumab+emtansine+%28T-DM1%29%3A+an+emphasis+on+preclinical+and+clinical+catabolism&doi=10.2174%2F138920012802138598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism</span></div><div class="casAuthors">Shen, Ben-Quan; Bumbaca, Daniela; Saad, Ola; Yue, Qin; Pastuskovas, Cinthia V.; Khojasteh, S. Cyrus; Tibbitts, Jay; Kaur, Surinder; Wang, Bei; Chu, Yu-Waye; LoRusso, Patricia M.; Girish, Sandhya</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">901-910</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate in clin. development for the treatment of human epidermal growth factor receptor 2 (HER2)-pos. cancers.  Herein, we describe a series of studies to assess T-DM1 absorption, distribution, metab., and excretion (ADME) in rats as well as to assess human exposure to T-DM1 catabolites.  Following administration of unlabeled and radiolabeled T-DM1 in female Sprague Dawley rats as a single dose, plasma, urine, bile and feces were assessed for mass balance, profiling and identification of catabolites.  In rats, the major circulating species in plasma was T-DM1, while DM1 concns. were low (1.08 to 15.6 ng/mL).  The major catabolites found circulating in rat plasma were DM1, [N-maleimidomethyl] cyclohexane-1-carboxylate-DM1 (MCC-DM1), and Lysine-MCC-DM1.  These catabolites identified in rats were also detected in plasma samples from patients with HER2-pos. metastatic breast cancer who received single-agent T-DM1 (3.6 mg/kg every 3 wk) in a phase 2 clin. study.  There was no evidence of tissue accumulation in rats or catabolite accumulation in human plasma following multiple dosing.  In rats, T-DM1 was distributed nonspecifically to the organs without accumulation.  The major pathway of DM1-contg. catabolite elimination in rats was the fecal/biliary route, with up to 80% of radioactivity recovered in the feces and 50% in the bile.  The rat T-DM1 ADME profile is likely similar to the human profile, although there may be differences since trastuzumab does not bind the rat HER2- like receptor.  Further research is necessary to more fully understand the T-DM1 ADME profile in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDuHn1EbzEhLVg90H21EOLACvtfcHk0lh7ys0C11teHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1OlurrN&md5=faf70e5692e4d6a5a7789a0510705837</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.2174%2F138920012802138598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920012802138598%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DB.%2BQ.%26aulast%3DBumbaca%26aufirst%3DD.%26aulast%3DSaad%26aufirst%3DO.%26aulast%3DYue%26aufirst%3DQ.%26aulast%3DPastuskovas%26aufirst%3DC.%2BV.%26aulast%3DKhojasteh%26aufirst%3DS.%2BC.%26aulast%3DTibbitts%26aufirst%3DJ.%26aulast%3DKaur%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DChu%26aufirst%3DY.%2BW.%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26aulast%3DGirish%26aufirst%3DS.%26atitle%3DCatabolic%2520fate%2520and%2520pharmacokinetic%2520characterization%2520of%2520trastuzumab%2520emtansine%2520%2528T-DM1%2529%253A%2520an%2520emphasis%2520on%2520preclinical%2520and%2520clinical%2520catabolism%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2012%26volume%3D13%26issue%3D7%26spage%3D901%26epage%3D910%26doi%3D10.2174%2F138920012802138598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Lewis Phillips, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dugger, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crocker, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mai, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blattler, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambert, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chari, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobson, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeppen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwall, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenkare-Mitra, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span> </span><span class="NLM_article-title">Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x"> (</span><span class="NLM_issue">22</span><span class="NLM_x">) </span> <span class="NLM_fpage">9280</span><span class="NLM_x">–</span> <span class="NLM_lpage">9290</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-1776</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1158%2F0008-5472.CAN-08-1776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=19010901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlOmt7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=9280-9290&issue=22&author=G.+D.+Lewis+Phillipsauthor=G.+Liauthor=D.+L.+Duggerauthor=L.+M.+Crockerauthor=K.+L.+Parsonsauthor=E.+Maiauthor=W.+A.+Blattlerauthor=J.+M.+Lambertauthor=R.+V.+Chariauthor=R.+J.+Lutzauthor=W.+L.+Wongauthor=F.+S.+Jacobsonauthor=H.+Koeppenauthor=R.+H.+Schwallauthor=S.+R.+Kenkare-Mitraauthor=S.+D.+Spencerauthor=M.+X.+Sliwkowski&title=Targeting+HER2-positive+breast+cancer+with+trastuzumab-DM1%2C+an+antibody-cytotoxic+drug+conjugate&doi=10.1158%2F0008-5472.CAN-08-1776"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate</span></div><div class="casAuthors">Lewis Phillips, Gail D.; Li, Guangmin; Dugger, Debra L.; Crocker, Lisa M.; Parsons, Kathryn L.; Mai, Elaine; Blaettler, Walter A.; Lambert, John M.; Chari, Ravi V. J.; Lutz, Robert J.; Wong, Wai Lee T.; Jacobson, Frederic S.; Koeppen, Hartmut; Schwall, Ralph H.; Kenkare-Mitra, Sara R.; Spencer, Susan D.; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9280-9290</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">HER2 is a validated target in breast cancer therapy.  Two drugs are currently approved for HER2-pos. breast cancer: trastuzumab (Herceptin), introduced in 1998, and lapatinib (Tykerb), in 2007.  Despite these advances, some patients progress through therapy and succumb to their disease.  A variation on antibody-targeted therapy is utilization of antibodies to deliver cytotoxic agents specifically to antigen-expressing tumors.  We detd. in vitro and in vivo efficacy, pharmacokinetics, and toxicity of trastuzumab-maytansinoid (microtubule-depolymg. agents) conjugates using disulfide and thioether linkers.  Antiproliferative effects of trastuzumab-maytansinoid conjugates were evaluated on cultured normal and tumor cells.  In vivo activity was detd. in mouse breast cancer models, and toxicity was assessed in rats as measured by body wt. loss.  Surprisingly, trastuzumab linked to DM1 through a nonreducible thioether linkage (SMCC), displayed superior activity compared with unconjugated trastuzumab or trastuzumab linked to other maytansinoids through disulfide linkers.  Serum concns. of trastuzumab-MCC-DM1 remained elevated compared with other conjugates, and toxicity in rats was negligible compared with free DM1 or trastuzumab linked to DM1 through a reducible linker.  Potent activity was obsd. on all HER2-overexpressing tumor cells, whereas nontransformed cells and tumor cell lines with normal HER2 expression were unaffected.  In addn., trastuzumab-DM1 was active on HER2-overexpressing, trastuzumab-refractory tumors.  In summary, trastuzumab-DM1 shows greater activity compared with nonconjugated trastuzumab while maintaining selectivity for HER2-overexpressing tumor cells.  Because trastuzumab linked to DM1 through a nonreducible linker offers improved efficacy and pharmacokinetics and reduced toxicity over the reducible disulfide linkers evaluated, trastuzumab-MCC-DM1 was selected for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpP5fkJnRorrVg90H21EOLACvtfcHk0lhgKyyk885j-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlOmt7rK&md5=e86e8687d5f8884f8e28514299dcbbf1</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-1776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-1776%26sid%3Dliteratum%253Aachs%26aulast%3DLewis%2BPhillips%26aufirst%3DG.%2BD.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DDugger%26aufirst%3DD.%2BL.%26aulast%3DCrocker%26aufirst%3DL.%2BM.%26aulast%3DParsons%26aufirst%3DK.%2BL.%26aulast%3DMai%26aufirst%3DE.%26aulast%3DBlattler%26aufirst%3DW.%2BA.%26aulast%3DLambert%26aufirst%3DJ.%2BM.%26aulast%3DChari%26aufirst%3DR.%2BV.%26aulast%3DLutz%26aufirst%3DR.%2BJ.%26aulast%3DWong%26aufirst%3DW.%2BL.%26aulast%3DJacobson%26aufirst%3DF.%2BS.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DSchwall%26aufirst%3DR.%2BH.%26aulast%3DKenkare-Mitra%26aufirst%3DS.%2BR.%26aulast%3DSpencer%26aufirst%3DS.%2BD.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DTargeting%2520HER2-positive%2520breast%2520cancer%2520with%2520trastuzumab-DM1%252C%2520an%2520antibody-cytotoxic%2520drug%2520conjugate%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26issue%3D22%26spage%3D9280%26epage%3D9290%26doi%3D10.1158%2F0008-5472.CAN-08-1776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Doronina, S. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendelsohn, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bovee, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cerveny, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alley, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oflazoglu, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toki, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanderson, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zabinski, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahl, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senter, P. D.</span><span> </span><span class="NLM_article-title">Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity</span> <span class="citation_source-journal">Bioconjugate Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">114</span><span class="NLM_x">–</span> <span class="NLM_lpage">124</span><span class="refDoi"> DOI: 10.1021/bc0502917</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bc0502917" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlars7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=114-124&issue=1&author=S.+O.+Doroninaauthor=B.+A.+Mendelsohnauthor=T.+D.+Boveeauthor=C.+G.+Cervenyauthor=S.+C.+Alleyauthor=D.+L.+Meyerauthor=E.+Oflazogluauthor=B.+E.+Tokiauthor=R.+J.+Sandersonauthor=R.+F.+Zabinskiauthor=A.+F.+Wahlauthor=P.+D.+Senter&title=Enhanced+activity+of+monomethylauristatin+F+through+monoclonal+antibody+delivery%3A+effects+of+linker+technology+on+efficacy+and+toxicity&doi=10.1021%2Fbc0502917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and Toxicity</span></div><div class="casAuthors">Doronina, Svetlana O.; Mendelsohn, Brian A.; Bovee, Tim D.; Cerveny, Charles G.; Alley, Stephen C.; Meyer, Damon L.; Oflazoglu, Ezogelin; Toki, Brian E.; Sanderson, Russell J.; Zabinski, Roger F.; Wahl, Alan F.; Senter, Peter D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">114-124</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have previously shown that antibody-drug conjugates (ADCs) consisting of cAC10 (anti-CD30) linked to the antimitotic agent monomethylauristatin E (MMAE) lead to potent in vitro and in vivo activities against antigen pos. tumor models.  MMAF is a new antimitotic auristatin deriv. with a charged C-terminal phenylalanine residue that attenuates its cytotoxic activity compared to its uncharged counterpart, MMAE, most likely due to impaired intracellular access.  In vitro cytotoxicity studies indicated that mAb-maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl-MMAF (mAb-L1-MMAF) conjugates were >2200-fold more potent than free MMAF on a large panel of CD30 pos. hematol. cell lines.  As with cAC10-L1-MMAE, the corresponding MMAF ADC induced cures and regressions of established xenograft tumors at well tolerated doses.  To further optimize the ADC, several new linkers were generated in which various components within the L1 linker were either altered or deleted.  One of the most promising linkers contained a noncleavable maleimidocaproyl (L4) spacer between the drug and the mAb.  CAC10-L4-MMAF was approx. as potent in vitro as cAC10-L1-MMAF against a large panel of cell lines and was equally potent in vivo.  Importantly, cAC10-L4-MMAF was tolerated at >3 times the MTD of cAC10-L1-MMAF.  LCMS studies indicated that drug released from cAC10-L4-MMAF was the cysteine-L4-MMAF adduct, which likely arises from mAb degrdn. within the lysosomes of target cells.  This new linker technol. appears to be ideally suited for drugs that are both relatively cell-impermeable and tolerant of substitution with amino acids.  Thus, alterations of the linker have pronounced impacts on toxicity and lead to new ADCs with greatly improved therapeutic indexes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfwQJyn8sp0LVg90H21EOLACvtfcHk0lhgKyyk885j-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlars7%252FL&md5=92da0266f0a83c7680006ef94956c879</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fbc0502917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbc0502917%26sid%3Dliteratum%253Aachs%26aulast%3DDoronina%26aufirst%3DS.%2BO.%26aulast%3DMendelsohn%26aufirst%3DB.%2BA.%26aulast%3DBovee%26aufirst%3DT.%2BD.%26aulast%3DCerveny%26aufirst%3DC.%2BG.%26aulast%3DAlley%26aufirst%3DS.%2BC.%26aulast%3DMeyer%26aufirst%3DD.%2BL.%26aulast%3DOflazoglu%26aufirst%3DE.%26aulast%3DToki%26aufirst%3DB.%2BE.%26aulast%3DSanderson%26aufirst%3DR.%2BJ.%26aulast%3DZabinski%26aufirst%3DR.%2BF.%26aulast%3DWahl%26aufirst%3DA.%2BF.%26aulast%3DSenter%26aufirst%3DP.%2BD.%26atitle%3DEnhanced%2520activity%2520of%2520monomethylauristatin%2520F%2520through%2520monoclonal%2520antibody%2520delivery%253A%2520effects%2520of%2520linker%2520technology%2520on%2520efficacy%2520and%2520toxicity%26jtitle%3DBioconjugate%2520Chem.%26date%3D2006%26volume%3D17%26issue%3D1%26spage%3D114%26epage%3D124%26doi%3D10.1021%2Fbc0502917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Gregson, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelland, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thurston, D. E.</span><span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">737</span><span class="NLM_x">–</span> <span class="NLM_lpage">748</span><span class="refDoi"> DOI: 10.1021/jm001064n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm001064n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=737-748&issue=5&author=S.+J.+Gregsonauthor=P.+W.+Howardauthor=J.+A.+Hartleyauthor=N.+A.+Brooksauthor=L.+J.+Adamsauthor=T.+C.+Jenkinsauthor=L.+R.+Kellandauthor=D.+E.+Thurston&title=Design%2C+synthesis%2C+and+evaluation+of+a+novel+pyrrolobenzodiazepine+DNA-interactive+agent+with+highly+efficient+cross-linking+ability+and+potent+cytotoxicity&doi=10.1021%2Fjm001064n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm001064n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm001064n%26sid%3Dliteratum%253Aachs%26aulast%3DGregson%26aufirst%3DS.%2BJ.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3DBrooks%26aufirst%3DN.%2BA.%26aulast%3DAdams%26aufirst%3DL.%2BJ.%26aulast%3DJenkins%26aufirst%3DT.%2BC.%26aulast%3DKelland%26aufirst%3DL.%2BR.%26aulast%3DThurston%26aufirst%3DD.%2BE.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520a%2520novel%2520pyrrolobenzodiazepine%2520DNA-interactive%2520agent%2520with%2520highly%2520efficient%2520cross-linking%2520ability%2520and%2520potent%2520cytotoxicity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26issue%3D5%26spage%3D737%26epage%3D748%26doi%3D10.1021%2Fjm001064n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Gregson, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gullick, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamaguchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corcoran, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guille, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thurston, D. E.</span><span> </span><span class="NLM_article-title">Linker length modulates DNA cross-linking reactivity and cytotoxic potency of C8/C8′ ether-linked C2-exo-unsaturated pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimers</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">1161</span><span class="NLM_x">–</span> <span class="NLM_lpage">1174</span><span class="refDoi"> DOI: 10.1021/jm030897l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030897l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1161-1174&issue=5&author=S.+J.+Gregsonauthor=P.+W.+Howardauthor=D.+R.+Gullickauthor=A.+Hamaguchiauthor=K.+E.+Corcoranauthor=N.+A.+Brooksauthor=J.+A.+Hartleyauthor=T.+C.+Jenkinsauthor=S.+Patelauthor=M.+J.+Guilleauthor=D.+E.+Thurston&title=Linker+length+modulates+DNA+cross-linking+reactivity+and+cytotoxic+potency+of+C8%2FC8%E2%80%B2+ether-linked+C2-exo-unsaturated+pyrrolo%5B2%2C1-c%5D%5B1%2C4%5Dbenzodiazepine+%28PBD%29+dimers&doi=10.1021%2Fjm030897l"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm030897l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030897l%26sid%3Dliteratum%253Aachs%26aulast%3DGregson%26aufirst%3DS.%2BJ.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26aulast%3DGullick%26aufirst%3DD.%2BR.%26aulast%3DHamaguchi%26aufirst%3DA.%26aulast%3DCorcoran%26aufirst%3DK.%2BE.%26aulast%3DBrooks%26aufirst%3DN.%2BA.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3DJenkins%26aufirst%3DT.%2BC.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DGuille%26aufirst%3DM.%2BJ.%26aulast%3DThurston%26aufirst%3DD.%2BE.%26atitle%3DLinker%2520length%2520modulates%2520DNA%2520cross-linking%2520reactivity%2520and%2520cytotoxic%2520potency%2520of%2520C8%252FC8%25E2%2580%25B2%2520ether-linked%2520C2-exo-unsaturated%2520pyrrolo%255B2%252C1-c%255D%255B1%252C4%255Dbenzodiazepine%2520%2528PBD%2529%2520dimers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26issue%3D5%26spage%3D1161%26epage%3D1174%26doi%3D10.1021%2Fjm030897l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Hartley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamaguchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suggitt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregson, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thurston, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, P. W.</span><span> </span><span class="NLM_article-title">DNA interstrand cross-linking and <i>in vivo</i> antitumor activity of the extended pyrrolo[2,1-c][1,4]benzodiazepine dimer SG2057</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">950</span><span class="NLM_x">–</span> <span class="NLM_lpage">958</span><span class="refDoi"> DOI: 10.1007/s10637-011-9647-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1007%2Fs10637-011-9647-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=21384134" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvFamtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=950-958&issue=3&author=J.+A.+Hartleyauthor=A.+Hamaguchiauthor=M.+Suggittauthor=S.+J.+Gregsonauthor=D.+E.+Thurstonauthor=P.+W.+Howard&title=DNA+interstrand+cross-linking+and+in+vivo+antitumor+activity+of+the+extended+pyrrolo%5B2%2C1-c%5D%5B1%2C4%5Dbenzodiazepine+dimer+SG2057&doi=10.1007%2Fs10637-011-9647-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">DNA interstrand cross-linking and in vivo antitumor activity of the extended pyrrolo[2,1-c][1,4]benzodiazepine dimer SG2057</span></div><div class="casAuthors">Hartley, John A.; Hamaguchi, Anzu; Suggitt, Marie; Gregson, Stephen J.; Thurston, David E.; Howard, Philip W.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">950-958</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The pyrrolobenzodiazepines (PBDs) are naturally occurring antitumor antibiotics and a PBD dimer (SJG-136, SG2000) is in Phase II trials.  SG2000 is a propyldioxy linked PBD dimer which binds sequence selectively in the minor groove of DNA forming DNA interstrand and intrastrand cross-linked adducts, and also mono-adducts depending on sequence.  SG2057 is the corresponding dimer contg. a pentyldioxy linkage.  SG2057 has multilog differential in vitro cytotoxicity against a panel of human tumor cell lines with a mean GI50 of 212 pM.  The agent is highly efficient at producing DNA interstrand cross-links in cells which form rapidly and persist over a 48 h period.  Significant antitumor activity was demonstrated in several human tumor xenograft models.  Cures were obtained in a LOX-IMVI melanoma model following a single administration and dose-dependent activity, including regression responses, obsd. in SKOV-3 ovarian and HL-60 promyelocytic leukemia models following repeat dose schedules.  In the advanced stage LS174T model, SG2057 administered either as a single dose, or in two repeat dose schedules, was superior to irinotecan.  SG2057 is therefore a highly active antitumor agent, with more potent in vitro activity and superior in vivo activity to SG2000, warranting further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXu8VuTWqyI7Vg90H21EOLACvtfcHk0lgOVDT33w--lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvFamtLk%253D&md5=083b09bc0bf01b580e479e50e3c9080e</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1007%2Fs10637-011-9647-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-011-9647-z%26sid%3Dliteratum%253Aachs%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3DHamaguchi%26aufirst%3DA.%26aulast%3DSuggitt%26aufirst%3DM.%26aulast%3DGregson%26aufirst%3DS.%2BJ.%26aulast%3DThurston%26aufirst%3DD.%2BE.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26atitle%3DDNA%2520interstrand%2520cross-linking%2520and%2520in%2520vivo%2520antitumor%2520activity%2520of%2520the%2520extended%2520pyrrolo%255B2%252C1-c%255D%255B1%252C4%255Dbenzodiazepine%2520dimer%2520SG2057%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2012%26volume%3D30%26issue%3D3%26spage%3D950%26epage%3D958%26doi%3D10.1007%2Fs10637-011-9647-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Rettig, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weingarth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langel, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisz, K.</span><span> </span><span class="NLM_article-title">Solution structure of a covalently bound pyrrolo[2,1-c][1,4]benzodiazepine-benzimidazole hybrid to a 10mer DNA duplex</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x"> (</span><span class="NLM_issue">51</span><span class="NLM_x">) </span> <span class="NLM_fpage">12223</span><span class="NLM_x">–</span> <span class="NLM_lpage">12232</span><span class="refDoi"> DOI: 10.1021/bi901655t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi901655t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2009&pages=12223-12232&issue=51&author=M.+Rettigauthor=M.+Weingarthauthor=W.+Langelauthor=A.+Kamalauthor=P.+P.+Kumarauthor=K.+Weisz&title=Solution+structure+of+a+covalently+bound+pyrrolo%5B2%2C1-c%5D%5B1%2C4%5Dbenzodiazepine-benzimidazole+hybrid+to+a+10mer+DNA+duplex&doi=10.1021%2Fbi901655t"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fbi901655t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi901655t%26sid%3Dliteratum%253Aachs%26aulast%3DRettig%26aufirst%3DM.%26aulast%3DWeingarth%26aufirst%3DM.%26aulast%3DLangel%26aufirst%3DW.%26aulast%3DKamal%26aufirst%3DA.%26aulast%3DKumar%26aufirst%3DP.%2BP.%26aulast%3DWeisz%26aufirst%3DK.%26atitle%3DSolution%2520structure%2520of%2520a%2520covalently%2520bound%2520pyrrolo%255B2%252C1-c%255D%255B1%252C4%255Dbenzodiazepine-benzimidazole%2520hybrid%2520to%2520a%252010mer%2520DNA%2520duplex%26jtitle%3DBiochemistry%26date%3D2009%26volume%3D48%26issue%3D51%26spage%3D12223%26epage%3D12232%26doi%3D10.1021%2Fbi901655t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Harder, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grunze, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahint, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitesides, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laibinis, P. E.</span><span> </span><span class="NLM_article-title">Molecular conformation in oligo(ethylene glycol)-terminated self-assembled monolayers on gold and silver surfaces determines their ability to resist protein adsorption</span> <span class="citation_source-journal">J. Phys. Chem. B</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">426</span><span class="NLM_x">–</span> <span class="NLM_lpage">436</span><span class="refDoi"> DOI: 10.1021/jp972635z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jp972635z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADyaK1cXksFWgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=1998&pages=426-436&issue=2&author=P.+Harderauthor=M.+Grunzeauthor=R.+Dahintauthor=G.+M.+Whitesidesauthor=P.+E.+Laibinis&title=Molecular+conformation+in+oligo%28ethylene+glycol%29-terminated+self-assembled+monolayers+on+gold+and+silver+surfaces+determines+their+ability+to+resist+protein+adsorption&doi=10.1021%2Fjp972635z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Conformation in Oligo(ethylene glycol)-Terminated Self-Assembled Monolayers on Gold and Silver Surfaces Determines Their Ability To Resist Protein Adsorption</span></div><div class="casAuthors">Harder, P.; Grunze, M.; Dahint, R.; Whitesides, G. M.; Laibinis, P. E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry B</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">426-436</span>CODEN:
                <span class="NLM_cas:coden">JPCBFK</span>;
        ISSN:<span class="NLM_cas:issn">1089-5647</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Data from IR absorption (FTIR) and X-ray photoelectron spectroscopies that correlate the mol. conformation of oligo(ethylene glycol) (OEG)-terminated self-assembled alkanethiolate monolayers (SAMs) with the ability of these films to resist protein adsorption was reported.  Three different SAMs of alkanethiolates on evapd. Au and Ag surfaces.  The SAMs were formed from substituted 1-undecanethiols with either a hydroxyl-terminated hexa(ethylene glycol) (EG6-OH) or a methoxy-terminated tri(ethylene glycol) (EG3-OMe) end group, or a substituted 1-tridecanethiol chain with a methoxy-terminated tri(ethylene glycol) end group and a -CH2OCH3 side chain at the C-12 atom (EG[3,1]-OMe).  The IR data of EG6-OH-terminated SAMs on both Au and Ag surfaces reveal the presence of a cryst. helical OEG phase, coexisting with amorphous OEG moieties; the EG[3,1]-OMe-terminated alkanethiolates on Au and Ag show a lower abs. coverage and greater disorder than the two other compds.  The mol. conformation of the methoxy-terminated tri(ethylene glycol) (EG3-OMe) is different on Au and Ag surfaces due to the different lateral densities of SAMs on these substrates: on Au we find a conformation similar to that of EG6-OH alkanethiolates, whereas on Ag the IR spectra indicate a densely packed film with trans conformation around the C-C bonds of the glycol units.  The resistance of these OEG-functionalized alkanethiolate SAMs to adsorption of fibrinogen from a buffered soln. correlates with the mol. conformation of the OEG moieties.  The predominantly cryst. helical and the amorphous forms of OEG on gold substrates are resistant to adsorption of proteins, while a densely packed "all-trans" form of EG3-OMe present on silver surfaces adsorbs protein.  The exptl. observations are compatible with the hypothesis that binding of interfacial water by the OEG moieties is important in their ability to resist protein adsorption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3ZjvnsVdbXbVg90H21EOLACvtfcHk0lgOVDT33w--lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXksFWgug%253D%253D&md5=159b7b18ae2b544412935b075d2d2868</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjp972635z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjp972635z%26sid%3Dliteratum%253Aachs%26aulast%3DHarder%26aufirst%3DP.%26aulast%3DGrunze%26aufirst%3DM.%26aulast%3DDahint%26aufirst%3DR.%26aulast%3DWhitesides%26aufirst%3DG.%2BM.%26aulast%3DLaibinis%26aufirst%3DP.%2BE.%26atitle%3DMolecular%2520conformation%2520in%2520oligo%2528ethylene%2520glycol%2529-terminated%2520self-assembled%2520monolayers%2520on%2520gold%2520and%2520silver%2520surfaces%2520determines%2520their%2520ability%2520to%2520resist%2520protein%2520adsorption%26jtitle%3DJ.%2520Phys.%2520Chem.%2520B%26date%3D1998%26volume%3D102%26issue%3D2%26spage%3D426%26epage%3D436%26doi%3D10.1021%2Fjp972635z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Althuis, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hess, H. J.</span><span> </span><span class="NLM_article-title">Synthesis and identification of the major metabolites of prazosin formed in dog and rat</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">146</span><span class="NLM_x">–</span> <span class="NLM_lpage">149</span><span class="refDoi"> DOI: 10.1021/jm00211a031</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00211a031" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1977&pages=146-149&issue=1&author=T.+H.+Althuisauthor=H.+J.+Hess&title=Synthesis+and+identification+of+the+major+metabolites+of+prazosin+formed+in+dog+and+rat&doi=10.1021%2Fjm00211a031"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm00211a031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00211a031%26sid%3Dliteratum%253Aachs%26aulast%3DAlthuis%26aufirst%3DT.%2BH.%26aulast%3DHess%26aufirst%3DH.%2BJ.%26atitle%3DSynthesis%2520and%2520identification%2520of%2520the%2520major%2520metabolites%2520of%2520prazosin%2520formed%2520in%2520dog%2520and%2520rat%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1977%26volume%3D20%26issue%3D1%26spage%3D146%26epage%3D149%26doi%3D10.1021%2Fjm00211a031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Tercel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stribbling, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheppard, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siim, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pullen, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botting, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Unsymmetrical DNA cross-linking agents: combination of the CBI and PBD pharmacophores</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">2132</span><span class="NLM_x">–</span> <span class="NLM_lpage">2151</span><span class="refDoi"> DOI: 10.1021/jm020526p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020526p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=2132-2151&issue=11&author=M.+Tercelauthor=S.+M.+Stribblingauthor=H.+Sheppardauthor=B.+G.+Siimauthor=K.+Wuauthor=S.+M.+Pullenauthor=K.+J.+Bottingauthor=W.+R.+Wilsonauthor=W.+A.+Denny&title=Unsymmetrical+DNA+cross-linking+agents%3A+combination+of+the+CBI+and+PBD+pharmacophores&doi=10.1021%2Fjm020526p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm020526p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020526p%26sid%3Dliteratum%253Aachs%26aulast%3DTercel%26aufirst%3DM.%26aulast%3DStribbling%26aufirst%3DS.%2BM.%26aulast%3DSheppard%26aufirst%3DH.%26aulast%3DSiim%26aufirst%3DB.%2BG.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DPullen%26aufirst%3DS.%2BM.%26aulast%3DBotting%26aufirst%3DK.%2BJ.%26aulast%3DWilson%26aufirst%3DW.%2BR.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DUnsymmetrical%2520DNA%2520cross-linking%2520agents%253A%2520combination%2520of%2520the%2520CBI%2520and%2520PBD%2520pharmacophores%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26issue%3D11%26spage%3D2132%26epage%3D2151%26doi%3D10.1021%2Fjm020526p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Wells, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sands, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laughton, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiberghien, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masterson, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephenson, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jenkins, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shnyder, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loadman, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waring, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thurston, D. E.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biophysical and biological evaluation of a series of pyrrolobenzodiazepine-poly(<i>N</i>-methylpyrrole) conjugates</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x"> (</span><span class="NLM_issue">18</span><span class="NLM_x">) </span> <span class="NLM_fpage">5442</span><span class="NLM_x">–</span> <span class="NLM_lpage">5461</span><span class="refDoi"> DOI: 10.1021/jm051199z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm051199z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5442-5461&issue=18&author=G.+Wellsauthor=C.+R.+Martinauthor=P.+W.+Howardauthor=Z.+A.+Sandsauthor=C.+A.+Laughtonauthor=A.+Tiberghienauthor=C.+K.+Wooauthor=L.+A.+Mastersonauthor=M.+J.+Stephensonauthor=J.+A.+Hartleyauthor=T.+C.+Jenkinsauthor=S.+D.+Shnyderauthor=P.+M.+Loadmanauthor=M.+J.+Waringauthor=D.+E.+Thurston&title=Design%2C+synthesis%2C+and+biophysical+and+biological+evaluation+of+a+series+of+pyrrolobenzodiazepine-poly%28N-methylpyrrole%29+conjugates&doi=10.1021%2Fjm051199z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm051199z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm051199z%26sid%3Dliteratum%253Aachs%26aulast%3DWells%26aufirst%3DG.%26aulast%3DMartin%26aufirst%3DC.%2BR.%26aulast%3DHoward%26aufirst%3DP.%2BW.%26aulast%3DSands%26aufirst%3DZ.%2BA.%26aulast%3DLaughton%26aufirst%3DC.%2BA.%26aulast%3DTiberghien%26aufirst%3DA.%26aulast%3DWoo%26aufirst%3DC.%2BK.%26aulast%3DMasterson%26aufirst%3DL.%2BA.%26aulast%3DStephenson%26aufirst%3DM.%2BJ.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3DJenkins%26aufirst%3DT.%2BC.%26aulast%3DShnyder%26aufirst%3DS.%2BD.%26aulast%3DLoadman%26aufirst%3DP.%2BM.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DThurston%26aufirst%3DD.%2BE.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biophysical%2520and%2520biological%2520evaluation%2520of%2520a%2520series%2520of%2520pyrrolobenzodiazepine-poly%2528N-methylpyrrole%2529%2520conjugates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26issue%3D18%26spage%3D5442%26epage%3D5461%26doi%3D10.1021%2Fjm051199z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Alberico, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lautens, M.</span><span> </span><span class="NLM_article-title">Synthesis of tricyclic heterocycles via a tandem aryl alkylation/Heck coupling sequence</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">775</span><span class="NLM_x">–</span> <span class="NLM_lpage">781</span><span class="refDoi"> DOI: 10.1021/jo0617868</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo0617868" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2007&pages=775-781&issue=3&author=D.+Albericoauthor=A.+Rudolphauthor=M.+Lautens&title=Synthesis+of+tricyclic+heterocycles+via+a+tandem+aryl+alkylation%2FHeck+coupling+sequence&doi=10.1021%2Fjo0617868"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjo0617868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0617868%26sid%3Dliteratum%253Aachs%26aulast%3DAlberico%26aufirst%3DD.%26aulast%3DRudolph%26aufirst%3DA.%26aulast%3DLautens%26aufirst%3DM.%26atitle%3DSynthesis%2520of%2520tricyclic%2520heterocycles%2520via%2520a%2520tandem%2520aryl%2520alkylation%252FHeck%2520coupling%2520sequence%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2007%26volume%3D72%26issue%3D3%26spage%3D775%26epage%3D781%26doi%3D10.1021%2Fjo0617868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Peterle, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ringler, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayor, M.</span><span> </span><span class="NLM_article-title">Gold nanoparticles stabilized by acetylene-functionalized multidentate thioether ligands: building blocks for nanoparticle superstructures</span> <span class="citation_source-journal">Adv. Funct. Mater.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x"> (</span><span class="NLM_issue">21</span><span class="NLM_x">) </span> <span class="NLM_fpage">3497</span><span class="NLM_x">–</span> <span class="NLM_lpage">3506</span><span class="refDoi"> DOI: 10.1002/adfm.200901410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1002%2Fadfm.200901410" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=3497-3506&issue=21&author=T.+Peterleauthor=P.+Ringlerauthor=M.+Mayor&title=Gold+nanoparticles+stabilized+by+acetylene-functionalized+multidentate+thioether+ligands%3A+building+blocks+for+nanoparticle+superstructures&doi=10.1002%2Fadfm.200901410"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fadfm.200901410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fadfm.200901410%26sid%3Dliteratum%253Aachs%26aulast%3DPeterle%26aufirst%3DT.%26aulast%3DRingler%26aufirst%3DP.%26aulast%3DMayor%26aufirst%3DM.%26atitle%3DGold%2520nanoparticles%2520stabilized%2520by%2520acetylene-functionalized%2520multidentate%2520thioether%2520ligands%253A%2520building%2520blocks%2520for%2520nanoparticle%2520superstructures%26jtitle%3DAdv.%2520Funct.%2520Mater.%26date%3D2009%26volume%3D19%26issue%3D21%26spage%3D3497%26epage%3D3506%26doi%3D10.1002%2Fadfm.200901410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Sakaitani, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohfune, Y.</span><span> </span><span class="NLM_article-title">Selective transformation of <i>N</i>-<i>t</i>-butoxycarbonyl group into <i>N</i>-alkoxy-carbonyl group <i>via N</i>-carboxylate ion equivalent</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x"> (</span><span class="NLM_issue">45</span><span class="NLM_x">) </span> <span class="NLM_fpage">5543</span><span class="NLM_x">–</span> <span class="NLM_lpage">5546</span><span class="refDoi"> DOI: 10.1016/S0040-4039(01)80883-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1016%2FS0040-4039%2801%2980883-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1985&pages=5543-5546&issue=45&author=M.+Sakaitaniauthor=Y.+Ohfune&title=Selective+transformation+of+N-t-butoxycarbonyl+group+into+N-alkoxy-carbonyl+group+via+N-carboxylate+ion+equivalent&doi=10.1016%2FS0040-4039%2801%2980883-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2801%2980883-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252801%252980883-2%26sid%3Dliteratum%253Aachs%26aulast%3DSakaitani%26aufirst%3DM.%26aulast%3DOhfune%26aufirst%3DY.%26atitle%3DSelective%2520transformation%2520of%2520N-t-butoxycarbonyl%2520group%2520into%2520N-alkoxy-carbonyl%2520group%2520via%2520N-carboxylate%2520ion%2520equivalent%26jtitle%3DTetrahedron%2520Lett.%26date%3D1985%26volume%3D26%26issue%3D45%26spage%3D5543%26epage%3D5546%26doi%3D10.1016%2FS0040-4039%2801%2980883-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Maiti, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fors, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henderson, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchwald, S. L.</span><span> </span><span class="NLM_article-title">Palladium-catalyzed coupling of functionalized primary and secondary amines with aryl and heteroaryl halides: two ligands suffice in most cases</span> <span class="citation_source-journal">Chem. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">57</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span><span class="refDoi"> DOI: 10.1039/C0SC00330A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1039%2FC0SC00330A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=22384311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFWqsbjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=57-68&issue=1&author=D.+Maitiauthor=B.+P.+Forsauthor=J.+L.+Hendersonauthor=Y.+Nakamuraauthor=S.+L.+Buchwald&title=Palladium-catalyzed+coupling+of+functionalized+primary+and+secondary+amines+with+aryl+and+heteroaryl+halides%3A+two+ligands+suffice+in+most+cases&doi=10.1039%2FC0SC00330A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-catalyzed coupling of functionalized primary and secondary amines with aryl and heteroaryl halides: two ligands suffice in most cases</span></div><div class="casAuthors">Maiti, Debabrata; Fors, Brett P.; Henderson, Jaclyn L.; Nakamura, Yoshinori; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-68</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A study on the use of two catalyst systems is reported here.  The ligands used in this study were BrettPhos [i.e., dicyclohexyl[3,6-dimethoxy-2',4',6'-tris(1-methylethyl)[1,1'-biphenyl]-2-yl]phosphine] and RuPhos [i.e., [2',6'-bis(1-methylethoxy)[1,1'-biphenyl]-2-yl]dicyclohexylphosphine].  These ligands provide a wide scope for Pd-catalyzed C-N cross-coupling reactions.  Often low catalyst loadings and short reaction times can be used with functionalized aryl and heteroaryl coupling partners.  The reactions are highly robust and can be set up and performed without the use of a glove box.  These catalysts should find wide application in the synthesis of complex mols. including pharmaceuticals, natural products and functional materials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7MMWmsn65tLVg90H21EOLACvtfcHk0liU-zNV8dV0FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFWqsbjF&md5=217f0d978b9cc44b2b3c468fd291c2b2</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1039%2FC0SC00330A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC0SC00330A%26sid%3Dliteratum%253Aachs%26aulast%3DMaiti%26aufirst%3DD.%26aulast%3DFors%26aufirst%3DB.%2BP.%26aulast%3DHenderson%26aufirst%3DJ.%2BL.%26aulast%3DNakamura%26aufirst%3DY.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DPalladium-catalyzed%2520coupling%2520of%2520functionalized%2520primary%2520and%2520secondary%2520amines%2520with%2520aryl%2520and%2520heteroaryl%2520halides%253A%2520two%2520ligands%2520suffice%2520in%2520most%2520cases%26jtitle%3DChem.%2520Sci.%26date%3D2011%26volume%3D2%26issue%3D1%26spage%3D57%26epage%3D68%26doi%3D10.1039%2FC0SC00330A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Junutula, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raab, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhakta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leipold, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weir, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simpson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dennis, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, Y. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duenas, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorrell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katta, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDorman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flagella, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Venook, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee Wong, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowman, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandlen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheller, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polakis, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallet, W.</span><span> </span><span class="NLM_article-title">Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">925</span><span class="NLM_x">–</span> <span class="NLM_lpage">932</span><span class="refDoi"> DOI: 10.1038/nbt.1480</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1038%2Fnbt.1480" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=18641636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1Wmu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=925-932&issue=8&author=J.+R.+Junutulaauthor=H.+Raabauthor=S.+Clarkauthor=S.+Bhaktaauthor=D.+D.+Leipoldauthor=S.+Weirauthor=Y.+Chenauthor=M.+Simpsonauthor=S.+P.+Tsaiauthor=M.+S.+Dennisauthor=Y.+Luauthor=Y.+G.+Mengauthor=C.+Ngauthor=J.+Yangauthor=C.+C.+Leeauthor=E.+Duenasauthor=J.+Gorrellauthor=V.+Kattaauthor=A.+Kimauthor=K.+McDormanauthor=K.+Flagellaauthor=R.+Venookauthor=S.+Rossauthor=S.+D.+Spencerauthor=W.+Lee+Wongauthor=H.+B.+Lowmanauthor=R.+Vandlenauthor=M.+X.+Sliwkowskiauthor=R.+H.+Schellerauthor=P.+Polakisauthor=W.+Mallet&title=Site-specific+conjugation+of+a+cytotoxic+drug+to+an+antibody+improves+the+therapeutic+index&doi=10.1038%2Fnbt.1480"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index</span></div><div class="casAuthors">Junutula, Jagath R.; Raab, Helga; Clark, Suzanna; Bhakta, Sunil; Leipold, Douglas D.; Weir, Sylvia; Chen, Yvonne; Simpson, Michelle; Tsai, Siao Ping; Dennis, Mark S.; Lu, Yanmei; Meng, Y. Gloria; Ng, Carl; Yang, Jihong; Lee, Chien C.; Duenas, Eileen; Gorrell, Jeffrey; Katta, Viswanatham; Kim, Amy; McDorman, Kevin; Flagella, Kelly; Venook, Rayna; Ross, Sarajane; Spencer, Susan D.; Wong, Wai Lee; Lowman, Henry B.; Vandlen, Richard; Sliwkowski, Mark X.; Scheller, Richard H.; Polakis, Paul; Mallet, William</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">925-932</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Antibody-drug conjugates enhance the antitumor effects of antibodies and reduce adverse systemic effects of potent cytotoxic drugs.  However, conventional drug conjugation strategies yield heterogeneous conjugates with relatively narrow therapeutic index (max. tolerated dose/curative dose).  Using leads from the authors' previously described phage display-based method to predict suitable conjugation sites, the authors engineered cysteine substitutions at positions on light and heavy chains that provide reactive thiol groups and do not perturb Ig folding and assembly, or alter antigen binding.  When conjugated to monomethyl auristatin E, an antibody against the ovarian cancer antigen MUC16 is as efficacious as a conventional conjugate in mouse xenograft models.  Moreover, it is tolerated at higher doses in rats and cynomolgus monkeys than the same conjugate prepd. by conventional approaches.  The favorable in vivo properties of the near-homogeneous compn. of this conjugate suggest that this strategy offers a general approach to retaining the antitumor efficacy of antibody-drug conjugates, while minimizing their systemic toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4HIiPBABzRLVg90H21EOLACvtfcHk0liaTlL2wbEwVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1Wmu7s%253D&md5=d55f59594fb6349d0337dfed2783e83c</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1480&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1480%26sid%3Dliteratum%253Aachs%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26aulast%3DRaab%26aufirst%3DH.%26aulast%3DClark%26aufirst%3DS.%26aulast%3DBhakta%26aufirst%3DS.%26aulast%3DLeipold%26aufirst%3DD.%2BD.%26aulast%3DWeir%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DSimpson%26aufirst%3DM.%26aulast%3DTsai%26aufirst%3DS.%2BP.%26aulast%3DDennis%26aufirst%3DM.%2BS.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DMeng%26aufirst%3DY.%2BG.%26aulast%3DNg%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DDuenas%26aufirst%3DE.%26aulast%3DGorrell%26aufirst%3DJ.%26aulast%3DKatta%26aufirst%3DV.%26aulast%3DKim%26aufirst%3DA.%26aulast%3DMcDorman%26aufirst%3DK.%26aulast%3DFlagella%26aufirst%3DK.%26aulast%3DVenook%26aufirst%3DR.%26aulast%3DRoss%26aufirst%3DS.%26aulast%3DSpencer%26aufirst%3DS.%2BD.%26aulast%3DLee%2BWong%26aufirst%3DW.%26aulast%3DLowman%26aufirst%3DH.%2BB.%26aulast%3DVandlen%26aufirst%3DR.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DScheller%26aufirst%3DR.%2BH.%26aulast%3DPolakis%26aufirst%3DP.%26aulast%3DMallet%26aufirst%3DW.%26atitle%3DSite-specific%2520conjugation%2520of%2520a%2520cytotoxic%2520drug%2520to%2520an%2520antibody%2520improves%2520the%2520therapeutic%2520index%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26issue%3D8%26spage%3D925%26epage%3D932%26doi%3D10.1038%2Fnbt.1480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Verma, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pillow, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DePalatis, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raab, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, B.</span><span> </span><span class="NLM_article-title">The cryptophycins as potent payloads for antibody drug conjugates</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">864</span><span class="NLM_x">–</span> <span class="NLM_lpage">868</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2014.12.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1016%2Fj.bmcl.2014.12.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=25613677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVOitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=864-868&issue=4&author=V.+A.+Vermaauthor=T.+H.+Pillowauthor=L.+DePalatisauthor=G.+Liauthor=G.+L.+Phillipsauthor=A.+G.+Polsonauthor=H.+E.+Raabauthor=S.+Spencerauthor=B.+Zheng&title=The+cryptophycins+as+potent+payloads+for+antibody+drug+conjugates&doi=10.1016%2Fj.bmcl.2014.12.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">The cryptophycins as potent payloads for antibody drug conjugates</span></div><div class="casAuthors">Verma, Vishal A.; Pillow, Thomas H.; DePalatis, Laura; Li, Guangmin; Phillips, Gail Lewis; Polson, Andrew G.; Raab, Helga E.; Spencer, Susan; Zheng, Bing</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">864-868</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The cryptophycins are a potent class of cytotoxic agents that were evaluated as antibody drug conjugate (ADC) payloads.  Free cryptophycin analog (I) displayed cell activity an order of magnitude more potent than approved ADC payloads MMAE and DM1.  This potency increase was also reflected in the activity of the cryptophycin ADCs, attached via a either cleavable or non-cleavable linker.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMHocqt_vwd7Vg90H21EOLACvtfcHk0liaTlL2wbEwVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVOitQ%253D%253D&md5=6074661a1ad89ae71f88401f24c45ec7</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.12.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.12.070%26sid%3Dliteratum%253Aachs%26aulast%3DVerma%26aufirst%3DV.%2BA.%26aulast%3DPillow%26aufirst%3DT.%2BH.%26aulast%3DDePalatis%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DPhillips%26aufirst%3DG.%2BL.%26aulast%3DPolson%26aufirst%3DA.%2BG.%26aulast%3DRaab%26aufirst%3DH.%2BE.%26aulast%3DSpencer%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DB.%26atitle%3DThe%2520cryptophycins%2520as%2520potent%2520payloads%2520for%2520antibody%2520drug%2520conjugates%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26issue%3D4%26spage%3D864%26epage%3D868%26doi%3D10.1016%2Fj.bmcl.2014.12.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Dornan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dennis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eaton, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elkins, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">French, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Go, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jack, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Junutula, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeppen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBride, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rawstron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yue, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebens, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polson, A. G.</span><span> </span><span class="NLM_article-title">Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x"> (</span><span class="NLM_issue">13</span><span class="NLM_x">) </span> <span class="NLM_fpage">2721</span><span class="NLM_x">–</span> <span class="NLM_lpage">2729</span><span class="refDoi"> DOI: 10.1182/blood-2009-02-205500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1182%2Fblood-2009-02-205500" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=19633198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1eit7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2009&pages=2721-2729&issue=13&author=D.+Dornanauthor=F.+Bennettauthor=Y.+Chenauthor=M.+Dennisauthor=D.+Eatonauthor=K.+Elkinsauthor=D.+Frenchauthor=M.+A.+Goauthor=A.+Jackauthor=J.+R.+Junutulaauthor=H.+Koeppenauthor=J.+Lauauthor=J.+McBrideauthor=A.+Rawstronauthor=X.+Shiauthor=N.+Yuauthor=S.+F.+Yuauthor=P.+Yueauthor=B.+Zhengauthor=A.+Ebensauthor=A.+G.+Polson&title=Therapeutic+potential+of+an+anti-CD79b+antibody-drug+conjugate%2C+anti-CD79b-vc-MMAE%2C+for+the+treatment+of+non-Hodgkin+lymphoma&doi=10.1182%2Fblood-2009-02-205500"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma</span></div><div class="casAuthors">Dornan, David; Bennett, Fiona; Chen, Yvonne; Dennis, Mark; Eaton, Dan; Elkins, Kristi; French, Dorothy; Go, Mary Ann T.; Jack, Andrew; Junutula, Jagath R.; Koeppen, Hartmut; Lau, Jeffrey; McBride, Jacqueline; Rawstron, Andy; Shi, Xiaoyan; Yu, Nancy; Yu, Shang-Fan; Yue, Peng; Zheng, Bing; Ebens, Allen; Polson, Andrew G.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2721-2729</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Here we describe the generation of an antibody-drug conjugate (ADC) consisting of a humanized anti-CD79b antibody that is conjugated to monomethylauristatin E (MMAE) through engineered cysteines (THIOMABs) by a protease cleavable linker.  By using flow cytometry, we detected the surface expression of CD79b in almost all non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia patients, suggesting that anti-CD79b-vcMMAE could be widely used in these malignancies.  By using NHL cell lines to simulate a patient population we discovered that a minimal cell-surface expression level of CD79b was required for in vitro activity.  Within the subpopulation of cell lines above this minimal threshold, we found that sensitivity to free MMAE, mutation of cancer genes, and cell doubling time were poorly correlated with in vitro activity; however, the expression level of BCL-XL was correlated with reduced sensitivity to anti-CD79b-vcMMAE.  This observation was supported by in vivo data showing that a Bcl-2 family inhibitor, ABT-263, strikingly enhanced the activity of anti-CD79b-vcMMAE.  Furthermore, anti-CD79b-vcMMAE was significantly more effective than a std.-of-care regimen, R-CHOP (ie, rituximab with a single i.v. injection of 30 mg/kg cyclophosphamide, 2.475 mg/kg doxorubicin, 0.375 mg/kg vincristine, and oral dosing of 0.15 mg/kg prednisone once a day for 5 days), in 3 xenograft models of NHL.  Together, these data suggest that anti-CD79b-vcMMAE could be broadly efficacious for the treatment of NHL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvpWja1X5Ce7Vg90H21EOLACvtfcHk0lgP3L-V9_nDZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1eit7jO&md5=02b943d887958c47dd2e5d1a3d490371</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-02-205500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-02-205500%26sid%3Dliteratum%253Aachs%26aulast%3DDornan%26aufirst%3DD.%26aulast%3DBennett%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDennis%26aufirst%3DM.%26aulast%3DEaton%26aufirst%3DD.%26aulast%3DElkins%26aufirst%3DK.%26aulast%3DFrench%26aufirst%3DD.%26aulast%3DGo%26aufirst%3DM.%2BA.%26aulast%3DJack%26aufirst%3DA.%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DLau%26aufirst%3DJ.%26aulast%3DMcBride%26aufirst%3DJ.%26aulast%3DRawstron%26aufirst%3DA.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DN.%26aulast%3DYu%26aufirst%3DS.%2BF.%26aulast%3DYue%26aufirst%3DP.%26aulast%3DZheng%26aufirst%3DB.%26aulast%3DEbens%26aufirst%3DA.%26aulast%3DPolson%26aufirst%3DA.%2BG.%26atitle%3DTherapeutic%2520potential%2520of%2520an%2520anti-CD79b%2520antibody-drug%2520conjugate%252C%2520anti-CD79b-vc-MMAE%252C%2520for%2520the%2520treatment%2520of%2520non-Hodgkin%2520lymphoma%26jtitle%3DBlood%26date%3D2009%26volume%3D114%26issue%3D13%26spage%3D2721%26epage%3D2729%26doi%3D10.1182%2Fblood-2009-02-205500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Shen, B.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raab, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhakta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenrick, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parsons-Reponte, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tien, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, S.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mai, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tibbitts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baudys, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saad, O. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scales, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hass, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solis, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fuji, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flagella, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khawli, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebens, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandlen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaur, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheller, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polakis, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Junutula, J. R.</span><span> </span><span class="NLM_article-title">Conjugation site modulates the <i>in vivo</i> stability and therapeutic activity of antibody-drug conjugates</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">184</span><span class="NLM_x">–</span> <span class="NLM_lpage">189</span><span class="refDoi"> DOI: 10.1038/nbt.2108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1038%2Fnbt.2108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=22267010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVGqtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=184-189&issue=2&author=B.-Q.+Shenauthor=K.+Xuauthor=L.+Liuauthor=H.+Raabauthor=S.+Bhaktaauthor=M.+Kenrickauthor=K.+L.+Parsons-Reponteauthor=J.+Tienauthor=S.-F.+Yuauthor=E.+Maiauthor=D.+Liauthor=J.+Tibbittsauthor=J.+Baudysauthor=O.+M.+Saadauthor=S.+J.+Scalesauthor=P.+J.+McDonaldauthor=P.+E.+Hassauthor=C.+Eigenbrotauthor=T.+Nguyenauthor=W.+A.+Solisauthor=R.+N.+Fujiauthor=K.+M.+Flagellaauthor=D.+Patelauthor=S.+D.+Spencerauthor=L.+A.+Khawliauthor=A.+Ebensauthor=W.+L.+Wongauthor=R.+Vandlenauthor=S.+Kaurauthor=M.+X.+Sliwkowskiauthor=R.+H.+Schellerauthor=P.+Polakisauthor=J.+R.+Junutula&title=Conjugation+site+modulates+the+in+vivo+stability+and+therapeutic+activity+of+antibody-drug+conjugates&doi=10.1038%2Fnbt.2108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates</span></div><div class="casAuthors">Shen, Ben-Quan; Xu, Keyang; Liu, Luna; Raab, Helga; Bhakta, Sunil; Kenrick, Margaret; Parsons-Reponte, Kathryn L.; Tien, Janet; Yu, Shang-Fan; Mai, Elaine; Li, Dongwei; Tibbitts, Jay; Baudys, Jakub; Saad, Ola M.; Scales, Suzie J.; McDonald, Paul J.; Hass, Philip E.; Eigenbrot, Charles; Nguyen, Trung; Solis, Willy A.; Fuji, Reina N.; Flagella, Kelly M.; Patel, Darshana; Spencer, Susan D.; Khawli, Leslie A.; Ebens, Allen; Wong, Wai Lee; Vandlen, Richard; Kaur, Surinder; Sliwkowski, Mark X.; Scheller, Richard H.; Polakis, Paul; Junutula, Jagath R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">184-189</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The reactive thiol in cysteine is used for coupling maleimide linkers in the generation of antibody conjugates.  To assess the impact of the conjugation site, we engineered cysteines into a therapeutic HER2/neu antibody at three sites differing in solvent accessibility and local charge.  The highly solvent-accessible site rapidly lost conjugated thiol-reactive linkers in plasma owing to maleimide exchange with reactive thiols in albumin, free cysteine or glutathione.  In contrast, a partially accessible site with a pos. charged environment promoted hydrolysis of the succinimide ring in the linker, thereby preventing this exchange reaction.  The site with partial solvent-accessibility and neutral charge displayed both properties.  In a mouse mammary tumor model, the stability and therapeutic activity of the antibody conjugate were affected pos. by succinimide ring hydrolysis and neg. by maleimide exchange with thiol-reactive constituents in plasma.  Thus, the chem. and structural dynamics of the conjugation site can influence antibody conjugate performance by modulating the stability of the antibody-linker interface.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkINkMwQTMFrVg90H21EOLACvtfcHk0lgP3L-V9_nDZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVGqtLg%253D&md5=c647fc5bdfe93dfdabb15ca40934837f</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2108%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DB.-Q.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DRaab%26aufirst%3DH.%26aulast%3DBhakta%26aufirst%3DS.%26aulast%3DKenrick%26aufirst%3DM.%26aulast%3DParsons-Reponte%26aufirst%3DK.%2BL.%26aulast%3DTien%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DS.-F.%26aulast%3DMai%26aufirst%3DE.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DTibbitts%26aufirst%3DJ.%26aulast%3DBaudys%26aufirst%3DJ.%26aulast%3DSaad%26aufirst%3DO.%2BM.%26aulast%3DScales%26aufirst%3DS.%2BJ.%26aulast%3DMcDonald%26aufirst%3DP.%2BJ.%26aulast%3DHass%26aufirst%3DP.%2BE.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DSolis%26aufirst%3DW.%2BA.%26aulast%3DFuji%26aufirst%3DR.%2BN.%26aulast%3DFlagella%26aufirst%3DK.%2BM.%26aulast%3DPatel%26aufirst%3DD.%26aulast%3DSpencer%26aufirst%3DS.%2BD.%26aulast%3DKhawli%26aufirst%3DL.%2BA.%26aulast%3DEbens%26aufirst%3DA.%26aulast%3DWong%26aufirst%3DW.%2BL.%26aulast%3DVandlen%26aufirst%3DR.%26aulast%3DKaur%26aufirst%3DS.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DScheller%26aufirst%3DR.%2BH.%26aulast%3DPolakis%26aufirst%3DP.%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26atitle%3DConjugation%2520site%2520modulates%2520the%2520in%2520vivo%2520stability%2520and%2520therapeutic%2520activity%2520of%2520antibody-drug%2520conjugates%26jtitle%3DNat.%2520Biotechnol.%26date%3D2012%26volume%3D30%26issue%3D2%26spage%3D184%26epage%3D189%26doi%3D10.1038%2Fnbt.2108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Junutula, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhakta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raab, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ervin, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vandlen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheller, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowman, H. B.</span><span> </span><span class="NLM_article-title">Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs</span> <span class="citation_source-journal">J. Immunol. Methods</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">332</span><span class="NLM_x"> (</span><span class="NLM_issue">1–2</span><span class="NLM_x">) </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">52</span><span class="refDoi"> DOI: 10.1016/j.jim.2007.12.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1016%2Fj.jim.2007.12.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=18230399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtlygur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=332&publication_year=2008&pages=41-52&issue=1%E2%80%932&author=J.+R.+Junutulaauthor=S.+Bhaktaauthor=H.+Raabauthor=K.+E.+Ervinauthor=C.+Eigenbrotauthor=R.+Vandlenauthor=R.+H.+Schellerauthor=H.+B.+Lowman&title=Rapid+identification+of+reactive+cysteine+residues+for+site-specific+labeling+of+antibody-Fabs&doi=10.1016%2Fj.jim.2007.12.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs</span></div><div class="casAuthors">Junutula, Jagath R.; Bhakta, Sunil; Raab, Helga; Ervin, Karen E.; Eigenbrot, Charles; Vandlen, Richard; Scheller, Richard H.; Lowman, Henry B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunological Methods</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">332</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">41-52</span>CODEN:
                <span class="NLM_cas:coden">JIMMBG</span>;
        ISSN:<span class="NLM_cas:issn">0022-1759</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Cysteines with reactive thiol groups are attractive tools for site-specific labeling of proteins.  Engineering a reactive cysteine residue into proteins with multiple disulfide bonds is often a challenging task as it may interfere with structural and functional properties of the protein.  Here we developed a phage display-based biochem. assay, PHESELECTOR (Phage ELISA for Selection of Reactive Thiols) to rapidly screen reactive thiol groups on antibody fragments without interfering with their antigen binding, using trastuzumab-Fab (hu4D5Fab) as a model system.  The solvent accessibility values for all the amino acid residues in the hu4D5Fab were calcd. using available crystal structure information.  Serine, alanine and valine residues with highest solvent accessibility values were selected and tested to compare structure-based design with the PHESELECTOR biochem. method.  Cysteine substitutions at partially solvent-accessible alanine or valine residues exhibited better thiol reactivity values than substitutions at serine residues.  The poor correlation between fractional solvent accessibility and thiol reactivity of the engineered hu4D5Fab variants indicated the value of PHESELECTOR biochem. assay to identify reactive thiol groups on the antibody-Fab surface.  Mass spectrometric anal. of biotinylated ThioFab (Fab with engineered cysteine) variants confirmed that conjugation occurred only at the engineered cysteine thiols of either light or heavy chains.  ThioFabs with engineered cysteine residues in the const. domains (CL and CH1) should allow universal application for site-specific conjugation of antibody-Fabs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw4ofIVb0hO7Vg90H21EOLACvtfcHk0lgP3L-V9_nDZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtlygur0%253D&md5=55f3c07ff74193fa1160aafc99e02c50</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.jim.2007.12.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jim.2007.12.011%26sid%3Dliteratum%253Aachs%26aulast%3DJunutula%26aufirst%3DJ.%2BR.%26aulast%3DBhakta%26aufirst%3DS.%26aulast%3DRaab%26aufirst%3DH.%26aulast%3DErvin%26aufirst%3DK.%2BE.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DVandlen%26aufirst%3DR.%26aulast%3DScheller%26aufirst%3DR.%2BH.%26aulast%3DLowman%26aufirst%3DH.%2BB.%26atitle%3DRapid%2520identification%2520of%2520reactive%2520cysteine%2520residues%2520for%2520site-specific%2520labeling%2520of%2520antibody-Fabs%26jtitle%3DJ.%2520Immunol.%2520Methods%26date%3D2008%26volume%3D332%26issue%3D1%25E2%2580%25932%26spage%3D41%26epage%3D52%26doi%3D10.1016%2Fj.jim.2007.12.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Getz, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakrabarty, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selvin, P. R.</span><span> </span><span class="NLM_article-title">A comparison between the sulfhydryl reductants tris(2-carboxyethyl)phosphine and dithiothreitol for use in protein biochemistry</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">273</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">73</span><span class="NLM_x">–</span> <span class="NLM_lpage">80</span><span class="refDoi"> DOI: 10.1006/abio.1999.4203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10.1006%2Fabio.1999.4203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=10452801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;key=1%3ACAS%3A528%3ADyaK1MXlt1Wktbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1999&pages=73-80&issue=1&author=E.+B.+Getzauthor=M.+Xiaoauthor=T.+Chakrabartyauthor=R.+Cookeauthor=P.+R.+Selvin&title=A+comparison+between+the+sulfhydryl+reductants+tris%282-carboxyethyl%29phosphine+and+dithiothreitol+for+use+in+protein+biochemistry&doi=10.1006%2Fabio.1999.4203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">A Comparison between the Sulfhydryl Reductants Tris(2-carboxyethyl)phosphine and Dithiothreitol for Use in Protein Biochemistry</span></div><div class="casAuthors">Getz, Elise Burmeister; Xiao, Ming; Chakrabarty, Tania; Cooke, Roger; Selvin, Paul R.</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">273</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">73-80</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">The newly introduced sulfhydryl reductant tris(2-carboxyethyl)phosphine (TCEP) is a potentially attractive alternative to commonly used dithiothreitol (DTT).  We compare properties of DTT and TCEP important in protein biochem., using the motor enzyme myosin as an example protein.  The reductants equally preserve myosin's enzymic activity, which is sensitive to sulfhydryl oxidn.  When labeling with extrinsic probes, DTT inhibits maleimide attachment to myosin and must be removed before labeling.  In contrast, maleimide attachment to myosin was achieved in the presence of TCEP, although with less efficiency than no reductant.  Surprisingly, iodoacetamide attachment to myosin was nearly unaffected by either reductant at low (0.1 mM) concns.  In ESR (EPR) spectroscopy utilizing nitroxide spin labels, TCEP is highly advantageous: spin labels are two to four times more stable in TCEP than DTT, thereby alleviating a long-standing problem in EPR.  During protein purifn., Ni2+ concns. contaminating proteins eluted from Ni2+ affinity columns cause rapid oxidn. of DTT without affecting TCEP.  For long-term storage of proteins, TCEP is significantly more stable than DTT without metal chelates such as EGTA in the buffer, whereas DTT is more stable if metal chelates are present.  Thus TCEP has advantages over DTT, although the choice of reductant is application specific.  (c) 1999 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdtHBL1_btC7Vg90H21EOLACvtfcHk0ljorZirUh_Tiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlt1Wktbg%253D&md5=7cef8b931982ecbdddf2c92774c438ee</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1006%2Fabio.1999.4203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fabio.1999.4203%26sid%3Dliteratum%253Aachs%26aulast%3DGetz%26aufirst%3DE.%2BB.%26aulast%3DXiao%26aufirst%3DM.%26aulast%3DChakrabarty%26aufirst%3DT.%26aulast%3DCooke%26aufirst%3DR.%26aulast%3DSelvin%26aufirst%3DP.%2BR.%26atitle%3DA%2520comparison%2520between%2520the%2520sulfhydryl%2520reductants%2520tris%25282-carboxyethyl%2529phosphine%2520and%2520dithiothreitol%2520for%2520use%2520in%2520protein%2520biochemistry%26jtitle%3DAnal.%2520Biochem.%26date%3D1999%26volume%3D273%26issue%3D1%26spage%3D73%26epage%3D80%26doi%3D10.1006%2Fabio.1999.4203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Zhang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pillow, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cruz-Chuh, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozak, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadowsky, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis Phillips, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darwish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hop, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khojasteh, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span> </span><span class="NLM_article-title">Linker immolation determines cell killing activity of disulfide-linked pyrrolobenzodiazepine antibody-drug conjugates</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">988</span><span class="NLM_x">–</span> <span class="NLM_lpage">993</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00233</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00233" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=988-993&issue=11&author=D.+Zhangauthor=T.+H.+Pillowauthor=Y.+Maauthor=J.+D.+Cruz-Chuhauthor=K.+R.+Kozakauthor=J.+D.+Sadowskyauthor=G.+D.+Lewis+Phillipsauthor=J.+Guoauthor=M.+Darwishauthor=P.+Fanauthor=J.+Chenauthor=C.+Heauthor=T.+Wangauthor=H.+Yaoauthor=Z.+Xuauthor=J.+Chenauthor=J.+Waiauthor=Z.+Peiauthor=C.+E.+Hopauthor=S.+C.+Khojastehauthor=P.+S.+Dragovich&title=Linker+immolation+determines+cell+killing+activity+of+disulfide-linked+pyrrolobenzodiazepine+antibody-drug+conjugates&doi=10.1021%2Facsmedchemlett.6b00233"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00233%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DPillow%26aufirst%3DT.%2BH.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DCruz-Chuh%26aufirst%3DJ.%2BD.%26aulast%3DKozak%26aufirst%3DK.%2BR.%26aulast%3DSadowsky%26aufirst%3DJ.%2BD.%26aulast%3DLewis%2BPhillips%26aufirst%3DG.%2BD.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DDarwish%26aufirst%3DM.%26aulast%3DFan%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DYao%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DWai%26aufirst%3DJ.%26aulast%3DPei%26aufirst%3DZ.%26aulast%3DHop%26aufirst%3DC.%2BE.%26aulast%3DKhojasteh%26aufirst%3DS.%2BC.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26atitle%3DLinker%2520immolation%2520determines%2520cell%2520killing%2520activity%2520of%2520disulfide-linked%2520pyrrolobenzodiazepine%2520antibody-drug%2520conjugates%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26issue%3D11%26spage%3D988%26epage%3D993%26doi%3D10.1021%2Facsmedchemlett.6b00233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2KTT" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2KTT','PDB','2KTT'); return false;">PDB: 2KTT</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i47"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00736">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_22364"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b00736">10.1021/acs.jmedchem.7b00736</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Atomic coordinates for models (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00736/suppl_file/jm7b00736_si_001.pdb">PDB</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00736/suppl_file/jm7b00736_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00736/suppl_file/jm7b00736_si_001.pdb">jm7b00736_si_001.pdb (103.93 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00736/suppl_file/jm7b00736_si_002.csv">jm7b00736_si_002.csv (0.94 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b00736&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-23%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b00736%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b00736" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6798fd25e93024c7","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
